Procoagulant Signalling In Lung Injury And Fibrosis by Smoktunowicz, N
 
 
  1  
  
Procoagulant 
signalling in lung 
injury and fibrosis 
 
 
By Natalia Smoktunowicz 
 
A thesis submitted to University College London 
for the degree of Doctor of Philosophy 
  
Centre for Inflammation and Tissue Repair,  
Rayne Institute, University College London 
 5 University Street, London, WCE1 6JJ 
 
 
 
 
  2  
  
Acknowledgments 
  
I would like to thank many people that I have met during my time at the Centre for 
Respiratory Research, and more recently Centre for Inflammation and Tissue Repair, 
who generously shared their knowledge with me, offered support as well as 
friendship and laughter.   
I would like to express my special thanks to my primary supervisor, Professor Rachel 
Chambers, for nurturing my passion for science, her immense knowledge, guidance 
and advice through the world of scientific thinking and writing, and critical appraisal 
of this thesis.   
Dr Paul Mercer, my secondary supervisor, for igniting my curiosity and passion for 
science and for guiding my first steps as a scientist. 
Dr Chris Scotton for his invaluable expertise, advice and enthusiasm while discussing 
endless possible answers to my numerous scientific questions.   
Mr Robert Alexander for his help, support and most importantly friendship for life.  
Dr Gabor Jarai for his scientific advice and support during my work at Novartis. 
Medical Research Council and Novartis for funding this study.  
My family in Poland and England for their love, support and encouragement in the 
course of my studies. 
Finally, thank you to my partner, David, who has embarked on this journey with me 
and has been source of love, understanding and motivation to keep going, and to 
whom I dedicate this thesis.   
 
Declaration 
 
I confirm that the work contained in this thesis is entirely my own.  
 
 
 
 
 
  3  
  
 
 
 
 
 
 
 
 
 
To David 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  4  
  
Abstract 
Coagulation proteinases, such as thrombin, exert a plethora of cellular effects via 
activation of proteinase-activated receptors (PARs). Abnormal activation of the 
coagulation cascade has been widely implicated in the pathology of 
fibroproliferative lung disease, including the most common form idiopathic 
pulmonary fibrosis (IPF). The high-affinity thrombin receptor PAR-1 is over-
expressed in the lungs of IPF patients, particularly by the hyperplastic epithelium 
and fibroblasts within fibrotic foci. Moreover, viral infections are implicated in 
aberrant coagulation activation and accumulating evidence points to viruses as 
contributory factors to acute exacerbations that lead to deterioration of lung 
function in IPF patients.   
This thesis focuses on investigating and extending our current understanding of the 
role of PAR-1 in driving lung injury and fibrosis. Data show that primary human lung 
fibroblasts and microvascular endothelial cells express abundant PAR-1 and elicit 
robust calcium signalling responses following thrombin stimulation. In contrast, 
normal human alveolar and bronchial epithelial cells express low levels of PAR-1 but 
high levels of PAR-2. Exposure of the alveolar epithelial cell line, A549, to TGFβ 
increases PAR-1 expression and functional responses but this was not seen in 
freshly isolated primary human alveolar and bronchial epithelial cells. 
The role of TGFβ and pro-coagulant signalling responses was also investigated in an 
in vivo model of viral infection on a background of pulmonary fibrosis. Herpesvirus 
infection in the fibrotic lung promoted robust inflammatory responses 
characterized by extensive pulmonary consolidation but did not lead to an increase 
in lung collagen deposition. Importantly, viral infection was associated with the local 
upregulation of key components of the extrinsic coagulation pathway. Although 
PAR-1 is known to contribute to lung injury and fibrosis in a single hit experimental 
model of pulmonary fibrosis by promoting the activation of latent TGFβ, systemic 
targeting of TGFβ and the coagulation cascade does not impact on inflammation 
induced by viral infection in the fibrotic lung. 
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Chapter 1: Introduction 
1.1 Pulmonary fibrosis 
Pulmonary fibrosis (PF) is an end stage of a heterogeneous group of 
fibroproliferative lung diseases categorised as interstitial lung diseases (ILD). The 
hallmark of ILDs is the deposition of extracellular matrix (ECM) proteins in the 
interstitium suggestive of extensive and abnormal tissue repair responses. Large 
areas of disorganised fibrotic tissue composed of proliferating mesenchymal cells 
and accumulated collagen replace alveolar spaces and thereby prevent efficient gas 
exchange. The disease is progressive and inevitably leads to respiratory failure and 
premature death. 
ILDs, also termed diffuse parenchymal lung diseases (DPLD) include a range of 
disorders that frequently share features of clinical presentation but aetiologically 
and pathologically are independent entities. A number of ILDs have well-
characterised causes that include radiation, drug toxicity and environmental 
exposures (e.g. asbestos in the case of asbestosis). Systemic fibrotic conditions, for 
example systemic sclerosis, collagen vascular disease or rheumatoid arthritis can 
also lead to the development of ILD. However, the largest group of ILDs are of 
unknown aetiology and are termed idiopathic interstitial pneumonias (IIPs). 
Although there are different molecular mechanisms underlying IIPs, many exhibit 
similar clinical presentations and radiological and pathological features. This makes 
diagnosis, associated treatment and prognosis problematic and in 2002 the 
American Thoracic Society (ATS) in collaboration with the European Respiratory 
Society (ERS) introduced criteria for the characterisation and diagnosis of IIPs (Table 
1.1). 
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Histological pattern Diagnosis based on clinical, radiological 
and histological findings 
Usual interstitial pneumonia (UIP) Idiopathic pulmonary fibrosis (IPF) 
Non-specific interstitial pneumonia 
(NSIP) 
Non-specific interstitial pneumonia 
(NSIP) 
Organizing pneumonia Cryptogenic organizing pneumonia 
Diffuse alveolar damage Acute interstitial pneumonia  
Respiratory bronchiolitis Respiratory bronchiolitis-associated 
interstitial lung disease 
Desquamative interstitial pneumonia Desquamative interstitial pneumonia 
Lymphoid interstitial pneumonia Lymphoid interstitial pneumonia 
 
Table 1.1. Classification of the Idiopathic Interstitial Pneumonias (ATS, ERS 2002). 
1.2 Idiopathic pulmonary fibrosis 
IPF is a progressive lung disease with an estimated incidence in the UK of 4.6 per 
100,000 people and 1,500 deaths registered every year. Furthermore, between 
1991 and 2003 the incidence of IPF increased by 11% and the overall trend is rising 
(Gribbin et al. 2006; Hubbard et al. 1996). The disease affects largely middle-aged 
people with around two-thirds being over 60 at the time of diagnosis. The median 
survival rate of IPF patients is approximately three years from the time of diagnosis, 
which is the worst prognosis of all IIPs. The prevalence is higher in men and there is 
an emerging pattern of differences in IPF occurrence and progression between 
ethnic/racial populations (Swigris et al., 2012).  
Clinical presentation of IPF includes long-lasting, progressive dyspnoea and 
significant gas exchange abnormalities confirmed by respiratory tests. Non-
productive cough and systemic symptoms, such as fever and weight loss, are also 
reported (ATS, ERS 2002). Radiology and high-resolution computer tomography 
scans (HRCT) show basal reticular opacities, subpleural honeycombing and traction 
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bronchiectasis. Histological analysis of lung biopsies classically reveals the pattern of 
Usual Interstitial Pneumonia (UIP) with heterogeneous appearance of a healthy lung 
interspersed with well-defined areas of dense interstitial fibrosis, predominantly 
found in peripheral subpleural parenchyma. The hallmark histological features of 
fibrotic areas are honeycomb changes resulting from enlarged and distorted air 
spaces lined with bronchial epithelium and filled with mucin, and prominent fibrotic 
foci composed of aggregates of hyperproliferative and hypersynthetic fibroblasts 
and myofibroblasts enclosed in extracellular matrix and overlaid by hyperplastic and 
injured alveolar epithelium (Figure 1.1) (Chambers, 2008; Katzenstein et al., 2002; 
2002). As the disease progresses, the fibrotic tissue obliterates alveolar spaces 
leading to irreversible architectural distortion of the lung that results in respiratory 
failure. The UIP pattern is distinctively different from other lung diseases, however 
non-specific interstitial pneumonia (NSIP)-like areas, characterised by thickening of 
alveolar septae and varying degrees of inflammatory infiltrates, have been observed 
in the background of otherwise typical UIP (Katzenstein et al., 2002). These findings 
can lead to discordant diagnosis of the condition when the biopsies are taken from 
different lobes of the lung (Flaherty et al., 2001) but can also provide an explanation 
for a heterogeneous clinical outcome in IPF patients. 
The median survival of IPF is less than three years (Kim et al., 2006a) and clinical 
progression is highly variable between patients. IPF is usually diagnosed when the 
disease is advanced and the fibrotic changes in the lung begin to have a significant 
restrictive effect on respiratory physiology. Nonetheless, recent studies in familial 
IPF identified patients in the  asymptomatic phase of disease with fibrotic and 
architectural changes in the lung detected by HRCT scans (Rosas et al., 2007; Steele 
et al., 2005) confirming the temporal separation between the onset of disease and 
the symptoms becoming apparent.  
Following diagnosis, IPF patients can experience steady or rapid progression of the 
disease with a subpopulation of patients experiencing periods of acute exacerbation 
that greatly increase morbidity and mortality. The acute exacerbation of IPF will be 
discussed in detail in the next section. Accelerated progression of IPF and 
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premature death correlate with decline in lung function as clinically assessed by 
physiological tests, the most predictive being lung forced vital capacity (FVC), 
diffusing capacity of lung for carbon monoxide (DLCO) and the 6 minute walk test 
(6MWT). Other risk factors also predictive of a worse outcome include high 
dyspnoea score, old age, male sex, smoking status and comorbidities with 
pulmonary hypertension being the most severe (Ley et al., 2011).  
 
 
Figure 1.1 Fibrotic foci– a histological hallmark of IPF. 
Histological analysis of human IPF tissue reveals the presence of dense collagen 
deposition within the interstitium (Martius Scarlet Blue staining; original 
magnification ×10). Fibroblastic foci are revealed as accumulations of fibroblasts 
and alpha-SMA positive myofibroblasts, which are highly synthetic for collagen and 
have a contractile phenotype (B: Martius Scarlet Blue staining; C: 
immunohistochemistry for alpha-SMA. Original magnification ×20). The overlying 
epithelium is often hyperplastic, with frequent apoptosis and areas of denudation. 
The presence and distribution of fibrotic foci, together with the spatial and 
temporal heterogeneity of the pathology is crucial to defining a UIP pattern. 
[reproduced from (Datta et al., 2011)] 
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1.2.1 Acute exacerbation of IPF 
The progressive course of IPF can be further accelerated by incidents of rapid 
deterioration termed acute exacerbations (AE). Clinical presentation includes the 
development of severe dyspnoea within 30 days and often additional flu-like 
symptoms. Hospitalization is often necessary due to severe hypoxia and the need 
for mechanical ventilation. 
Acute exacerbation of IPF (AE IPF) can have well-determined causes, such as 
infection, left heart failure and pulmonary embolism or can be triggered by 
unknown factors. Collard and colleagues performed a retrospective analysis of 
patients with rapid deterioration of unknown aetiology and estimated that the 
incidence of AE IPF is 9.6% and mortality as high as 78% (Collard et al., 2007). This 
study also proposed diagnostic criteria for AE IPF that include previous or 
concurrent diagnosis of IPF, unexplained worsening or development of dyspnoea 
within 30 days, new pulmonary changes and abnormalities visible on the HRCT 
scans, and lack of evidence for common pulmonary infection.  
Prominent progressive changes identified on radiological and HRCT scans are 
central features of AE IPF. The images of exacerbated lungs reveal the presence of 
new bilateral ground-glass abnormalities and consolidation superimposed on a 
background of UIP pattern typical of IPF (Figure 1.2). Histological evaluation of AE 
IPF reveals interstitial oedema, hyaline membrane formation and extensive diffuse 
alveolar damage and haemorrhage (Collard et al., 2007). These features are 
hallmark findings of acute lung injury (ALI) suggesting that AE IPF and ALI have 
similar clinical and pathological features.   
Although radiological and histological findings imply that AEs are caused by ALI in 
the setting of fibrotic lung disease, these conditions have significantly different 
plasma biomarker profiles indicating distinct underlying pathologies. Plasma 
biomarkers are useful tools for defining the biological phenotype of the disease and 
are frequently adequate predictors of survival. ALI has a well-characterised plasma 
biomarker profile that includes increase in markers of type I and type II alveolar 
epithelial cell (AEC I and II) injury and/or proliferation and endothelial cell injury, 
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elevated pro-inflammatory cytokines and changes in markers of coagulation. 
Protein C is significantly reduced and plasminogen activator inhibitor (PAI) levels are 
increased (Ware et al. 2007), which indicates an altered balance between 
coagulation and fibrinolysis and propagation of a procoagulant state and fibrin 
generation. Indeed, fibrin deposition in the lung, evident as hyaline membranes, is a 
hallmark feature of ALI (Chambers, 2008). In AE IPF, biomarkers of AEC II damage 
and death are also elevated but there is no difference in markers of AEC I injury or 
inflammatory mediators. Total protein C levels are significantly increased and 
thrombomodulin concentration is reduced (Collard et al., 2010). This biomarker 
profile suggests that AEs are driven by damage to the type II alveolar epithelium, 
which is central to the pathogenesis of IPF and will be described in detail later in 
this thesis. Furthermore, there is a clear indication that major anticoagulant 
pathways are dysregulated in AE IPF suggesting that coagulation abnormalities may 
also contribute to the progression of disease.   
Taken together, current evidence suggest that the pathology of AE IPF is distinct 
from the pathology of ALI, which is further corroborated by data obtained from 
genetic profiling of lung tissue from patients with these respiratory conditions 
(Konishi et al., 2009). Gene expression in AE IPF is similar to stable IPF and there is 
no dramatic shift or upregulation of pro-inflammatory genes that is evident in ALI. 
The cell cycle regulator cyclin A2 encoding gene- CCNA2 was one of a few 
significantly upregulated genes and was found to be localised to epithelial cells, but 
not mesenchymal cells (Konishi et al., 2009). These results support the emerging 
hypothesis that AE IPF is driven by acute injury to AEC II leading to severe 
deterioration of the underlying fibroproliferative condition (Collard et al., 2007).   
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Figure 1.2 Acute exacerbation of IPF. 
Case study of IPF patient at baseline- upper panel and with acute exacerbation- 
lower panel. The patient initially presented with mild disease, distinct subpleural 
reticular opacities and honeycombing as identified on the upper HRCT. Within 4 
weeks the patient developed an acute exacerbation with HRCT scan revealing 
extensive bilateral ground glass opacities and infiltrations (courtesy of Dr Toby 
Maher, Royal Brompton Hospital). 
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1.3 Pathogenesis of IPF 
Although the aetiology of IPF is unknown, the current consensus is that persistent 
and repetitive damage to the epithelium leads to dysregulation of repair 
mechanisms, irreversible destruction of the basement membrane and altered 
interactions between epithelial and mesenchymal cells. The following risk factors 
have been implicated in the development of IPF: cigarette smoking (Baumgartner et 
al., 1997), gastro-oesophageal reflux (Kottmann et al., 2009), drug toxicity, 
prolonged environmental exposure (wood or metal dust), viral infections (Tang et 
al. 2003) and genetic predisposition (Lawson et al., 2011). The incomplete 
understanding of the pathogenesis of IPF is reflected by the lack of effective 
treatment for this disease.   
Initial investigations into the mechanism of the disease led to the belief that IPF is a 
chronic inflammatory disorder and immunomodulatory agents have been used 
extensively in IPF. Their limited efficacy suggests that the role of inflammation in 
pulmonary fibrosis is of lesser relevance than predicted and the pathogenesis of the 
disease is more complex. Nevertheless, low doses of steroids and other 
immunosuppressive drugs such as azathioprine, lately supplemented with 
antioxidant N-acetylcysteine (NAC) remained the main line of treatment for IPF 
(Raghu et al., 2012). Recently a combination therapy of prednisone, azathioprine 
and NAC was tested in the PANTHER double-blinded, randomised and placebo-
controlled clinical trial, which was stopped at interim analysis due to increased 
mortality, hospitalisations and the adverse effects in the treatment arm when 
compared with placebo (Raghu et al., 2012). The NAC-only arm of this study is still 
ongoing as the evidence from previous IFIGENIA trail showed that high dose of NAC 
significantly ameliorates progression of the disease in IPF patients (Behr et al., 2009; 
Demedts et al., 2005). 
The latest treatment for IPF involves the recently approved drug- pirfenidone, 
which has been shown to prevent the deterioration of lung function in IPF patients 
(Noble et al., 2011). Although the exact mechanism of action is not known, 
pirfenidone has broad anti-inflammatory and anti-fibrotic effects and has been 
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shown to inhibit fibroblast proliferation and collagen production in vitro (Hisatomi 
et al., 2012). 
Despite numerous studies and clinical trials there is currently a dramatic lack of 
efficacious treatments for IPF. The conventionally used therapies appear to 
accelerate the disease while new agents are being evaluated in a slow and 
opportunistic manner. There is a pressing need to improve the understanding of IPF 
pathogenesis and respond with better-suited and targeted treatments.      
1.3.1 Bleomycin model of acute lung injury and fibrosis 
A great deal of insight into the molecular and cellular mechanisms of pulmonary 
fibrosis comes from animal models. The most common model of pulmonary fibrosis 
involves administration of bleomycin to mice via multiple routes including: 
subcutaneous, intravenous and intraperitoneal. A direct and most widely used 
route of administration to induce localised lung injury and fibrosis involves 
intratracheal instillation of bleomycin that produces fibrosis with bronchiocentric 
distribution. Oropharyngeal instillation (Lakatos et al., 2006) is also a direct route of 
bleomycin administration that is currently used in our laboratory and causes a more 
homogenous injury with peripheral and subpleural fibrosis, and hence is considered 
to be a more representative model of human disease (Scotton et al., 2013).  
Bleomycin is an antibiotic glycopeptide with antineoplastic properties produced by 
bacterium Streptomyces verticillus, which is used as a chemotherapy agent to treat 
many types of cancer including testicular cancer, lymphomas, head and neck 
cancers (Bokemeyer, 2008). Bleomycin causes extensive DNA damage and has been 
strongly associated with pulmonary toxicity in cancer patients and the development 
of interstitial and alveolar fibrosis in animal models (Bokemeyer, 2008; Chaudhary 
et al., 2006; Sikic et al., 1978). Administration of bleomycin causes acute lung injury 
that is characterised by extensive epithelial damage and vascular leak, upregulation 
of inflammatory cytokines and subsequent infiltration of neutrophils, macrophages 
and lymphocytes into the lung (Janick-Buckner et al., 1989). This early inflammatory 
phase of the model peaks during the first week following the injury. Fibrotic lesions 
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develop subsequently and fibrosis establishes at 2-3 weeks post-injury (Scotton et 
al., 2009). Typical histological features include hyperplasia of alveolar epithelial 
cells, basement membrane damage and interstitial and intraalveolar fibrosis (Usuki 
and Fukuda, 1995). Marked expansion of fibroblasts and myofibroblasts and 
extensive deposition of extracellular matrix are evident in the areas of the repairing 
lung (Chaudhary et al., 2006).  
The major drawback of this model is the lack of restrictive physiology and 
progression of fibrosis. Furthermore, the question of resolution of bleomycin-
induced pulmonary fibrosis has been controversial with some research groups 
showing complete resolution within three months (Degryse et al., 2010) while 
others report persistent and lasting fibrotic lesions (Hodges et al., 2004; Scotton et 
al., 2013). Nonetheless, the bleomycin model of pulmonary fibrosis has contributed 
immensely to our understanding of mechanisms leading to fibrosis and proven 
invaluable in the identification of many key pathways and cytokines involved in the 
development of pulmonary fibrosis in vivo. 
1.3.2 Lung injury in pulmonary fibrosis   
On average 11,000 litres of air enters the respiratory system on a daily basis 
carrying the oxygen essential for eukaryotic life but also noxious agents such as 
dust, pollutants and microbial agents that contribute a constant source of potential 
microinjury to the lung epithelium. The lungs therefore are maintained in a state of 
subtle equilibrium between swift responses to injury and wound healing processes 
to minimise the alterations to delicate lung architecture. The haemostatic balance 
in the normal lung is generally antithrombotic and pro-fibrinolytic (Chambers, 
2008). The loss of this balance combined with extensive and persistent damage to 
the alveolar spaces and over-exuberant activation of tissue repair mechanisms can 
result in a number of detrimental fibroproliferative conditions. Indeed, pulmonary 
fibrosis is a potential complication of ALI and its most severe form- acute 
respiratory distress syndrome (ARDS). ALI and ARDS are most commonly caused by 
infection, such as sepsis or pneumonia, or trauma to the lung caused by aspiration 
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of gastric contents or drowning. It is estimated that 40% of ARDS patients develop 
terminal pulmonary fibrosis (Marshall et al. 1998).  
The initial stages of lung injury involve diffuse alveolar damage that is characterised 
by disruption to epithelial and endothelial barrier and cell death. Subsequent loss of 
basement membrane integrity leads to increased vascular permeability and leak, 
inflammatory cell influx into the lung and proliferation of interstitial mesenchymal 
cells with the deposition of provisional ECM. The newly deposited ECM is utilised as 
a scaffold for wound closure mediated by fibroblasts and myofibroblasts. The 
central features of a normal wound healing response in the lung are re-
epithelialisation and re-endothelisation with subsequent ECM remodelling and 
reabsorption. During the resolution phase fibroblasts and myofibroblasts undergo 
apoptosis and homeostasis is restored with minimal alteration to the lung 
architecture (reviewed in Chambers 2008). In contrast, in a fibrotic lung these tissue 
repair mechanisms are dysregulated and lead to major alteration in the architecture 
of the organ eventually leading to its dysfunction and failure. The persistent and/or 
repetitive injuries to the alveolar epithelial cells followed by the denudation and 
loss of integrity of basement membrane have been proposed as the tipping point 
between the healthy response and the fibrotic phenotype (Strieter and Mehrad, 
2009). 
1.3.3 Dysregulated epithelial-mesenchymal crosstalk in IPF 
Current hypothesis states that IPF is the consequence of an aberrant wound healing 
response. Persistent or repetitive injury to the alveolar epithelium and over-
exuberant mesenchymal cell response leads to denudation of alveolar spaces, 
extensive deposition of extracellular matrix and fibroblasts expansion that 
eventually obliterates the normal architecture of the lung. The paradox evident in 
fibrosis revolves around increased apoptosis of the injured epithelium and 
increased survival of the mesenchymal cells (Maher et al., 2010).  
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1.3.3.1 The epithelium in IPF 
Recurrent and non-resolving injury to the alveolar epithelium is a major factor 
driving the pathogenesis of pulmonary fibrosis and extensive apoptosis of AECII is a 
hallmark of IPF lung (Kuwano et al. 2012; Plataki et al. 2005; Uhal et al. 1998). 
Mutations in the structure of surfactant C protein are a proposed genetic factor 
leading to an increased death of AECII in fibrosis. The resultant abnormal protein 
fails to fold correctly and cannot be secreted from cells, which subsequently leads 
to the protein retention in the endoplasmic reticulum and causes cellular stress and 
apoptosis of AECII (Thomas et al., 2002; Wang et al., 2009). Endoplasmic reticulum 
stress has been described as a pathologic feature of IPF (Lawson et al., 2008). 
Moreover, IPF has been primarily associated with the damage to the alveolar 
epithelium but emerging evidence points to the airway epithelium also being 
affected by the pathogenesis of the disease. A genetic variant in mucin (MUC5B) is 
significantly associated with familial and sporadic IPF (Seibold et al., 2011).  
Extensive apoptosis of lung epithelial cells negatively impacts on the re-
epithelisation process and results in alterations in the phenotype of surviving AECII. 
These changes include regenerative hyperplasia and bronchiolarization. 
Furthermore, excessive epithelial apoptosis leads to the disruption of the integrity 
of the alveolar basement membrane, which in turn facilitates the continuous influx 
of fibroblasts and further perpetuates the destruction of alveoli (Strieter and 
Mehrad, 2009). Pockets of hyperproliferative and hypersynthetic fibroblasts and 
myofibroblasts overlaid by hyperplastic alveolar epithelium protrude from the 
alveolar septae and form characteristic fibrotic foci that are considered to be the 
leading edge of the fibroproliferative processes in IPF (Uhal et al. 1998) (Figure 1.1). 
Furthermore, in vitro co-culture experiments demonstrated that interstitial 
fibroblasts can induce apoptosis in injured epithelial cells through secretion of 
angiotensin II (ANGII) (Uhal et al., 1998; Wang et al., 1999). In addition, injured 
epithelium is a prominent source of major profibrotic mediators, including TGFβ 
(Kapanci et al., 1995), TNFα (Kapanci et al. 1995; Nash et al. 1993), CCL2 (Mercer et 
al., 2009) and CTGF (Pan et al., 2001), all of which will be described in detail in 
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Section 1.3.4 of this thesis. Furthermore, injured alveolar epithelium has increased 
capacity to activate TGFβ via αvβ6 integrin-mediated mechanism (Jenkins et al., 
2006). The expression of αvβ6 integrin is considered to be restricted to the alveolar 
epithelium in the lung and becomes upregulated in lung injury and fibrosis (Munger 
et al. 1999; Breuss et al. 1995; Zambruno et al. 1995; Breuss et al. 1993). TGFβ has 
also been shown to induce expression of β6 integrin subunit in epithelial cells 
(Wang et al., 1996) and targeting αvβ6 in experimental pulmonary fibrosis 
attenuates the fibrosis (Horan et al., 2008; Puthawala et al., 2008).    
Targeted injury to alveolar AECII directly causes the development of pulmonary 
fibrosis. Transgenic mice with AECII susceptible to diphtheria toxin injury were 
generated by conjoining the murine surfactant protein C promoter with the 
diphtheria toxin receptor. Diphtheria toxin interferes with protein synthesis in 
eukaryotic cells and leads to apoptosis and increased regenerative proliferation. A 
causal relationship was established between AECII injury and weight loss, collagen 
accumulation and eventually development of pulmonary fibrosis in these mice 
(Sisson et al. 2010). Epithelial cell apoptosis in response to TGFβ overexpression also 
inevitably triggers fibroproliferative disease in vivo  that can be attenuated by 
targeting the apoptotic pathways and TGFβ signalling (Lee et al., 2004).  
Furthermore, following exposure to fibrotic mediators, primarily TGFβ, epithelial 
cells have been shown to undergo epithelial to mesenchymal transition (EMT). This 
process is characterised by the loss of cell polarity, loss of epithelial markers 
including tight junctions Zona Occludens 1 (ZO-1) and E-cadherin, reorganisation of 
the cytoskeleton and acquisition of mesenchymal cell markers including αSMA 
(Kalluri and Neilson, 2003). EMT has been observed in vitro (Willis et al., 2005) and 
TGFβ readily induced EMT in epithelial cells cultured on fibronectin, which is 
representative of provisional matrix deposited in an early wound healing response. 
However, when cells were grown on mature matrix mimicked by collagen and 
matrigel, exposure to TGFβ caused epithelial cell apoptosis (Kim et al., 2006b). A 
similar behaviour was reported in bronchial epithelial cells cultured on fibronectin 
that acquired mesenchymal phenotype when exposed to TGFβ (Câmara and Jarai, 
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2010). EMT has also been demonstrated to occur in vivo in a model of renal fibrosis 
where a third of fibroblasts in fibrotic tissue was shown to be of epithelial origin 
using cell-specific genetic tagging technology (Iwano, 2002). Using a similar 
approach in the model of lung injury and fibrosis, AECII were selectively tagged with 
β-galactosidase (β-gal) and following overexpression of TGFβ in the lung it was 
noted that majority of cells expressing fibroblast marker N-vimentin were also β-gal 
positive (Kim et al., 2006b). In contrast, another study using cell lineage tracing 
technology to investigate the origin of myofibroblasts in bleomycin-induced 
pulmonary fibrosis failed to detect fibroblast or myofibroblasts of epithelial origin 
(Rock et al., 2011). EMT in the human lung is difficult to investigate and many in 
vitro studies with alveolar epithelium have been performed in cancer cell lines, 
where EMT is an established process in tumour invasiveness and metastasis. 
Therefore, the relevance of EMT process in the progression of fibrosis has been 
recently closely scrutinised, particularly in the light of contradictory experimental 
data. However, there are suggestions that EMT may be a part of response to injury 
and a potential mechanism to escape apoptosis in epithelial cells and does not 
necessarily involve a full conversion to mesenchymal phenotype (Kage and Borok, 
2012).       
1.3.3.2 Fibroblasts and myofibroblasts in IPF 
Fibroblasts and myofibroblasts are cells of mesenchymal origin, which are crucial for 
wound healing. However, in fibroproliferative lung disease these cell types acquire a 
proliferative, synthetic and contractile phenotype and drive fibrosis. Human fibrotic 
fibroblasts have the potential to induce pulmonary fibrosis demonstrated by a study 
with transgenic mice that lack innate and adaptive immunity (Pierce et al. 2007). 
Adoptive transfer of fibrotic lung fibroblasts into these mice resulted in the 
development of pulmonary fibrosis. Transfer of normal lung fibroblasts did not 
cause any pathologies providing evidence that the fibrotic fibroblasts have a distinct 
and aggressive phenotype (Pierce et al. 2007) .    
Myofibroblast is a mesenchymal cell characterised by an intermediate phenotype 
between a fibroblast and a smooth muscle cell. It lacks desmin, heavy chain myosin 
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chains and smoothelin expressed by smooth muscle cells but expresses stress fibres 
composed of α-SMA that account for its contractility and make it a key cell 
responsible for a wound closure in the physiological healing processes. 
Mesenchymal cells orchestrating wound closure are a heterogeneous population 
and include fibroblasts, fully-differentiated myofibroblasts and also cells that 
express stress fibres but are αSMA-negative. These cells have intermediate 
properties between fibroblast and myofibroblast and are termed proto-
myofibroblast (reviewed in Hinz 2010). Myofibroblast is central to the pathogenesis 
of fibroproliferative disorders due to its increased contractile potential (Miki et al., 
2000) and greater capacity for ECM protein synthesis in response to profibrotic 
mediator stimulation (Hetzel et al., 2005). In IPF, three main possible cellular 
sources of myofibroblasts have been described: fibroblast to myofibroblast 
differentiation, epithelial-mesenchymal transition (EMT) and recruitment of bone-
marrow derived fibrocytes (Datta et al., 2011; Scotton and Chambers, 2007). TGFβ, 
mechanical stress and matrix remodelling are recognized contributory factors for 
myofibroblast differentiation and proliferation.  
Myofibroblasts and fibroblasts isolated from IPF patients display increased 
migratory potential (Suganuma et al., 1995) and greater capacity for profibrotic 
mediators production in comparison to fibroblasts derived from healthy lungs 
(Moodley et al., 2003). Furthermore, in healthy lungs a prostaglandin-based anti-
fibrotic mechanism regulates the activation of fibroblasts in an autocrine negative 
feedback loop. Stimulated fibroblasts secrete prostaglandins, primarily PGE2, which 
in turn inhibit their proliferation, differentiation, chemotaxis and collagen synthesis 
(Bauman et al. 2010; Hodges et al. 2004; Jenkins et al. 2002; McAnulty et al. 1995). 
In the fibrotic phenotype this auto-regulatory pathway is disrupted and IPF 
fibroblasts have diminished potential to upregulate cyclooxygenase-2 (COX-2) 
expression necessary to generate and release prostaglandins (Keerthisingam et al. 
2001). This failure to produce PGE2 by the fibrotic fibroblasts promotes cell survival 
and addition of exogenous PGE2 to the cell culture leads to fibroblast apoptosis. 
Moreover, inhibition of PGE2 production in the normal fibroblasts produces an 
apoptosis-resistant phenotype (Maher et al., 2010). 
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Fibroblasts are robust producers of ECM and have mechanosensory and 
mechanotransducing properties. Tissue fibroblasts attach to and communicate with 
ECM through assembly of focal adhesions (FAs) and reorganisation of FAs occurs in 
the process of differentiation to myofibroblasts. FAs formation is mediated by 
integrins, which link actin cytoskeleton on the intracellular interface with the ECM. 
Fibronectin ectodomain splice variant ED-A is an ECM protein which contains RGD-
integrin binding sequence and enhances formation of FAs (Dugina et al., 2001). 
Fibronectin, fibrin and intracellular actin stress fibres align alongside the cell 
membrane and converge at the FAs, which sets in place all the components of the 
feedback mechanism that allows cells to continuously sense changes in the 
environment and rearrange the cytoskeleton accordingly. FAs communicate 
changes in the matrix stiffness to the cell, which responds by adjusting FAs size and 
the ability to contract in a linear fashion (Hinz and Gabbiani, 2003). This process, 
known as maturation of FAs, usually occurs in the wound healing scenario and also 
involves expression of FA-specific proteins including vinculin, paxilin, tensin and 
focal adhesion kinase (FAK). Differentiation to myofibroblasts is associated with 
supermaturation of FAs, which involves increased expression of ED-A fibronectin 
and other FAs proteins. Furthermore, FAs increase in size and assemble into 
organised networks in myofibroblasts, which in turn increase the formation of 
αSMA-positive stress fibres (Dugina et al., 2001). Therefore, increasing matrix 
stiffness stimulates myofibroblast contractility, collagen synthesis and ECM 
deposition. As measured by Young’s elastic modulus the stiffness of a normal lung is 
between 1-5 kPa, which in fibrotic lung can increase to 20-100 kPa (Hinz, 2012). 
Studies subjecting fibroblasts to stretch forces in vitro have determined a range in 
which fibroblast acquire stress fibres to be between 3-5 kPa, while the pressure 
needs to increase to 16-20 kPa for αSMA to be incorporated into these stress fibres 
(Hinz, 2010). However, intermediate matrix stiffness of 5-9 kPa is required for cells 
to be sufficiently contractile to cause putative conformational change in TGFβ 
latency complex and release active cytokine, which subsequently induces the 
expression of proteins of contractility apparatus and stimulates ECM production in 
fibroblasts and myofibroblasts (Hinz, 2010).  
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Although fibroblasts have been shown to express αSMA de novo when cultured on 
a stiff matrix, TGFβ is required for uniform and global differentiation into 
myofibroblasts. TGFβ is a potent inducer of fibroblast to myofibroblast 
differentiation (Desmoulière et al., 1993) and can engage multiple cellular pathways 
in the process, which will be described further in this thesis (Section 1.3.4.2).  
1.3.4 Inflammatory and profibrotic mediators in pulmonary 
fibrosis  
IPF is a complex disease and a number of highly profibrotic mediators have been 
shown to be upregulated in IPF patients as well as in the experimental models of 
fibrosis. Key mediators with the strongest causative relationship in pulmonary 
fibrosis will be described in this section and are summarised in Table 1.2.  
1.3.4.1 Overview of fibrotic mediators  
The role of inflammation in IPF has been questioned primarily due to 
immunosuppressive therapies being ineffective in the treatment of the disease. 
However, aggregates of lymphoid tissue with reactivated B and T cells are 
prominent in the IPF lung (Marchal-Sommé et al., 2007) and microarray studies 
have revealed that several inflammatory genes are upregulated in IPF (Zuo et al., 
2002). Furthermore, in the fibrotic lung the immune responses are largely 
influenced by the type 2 T-helper lymphocytes (Th2) (Wynn, 2004) and their 
signature cytokines IL-4 and IL-13 (Wilson and Wynn, 2009). IL-4 has been shown to 
promote the production of extracellular matrix proteins in fibroblasts  (Sempowski 
et al., 1994) while IL-13 increases the production of TGFβ (Lee et al., 2001) and 
monocyte chemoattractant proteins (MCP) including CCL2 (Zhu et al., 2002). 
Furthermore, overexpression of IL-13 in mice leads to the development of allergic 
airway disease and airway fibrosis that subsequently progresses to the parenchyma 
(Zhu et al., 2001). Interestingly, in experimental pulmonary fibrosis IL-13 deficient 
mice, but not IL-4 deficient mice, develop less fibrosis due to diminished collagen 
production by fibroblasts (Kolodsick et al., 2004). These findings were corroborated 
by a recent study showing that IL-13 induces collagen production in airway 
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fibroblasts and subsequent airway remodelling in an MMP-2- and TGFβ-dependent 
manner (Firszt et al., 2013).   
The Th1 and Th2 imbalance in the lungs of IPF patients also leads to decreased 
levels of IFNγ, which is an important component of antiviral immunity but also has 
anti-fibrotic effects. IFNγ inhibits fibroblast proliferation (Rosenbloom et al., 1984), 
collagen production (Narayanan et al., 1992) and disrupts TGFβ expression and 
signalling (Ulloa et al., 1999; Varga et al., 1990). Administration of IFNγ in the 
bleomycin model of pulmonary fibrosis reduced expression of TGFβ and collagen 
and consequently attenuated fibrosis (Gurujeyalakshmi and Giri, 1995). In a small 
clinical study, combined IFNγ and prednisolone therapy showed beneficial effect on 
improving the lung function of IPF patients resistant to glucocorticoids treatment 
(Ziesche et al., 1999). Following from this encouraging result, a large randomised 
and placebo-controlled clinical trial of IFNγ treatment in IPF was performed but 
failed to demonstrate a significant health benefit to IPF patients (Raghu et al., 
2004). However, a trend toward clinical improvement with long-term IFNγ 
treatment was identified (Raghu et al., 2004) and supported by another study 
showing that IFNγ treatment over two year period offered a significant 
improvement in the clinical outcome in mild to moderate IPF (Antoniou et al., 
2006). In contrast, another large phase III clinical trial INSPIRE has been terminated 
early after having shown no survival benefit in patients receiving IFNγ (King et al., 
2009). Despite these contradictory results, IFNγ is still being tested in IPF patients in 
inhaled aerosol form with a view to localise the administration to the lung and 
reduce systemic side effects (Diaz et al., 2012). Furthermore, the scientific rationale 
for beneficial effect of IFNγ therapy in IPF patients has been reinforced by analysis 
of IPF lung biopsies, plasma and bronchoalveolar lavage fluids (BALF) that showed 
reduction in profibrotic and proliferative mediators (including procollagen I and III, 
elastin, platelet derived growth factor PDGF) with IFNγ treatment (Strieter et al., 
2004).  
IL-1β and TNFα are potent cytokines highly expressed in the acute and chronic 
inflammation of the lung and have been shown to be elevated in BALF from IPF and 
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asbestosis patients (Zhang et al., 1993). Furthermore, stimulation of fibroblasts with 
IL-1β and TNFα increased the gene expression of extracellular matrix proteins 
including collagen and fibronectin (Zhang et al., 1993). Overexpression of IL-1β in 
vivo leads to acute alveolar and parenchymal inflammation that progresses into 
interstitial fibrosis with accumulation of fibroblasts and myofibroblasts in the lung 
(Kolb et al., 2001). Moreover, IL-1β-mediated fibrosis depends on activation and 
signalling via TGFβ/Smad3 pathway. This causative relationship was confirmed in a 
study where IL-1β was overexpressed in a Smad3-null rats, which developed 
inflammatory response but showed attenuated fibrosis (Bonniaud et al., 2005a).  
TNFα has been shown to upregulate TGFβ gene expression (Sullivan et al., 2009) 
and overexpression of TNFα in rat lungs leads to acute inflammation that 
progresses into mild but persistent fibrosis (Sime et al., 1998). The fibrotic phase is 
marked by increased levels of TGFβ in the BALFs and accumulation of αSMA positive 
myofibroblasts in the lung. Furthermore, TNFα receptor knockout mice are 
protected from fibroproliferative lung disease induced by bleomycin and silica (Ortiz 
et al., 1999) but develop fibrosis following overexpression of TGFβ (Liu et al., 2001). 
Taken together, these data suggest that the main profibrotic effect mediated by IL-
1β and TNFα occurs via stimulation of TGFβ expression.    
Platelet derived growth factor (PDGF) is a potent mitogen and chemoattractant for 
mesenchymal cells and mediator of extracellular matrix production (Bonner, 2004). 
PDGF is secreted from alveolar macrophages, fibroblasts and myofibroblasts in the 
pulmonary fibrosis creating paracrine and autocrine feedback loops that stimulate 
production of extracellular matrix (Scotton and Chambers, 2007). Alveolar 
macrophages isolated from bronchoalveolar lavage fluid of IPF patients secrete four 
times more PDGF than macrophages from healthy controls (Martinet et al., 1987). 
Moreover, dual inhibition of TGFβ and PDGF signalling pathways by imatinib 
mesylate, a receptor tyrosine kinase inhibitor that blocks PDGF receptor, has been 
shown to have an anti-fibrotic effect in the bleomycin model of dermal fibrosis 
(Distler et al., 2007), asbestos-induced pulmonary fibrosis (Vuorinen et al., 2007) 
and radiation-induced pulmonary fibrosis (Li et al., 2009). Furthermore, imatinib 
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mesylate attenuates bleomycin-induced pulmonary fibrosis when administered 
prophylactically (Daniels et al., 2004). Despite promising in vitro and in vivo data 
and some clinical evidence that imatinib mesylate can improve outcome of 
interstitial lung disease (Distler et al., 2008), a large randomised and placebo-
controlled trial failed to show improvement in the clinical outcome of IPF patients 
(Daniels et al., 2010). Nonetheless, PDGF continues to be targeted in IPF by a 
multiple receptor tyrosine kinase inhibitor nintedanib (BIBF1120) that also inhibits 
fibroblasts growth factor 2 (FGF2) and vascular endothelial growth factors (VEGF). 
FGF2 is a potent mitogen of smooth muscle cells, fibroblasts and myofibroblasts and 
is strongly expressed in IPF (Inoue et al., 2002). VEGF is potent promoter of 
endothelial cells proliferation and neovascularisation. Loss of microvasculature, 
redistribution of blood vessels and thickening of small vessel walls is well 
characterised in IPF (Renzoni et al., 2003). Reduced level of VEGF was reported in 
the model of pulmonary fibrosis mediated by TGFβ overexpression, which was 
reflected in excessive endothelial cells apoptosis and loss of microvasculature 
(Farkas et al., 2009). In turn, loss of small blood vessels inversely correlated with the 
pulmonary arterial pressure and increased the risk of development of pulmonary 
hypertension, which is a major comorbidity in IPF. This abnormal phenotype was 
rescued by restoring VEGF but interestingly was associated with worse fibrosis 
(Farkas et al., 2009). In contrast, early administration of decoy VEGF receptor in 
murine model of bleomycin-induced pulmonary fibrosis attenuated inflammation 
and vascular leak and resulted in attenuated fibrosis (Hamada et al., 2005). 
Although there is a controversy regarding the role of VEGF in IPF and development 
of associated pulmonary hypertension, aberrant neovascularisation contributes to 
pathogenesis of pulmonary fibrosis. Moreover, PDGF and FGF2 have been shown to 
act synergistically to promote angiogenesis independently of VEGF (Nissen et al., 
2007). Preliminary clinical testing of nintedanib in IPF has shown that this 
compound has a potential to prevent decline in lung function, reduce incidence of 
acute exacerbations and preserve the quality of life in IPF patients (Richeldi et al., 
2011).          
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Endothelin (ET-1) is a potent vasoconstrictor and is mainly secreted by endothelial 
cells. In the lung, ET-1 regulates the tone of airways and blood vessels (Kedzierski 
and Yanagisawa, 2001) and is secreted by AECII, Clara cells and alveolar 
macrophages. The expression of ET-1 is upregulated in IPF lungs, most intensely in 
the alveolar epithelium (Giaid et al., 1993; Saleh et al., 1997), in sera of IPF patients 
(Uguccioni et al., 1995) and BALF (Reichenberger et al., 2001). In vitro ET-1 
promotes fibroblast proliferation and differentiation to myofibroblasts (Shahar et 
al., 1999), production of collagen and synthesis of extracellular matrix (Shi-wen et 
al., 2004; Simonson and Ismail-Beigi, 2011). Furthermore, ET-1 promotes fibroblasts 
and myofibroblasts resistance to apoptosis (Kulasekaran et al., 2009), which is a 
prominent feature of fibrotic fibroblasts. In animal models of pulmonary fibrosis 
inhibition of ET-1 receptors by bosentan has been shown to attenuate bleomycin-
induced fibrosis (Park et al., 1997). In contrast, a study with bosentan in our 
laboratory did not show a reduction in collagen deposition and the severity of 
fibrosis in the bleomycin model (Mutsaers et al., 1998). Nonetheless, bosentan was 
taken into a clinical trial in IPF patients without pulmonary hypertension (King et al., 
2008) but the trial was terminated early due to overall lack of beneficial effect.  
Angiotensin II (ANG II) is converted from angiotensinogen by the angiotensin-
converting enzyme (ACE) and signals via angiotensin receptor I and II (AT I and AT II) 
to promote tissue repair in normal wound healing. In IPF ANG II is upregulated in 
apoptotic alveolar epithelium and myofibroblasts (Li et al., 2006), which is matched 
by increased expression of AT I and ATII receptors in the interstitial mesenchymal 
cells (Königshoff et al., 2007). Furthermore, ACE polymorphism is associated with 
increased risk of development of pulmonary fibrosis (Uh et al., 2013) and 
angiotensinogen promoter polymorphism has been recently shown to predict the 
decline in lung function in IPF patients (Dang et al., 2013). Targeting ANG II 
receptors and ACE activity in vivo attenuated radiation- and bleomycin-induced 
fibrosis (Molteni et al. 2007; Wang et al. 2000) while local suppression of ANG II 
expression in the lung also resulted in protection from bleomycin-induced 
pulmonary fibrosis (Li et al., 2007). ANG II exerts a potent mitogenic effect on lung 
fibroblasts that can be inhibited by ATI receptor antagonist losartan (Marshall et al., 
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2000). Furthermore, myofibroblasts from IPF patients have been shown to 
constitutively produce angiotensinogen and express increased level of TGFβ mRNA 
(Marshall et al., 2000; Uhal et al., 2007). Subsequently, high concentrations of ANG 
II and active TGFβ are detected in the supernatants from in vitro cultures of these 
cells. Blocking ANG II receptors abrogates the increase in TGFβ mRNA and active 
protein expression (Uhal et al., 2007). Furthermore, ANG II expression is induced de 
novo in the alveolar epithelium in pulmonary fibrosis and in an autocrine fashion 
promotes apoptosis of alveolar epithelium (Uhal et al. 1998) that again can be 
blocked by AT I inhibitor losartan (Wang et al. 1999). All these data confirm that 
ANG II is a prominent profibrotic mediator produced locally in the fibrotic lung and 
contributes to the pathogenesis of disease by stimulating mesenchymal cell 
proliferation, epithelial cell apoptosis and upregulating the expression and 
activation of TGFβ by means of ANG II/TGFβ autocrine positive feedback loop.            
Connective tissue growth factor (CTGF) has also been shown to contribute to the 
pathogenesis of pulmonary fibrosis. CTGF is produced and secreted downstream of 
TGFβ activation and perpetuates ECM synthesis and deposition by fibroblasts and 
myofibroblasts. Increased levels of CTGF have been detected in the fibrotic tissue of 
IPF patients (Scotton and Chambers, 2007). Although CTGF alone does not induce 
fibrosis, it increases susceptibility to pulmonary fibrosis in BALB/c mice, a strain of 
laboratory animals that are inherently resistant to bleomycin-driven lung injury and 
fibrosis (Bonniaud et al., 2004a). 
1.3.4.2 Transforming growth factor β   
There is overwhelming evidence that TGFβ is a central mediator of pulmonary 
fibrosis in human disease and animal models (Coker et al., 1997, 2001; Khalil et al., 
1991). TGFβ is a pleiotropic and ubiquitously expressed cytokine and elicits a wide 
range of cell- and tissue-specific responses, which include regulation of cell growth 
and survival, cell and tissue differentiation, developmental, inflammatory and 
haematopoietic processes, tissue remodelling and repair and synthesis of ECM 
(reviewed in Akhurst and Hata 2012). Primary function of TGFβ is 
immunomodulation and its importance is fully demonstrated in TGFβ1 knockout 
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mice, which develop postnatal lethal multifocal inflammatory syndrome that leads 
to tissue necrosis and organ failure (Shull et al., 1992). TGFβ has suppressive and 
anti-proliferative effects on cells of both innate and adaptive immunity (Akhurst and 
Hata, 2012). There are three TGFβ isoforms in humans: TGFβ1, TGFβ2 and TGFβ3. 
However, unlike TGFβ1, TGFβ3 overexpression does not lead to upregulation of 
TGFβ receptors and progressive fibrosis in the lung  (Ask et al., 2008).  
TGFβ gene expression is upregulated by inflammatory mediators such as TNFα 
(Sullivan et al., 2009) and ANGII as described previously. However, TGFβ activity is 
mostly regulated post-transcriptionally and the cytokine is secreted from cells in an 
inactive form and sequestered in ECM as part of a latent complex formed by the 
latency associated peptide (LAP) and latent TGFβ binding proteins (LTBP). This 
latent complex is covalently bound to the extracellular matrix and the dissociation 
of active TGFβ occurs following a conformational change in the LAP that can be 
triggered by a number of mechanisms of activation, including interaction with 
thrombospondin I or proteolytic activity exerted by matrix metalloproteinases, 
particularly MMP2 and MMP9. Changes in the environment such as low pH and 
mechanical stretch also contribute to the release of active TGFβ (Akhurst and Hata, 
2012). However, current evidence suggests that the most relevant in vivo 
mechanism of TGFβ activation, particularly in the context of pulmonary fibrosis, 
occurs via integrins.   
Integrins are transmembrane heterodimeric proteins and adhesion molecules that 
convey bidirectional communication between the cell and the environment. 
Different isoforms of α and β subunits assemble into 24 combinations of integrins, 
of which eight have arginine-glycine-aspartate (RGD) domain that is capable of 
binding the latent TGFβ complex (Munger et al. 1999). The intracellular domain of 
integrin connects with the actin cytoskeleton of cells while the extracellular domain 
interacts with extracellular matrix and LAP. The interaction between the LTBP and 
ECM is necessary for integrin-mediated TGFβ activation and the activity of TGFβ is 
greatly reduced when LTBP lacks the ECM binding domain (Annes et al., 2004). 
Integrins αvβ3, αvβ5, αvβ6 and αvβ8 have been shown to activate TGFβ in vitro. 
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Integrins αvβ6 and αvβ5 are physiologically most relevant to the injured lung 
responses as they are expressed on alveolar epithelium and fibroblasts, 
respectively, and hence can contribute to local activation of TGFβ in the lung 
(Scotton et al. 2009; Jenkins et al. 2006; Sheppard 2005; Munger et al. 1999). 
Although αvβ6 is expressed at low levels in a normal lung, it has been shown to be 
upregulated in pulmonary fibrosis (Xu et al., 2009). Furthermore, neutralising αvβ6 
integrin in vivo attenuates pulmonary fibrosis (Puthawala et al., 2008). Another 
integrin implicated in pulmonary fibrosis is αvβ8 that has been shown to delay 
epithelial wound closure and inhibit bronchial epithelial cell proliferation in vitro 
(Neurohr et al., 2006). 
The mechanism of integrin-mediated TGFβ activation can occur downstream of G-
protein coupled receptor (GPCR) activation and reorganisation of cellular 
cytoskeleton. It was initially demonstrated that thrombin and direct PAR-1 
activating peptide signal via Gαq and RhoA kinases to induce cytoskeletal re-
arrangement, which in turn increases the degree of mechanical stress between the 
integrins and LAP, disrupting the latent complex and leading to release of active 
TGFβ (Jenkins et al., 2006; Scotton et al., 2009). Since then other GPCRs agonists, 
including lysophosphatidic acid (LPA), have been shown to also activate TGFβ via a 
similar integrin-mediated mechanism (Xu et al., 2009). Furthermore, both PAR-1 
knockout mice and LPA receptor deficient mice are protected from bleomycin-
induced pulmonary fibrosis and show reduced expression of TGFβ, α-smooth 
muscle actin (αSMA), collagen and fibronectin (Howell et al., 2005; Huang et al., 
2013).      
Active TGFβ signals in a paracrine manner via transmembrane serine/threonine 
kinase receptors type I and type II (TβRI and II) that form heterotetrameric 
complexes following agonist binding. TβRI is also termed activin receptor-like kinase 
receptor (ALK) and ALK5 in particular is widely expressed in different cell types in 
the lung and recruits Smad2 and Smad3 transcription activators. The canonical 
Smad-dependent signalling pathway involves phosphorylation of Smad2 and 
Smad3, which then form complexes with Smad4 and translocate to the nucleus. 
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Smad complexes act as transcription factors for regulation of expression of many 
genes (Massague, 2000). The canonical signalling pathway is negatively regulated by 
an inhibitory member of Smad family- Smad7.  
TGFβ can also activate multiple Smad-independent signalling pathways, including all 
three mitogen-activate protein kinases (MAPK) pathways: p38, C-Jun N-terminal 
kinase (JNK) and extracellular signal regulation kinase (ERK). TGFβ can also interact 
with Rho kinases, nuclear factor kB ( NF-kB), Wnt-β catenin and PI3-AKT signalling 
pathways (reviewed in Akhurst and Hata 2012; Biernacka et al. 2011).  
The effect of TGFβ signalling on the progression of fibrosis has been extensively 
studied in vivo. Overexpression of TGFβ results in lung fibrosis while inhibition of 
TGFβ attenuates fibrosis in the bleomycin-induced model of pulmonary fibrosis (Giri 
et al. 1993). Furthermore, Smad3 knockout mice show enlarged airspace phenotype 
but are also protected from pulmonary fibrosis (Bonniaud et al., 2004b). Similarly, 
targeted knockout of TβRII in the alveolar epithelium causes emphysema but also 
offers protection from bleomycin-induced lung injury and fibrosis (Li et al., 2011). 
Integrin αvβ6-null mice show MMP-12-dependent enlargement of airspaces and 
reduced surfactant clearance (Koth et al., 2007; Morris et al., 2003).  
Furthermore, in vitro studies have shown that TGFβ can activate multiple signalling 
pathways simultaneously, which can interplay to produce similar biological effect. 
TGFβ signalling leads to fibroblast to myofibroblast differentiation and TGFβ induces 
αSMA and collagen gene expression in Smad3-dependent manner (Hu et al., 2003). 
Smad3-null mice have reduced numbers of αSMA-positive myofibroblasts 
(Bonniaud et al., 2005a). However, non-canonical and MAPK-dependent TGFβ 
signalling pathways also play a role in fibroblast to myofibroblast differentiation. 
MAPK p38 activation is required for fibronectin expression and polymerisation 
(Dugina et al., 2001) and both p38 and ERK kinases induce αSMA expression (Hu et 
al., 2006a). C-Jun N-terminal kinase (JNK) has been shown to be phosphorylated in 
human lung fibroblast prior to αSMA induction (Hashimoto et al., 2001) while TGFβ-
ERK signalling also induces collagen expression in fibroblasts (Caraci et al., 2008). 
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Furthermore, interaction between Smad3 and MAPK pathways promotes fibroblast 
survival (Horowitz et al., 2004).  
Taken together these data strongly suggest that TGFβ plays a key role in the 
pathogenesis of fibrosis, as summarised in Figure 1.3., but is also necessary for the 
development and maintenance of alveolar homeostasis.  
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.3 TGFβ-mediated profibrotic effects.  
Following injury to the lung, mechanisms for the activation of TGFβ are set in 
motion. Subsequently, TGFβ acts in a paracrine mode on inflammatory cells, 
fibroblasts and epithelial cells in the lung and triggers ECM deposition. This 
perpetuation of a profibrotic environment can eventually lead to the development 
of fibroproliferative lung disease.  
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Mediator Major Biological Activities 
Target cell Proliferation Apoptosis Chemotaxis Collagen 
synthesis 
Fibrogenic 
TGFβ Fibroblast + - + ++ ++ 
Epithelium - + - + + 
PDGF Fibroblast ++ 0 + + + 
FGF2 Fibroblast + 0 + + + 
TNFα Fibroblast + + 0 + + 
IL-1β Fibroblast + + 0 + + 
IL-4 Fibroblast + + + + + 
IL-10 Fibroblast - + + - + 
IL-13 Fibroblast + + - + + 
IFNγ Fibroblast - + + - - 
CCL2/ 
MCP-1 
Macrophage - - + + + 
Fibrocyte + - + + + 
CTGF Fibroblast + 0 + + + 
Thrombin Fibroblast ++ 0 + + ++ 
FXa Fibroblast  ++ 0 - + ++ 
ANG II Fibroblast + - 0 + ++ 
Epithelium - + - - + 
ET-1  Fibroblast + - 0 + + 
 
Table 1.2 Profibrotic mediators and their biological activity in pulmonary fibrosis. 
Updated from (Gharaee-Kermani et al. 2009; Gharaee-Kermani et al. 2007), ++, 
major role or strongly stimulatory, +, stimulatory, -, inhibitory, 0, no known effect. 
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1.3.4.3 Chemokines 
Chemokines form an extensive family of proinflammatory mediators and 
chemoattractants that are released following injury to the lung and act to recruit 
neutrophils, lymphocytes, fibrocytes and other effector cells to the site of injury. 
Certain chemokines have been proposed as biomarkers for fibrotic lung disease. In 
experimental models of pulmonary fibrosis, CXCL11 has been demonstrated to 
attenuate bleomycin-induced fibrosis by preventing aberrant vascular remodelling 
(Burdick et al., 2005) and CXCL10 disrupts fibroblast migration (Jiang et al., 2010). 
Mice deficient in CXCL11 and CXCL10 receptor, CXCR3, have reduced levels of IFNγ 
and develop worse interstitial fibrosis following bleomycin administration (Jiang et 
al., 2004). CCL18 has also been shown to inversely correlates with the decline in 
pulmonary function (Prasse and Müller-Quernheim, 2009; Prasse et al., 2006).  
Levels of CCL2 (monocyte chemoattractant protein 1, MCP-1) are increased in sera 
and bronchoalveolar lavage fluid from IPF patients (Baran et al., 2007; Suga et al., 
1999) and fibroblasts from fibrotic lungs produce significantly higher levels of CCL2 
(Deng et al., 2013). CCL2 is a potent chemoattractant of immune cells including 
neutrophils, monocytes, T-cells and immature dendritic cells. Moreover, CCL2 
mediates recruitment of fibrocytes into the lung (Moore et al. 2006), their 
proliferation and differentiation into myofibroblasts (Ekert et al., 2011). CCL2 
expression is induced by multiple profibrotic mediators including TGFβ and in an 
autocrine loop CCL2 subsequently upregulates TGFβ gene expression (Gharaee-
Kermani et al. 1996). Cytokines IL-4, IL-13, IL-10 also mediate CCL2 release, which in 
turn propagates accumulation of Th2 lymphocytes and alternatively activated 
macrophages in the lung (Sun et al. 2011; Martinez et al. 2009; Ip et al. 2006). 
Alternatively activated macrophages are characterised by expression of arginase 
and mannose receptors and are involved in immunomodulation, tissue remodelling 
and angiogenesis. Furthermore, alternatively activated macrophages are potent 
producers of TGFβ and PDGF, can have a stimulatory effect on collagen production 
in normal lung fibroblasts and have been isolated from BALF of IPF patients (Prasse 
et al., 2006). CCL2 is also induced downstream of activation of extrinsic coagulation 
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cascade (Deng et al., 2008; Mercer et al., 2009), which will be discussed in more 
detail later in this thesis.     
1.4 Viruses and IPF 
There is accumulating evidence that viruses contribute to the pathogenesis of IPF 
and acute exacerbation of IPF. Hepatitis C virus and adenovirus have been linked 
with fibrosis but the strongest correlation has been described for the herpesvirus 
family (reviewed in Vannella and Moore 2008).  
Herpesviruses have a double-stranded DNA genome, enclosed in icosapentahedral 
capsid that is surrounded by the amorphous protein layer called tegument, and 
finally enclosed in the glycoprotein envelope. The family is divided into three 
groups: α-herpesviruses include herpes simplex virus, β-herpesviruses, for example 
human cytomegalovirus (CMV) and human herpes virus 7 (HHV-7), and γ-
herpesviruses such as Epstein Barr virus (EBV) and human herpes virus 8 (HHV-8). 
EBV infects asymptomatically 95% of the population, entering the organism via 
nasopharynx epithelium, where it replicates and migrates into lymph nodes to 
establish latency in the B-lymphocytes.  
In experimental models, murine γ-herpesvirus-68 (γHV68) has been used to 
investigate the role of viral infection in the pathogenesis of pulmonary fibrosis (PF). 
Murine γHV68 is genetically co-linear with EBV and HHV-8 and occurs naturally 
following a similar infection pattern as human herpesviruses i.e. infects the 
respiratory system and persists in B-cells and epithelial cells (reviewed in Vannella 
and Moore 2008).  
1.4.1 Detection of Herpesviruses in IPF patients  
Evidence of persistent occult viral infections in the lungs of IPF patients have been 
reported by many studies. Lung tissue from IPF patients tested positive for herpes 
viruses in 97% cases, while in a control group composed of a cohort of patients with 
other lung conditions 36% harboured viral DNA (Tang et al., 2003). EBV, CMV, HHV-
8 and HHV-7 were most commonly detected in the lungs of IPF patients, and 60% of 
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IPF patients harboured infection with 2 or more different types of herpesviruses 
(Tang et al., 2003). The findings of this study were also corroborated in another 
study, which showed that EBV genetic material was detected in IPF lung tissue with 
significant greater incidence (48%) than in control groups (12%) (Stewart et al., 
1999). IPF patients have been shown to have increased serological levels of anti-EBV 
IgA and IgG in comparison to patients with pulmonary fibrosis of known aetiology 
(Vergnon et al., 1984) and the replicating virus is detected at higher frequency in 
alveolar epithelial cells in the lower respiratory system (Egan et al. 1995). 
Furthermore, EBV-positive IPF patients harboured virus with WZhet-rearranged 
genome containing a recombinant BZLF1 reactivation gene open reading frame, 
which allows the virus to spontaneously reactivate from latency, proliferate and 
spread between cells (Kelly et al., 2002). Indeed, detection of latent membrane 1 
(LMP-1) of EBV virus is associated with a worse outcome and increased mortality in 
IPF patients (Tsukamoto et al., 2000). 
It has also been postulated that the acute exacerbation of IPF can be a 
manifestation of an occult infection, not detected in the lung due to inadequate 
sensitivity of screening methods and a delay between onset of the symptoms and 
clinical presentation. A prospective study of BAL samples from IPF patients 
experiencing acute exacerbation and stable patients has shown that a third of 
exacerbating patients harboured viruses (Wootton et al., 2011). This study has 
employed three genetic screening methods to address the technological limitations 
of viral detection. By means of multiplex PCR, the presence of common respiratory 
viruses was detected in 9% of patients; pan-viral microarray revealed Torque teno 
virus (TTV) and herpesviruses in 35% of patients and finally the presence and 
identity of these viruses was also confirmed by DNA sequencing. Interestingly 
infection with two or more viruses was detected in a third of virally positive 
samples. Although this study found no significant correlation between the presence 
of viruses and incidence of acute exacerbations, patients harbouring viral infections 
required mechanical ventilation more often and had reduced lifespan post 
exacerbation (Wootton et al., 2011). Another study has previously identified TTV 
virus DNA in the blood sera of IPF patients, which was associated with increased 
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incidence of acute exacerbation and mortality (Bando et al., 2001). This virus is also 
detected at higher frequency in IPF patients that develop lung cancer when 
compared to IPF control and lung cancer control patients (Bando et al., 2008). A 
population of IPF patients that harbour TTV appear to have a poorer prognosis but 
more clinical evaluations and studies into the potential pathological mechanisms 
are required to establish a causative relationship between TTV infection and 
progression of IPF.       
In contrast another study compared gene expression between IPF patients in a 
stable phase of disease and experiencing acute exacerbation and did not find any 
evidence of viral DNA presence (Konishi et al., 2009). However, the same study 
found upregulated markers of AECII damage and increased levels of mediators of 
innate immunity, α-defensins, which act as a broad spectrum endogenous 
antibiotics. In the lung α-defensins are secreted by the epithelium and inflammatory 
cells and display antimicrobial properties toward Gram-positive and Gram-negative 
bacteria, fungi and enveloped viruses (reviewed in Bals and Hiemstra 2004). 
Defensins also stimulate inflammatory cell recruitment into the lung by inducing the 
release of IL-8 from airway and alveolar epithelia (Wetering et al., 1997) and IFNγ, 
IL-6 and IL-10 from T-lymphocytes (Lillard et al., 1999). These data confirm that 
acute exacerbation is driven by injury to the epithelium that evokes inflammatory 
response, even though the potential infectious aetiology was not confirmed 
(Konishi et al., 2009).    
1.4.2 Herpesvirus infection in experimental pulmonary fibrosis  
Although evidence exists showing that herpesviruses are prevalent in patients with 
IPF, no definitive causal relationship between viral presence and the development 
of the human disease has been established. However, naturally-occurring equine γ-
herpesvirus-5 has been associated with the development of interstitial pulmonary 
fibrosis in horses as a complication of viral pneumonia (Williams et al., 2007). 
Moreover, animal models of pulmonary fibrosis have been used to investigate the 
potential role of viruses in pulmonary fibrosis (PF).  
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The natural rodent pathogen, murine γHV68, shares 80% homology with human 
EBV and displays parallel invasive features: epithelial and B cell tropism, virus-driven 
B-cell activation and proliferation, and an acute infectious mononucleosis syndrome 
(Nash and Sunil-Chandra, 1994). Both EBV and γHV68 enter their respective hosts 
via oropharyngeal epithelium, preferentially replicate in the lung epithelium and 
traffic to lymphoid tissue where they establish a persistent, latent reservoir of the 
virus in B lymphocytes.      
BALB/c mice are inherently resistant to bleomycin-induced pulmonary fibrosis and 
do not develop fibrosis following infection with γHV68. However, γHV68 infected 
mice develop pulmonary fibrosis when administered bleomycin (Lok et al., 2001). 
This two-hit model of pulmonary fibrosis in a resistant strain of mice demonstrates 
that a combination of pathological cues is required to trigger the fibroproliferative 
disease in the lung and validated viral infection as a potent contributor to the 
pathogenesis of pulmonary fibrosis. Furthermore, transgenic mice lacking the 
interferon gamma receptor (IFNγR) develop multi-organ fibrosis following infection 
with γHV68 (Ebrahimi et al., 2001) that can be attenuated by antiviral therapy. In 
these mice, the cytokine milieu is skewed towards T helper 2 (Th2) lymphocyte 
responses characterised by overproduction of profibrotic mediators, including TNF-
α, TNF-β, IL-1β, TGF-β and lymphotactin. The IFNγR deficiency mimics the Th1-Th2 
imbalance observed in IPF patients (Mora et al., 2007) and the results of this study 
support the notion that skewed immune responses can create a profibrotic 
environment in the lung that can act as cofactors for the development of fibrosis. 
Furthermore, adenoviral transfer of EBV transactivator protein Zta into mouse lungs 
caused neutrophilic inflammation, induced IL-13 production from alveolar epithelial 
cells prompting Th2 phenotype in the lung and increased secretion of profibrotic 
chemokines, mainly CCL2 from infiltrating immune cells (Guenther et al., 2010). In 
this study the inflammation resolved after four weeks with no fibrosis in the lung.    
Animal models of pulmonary fibrosis concomitant with latent viral infection 
demonstrated aggravated fibrosis with a worse outcome in comparison to mice 
given a fibrotic stimulus only (Vannella et al., 2010a). Latent viral infection 
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augmented the response to the fibrotic injury and led to significantly increased 
collagen deposition in the lung, upregulation of CCL2 and CCL12 expression and 
release, increased fibrocyte recruitment, increased basal levels and activity of TGFβ. 
Also, infected mice were susceptible to sub-threshold doses of fibrotic stimuli 
(Vannella et al., 2010a). Furthermore, the virus has infected alveolar macrophages 
that produced large amounts of IFNγ, TNFα, CCL2, CCL12 as well as TGFβ four weeks 
after the infection (Stoolman et al., 2010). Mesenchymal cells isolated from the 
infected mice also showed long-lasting upregulation of profibrotic mediators, 
notably TGFβ and CCL2. These data suggest that the latent viral infection can prime 
the lung toward a profibrotic phenotype.      
A link between viral infection and acute exacerbation of pulmonary fibrosis was also 
established in experimental model of fibrosis (McMillan et al., 2008). During the 
course of fluorescein isothiocyanate-induced (FITC) fibrosis mice were infected with 
γHV68 and displayed more rapid deterioration in comparison with mock-infected 
mice. Collagen deposition was significantly increased in infected mice as was CCL2 
and CCL12 release and fibrocyte recruitment into the lung. In this study mice 
mounted a competent IFNγ-mediated antiviral response which showed that the 
virus is able to affect the progression of fibrosis independently of the cytokine 
environment. This observation was reinforced when this model of viral 
exacerbation of pulmonary fibrosis was repeated in Th1 biased mice deficient in the 
Th2 cytokines- IL-4 and IL-13 (McMillan et al., 2008).   
Pulmonary fibrosis largely affects the ageing population and therefore the 
responses to viral infection have been investigated in aged mice to recapitulate the 
human disease better and to dissect any potential difference in fibrosis pattern that 
can be influenced by age. Aged mice have been shown to develop pulmonary 
fibrosis in response to gammaherpesvirus infection alone despite fully competent 
antiviral immune responses and control of the viral load (Naik et al., 2011). 
However, aged mice expressed higher levels of TGFβ concomitant with upregulation 
of TGFβ receptors on fibroblasts. An increase in fibroblast sensitivity to TGFβ and 
subsequent resistance to apoptosis was postulated as a mechanism for 
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development of fibrosis in these mice (Naik et al., 2011). Furthermore, viral 
infection in the lungs of aged mice was associated with increased markers of 
endoplasmic reticulum stress and AECII apoptosis (Torres-González et al., 2012). 
Aged mice also showed increased inflammation and TGFβ levels in the early phase 
of infection. Overall these data suggest that although young and aged mice can 
mount antiviral immunity to viral infection, there are marked differences in the 
resolution of inflammation and tissue repair mechanisms that in aged mice can lead 
to the development of fibroproliferative lung disease.      
1.4.3 Viruses as cofactors in pulmonary fibrosis  
Although herpesviruses preferentially infect B-lymphocytes, where they establish 
latency, they also display tissue tropism towards the alveolar epithelium. The virus 
is presumed to exist in a state of equilibrium, continuously shuttling between B 
lymphocytes, which is its main latency reservoir and epithelium, which is considered 
to be the main replication site. Furthermore, viral tropism is dictated by the 
specialised and discordant fusion proteins expressed by different cell types and 
necessary for the viral entry into cells. The viral glycoproteins B, H and L are 
essential for fusion with epithelial cells while glycoprotein gp42 is crucial for 
attachment to the HLA class II receptor present on B-lymphocytes. Subsequently 
progeny virions emerging from B-cell express more gBgHgL complexes which primes 
them for epithelial cell infection while epithelial cell released virions contain 
relatively more gp42 and target the B-cells (Borza and Hutt-Fletcher, 2002). In 
epithelial cells the auxiliary molecules required for the viral entry into the cell are 
integrins and particularly αvβ6 and αvβ8 have been shown to aid the viral entry into 
the epithelial cells (Chesnokova et al., 2009). As previously described in this thesis, 
both integrins are associated with pulmonary fibrosis as they have a high affinity for 
the latency associated peptide LAP-TGFβ complex and contribute to TGFβ activation 
(Goodwin and Jenkins, 2009; Sheppard, 2005). Furthermore, the αvβ6 integrin is 
expressed on normal lung epithelium at low levels and is upregulated in response to 
injury (Thomas et al., 2006). This may be a potential mechanism by which 
herpesviruses infection spreads to the alveolar epithelium in IPF patients. 
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Furthermore, alveolar epithelium expresses CD24 receptor, which EBV can also 
utilise as a co-receptor aiding the attachment and entry into the cell and this 
receptor is upregulated by IL-4 (Malizia et al., 2009a). This can lead to enhanced 
infection of AECII in Th2- skewed environment that is documented in IPF lung.  
The viral life cycle is detrimental to infected cells. In the lytic phase virus attaches to 
the cell surface in order to enter the intracellular compartment. It subsequently 
hijacks and re-programmes host’s replication and protein production machinery to 
produce viral structural components. Viral progeny assemble in the cytoplasm and 
trigger cell lysis in order to be released into the extracellular space, where the 
infection process can start again. Therefore viral infection leads to extensive 
epithelial cell damage as a direct result of the viral life cycle, which also produces an 
inflammatory responses that could lead to the remodelling of alveolar spaces and 
the development of fibrotic lesions similar to those observed in IPF (Mora et al., 
2007). γHV68 has been shown to preferentially infect AEC II and may contribute to 
dysregulated cell repair and surfactant abnormalities associated with increased 
apoptosis of AECII and alveolar collapse (Mora et al., 2006).  
Following invasion of the host cell and the incorporation of its genetic code into the 
host genome, viruses can switch into dormant mode and establish latency. This can 
create the potential for reactivation and be a source of repetitive epithelial injury, 
as implicated in the pathogenesis of IPF. Immunosuppression is a major trigger for 
viral reactivation and therefore IPF patients receiving steroids would be susceptible 
to recurring infections. Furthermore, the latent virus can alter the phenotype of 
infected cells. A study in human AECII shows that EBV latent membrane protein I 
(LMP-1) and TGFβ synergistically induce epithelial-mesenchymal transition (Sides et 
al., 2010). Also in the animal models it has been shown that latently infected 
epithelial cells upregulate TGFβ mRNA and protein expression and upon 
reactivation of the virus increase cell apoptosis (Malizia et al., 2008). Also, TGFβ has 
been shown to induce reactivation of the virus and promote phenotypic changes 
toward mesenchymal cells with loss of E-cadherin, increased cell proliferation, 
motility and invasion via Wnt/CUX-1 dependent mechanism (Malizia et al., 2009b). 
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CMV and parvovirus B19 infections induce microvascular injury (Magro et al., 2003), 
which is also a recognised feature of IPF and inevitably leads to activation of 
coagulation and fibrin deposition in alveolar spaces. Furthermore, human herpes 
simpex virus I (HSV I) and CMV have been shown to circumvent the host control of 
the coagulation cascade and activate it independently. HSV I and CMV express 
tissue factor and procoagulant phospholipids on their surface imitating the injury 
signal and providing a platform for the assembly of the TF-FVIIa-FXa complex 
leading to the generation of thrombin. These viruses also encode and express 
glycoprotein C which accelerates FVIIa-dependent activation of FXa, effectively 
improving the efficiency of the coagulation cascade (Sutherland et al., 1997). This 
viral behaviour is most likely an immune evasion strategy as it results in the virus 
being coated in host-derived proteins and hence hidden from the immune 
surveillance. However, thrombin has also been shown to enhance HSV I and CMV 
cell invasion in human umbilical vein endothelial cells (HUVEC) and human foreskin 
fibroblasts (HFF) (Sutherland et al. 2007). Herpesviruses can therefore directly 
contribute to excessive activation of coagulation implicated in the pathogenesis of 
pulmonary fibrosis, which will be the focus of the next section.  
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1.5  Coagulation in lung injury and fibrosis  
The coagulation cascade is a host defence mechanism that plays a key role in 
restoration of homeostasis following an injury. The coagulation cascade is activated 
in response to loss of tissue integrity resulting from injury or infection. It leads to 
blood clot formation that acts as an impenetrable protective barrier preventing 
further blood loss and reducing the risk of infection. Historically two coagulation 
pathways have been described: extrinsic, initiated in the event of tissue damage 
and intrinsic, also known as contact activation pathway. It is increasingly recognised 
that the two pathways are intertwined and mutually interdependent. The current 
consensus of activation of coagulation identifies three steps: initiation that involves 
exposure of tissue factor to coagulation factors, amplification and clot formation. 
There is a large body of evidence suggesting that activation of the coagulation plays 
a role in acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and 
pulmonary fibrosis. 
1.5.1 Overview of coagulation and anticoagulant pathways 
The extrinsic coagulation pathway is initiated by tissue factor (TF), which is a 
transmembrane glycoprotein constitutively expressed in the extravascular 
compartments in many different tissues and organs. TF is also expressed on 
quiescent endothelial cells but under normal physiological conditions TF is shielded 
from coagulation zymogens in the blood in the process of encryption, which is 
defined as post-translational suppression of the procoagulant activity. The exact 
mechanism of encryption is not fully elucidated and current theories postulate that 
TF requires anionic phospholipids (AP), such as phosphatidylserine (PS) for binding 
factor VIIa (FVIIa) and subsequent activation of factor X to factor Xa (FX to FXa) (Rao 
et al., 2012). Alternative hypothesis states that the coagulant activity of TF is 
regulated by the formation of allosteric cysteine disulphide bonds in the TF 
extracellular domain, which stabilises binding to FVIIa (Ruf, 2012). Bacterial 
lipopolysaccharide (Rivers et al., 1975), C-reactive protein (Cermak et al., 1993), 
PDGF and CCL2 (Ernofsson and Siegbahn, 1996) can all trigger unmasking of TF. 
These factors also alter the dynamic composition of the cell membrane and APs that 
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are normally expressed on the intracellular site of the cell membrane, flip to the 
extracellular part of the membrane.  APs actively participate in the de-encryption 
process of TF and formation of the ternary complex (TF-FVIIa-FXa) through PS 
binding to FX and hence increasing the local concentration of the substrate for TF-
FVIIa catalytic activity. It has also been suggested that PS can bind FVIIa and 
orientate it in the plasma membrane in the most efficient way for TF binding. 
Finally, it is possible that the electrostatic interactions between PS and TF can alter 
the quaternary structure of TF and position it in the cell membrane for the optimal 
alignment for assembly of the ternary complex (reviewed in Rao et al. 2012).      
TF binds to FVIIa, of which small quantities constantly circulate in blood and 
facilitates further activation of factor VII (FVII). Although a fraction of active FVII is 
constitutively present in the circulation, it does not exhibit catalytic activity toward 
FX nor factor IX (FIX) until bound to TF. This extrinsic tenase complex (TF-FVIIa + 
APs) increases the rate of FXa generation 15-million fold (Bom and Bertina, 1990) 
and also activates FIX. The complete and active ternary complex TF-FVIIa-FXa 
proceeds to generate thrombin from prothrombin in a sufficient manner to trigger 
platelet activation, fibrin generation and activate factors V and VIII (FV, FVIII) 
(reviewed in Mann 2003). The small amounts of FIXa generated by the ternary 
complex combine with FVIIIa on the platelet surface forming the intrinsic tenase 
complex, which is 100-fold more efficient in cleaving FX and greatly amplifies the 
rate and amount of generated FXa. Combined with FVa, FXa forms a 
prothrombinase complex that proceeds to generate large amounts of thrombin 
(Figure 1.4). Primary function of thrombin is activation of platelets that involve their 
shape change, aggregation and assembly of a weak haemostatic plug that initiates 
clot formation. Thrombin then converts fibrinogen to fibrin, which forms cross-
linked strands and provide the scaffold for stabilisation and reinforcement of the 
platelet plug, which altogether facilitate formation of a clot. Thrombin also exerts 
multiple cellular effects on many cell types by activating proteinase-activated 
receptors (PARs), in particular PAR-1 (described in detail in section 1.6). Thrombin 
also liberates FVIII bound to von Willebrand factor, which aids the switch from 
extrinsic to intrinsic coagulation cascade (Adams and Bird, 2009). It is generally 
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considered that the extrinsic coagulation is an initiation step in the thrombin 
generation cascade, while intrinsic coagulation activity serves as an amplification 
step to generated large quantities of thrombin.      
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Overview of the coagulation cascade. 
The extrinsic coagulation pathway is initiated by injury to the tissue that leads to 
upregulation of tissue factor (TF) and formation of the TF-FVIIa-FXa ternary 
complex. This complex triggers the conversion of prothrombin to thrombin and the 
subsequent generation of fibrin. The intrinsic coagulation pathway cascade is 
initiated upon assembly of the intrinsic tenase complex (FIXa-FVIIa) that greatly 
propagates FXa and thrombin generation hence amplifying the coagulation signal. 
This cascade is regulated by endogenous anticoagulants: TFPI- tissue factor pathway 
inhibitor, AT- antithrombin, TM- thrombomodulin, APC- activated protein C. Plasmin 
is a key regulator of reabsorption of the fibrin clot. 
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The coagulation cascade is tightly controlled by negative feedback loops and 
endogenous anticoagulants (Figure 1.4). Tissue factor pathway inhibitor (TFPI) is a 
key regulator of the extrinsic coagulation pathway through inhibition of the catalytic 
activity of the ternary complex. TFPI contains Kunitz-domains that first bind FXa and 
proceed to bind TF-FVIIa in a calcium-dependent mechanism forming a quaternary 
complex that prevents thrombin generation. In normal physiological conditions TFPI 
is constitutively produced by endothelial cells and around 80% remains bound to 
the cell surface. However, TFPI can also be induced in extravascular compartments 
in cell populations expressing tissue factor, including the activated alveolar 
epithelium and fibroblasts (Bajaj et al., 2001).   
Thrombomodulin is present on endothelial cells where it binds thrombin and 
switches its activity from activation of the platelets and thrombus formation to 
activation of protein C. The potential of protein C activation is greatly enhanced 
when protein C is bound to the endothelial protein C receptor (EPCR), which is 
believed to spatially orientate protein C for optimal cleavage. Once activated, APC-
EPCR complexes localise to caveolae and exert pleiotropic cytoprotective effects 
that will be described in more detail later in this thesis. The main anticoagulant 
function of APC is also to terminate thrombin generation by proteolytic inactivation 
of the components of the intrinsic coagulation pathway, namely FVa and FVIIa. 
Protein S is a major cofactor in this process by actively competing with FXa for 
binding to FVa (Figure 1.4) (Griffin et al., 2012). 
Antithrombin is a circulating glycoprotein produced in the liver that inhibits a broad 
spectrum of coagulation factors including thrombin, FVIIa, FIXa, FXa, FXIa. The 
antithrombin inhibitory action is greatly potentiated by heparin or endogenous 
equivalent heparan glycosaminoglycans present on the cell surfaces. These 
molecules are essential for the efficient formation of antithrombin-thrombin 
complexes (Kubier and O’Brien, 2012). 
The end result of the coagulation cascade is the formation of a fibrin clot that is 
subsequently reabsorbed in the tissue remodelling processes. Plasmin is the main 
executor of fibrinolysis and is generated from plasminogen by two types of 
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plasminogen activators (PA): tissue-type in the vasculature (tPA) and urokinase-type 
in the tissue (uPA). As well as dissolving the fibrin network, plasmin activates matrix 
metalloproteinases (MMPs) that are important in the remodelling of the 
extracellular matrix. The generation of plasmin is regulated by plasminogen 
activator inhibitors (PAI-1 and PAI-2), which irreversibly bind PA with high affinity. 
PAI expression is regulated by many growth factors including TGFβ, PDGF, 
inflammatory cytokines and endotoxins (Van De Craen et al., 2012). 
1.5.2 Coagulation in lung injury and fibrosis  
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) result 
from injury to the pulmonary epithelium and are characterised by diffuse alveolar 
damage (DAD), vascular leak and inflammation. TF is upregulated on the alveolar 
epithelium in the injured lung and co-localise with FVII and FX, strongly suggesting 
that extrinsic coagulation cascade is activated locally within the injured airspaces 
(Bastarache et al., 2007; Scotton et al., 2009). Furthermore, increased levels of TF 
are readily detected in the BALF from patients with ALI and ARDS (Idell, 2003a), 
both in a soluble form as well as associated with highly procoagulant microparticles 
(Bastarache et al., 2009). The current consensus states that locally activated 
extrinsic coagulation is then able to generate thrombin and subsequently form 
fibrin deposits from substrate coagulation zymogens present in the oedema fluid. 
Intraalveolar and interstitial fibrin deposition is a hallmark of ALI and manifests as 
hyaline membranes in alveolar spaces (reviewed in Chambers 2008; Idell 2003). 
Extensive fibrin deposition in the alveolar spaces leads to the collapse of alveoli 
(atelectasis) through inhibition of surfactant function (Seeger et al. 1993) and 
traction of remaining airspaces (honeycombing). Moreover, fibrin can act as a 
provisional matrix and a reservoir of growth factors and cytokines for the 
subsequent recruitment of inflammatory and mesenchymal cells. Inflammatory 
cytokines, namely IFNγ and TNFα, are released in abundance in ALI and have also 
been shown to upregulate the expression of TF by the alveolar epithelium 
(Bastarache et al., 2011) and hence perpetuate further the local activation of 
coagulation. ALI is also characterised by inadequate activation of intrinsic 
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anticoagulant and fibrinolysis pathways. Low levels of protein C and increased PAI 
levels in the serum of ALI patients are key features of the ALI biomarker profile and 
are predictive of poor clinical outcome (McClintock et al., 2008; Ware et al., 2007). 
Similarly in pulmonary fibrosis there is strong evidence that the extrinsic 
coagulation pathway is activated in the intraalveolar compartment and may play a 
role in the disease pathogenesis. Tissue factor is upregulated on AEC II and alveolar 
macrophages in the vicinity of fibrin deposits in IPF lung and overlying fibrotic foci 
suggesting that extravascular coagulation plays a role in the pathology of IPF 
(Imokawa et al., 1997). 
As already mentioned low levels of protein C are predictive of a poor outcome in ALI 
patients (McClintock et al., 2008; Ware et al., 2007). APC levels are also reduced in 
the lungs of patients with IPF and sarcoidosis as well as in collagen vascular disease-
associated interstitial lung disease (Kobayashi et al. 1998). Deficient anticoagulant 
mechanisms also have been shown to correlate with abnormal collagen turnover in 
the intraalveolar space of patients with fibroproliferative lung diseases (Yasui et al., 
2000).  
Thrombin levels are increased in BALF fluid from patients with pulmonary fibrosis 
associated with systemic sclerosis (Hernández-Rodríguez et al., 1995) and chronic 
lung disease of prematurity (Dik et al., 2003). The importance of fibrin accumulation 
in the alveoli was investigated in animal models of pulmonary fibrosis with the use 
of transgenic mice over-expressing or deficient in plasminogen activator inhibitor-1 
(PAI-1). PAI-1 is a negative regulator of the fibrinolytic pathway and inhibits 
plasminogen to plasmin conversion and hence prevents fibrin clearance. Mice over-
expressing PAI-1 develop more severe fibrosis following bleomycin injury while PAI-
1 knockout mice are protected (Eitzman et al., 1996). Interestingly, fibrinogen 
knockout mice are not protected from experimentally-induced pulmonary fibrosis, 
indicating that fibrin is most likely a symptomatic rather than a causative factor in 
the development of fibrosis in this animal model (Hattori et al., 2000). 
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1.5.3 Targeting coagulation in lung injury and fibrosis 
Evidence from human and animal studies of lung injury and fibrosis suggest that the 
coagulation cascade is highly activated in these conditions whereas fibrinolytic 
pathways appear to be deficient. Several coagulation targeting approaches have 
been utilised over the years showing that inhibition of coagulation at different 
levels affects the progression of lung injury and fibrosis (Tables 1.3 and 1.4). In ALI 
models, concomitant administration of endotoxin and hirudin led to reduced lung 
inflammation (Bao et al., 2012). Administration of tissue factor neutralizing 
antibodies in the model of endotoxin-induced sepsis and indirect ALI attenuated 
inflammatory cell influx and oedema, reduced secretion of inflammatory cytokines 
IL-6 and IL-8 both systemically and in the alveolar compartment and prevented a 
decline in lung function and compliance (Welty-Wolf et al., 2006). In contrast, low 
tissue factor-expressing mice displayed increased inflammatory responses and 
alveolar haemorrhage in the model of direct ALI (Bastarache et al., 2012), pointing 
to a more complex role for the coagulation factors in lung injury.   
In the bleomycin model of lung injury and fibrosis the coagulation cascade has been 
shown to be activated in the alveolar compartment with increased levels of 
thrombin detected from day three through to 21 after bleomycin administration 
(Yasui et al., 2001). This increase in coagulation proteinases levels can be reversed 
by administration of APC into the lung, which also reduces fibrotic alterations to the 
lung architecture (Yasui et al., 2001). Similarly, targeting tissue factor in the 
bleomycin model of pulmonary fibrosis by local overexpression of TFPI attenuates 
fibrosis (Kijiyama et al., 2006). Furthermore, administration of nebulised heparin 
and plasminogen activator (PA) has also had beneficial effects in pulmonary fibrosis 
in rabbits. The anticoagulant therapies attenuated the decline in lung compliance 
and respiratory physiology as reflected on molecular level by reduced collagen 
deposition in the lung (Günther et al., 2003).   
As previously mentioned, FXa is upregulated locally in the lungs of IPF patients and 
in the experimental model of pulmonary fibrosis. Inhibition of FXa in the early phase 
of bleomycin model of pulmonary fibrosis attenuates lung collagen deposition 
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(Scotton et al., 2009). Direct thrombin inhibition has also been shown to reduce 
ECM proteins synthesis and deposition by fibroblasts and attenuate bleomycin-
induced lung injury and fibrosis (Bogatkevich et al., 2011; Howell et al., 2001). 
Prophylactic (day 1) and therapeutic (day 8) thrombin inhibition reduced 
inflammation at day 14 post bleomycin instillation and reduced collagen deposition 
in the lung at day 21 post injury (Bogatkevich et al., 2011). 
Systemic administration of APC also reduces the local activation of coagulation in 
the endotoxin-driven lung injury in humans. Following instillation of endotoxin into 
healthy volunteers, increased levels of thrombin and tissue factor are detected in 
the BALF and this effect is attenuated by APC (Poll et al., 2005). Furthermore, the 
fibrinolytic balance of the lung is disturbed with reduced levels of plasminogen 
activator PA and increased levels of plasminogen activator inhibitor, PAI-1. APC 
treatment restored this balance by blocking PAI-1 levels without affecting the PA 
levels (Poll et al., 2005).  
The accumulated evidence that the coagulation cascade is activated in human lung 
disease and anticoagulant therapies reduce inflammation and fibrosis in the 
experimental models of lung injury and fibrosis provided a scientific rationale for 
two clinical trials that tested the effect of warfarin in IPF patients. A small, non-
blinded, randomised study of IPF patients receiving standard prednisolone therapy 
supplemented with warfarin or heparin showed that anticoagulants extended the 
hospitalisation-free time and 3-year survival of IPF patients and significantly 
reduced the mortality from acute exacerbations (Kubo et al., 2005). Contrary to 
these results, a double-blinded, randomised, placebo-control clinical trial of 
warfarin in IPF was terminated early due to high mortality rate in the warfarin-
treated patients (Noth et al., 2012). Almost 20% of patients given warfarin have 
died from respiratory-related causes and there was an overall trend pointing to 
anticoagulation having a detrimental effect on the progression of the disease (Noth 
et al., 2012).  
Warfarin is a broad spectrum anticoagulant that inhibits vitamin K epoxide 
reductase, an enzyme that is responsible for recycling vitamin K from epoxide form. 
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Vitamin K is necessary for post-translational carboxylation of glutamate residues in 
key coagulation factors: thrombin, factors VII, IX and X. This process allows for the 
conformational change of these coagulation factors in the presence of calcium ions 
and interaction with anionic phospholipids, which is crucial for their bioactivity. 
Furthermore, key endogenous anticoagulants protein C and protein S are also 
vitamin K-dependent and their activity is inhibited by warfarin (Hirsh et al., 1995a). 
The imbalance between activation of coagulation and anticoagulant mechanisms is 
documented in pulmonary fibrosis and there is evidence suggesting that local 
activation of coagulation may have different effects from systemic activation of 
coagulation. The potential explanation for the rapid deterioration of IPF patients 
treated with warfarin may be that warfarin broad inhibition mechanism is further 
aggravating the already dysregulated homeostasis in IPF. Furthermore, warfarin did 
not prevent acute exacerbations in the first study but upon hospitalisation patients 
were given low-molecular-weight heparins, which then accounted for better 
recovery when compared to the control group (Kubo et al., 2005). Heparins are 
glycosaminoglycans that bind to antithrombin III and greatly increase the rate of 
thrombin and FXa inactivation (Hirsh et al., 1995b). Therefore, it is possible that 
warfarin is a “double-edged sword” and any benefit from blocking coagulation 
proteinases is offset by the inhibition of endogenous anticoagulants. It is also 
plausible that the contradictory results of the two studies stem from ethnic 
differences in the patient cohorts. The first study was performed in Asian IPF 
patients and the second clinical trial recruited patients of Caucasian and Afro-
American origin. There are distinct differences in the disease progression and 
incidence of acute exacerbation between the two populations, most relevantly due 
to lower prevalence for cardiovascular disease and thromboembolism in Asian 
populations (reviewed in Song et al. 2011).   
Furthermore, by inhibiting the coagulation factors, warfarin is also blocking a 
plethora of cellular effects that these factors exert via proteinase activated 
receptors PARs, as described in detail in the next section.    
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Table 1.3 Anticoagulant therapies in lung injury and fibrosis- clinical studies 
 
 
 
 
 
 
 
 
 
 
Target/ 
Anticoagulant 
Model and outcome Reference 
Human studies 
APC 
administration 
Reduced activation of intraalveolar 
coagulation and restoration of fibrinolytic 
balance in endotoxin-induced lung injury  
(Poll et al., 2005) 
Warfarin/ 
Heparin 
administration 
Increased 3-year survival in IPF patients 
Hospitalised patients in the anticoagulant arm 
were administered low-molecular-weight 
heparin strongly associated with improved 
recovery and reduced mortality 
(Kubo et al., 2005) 
Warfarin 
administration 
Increased mortality in IPF patients due to 
respiratory complications  
(Noth et al., 2012) 
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Target/ 
Anticoagulant 
Model and outcome Study 
Animal studies 
Thrombin 
inhibition 
Reduced inflammation and fibrosis in 
bleomycin-induced lung injury and fibrosis 
(Bogatkevich et 
al., 2011; Howell 
et al., 2001) 
Tissue factor 
inhibition 
Attenuation of lung function abnormalities, 
reduced inflammation and oedema in LPS-
induced sepsis-associated ARDS  
(Welty-Wolf et 
al., 2006) 
Exacerbated inflammation and alveolar 
haemorrhage in ALI in TF-deficient mice 
(Bastarache et 
al., 2012) 
TFPI 
overexpression 
Attenuation of bleomycin-induced lung injury 
and fibrosis following intratracheal TFPI gene 
transfer 
(Kijiyama et al., 
2006) 
APC 
administration 
Reduced extent of bleomycin-induced 
activation of coagulation and fibrosis  
(Yasui et al., 
2001) 
Heparin 
administration 
Attenuation of bleomycin-induced lung injury 
and fibrosis 
(Günther et al., 
2003) 
Plasminogen 
activator 
administration 
Attenuation of bleomycin-induced lung injury 
and fibrosis 
(Günther et al., 
2003) 
FXa inhibition Attenuation of collagen deposition in the 
bleomycin model 
(Scotton et al., 
2009) 
Table 1.4 Anticoagulant therapies in experimental lung injury and fibrosis 
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1.6 Proteinase activated receptors in lung injury and fibrosis  
Proteinase-activated receptors (PARs) are G-protein coupled receptors (GPCRs) 
activated via proteolytic cleavage of the external N-terminus (Coughlin, 2001). 
There are four members of the PAR family (Table 1.5), with PAR-1 and PAR-2 being 
most ubiquitously expressed. The main activators of PAR receptors are the 
proteinases of the extrinsic coagulation pathway. PAR-1 is the major high affinity 
thrombin receptor implicated in homeostasis and pathological processes and will be 
the main focus of this section. 
 PAR-1 PAR-2 PAR-3 PAR-4 
Activating 
proteases 
Thrombin 
APC-EPCR 
TF-FVIIa-FXa 
Trypsin 
Plasmin 
Cathepsin G  
MMP-1 
Granzyme A 
Bacterial 
gingipains  
Trypsin 
Tryptase  
TF-FVIIa-FXa 
Der p1  
Bacterial 
gingipains 
 
Thrombin 
Trypsin  
Thrombin 
Trypsin  
TF-FVIIa-FXa 
Cathepsin G 
Bacterial 
gingipains 
Tethered ligand  SFLLRN (h) 
SFFLR (m,r) 
SLIGKV (h) 
SLIGRL (m,r) 
TFGRAP (h) 
SFNGGP (m) 
GYPGQV (h) 
GYPGKV (m) 
Inhibitory 
proteases 
Cathepsin G  
Elastase 
Chymase 
Der p1 
Elastase 
Chymase 
Cathepsin G  Unknown 
Chromosomal 
location 
5q13 5q13 5q13 19p12 
Main cleavage 
site  
Arg41-Ser42 Arg36-Ser37 Lys38-Thr39 Arg47-Gly48 
PAR-coupled- G 
proteins  
Gαi/o, Gαq/11, 
Gα12/13 
Gαq/11, Gα12/13 Gαo, Gαq Gαq, Gα12/13 
Expression in 
the lung  
Airways, blood 
vessels, lung 
parenchyma  
Airways, blood 
vessels, 
bronchial 
glands, lung 
parenchyma  
Airways Airways, blood 
vessels, 
cardiovascular 
system 
Table 1.5 Characterisation of PARs  
Updated from (Chambers 2008; Ramachandran and Hollenberg 2008; Steinhoff et 
al. 2005)  
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1.6.1 PAR-1 biological function 
PAR-1 is ubiquitously expressed on a variety of cell types including human platelets, 
endothelial cells, epithelial cells, fibroblasts, monocytes, macrophages, 
lymphocytes, smooth muscle cells, skeletal muscle cells, mast cells, natural killer 
cells, neurons and glial cells and certain tumour cell lines (Steinhoff et al., 2005). 
PAR-1 influences a wide range of cellular responses including proliferation, 
differentiation, cytoskeletal rearrangements, apoptosis, migration and extracellular 
matrix production. In the lung, PAR-1 has been shown to be expressed by 
fibroblasts (Sokolova et al., 2005), endothelial cells (Ellis et al. 1999) and receptor 
expression is significantly upregulated in the lungs of IPF patients (Howell et al., 
2001; Mercer et al., 2009).  
Thrombin-mediated PAR-1 activation leads to activation and aggregation of 
platelets. In human platelets the initial burst of activity in response to thrombin is 
accounted for by PAR-1 receptor activation and signalling. PAR-4 is also expressed 
by human platelets and becomes activated when high concentrations of thrombin 
are present and is responsible for prolonged responses. Mouse platelets do not 
express PAR-1 but instead PAR-3 acts as a cofactor for PAR-4 activation by 
concentrating thrombin to the cell surface until a threshold concentration for PAR-4 
activation is reached (Nakanishi-Matsui et al., 2000). PAR-3 and PAR-4 can form 
heterodimers reinforcing this mechanism (McLaughlin et al. 2007). Thrombin-PAR-1 
signalling in platelets also leads to release of thromboxane A2, PDGF and TGFβ.  
During acute lung injury, PAR-1 activation on endothelial cells leads to disruption of 
the endothelial-alveolar barrier and increased vascular permeability. High 
concentrations of thrombin act via PAR-1 and induce endothelial cell shape change 
and loss of tight junctions (Rabiet et al., 1996). PAR-1 signalling in endothelial cells 
also promotes tissue factor expression and the upregulation of adhesion molecule 
expression, such as intracellular adhesion molecules (ICAM), E-selectin and P-
selectin. These molecules facilitate platelet aggregation and leukocyte adhesion as 
well as extravasation of inflammatory cells and coagulation factors to the site of 
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injury. This is the major mechanism that leads to extravascular leak and deposition 
of fibrin in alveolar spaces (Idell 2003) .  
The role of inflammation in IPF is currently a highly debated subject, however PAR-1 
activation exerts potent pro-inflammatory effects including promoting the 
production of cytokines: IL-1β, TNF-α, IL-8, IL-6 (reviewed in Chambers 2008). 
Thrombin-mediated PAR-1 signalling also leads to CCL2 release from macrophages, 
fibroblasts, endothelial cells, alveolar and bronchial epithelium (Baran et al., 2007; 
Deng et al., 2008; Goebeler et al., 2001; Mercer et al., 2009). CCL2 is a potent 
chemoattractant for inflammatory cells and fibrocytes (Moore et al. 2005) and is 
strongly implicated in the pathogenesis of pulmonary fibrosis. Furthermore, CCL2 
induces the expression of TGFβ and suppresses the production of anti-fibrotic 
mediators, such as PGE2 by lung fibroblasts (Moore et al. 2003).  
Thrombin signalling via PAR-1 exerts potent mitogenic effects on lung fibroblasts 
(Trejo et al. 1996) and stimulates extracellular matrix production (Chambers et al. 
1998). Thrombin levels are increased in BALF from patients with pulmonary fibrosis 
associated with systemic sclerosis. Subsequent application of this BALF to in vitro 
cultured fibroblasts leads to increased proliferation that can be inhibited by the 
thrombin inhibitor hirudin (Hernández-Rodríguez et al., 1995). PAR-1 signalling in 
fibroblasts also leads to the release of profibrotic growth factors, including CTGF 
(Chambers et al. 2000) and PDGF (Blanc-Brude et al. 2005), which further promote 
fibroblast proliferation.  
PAR-1 signalling can also lead to integrin-mediated activation of latent TGFβ either 
via αvβ6 on epithelial cells (Jenkins et al. 2006) or αvβ5 on fibroblasts (Scotton et al. 
2009) and hence contribute to the fibroblast to myofibroblast differentiation in a 
paracrine fashion. Mice lacking the β6 subunit are protected in the bleomycin-
induced lung injury and fibrosis as well as lipopolysaccharide (LPS)-induced and 
ventilator-associated lung injury (Jenkins et al., 2006). Furthermore, thrombin-
induced PAR-1 activation on fibroblasts also promotes α-SMA induction and 
differentiation to myofibroblasts (Bogatkevich et al., 2001). Finally, FXa signalling via 
PAR-1 also stimulates lung fibroblast procollagen production, proliferation, and 
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drives differentiation to myofibroblasts (Blanc-Brude et al., 2005; Scotton et al., 
2009). 
PAR-1 signalling also contributes to innate immunity in viral infection. PAR-1 
activation, either with thrombin or specific agonist peptide, enhanced infection of 
endothelial cells and fibroblasts with herpes simplex I virus (Sutherland et al., 2007). 
Furthermore, human cytomegalovirus (CMV) increased expression of PAR-1 and 
PAR-3 at mRNA and protein levels in endothelial cells increasing their 
responsiveness to stimulation with thrombin (Popović et al., 2010).  
PAR-1 knockout mice infected with cardiotropic coxsackievirus have been shown to 
have increased viral load in the heart and reduced level of interferon β (IFNβ) in the 
early phase of infection. This lack of early immunity was later over-compensated by 
increased recruitment of inflammatory cells into the heart and higher levels of IL-
1β, TNFα, IL-6, which eventually resulted in extensive damage to the heart muscle 
(Antoniak et al., 2013). In contrast, mice over-expressing PAR-1 in cardiomyocytes 
had reduced viral infection-induced myocarditis (Antoniak et al., 2013). 
Furthermore, PAR-1 knockout mice had increased viral load in the lung following 
influenza A infection (Antoniak et al., 2013). PAR-1 and PAR-2 have also been shown 
to become upregulated in the airways following influenza infection and promote 
production of bronchodilatory prostanoids (Lan et al., 2004). Another study has 
demonstrated that activation of PAR-1 contributes to deleterious lung inflammation 
and decreased survival in influenza A infection in mice (Khoufache et al., 2013). 
PAR-1 agonist peptide has exacerbated the infection and increased mortality, while 
PAR-1 antagonist offered protection (Khoufache et al., 2013). These finding strongly 
suggest that PAR-1 plays a role in orchestrating responses to viral infection but 
further research is necessary to thoroughly dissect the mechanisms.    
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1.6.2 PAR-1 mechanisms of activation 
PARs are seven-transmembrane-domain receptors, activated via irreversible 
proteolytic cleavage of the extracellular N-terminus that leads to the unmasking of a 
tethered ligand. The tethered ligand binds to the second extracellular loop (ECL2) of 
the receptor and this interaction induces a conformational change in the 
intracellular domains of the receptor allowing activation of the heterotrimeric G-
proteins and downstream signalling (Figure 1.5). Interestingly, the amino acid 
sequence of the tethered ligand is a molecular signature of each PAR and has 
allowed the development of specific synthetic activating peptides. Their mechanism 
of action involves direct binding to ECL2 of appropriate PARs independently of 
proteolytic cleavage and they have proven invaluable tools for investigating 
biological functions of this group of receptors.   
The N-terminus of PAR-1 contains an acidic hirudin-like sequence in the vicinity of 
the LDPR2S cleavage site that thrombin binds to with high affinity before cleaving 
the receptor. The newly formed tethered ligand contains a six-amino acid sequence 
SFLLRN that interacts with ECL2 and elicits downstream G-protein activation and 
signalling (Figure 1.6). The PAR-1 tethered ligand can also bind to ECL2 of PAR-2 and 
activate PAR-2 signalling pathways by unidirectional transactivation mechanism 
(O’Brien et al., 2001).  
The remaining product of the PAR-1 N-terminal cleavage is a 41-amino-acid peptide 
termed parstatin. It is released into the extracellular milieu and may exert some 
biological activity. A study showed that parstatin inhibits VEGF and FGF-induced 
angiogenesis in vitro and in vivo (Zania et al., 2009) but the exact mechanism of 
action remains unclear. 
Thrombin displays high affinity towards PAR-1 and cleaves the receptor with 
significantly higher efficiency in comparison to other activating proteinases (Table 
1.5). In order to increase the potency of binding, other activating proteinases utilise 
cofactor molecules for efficacious PAR-1 cleavage. Factor Xa (FXa) cleaves PAR-1 
five times more efficiently when bound within the ternary complex TF-FVIIa-FXa 
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(Riewald et al. 2001). Activated protein C (APC) binds to the endothelial protein C 
receptor (EPCR) and cleaves a subpopulation of PAR-1 localised to lipid rafts (Russo 
et al. 2009). The affinity of APC for PAR-1 is 500 times less than that of thrombin 
and APC fails to efficiently cleave PAR-1 if EPCR is blocked (Schuepbach et al., 2008). 
Furthermore, APC-EPCR cleaved PAR-1 can be retained on the cell surface 
suggestive of a possible desensitization mechanism and is highly protective of 
endothelial barrier integrity (Schuepbach et al., 2008). The APC-mediated 
protection of vascular integrity is PAR-1-dependent as confirmed in in vivo studies 
of endotoxin-induced acute lung injury, where PAR-1 knockout mice were not 
protected from vascular leak upon administration of exogenous APC (Schuepbach et 
al., 2009). 
Deactivating proteinases have been described for PAR-1, PAR-2 and PAR-3 (Table 
1.5). Their mechanism of action involves the cleavage of the receptors between N-
terminus and tethered ligand and the loss of the latter yield the receptor insensitive 
to thrombin and other activating proteinases.  
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Figure 1.5 Mechanism of PAR-1 activation  
PAR-1 is a seven-transmembrane-domain receptor. The extracellular N-terminus of 
PAR-1 contains thrombin binding site composed of a hirudin-like amino acid 
sequence that has high affinity for thrombin and hence facilitates its binding and 
cleavage of the receptor at the indicated cleavage site. Following proteolytic 
cleavage, the newly generated tethered ligand binds to the second extracellular 
loop of the receptor. This induces a conformational change in the receptor that is 
then able to interact with heterotrimeric G-proteins and elicit downstream cell 
signalling. 
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1.6.3 PAR-1 signalling via G-proteins 
G-proteins are heterotrimeric guanine nucleotide-binding proteins that consist of α, 
β and γ subunits. There are four main classes of Gα-proteins: Gαi/o, Gαs, Gαq/11, 
Gα12/13 but only Gαi/o, Gαq/11, and Gα12/13 form stable complexes with intracellular 
parts of PAR-1 receptor (McCoy et al., 2012). Upon PAR-1 activation the associated 
G-protein complex is phosphorylated and the Gα protein acts as a guanine 
exchange factor (GEF) that drives the GDP to GTP exchange. This leads to 
dissociation of Gβγ subunits and initiates downstream cell signalling. The coupling 
to specific G-protein dictates the nature of cellular response and the signalling is 
cell- and tissue-specific but the focus of this report will be PAR-1 signalling in the 
lung and potential impact on lung injury and pulmonary fibrosis. 
PAR-1 preferentially couples to Gαq/11 and Gαi/o, and with less efficiency to Gα12/13. 
Gαq/11 interacts with the second intracellular loop (ICL2) (Verrall et al., 1997) and 
alanine scanning mutagenesis has revealed that one crucial amino acid (arginine 
R205A) in PAR-1 ICL2 sequence is essential for Gαq/11 uncoupling and signalling 
(McCoy et al., 2012). However, other sites on the PAR-1 intracellular interface have 
also been shown to interact with G-proteins including the cytoplasmic tail (Swift et 
al., 2006) and first and third intracellular loops (ICL1 and ICL3) (Cisowski et al., 
2011). These coupling sites were identified using pepducins, which are agonist or 
antagonist peptides specific to a GPCR. Pepducins have hydrophobic lipid moieties 
that allow them to anchor in the lipid membrane bilayer, be transported into cells 
and interact with the cognate receptor modulating the interaction with G-proteins 
(Covic et al., 2002). Pepducins targeting PAR-1 ICL1 and ICL3 had different effects on 
A549 cell behaviour. Both pepducins blocked cell motility but while ICL1 only 
partially suppressed calcium signalling, ICL3 completely blocked calcium signalling 
and ERK1/2 activation (Cisowski et al., 2011). These data strongly suggests that both 
ICL1 and ICL3 can couple to Gαi/o, which downstream effects influence cell shape 
and migratory potential. In addition ICL3 is also capable of interacting with Gαq/11. In 
conclusion, G-proteins utilise multiple intracellular sites for coupling to PAR-1 and 
the concomitant activation of different G-proteins can lead to the simultaneous 
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induction of various signalling pathways that can converge to produce a 
physiological effect (Figure 1.6).                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 PAR-1 mediated G-protein signalling pathways  
Gα12/13 pathway couples to Rho guanine-nucleotide exchange factors GEFs, resulting 
in activation of Rho, Rho kinase ROCK, and myosin light chain (MLC) kinase; Gαq 
activates phospholipase C-β (PLC-β) to generate inositol triphosphate (IP3) and 
diacylglycerol (DAG), which in turn mobilises intracellular Ca2+ and activates protein 
kinase C (PKC); the Gαi pathway inhibits adenylyl cyclase; Gβγ subunits activate 
phosphoinositide 3-kinase (PI3K), PLCβ, G protein-coupled receptor kinases (GRK), 
K+ channels; (updated from (Coughlin, 2001; McLaughlin et al., 2005). 
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PAR-1- Gαi/o signalling  
Pertussis toxin-sensitive Gαi/o uncoupling following PAR-1 activation leads to the 
inhibition of adenylyl cyclase and reduced generation of cyclic adenosine 
monophosphate (cAMP) (Hung et al., 1992). This in turn leads to intracellular 
calcium ion mobilisation and cell shape change, which is an important mechanism in 
thrombin-induced platelet activation and aggregation at sites of injury (McLaughlin 
et al. 2005). In endothelial cells, PAR-1-Gαi/o coupling leads to an increase in 
expression of thrombospondin-1 and thrombin-mediated vascular permeability 
(Riewald and Ruf 2005). 
PAR-1-Gαi/o also activates the Src tyrosine kinase pathway that stimulates Ras, Raf 
and the mitogen-activated protein kinases (MAPK). This pathway is important for 
thrombin- and FXa-induced fibroblast proliferation and transformation (Blanc-Brude 
et al., 2005; Della Rocca et al., 1999). Inhibition studies have also shown that 
blocking Gαi/o abrogates thrombin mitogenic effects on lung fibroblasts (Baffy et al., 
1994; LaMorte et al., 1993).  
PAR-1- Gαq/11 signalling 
Gαq/11 signals via activation of β-isoforms of phospholipase C (PLC-β) (Babich et al. 
1990), which triggers phosphoinositide (PIP2) hydrolysis to generate inositol 
triphosphate (IP3) and diacylglycerol (DAG). IP3 regulates the mobilisation of 
intracellular calcium and activation of protein kinase C (PKC) (Berridge, 1993). 
Calcium ions and PKC act as second messengers and activate cascades of kinases 
and phosphatases, such as Ras GEFs and MAPK, respectively.   
PAR-1- Gαq signalling also plays a role in fibroblast proliferation and differentiation. 
Blocking Gαq leads to a dramatic reduction in fibroblast DNA synthesis and inhibits 
calcium mobilisation following stimulation with thrombin (Baffy et al., 1994; 
LaMorte et al., 1993). It is also responsible for NFκB activation and ICAM-1 
upregulation in endothelial cells following activation by thrombin (Rahman et al., 
1999). 
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PAR-1 knockout mice have greatly reduced levels of CCL2 in the lung following 
bleomycin injury, which may contribute to the attenuation of fibrosis in this model 
(Howell et al. 2005). Further research in our laboratory has shown that thrombin 
induces CCL2 synthesis and release by murine fibroblasts via PAR-1-Gαq signalling 
(Deng et al., 2008). CCL2 gene transcription is upregulated as a result of thrombin-
PAR-1-Gαq signalling via Ca
2+-independent pathway leading to PKC, c-Raf and 
ERK1/2 phosphorylation. CCL2 production and release is then mediated by Ca2+-
dependent PKC activation in response to a rise in intracellular Ca2+ concentration 
and subsequent Rho kinase activation. These results were confirmed using a 
selective PAR-1-Gαq signalling inhibitor, Q94, which blocked thrombin-mediated 
CCL2 upregulation both at the mRNA and protein levels (Deng et al., 2008).  
PAR-1- Gα12/13 signalling 
 Gα12/13 downstream signalling leads to selective interactions with the small Rho 
GTPase- RAS superfamily that control the organisation of the actin cytoskeleton 
(Wennerberg et al. 2005). Thrombin-mediated activation of PAR-1-Gα12/13 signalling 
induces calcium-independent platelet shape change and aggregation (Moers et al., 
2003) and cytoskeletal re-organisation in endothelial cells.  
Of particular importance to the pathogenesis of IPF, the thrombin- PAR-1- Gα12/13 
signalling axis plays a key role in TGFβ activation via αvβ6 integrins in epithelial cells 
(Jenkins et al. 2006) and αvβ5 integrins in fibroblasts (Scotton et al. 2009).  
1.6.4 Signal termination, internalization and re-sensitization   
Unlike other GPCRs, which are reversibly activated by small hydrophilic agonists, 
PAR-1 ligand is tethered to the receptor and unmasked by a permanent proteolytic 
cleavage. The post-translational modifications, phosphorylation and internalization 
are crucial for spatial and temporal control of PAR-1 signalling.   
The phosphorylation of the PARs occurs rapidly after activation and effectively 
disrupts the receptor-G-protein interaction. Agonist-dependent internalisation of 
PAR-1 is critical for termination of signalling and involves phosphorylation of specific 
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C-terminal residues by G protein receptor kinases (GRKs) which require β-arrestins 
as cofactors (Yan et al. 1998). The receptors are then internalized in a clathrin-
dependent mechanism and targeted for lysosomal degradation (Hoxie et al., 1993). 
Unlike other GPCRs, PARs are used only once and not recycled (Trejo et al. 1998), 
though a small fraction is transported back to the cell surface in a cleaved, inactive 
form (Hammes and Coughlin, 1999). PAR-1 also exhibits constitutive turnover at the 
cell surface that occurs at a slower rate and plays a role in maintaining cell 
sensitivity to activating proteinases. Agonist-induced and constitutive 
internalization of PAR-1 is regulated differently with constitutive internalization 
requiring clathrin adaptor protein complex-2 (AP2), whereas agonist-induced 
internalization of PAR-1 is controlled by AP-2 and ubiquitination (Wolfe et al. 2007). 
Ubiquitination acts ultimately as a lysosomal sorting and degradation signal in 
mammalian GPCRs following covalent attachment of ubiquitin molecules to 
proteins by ligases. Agonist-induced ubiquitination of β2AR adrenergic receptor and 
CXCR4 chemokine receptor is critical for lysosomal degradation but is not required 
for internalization (reviewed in Wolfe et al. 2007). However, ubiquitination of PAR-1 
seems to retain the receptor on the cell surface while deubiquitination targets the 
receptor for lysosomal degradation (Wolfe et al. 2007). The main site for 
ubiquitination in PAR-1 is the C-terminal tyrosine-based motif, which also appears 
to be a site for AP2 binding that is required for constitutive internalization. 
Maintaining this site ubiquitinated provides a mechanism to retain the majority of 
the receptors at the cell surface where they are readily available for proteolytic 
activation by extracellular proteinases (Wolfe et al. 2007).  
N-linked glycosylation is another post-translational modification shown to regulate 
PAR-1 activation and trafficking to the cell surface. N-linked glycosylation is critical 
for correct protein folding and transport to the cell surface of many membrane-
spanning receptors. The main site of PAR-1 N-linked glycosylation is at ECL2 and the 
N-terminus. The ECL2 site is essential for proper regulation of ligand-induced 
receptor activation and endocytosis whereas N-linked glycosylation at the N-
terminus is responsible for PAR-1 trafficking to the cell surface (Soto and Trejo 
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2010). ECL2 N-linked glycosylation deficient PAR-1 showed increased signalling in 
response to thrombin or synthetic activating peptides and impaired trafficking in 
comparison to a wild-type receptor. This is an important observation since 
molecular pathologies of many conditions involve altered post-translational 
modifications of key receptors (Soto and Trejo 2010). The expression of PAR-1 is 
upregulated in many types of invasive cancers and defective receptor trafficking 
and persistent signalling may contribute to disease progression (Arora et al. 2008).  
The mechanisms to maintain PAR-1 surface expression are cell-specific and include 
trafficking of the receptor from pre-formed intracellular pools or de novo receptor 
synthesis. Epithelial cells engage in de novo receptor synthesis following activation 
by thrombin while platelets do not become re-sensitized as once activated these 
cells are not reused. Endothelial cells and fibroblasts have abundant intracellular 
pools of PAR-1 and can become rapidly re-sensitized by mobilising these 
intracellular receptor stores and only engage in de novo receptor synthesis after 
prolonged exposure to activating proteinases (Paing et al. 2006; Blanc-Brude et al. 
2005; Ellis et al. 1999).    
1.6.5 PAR-1 gene expression and regulation 
PAR-1 gene expression is differently regulated in homeostasis and disease, and 
displays cell- and tissue-specific variations. PAR-1 plays a role in early organogenesis 
and high levels of PAR-1 mRNA are detected in the murine mesenchymal cell 
populations at early stages of development (Soifer et al., 1994). Later in life, PAR-1 
expression and regulation is tissue-specific. PAR-1 expression is upregulated in 
many pathological conditions including in breast (Boire et al., 2005), colonic 
(Darmoul et al., 2003) and prostatic (Chay et al. 2002) cancers and fibrotic 
conditions including pulmonary, liver, kidney and heart fibrosis. 
PAR-1 is encoded by the F2R gene located on chromosome 5q13, between genes 
encoding PAR-2 and PAR-3 (Bahou et al., 1993). The gene has a two-exon structure, 
separated by a large intron. The first exon encodes the 5’ untranslated region (UTR), 
the start codon and the signal peptide. The second exon encodes the mature 
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receptor with the activating proteolytic cleavage site and the 3’UTR. The immediate 
promoter region has two GC-rich cluster boxes where transcription factors bind and 
initiate PAR-1 gene expression.       
The PAR-1 gene regulatory mechanisms are not well described and appear to be 
highly cell-specific (Table 1.6). In human melanoma cells, transcription factor AP-2 
represses PAR-1 gene expression. AP-2 competes with a positive regulator, Sp1, for 
the binding site in the promoter region of F2R gene and the loss of AP-2 and 
predominant binding of Sp1 is linked to the overexpression of PAR-1 and the 
metastatic phenotype of cancer cells (Tellez et al., 2003).  Mutations or loss of 
transcription factor p53 are documented in many cancer types and a positive 
correlation exists between p53 mutation or deficiency, upregulation of the PAR-1 
gene expression and the metastatic phenotype of cancer cells (Salah et al. 2008). In 
malignant prostate cancer cells, PAR-1 mRNA levels are upregulated by the 
transcription factor early growth response-1 (Egr-1) (Salah et al. 2007). Egr-1 is a 
short-lived, immediate, early response gene that encodes a zinc finger transcription 
factor. The expression of Egr-1 is rapid and transient in many cell types, including 
cancer cells, injured fibroblast and endothelial cells. Egr-1 can be induced by cell 
stress, injury by cytokines, hypoxia, shear stress and ultraviolet light. Egr-1 knockout 
mice showed enhanced survival in response to vascular injury (Yan et al. 2000). 
Interestingly, TGFβ is a major inducer of Egr-1 in mesenchymal cells in vitro and in 
vivo and TGFβ- mediated collagen gene expression is regulated by Egr-1 
downstream of Smad3-dependent and independent pathways (Chen et al. 2006). 
The findings in cancer do not appear to extrapolate to other cell types. In human 
lung fibroblasts, inhibition of AP-2 or Sp1 does not affect PAR-1 gene transcription 
(Sokolova et al., 2005). However, in human fibroblasts, PAR-1 gene and protein 
expression are negatively regulated by prostaglandins. Activation of PAR-1 in human 
lung fibroblasts induces COX-2 mRNA expression and release of prostaglandin PGE2, 
which in turn downregulates PAR-1 gene expression (Sokolova et al., 2005). PGE2 
also reduces PAR-1 surface expression and responsiveness to agonist and this effect 
is stable for 24 hours after fibroblast activation. PGE2 exerts a range of anti-fibrotic 
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effects through the EP2 receptor including inhibition of collagen synthesis, 
fibroblast proliferation and cell migration (Sokolova et al. 2008; Keerthisingam et al. 
2001). This negative feedback loop is disrupted in fibrotic fibroblasts that have a 
greatly reduced ability to upregulate COX-2 mRNA levels (Keerthisingam et al. 
2001). 
In human umbilical vein endothelial cells (HUVEC), microvascular endothelial cells 
(HMEC), and human arterial vascular smooth muscle cells PAR-1 mRNA and protein 
levels are downregulated following exposure to shear stress (Nguyen et al., 2001; 
Papadaki et al., 1998). Interestingly, these cells have intracellular PAR-1 reservoirs 
that rapidly replenish the receptor on the cell surface independently of de novo 
gene and protein expression. This can potentially explain the temporal separation 
between the PAR-1 gene expression and responsiveness to agonists at cellular level.  
In endothelial cells stimulation with thrombin and PAR-1 activating peptides 
upregulate PAR-1 mRNA level in a positive feedback mechanism (Ellis et al. 1999). In 
rat osteoblast-like cells, TGFβ has been shown to significantly upregulate PAR-1 
mRNA levels and increase the surface expression of the receptor. These effects 
translated to enhanced proliferative responses to thrombin in these cells (Abraham 
and MacKie, 1999). 
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Mediator/ 
Transcription 
factor 
Cell type PAR-1 
expression 
Reference 
TGFβ Rat osteoblast-like cells + (Abraham and 
MacKie, 1999)  
IL-4 Human macrophages  - (Colognato et 
al., 2003)  
COX-2 Human fibroblasts  - (Sokolova et 
al., 2005)  
Thrombin Human endothelial cells  + (Ellis et al. 
1999) 
p53  
-wild type 
-mutant or lost 
 
Human epithelial cells 
Human carcinoma  
 
- 
+ 
 
(Salah et al. 
2008) 
Sp1 Human melanoma  + (Tellez et al., 
2003) 
AP2 Human melanoma  - (Tellez et al., 
2003) 
Egr-1 Prostate cancer cells  + (Salah et al. 
2008) 
Table 1.6 Regulation of PAR-1 expression 
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1.6.6 PAR-1 antagonism  
PAR-1 is an attractive pharmacological target for blocking thrombin-mediated 
cellular effects without disrupting systemic coagulation pathways and fibrin 
generation. Studies with PAR-1 knockout mice demonstrate that blocking PAR-1 can 
be beneficial in injury and pulmonary fibrosis and can modulate viral infection in the 
lung. Several PAR-1 inhibitors are currently being tested in a clinical setting of 
cardiovascular disease as antiplatelet and antithrombotic agents (reviewed in Lang 
et al. 2010).  
The first PAR-1 antagonists developed were peptide-mimetics that blocked the 
receptor by binding to the second extracellular loop independently of proteolytic 
cleavage. Indole-based, RWJ-56110 and indazole-based, RWJ-58259, were the first 
selective PAR-1 antagonists with antiplatelet properties. Out of the two, RWJ-58259 
turned out to be more selective, potent and displayed a higher binding affinity with 
reduced side effects and was therefore developed further (Damiano et al., 2003). 
RWJ-58259 antithrombotic activity was validated in vivo in a cynomolgus monkey 
arterial injury models (Adams et al., 2011).  
E5555 (Atopaxar) is a bicyclic amide-derivative PAR-1 antagonist developed for oral 
administration. The compound was validated in Phase I clinical study and shown to 
inhibit platelet aggregation without affecting bleeding time and tested safe and 
well-tolerated in patients (reviewed in Lang et al. 2010). In Phase II trials carried out 
in patients with established coronary artery disease (Wiviott et al., 2011) and acute 
coronary syndrome (O’Donoghue et al., 2011), a trend toward reduction in major 
adverse cardiovascular effects was observed in patients treated with E5555. 
However, these patients also showed increased incidence of minor bleeding events 
and elevated liver enzymes indicating potential hepatic toxicity of the drug (Goto et 
al., 2010; de Souza Brito and Tricoci, 2013).  
Another class of PAR-1 antagonists is based on the core structure of the tetracycline 
piperidine alkaloid himbacine, naturally isolated from the bark of Australian 
magnolias. The most advanced compound, SCH530348 (Vorapaxar), is a synthetic 
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tricyclic 3-phenylpyridine that can be administered orally and inhibits thrombin-
PAR1-mediated platelet aggregation with an IC50 of 47 nM (Adams et al., 2011). The 
compound has a half-life of 20 hours in humans, which is reflected in the inhibitory 
effect that lasts 24 to 48 hours. In vivo studies in non-human primates 
demonstrated antithrombotic efficacy of SCH530348 in arteriovenous shunt models 
and in thrombosis models without any alterations to bleeding time or surgical blood 
loss. Phase I safety and tolerability studies in human volunteers showed that the 
drug does not cause any adverse effects and that platelet aggregation is significantly 
inhibited for up to 72 hours. SCH530348 safety and efficacy was further confirmed 
in a Phase II study in patients undergoing elective coronary angiography, who were 
randomly administered SCH530348 or placebo and the treatment with the 
compound was not associated with risk of minor or major bleeding (Becker et al., 
2009). The efficacy of SCH530348 was subsequently assessed in two large, 
randomised, multi-centre clinical trials. TRA 2P-TIMI tested SCH530348 in patients 
with atherosclerosis and history of myocardial infarction, ischemic stroke and 
peripheral arterial disease and TRACER investigated patients with acute coronary 
disease. Results from TRA 2P-TIMI trial showed that SCH530348 significantly 
reduces the risk of death from cardiovascular causes in patients with stable 
atherosclerosis (Morrow et al., 2012). A lesser protective effect was observed in 
patients with peripheral arterial disease although there was a significantly reduced 
risk of acute limb ischemia (Bonaca et al., 2013). However, in patients with history 
of ischemic stroke, addition of SCH530348 to the standard antiplatelet therapy was 
associated with increased the risk of intracranial haemorrhage without sufficient 
reduction in adverse vascular effects (Morrow et al., 2013). Furthermore, increased 
risk of bleeding was observed in all patients groups receiving SCH530348 in the TRA 
2P-TIMI study (Morrow et al., 2012). Results of TRACER study also showed 
significant and long-lasting protection from myocardial infarction even though the 
trial failed to reach the primary endpoint of reduction in the rate of cardiovascular-
related death (Leonardi et al., 2013; Tricoci et al., 2012). In both clinical studies 
increased risk of bleeding, particularly intracranial haemorrhage, was prominent in 
patients receiving SCH530348. However, patients in these studies were already 
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receiving standard antiplatelet therapy including thienpyridone (Clopidogrel) and 
therefore the bleeding risk could be a consequence of additive anticoagulant 
therapy with SCH530348.           
Furthermore, a group of cell-penetrating allosteric modulators of G-protein 
interactions with the receptor are currently being used to investigate the possibility 
of targeting specific signalling pathways downstream of PAR-1 activation. An 
allosteric inhibitor, Q94, specifically inhibits PAR-1 coupling to Gαq with an IC50 of 
916 nM and blocks signalling pathways that include intracellular calcium 
mobilisation and CCL2 release from fibroblasts (Deng et al. 2008). Also pepducins 
can be engineered to attach to different intracellular loops and so are excellent 
tools for investigating the different types of G proteins interactions with specific 
parts of the receptor. Blocking different sites at the intracellular interface of the 
receptor has been shown to have a varying impact of cell responses (Cisowski et al., 
2011). 
1.7 Hypothesis and aims 
Pulmonary fibrosis is the end stage of a heterogeneous group of respiratory 
conditions characterised by excessive and disordered ECM deposition within the 
pulmonary interstitium leading to obliteration of alveolar architecture and 
respiratory insufficiencies. Current evidence suggests that in IPF dysregulated cross-
talk between epithelial and mesenchymal cells following repetitive lung injury is a 
central mechanism driving the activation and persistence of fibroblasts and 
myofibroblasts. Furthermore, there is strong evidence showing that viral infections 
promote profibrotic and procoagulant responses in the lung and can therefore 
propagate the progression of fibrosis. The main feature of a profibrotic 
environment in the lung is an imbalance between the major inflammatory, 
coagulation and tissue repair pathways that perpetuate fibrogenesis.  
PAR-1 is a ubiquitously expressed receptor, which pluripotent actions link the 
inflammatory and coagulation pathways. In vivo models of lung injury support the 
notion that PAR-1 promotes inflammation and thrombin-mediated profibrotic 
signalling.     
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This thesis will therefore address the following hypothesis: 
Activation of the coagulation cascade in response to lung injury and viral infection 
promotes inflammation and fibrosis via PAR-1 signalling.  
And the following aims: 
• Identify PARs responsible for coagulation proteinases signalling responses 
in human primary lung cells.  
• Determine whether the coagulation cascade contributes to inflammatory 
and fibrogenic responses in the model of viral infection in pulmonary 
fibrosis.  
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Chapter 2: Materials and Methods 
Materials  
2.1 General plastic ware, chemical and solvents  
All chemicals were of analytical grade and obtained from Sigma Aldrich (UK) unless 
otherwise stated. All water used for the preparation of buffers was distilled and 
deionised using a Millipore Water Purification System (Millipore R010 followed by 
Milli-Q Plus; Millipore Ltd, UK). Sterile tissue culture flasks, plates and disposable 
pipettes were obtained from Nunc (Denmark). Sterile polypropylene centrifuge 
tubes were purchased from Falcon (New Jersey, USA). Dulbecco’s Modified Eagle 
Medium (DMEM) was purchased from Gibco (UK). Foetal bovine serum (FBS), sterile 
tissue grade trypsin/EDTA and antibiotic (penicillin/ streptomycin) were obtained 
from Invitrogen (UK).  
2.2 Reagents, antibodies and inhibitors 
Human α-thrombin, human FXa and antithrombin III were purchased from Enzyme 
Research Laboratories, UK. Transforming growth factor β-1 (TGFβ-1) was purchased 
from R&D Biosystems, UK. PAR-1 agonist peptide TFLLR-NH2, the control peptide 
RFLLT-NH2, PAR-2 activating peptide SLIGKV-NH2, PAR-2 control peptide VKGILS-
NH2, PAR-3 activating peptide TFRGAP-NH2 and PAR-4 activation peptide AYPGKF-
NH2 were purchased from Bachem AG, Switzerland. Hirudin was purchased from 
Sigma, UK. MEK inhibitors, UO126 and PD98059, ALK5 inhibitor, SB431542, and JNK 
inhibitor, SP600126, were purchased from Calbiochem, UK. SB203580 p38 inhibitor 
was purchased from Cell Signalling Technology, UK. Antibodies used in these studies 
are listed in Table 2.1. PAR-1 inhibitor, RWJ58259, was a kind gift from Department 
of Chemistry, UCL. PAR-1 inhibitor, SCH530348, and PAR-2 inhibitor, GB83, were 
purchased from Axon Medchem, Netherlands.  
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Table 2.1 Antibodies used for analysis of human and mouse cells and tissue.  
Target Antibody  Supplier Concentration  Application 
PAR-1 Mouse 
monoclonal 
ATAP2 
Santa Cruz 
Biotechnology, 
USA  
2 µg/ml Immunocytofluorescence 
PAR-2 Mouse 
monoclonal 
SAM11 
Santa Cruz 
Biotechnology, 
USA  
1 µg/ml Immunocytofluorescence 
Vimentin Rabbit 
monoclonal  
Abcam, UK 2 µg/ml Immunocytofluorescence 
αSMA Mouse 
monoclonal 
Sigma, UK 2 µg/ml Immunocytofluorescence 
E-cadherin Rabbit 
polyclonal 
Abcam, UK 4 µg/ml Immunocytofluorescence 
CK5 Rabbit 
polyclonal 
Abcam, UK 1 µg/ml Immunocytofluorescence 
CK14 Mouse 
monoclonal 
LL02 clone  
Abcam, UK 1 µg/ml Immunocytofluorescence 
PECAM Goat 
polyclonal  
Santa Cruz 
Biotechnology, 
USA  
2 µg/ml Immunocytofluorescence 
vWF Rabbit 
polyclonal  
Santa Cruz 
Biotechnology, 
USA  
2 µg/ml Immunocytofluorescence 
ProSurfactant 
protein C 
Rabbit 
polyclonal 
Millipore, USA 5 µg/ml Immunocytofluorescence 
ZO-1 Mouse 
monoclonal 
Invitrogen 2.5 µg/ml Immunocytofluorescence 
Tissue factor Rabbit 
polyclonal 
Santa Cruz 
Biotechnology, 
USA  
1 µg/ml Immunohistochemistry 
FX Rabbit 
polyclonal 
Santa Cruz 
Biotechnology, 
USA  
2 µg/ml Immunohistochemistry 
Smad 2 Mouse 
monoclonal 
Cell Signalling 
Technology, 
UK 
0.05 µg/ml Western blot 
Smad 3 Rabbit  
Monoclonal 
Cell Signalling 
Technology, 
UK 
0.075 µg/ml Western blot 
βactin Mouse 
monoclonal 
Sigma, UK 0.2 µg/ml Western blot 
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Methods 
2.3 Animals 
BALB/c female and C57BL/6 male mice (Charles River Laboratories, UK) were 
housed at the Central Biological Services Unit, University College London; in a 
specific pathogen-free facility in individually ventilated cages, with free access to 
food and water (12 hour light/dark cycle, normal sodium dry fishmeal diet, 
temperature 18-20°C). All procedures were performed on BALB/c mice between 6 
and 8 weeks of age and C57BL/6 mice between 10 and 12 weeks of age. All studies 
were ethically reviewed and carried out in accordance with the UK Home Office 
Animals for Scientific Procedures Act 1986.   
2.4 Bleomycin model of pulmonary fibrosis 
C57BL/6 male mice were used for the model of viral infection on the background of 
bleomycin-induced pulmonary fibrosis. Bleomycin (1 mg/kg of body weight in 50 μl 
of sterile 0.9% saline) or saline was administered by oropharyngeal instillation as 
previously described (Lakatos et al., 2006). Mice under light isofluorane-induced 
anaesthesia were suspended on an elastic band, their nose pinched shut and 
tongue held to prevent the swallow reflex and forcing the mouse to breathe 
through the mouth. Consequently saline/bleomycin was introduced to the back of 
their mouth with Gilson pipette and aspirated. Mice were sacrificed after 21 or 28 
days by intraperitoneal injection of pentobarbitone and severing of the abdominal 
inferior vena cava.  
For total collagen measurements and real-time RT-PCR the lungs were removed, 
blotted dry and immediately snap frozen in liquid nitrogen. Subsequently, the lungs 
were weighed and pulverised under liquid nitrogen. For μCT, histological and 
immunohistochemical analysis the trachea was cannulated and lungs insufflated 
with 4% paraformaldehyde in PBS at a pressure of 25 cm H2O, excised and 
submerged in fresh fixative for 4 hours. Following the fixation, the lungs were kept 
in 15% sucrose over night at 4°C and transferred into 70% ethanol for storage. Lung 
 
 
  93  
  
tissue homogenates were prepared by mixing the frozen lung powders with 0.5ml 
PBS with added proteinase inhibitors (Complete Mini, Roche Diagnostics, UK) and 
1% Triton-X. 
2.5 Viral infection in pulmonary fibrosis 
Mice were administered bleomycin via oropharyngeal route as described in 
previous section and the injury and subsequent fibrosis allowed to develop for 14 
days. Mice were then anaesthetised by intraperitoneal injection of ketamine and 
xylazine at a concentration of 100 mg/kg and 10 mg/kg, respectively, in 100 μl 
sterile saline. γHV68 (ATCC, USA) 1x105 plaque forming units (PFU) was suspended 
in 20 μl sterile saline and inoculated intranasally, delivering 10 μl into each nostril. 
Mice were sacrificed after 7 or 14 days post inoculation by intraperitoneal injection 
of pentobarbitone and severing of the abdominal inferior vena cava.  
Lungs were collected and processed as described in previous section. The spleens 
were also collected and snap frozen in liquid nitrogen, weighed and pulverised.       
2.6 TGFβ and FXa inhibition studies 
Pulmonary fibrosis and γHV68 infection were induced as described above. The 
highly selective small molecule ALK5 inhibitor, SB525334 was a kind gift from 
Novartis, Horsham, UK. Two weeks after bleomycin instillation and one day post-
viral inoculation SB525334 (30 mg/kg in 100 μl acidified saline/0.2% Tween 80 pH 
4.1) or vehicle (acidified saline/0.2% Tween 80 pH 4.1) was administered twice daily 
by oral gavage for the remaining duration of the experiment (Figure 2.1).  
BAY 59-7939 (Rivaroxaban) was purchased from Selleckchem, USA. The therapeutic 
dosing of BAY 59-7939 (3 mg/kg in 100 μl polyethylene glycol 400/water 60/40% 
v/v) or vehicle (polyethylene glycol 400/water 60/40% v/v) started 14 days after 
bleomycin administration and one day post-viral inoculation out to 28 days post-
bleomycin when the experiment was terminated (Figure 2.1).     
 
 
 
  94  
  
 
Figure 2.1. Experimental design of in vivo TGFβ and FXa inhibition studies 
Bleomycin was administered via oropharyngeal (OP) route on day 0. γHV68 was 
inoculated intranasally (IN) on day 14. Mice received the compounds via oral gavage 
(OG) twice daily from day 15 to 27, and were sacrificed on day 28. 
2.7 Determination of total lung collagen 
2.7.1 HPLC  
Total lung collagen was determined by measuring hydroxyproline content in 
aliquots of pulverised lung. Collagen contains 12.2% w/w hydroxyproline, which is 
detected and quantified by reverse-phase high performance liquid chromatography 
(HPLC) of 7-chloro-4-nitrobenzo-oxa-1,3-diazole (NBD-Cl)-derivatised acid 
hydrolysates. Hydroxyproline is a secondary amino acid that reacts with NBD-Cl to 
generate a chromophore detected at 495 nm wavelength. The specificity of the 
reaction is further ensured by keeping the derivation time to 20 minutes at 37°C, a 
time-point that has been confirmed experimentally to be maximal for 
hydroxyproline derivatisation with NBD-Cl for up to 20 nmol hydroxyproline.         
2.7.1.1 Sample preparation  
For each sample approximately 20 mg of lung powder was accurately weighed and 
hydrolysed in 2 ml 6 M HCl for 16 hours at 110° in a pyrex tube. Hydrolysates were 
decolourised with activated charcoal, filtered through 0.65 μm filter (Millipore Ltd., 
UK) and diluted 1 in 50. Aliquots (200 μl) of diluted hydrolysate were transferred to 
a microfuge tube and evaporated to dryness under vacuum on a Speedvac (Thermo 
Electron Corporation, UK). The resulting residue was reconstituted in 100 μl HPLC-
grade water, buffered with 100 μl of 0.4 M potassium tetraborate (pH 9.5) and 
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reacted with 100 μl 36 mM NBD-Cl (in methanol) to a final concentration of 12 mM 
NBD-Cl. The samples were then incubated in a hot block at 37° for 20 minutes. The 
reaction was stopped by addition of 50 μl 1.5 M HCl. At this point 150 μl of 3.33x 
buffer A (Table 2.2) was also added. Samples were then filtered through an HPLC 
low dead-volume filter (0.22 μ, Millipore Ltd., UK) into a polypropylene insert within 
an Amber Snap Seal vial (Laboratory Sales Ltd., UK). These vials were then loaded 
onto the HPLC apparatus and the samples were sequentially injected onto the HPLC 
column and eluted with acetonitrile gradient as described below.  
2.7.1.2 Chromatography conditions  
The HPLC apparatus used for measurements was Agilent series 1100 (Agilent 
Technologies, USA) with a reverse-phase cartridge column (LiChroCART LiCrospher, 
250mm length x 4 mm diameter, 5 μm particle size, 100 Rp-18; BDH/Merck, UK) 
protected by a directly coupled pre-column (LiChrosorb 4 mm x 4 mm, 5 μm particle 
size, 100 Rp-18; BDH/Merck, UK). The column was continuously maintained at 40°C 
in a heated column oven. At the beginning of each batch of samples, the HPLC 
system was equilibrated in running buffer A (Table 2.2) for minimum of 40 minutes. 
Hydroxyproline standards (equivalent to 50 pmol, Sigma) were subject to NBD-Cl 
derivatisation, processed alongside the samples and inserted at equal intervals 
throughout the run. NBD-Cl derivatives of samples and standards were individually 
injected onto the column and eluted with an acetonitrile gradient, which was 
achieved by changing the relative proportions of running buffers A and B over time. 
Chromatographic conditions and buffers used in this process are summarised in 
Table 2.2.  
Post-column detection was achieved by monitoring absorbance at 495 using a flow-
through variable wavelength monitor. Hydroxyproline elutes as a discreet peak 
between five and seven minutes following sample injection on the column, 
between glutamine (3.5 minutes) and serine (seven to nine minutes). The column 
running and regeneration time for each sample was 25 minutes.  
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The hydroxyproline content in each sample was determined by comparing peak 
areas of individual sample chromatograms with the average of the standard peak 
areas. This value represents the hydroxyproline level in the fraction of the acid 
hydrolysates of the pulverised lung and was used to calculate the total lung collagen 
based on the hydroxyproline content of the collagen, dilution factors at the 
processing steps, the weight of lung powder and the total lung weight. 
Column LiChrospher, 100 RP-18, 250 x 4mm, 5μm 
Buffers 
 
 
Column flow 
Column 
temperature 
Detection 
wavelength  
Buffer A- aqueous acetonitrile (8% v/v), 50mM sodium acetate, 
pH 6.4 
Buffer B- aqueous acetonitrile (75% v/v) 
 1 ml/min 
 
40°C 
 
495nm 
Table 2.2 HPLC buffers and conditions.  
2.7.2 Sircol collagen assay 
Sircol collagen assay kit was purchased from Biocolor, UK and used according to the 
manufacturer’s protocol. For each sample approximately 20 mg of pulverised lung 
powder was weighed out into 1.5 ml Eppendorf tube and soluble collagen extracted 
by an overnight incubation at 4°C in 1 ml of pepsin (0.1 mg/ml) in glacial acetic acid 
(0.5 M). Next day, the samples were centrifuged (16,100 RCF, 2 minutes) and 
supernatants removed to new tubes. Subsequently, 100 µl of Sircol acid neutralising 
reagent and 200 µl of Sircol isolation and concentration reagent were added to the 
supernatants before another overnight incubation at 4°C. Next day, the samples 
were centrifuged (13,300 RCF, 10 minutes) and supernatants removed revealing 
opaque concentrated collagen pellets. Collagen standards were diluted to a 
concentration range from 50 to 5 µg/ml collagen. Collagen in the standards and 
samples was then stained with Sircol dye reagent (1 ml) for 30 minutes with shaking 
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and excess dye was washed off with 750 µl of acid-salt wash. Standard and sample 
pellets were resuspended in Sircol alkali reagent and the absorbance measured at 
555 nm wavelength. The total lung collagen was quantified based on soluble 
collagen content of each sample, weight of lung powder and weight of the whole 
lung.        
2.8 μCT imaging 
2.8.1 Sample preparation for μCT imaging 
Fixed, insufflated lungs were incubated for two hours each in increasing 
concentration of ethanol: 70%, 80%, 90% and then in 100% ethanol overnight. 
Lungs were subsequently transferred to 100% hexamethyldisilazane for another 
two hours and air-dried. The lungs were then fixed on the tip of cannula for μCT 
scanning (Figure 2.2). 
 
  
 
 
 
 
 
Figure 2.2. Lung preparation for μCT scanning. 
2.8.2 μCT scanning 
The lungs were subsequently scanned in a Skyscan 1072 μCT scanner (SkyScan, 
Belgium) at 40 kV/100 μA, without a filter, using two frame averaging at 0.49° 
angular rotation step size; on the typical measured 10% Modulation Transfer 
Function (MTF) with spatial resolution in the region of 20-30 μm. The voxel size was 
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set to 12.8 μm and a scan time of around 10 minutes to allow high resolution 
visualisation and good throughput. Reconstruction was carried out with the SkyScan 
NRecon software (SkyScan, Belgium).     
2.8.3 μCT image analysis  
Tissue segmentation analysis was performed using InFormTM software (Caliper, 
PerkinElmer Company, UK). The software was “trained” to recognise areas of 
normal lung (green) and areas of abnormal lung (red) as well as other tissue (blue) 
that encompassed heart tissue, large airways and segments of oesophagus and 
trachea. Three representative μCT sections (8-bit greyscale) from each animal in the 
study were used for optimal training of the software until over 90% accuracy was 
achieved. All μCT sections (~900 sections per each lung) were subsequently 
segmented using the same training settings on a medium sample area at fine 
resolution. The output measurements were pixel area and pixel density for each 
category that were then compiled into a composite measurement of lung volume 
and greyscale density as described below.  
Normal/Abnormal/Total absolute lung volume (mm3) was calculated: 
Sum of pixel area x voxel size ([12.8]3) x 109 
The percentage of normal and abnormal area of the lung volume was calculated: 
Normal lung volume/ Total lung volume x100 
Abnormal lung volume/ Total lung volume x100 
Normal/Abnormal/Total voxel density was calculated: 
Sum of pixel density x voxel size ([12.8]3) x 109  
Voxel density of the lungs was further analysed by generating composite 256-colour 
greyscale histograms (from 0= back to 255= white) representing the frequency 
distribution of pixel densities for each lung. The mean number of pixels in each bin 
(1 greyscale unit wide) was then calculated for each group, along with a t-test 
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distribution showing the p-value for the comparison between each animal group at 
each greyscale bin.  
2.9 Histology and immunohistochemistry  
2.9.1 Histology 
Paraformaldehyde-insufflated mouse lungs or human biopsy were placed in 
processing cassettes, dehydrated through a serial alcohol gradient and embedded in 
paraffin wax blocks. Before standard histological processing 3-5 μm paraffin 
sections were cut, mounted on polylysine-coated glass slides and dewaxed. Two 
different staining methods were used to visualise the lung architecture. 
Hematoxylin and eosin stain (H&E stain) allows for discrimination of cellular 
components of the tissue. Heamatoxylin is a basic dye that interacts with nucleic 
acid and stains the nucleus blue. Eosin is an acidic dye that interacts with positively 
charged amino groups of proteins in the cytoplasm, staining it pink. A modified 
trichrome staining method (Martius Scarlet Blue (MSB)) was used to highlight 
collagen fibres deposition to visualise areas of fibrosis. This staining method relies 
on differential permeability of tissues to dyes of differing molecular size. The large 
Chicago Sky Blue 6GX dye permeates collagen fibrils causing areas of fibrosis to 
appear blue. Automated staining of sections was performed using a Sakura Tissue-
Tek DRS 2000 Multiple Slide Stainer. 
All sections were subsequently scanned on a Nanozoomer and images were 
captured using NDP.view v 1.2.36 (both from Hamamatsu Corporation, Japan). 
Direct comparisons between μCT and histology were performed on the same set of 
lungs: post-Ct lungs were rehydrated through an ethanol gradient (100%, 90%, 80% 
and 70% for two hours in each) prior to standard processing.  
2.9.2 Inflammatory cell aggregates counts 
Inflammatory cell aggregates identified in H&E sections were quantified using 
Nuance FX Multispectral Tissue Imaging Software (Caliper, PerkinElmer Company, 
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UK). The software unmixed and analysed the areas of intense heamatoxilin staining 
that corresponded to the inflammatory cell aggregates and quantified them as 
regions of interest (ROI). The area of the lung section was then calculated using 
NDP.view v 1.2.36 software and the ROI expressed per mm2 of the lung. 
2.9.3 Immunohistochemistry  
For mouse lung tissue, anitgens were unmasked by microwaving sections in 10 mM 
citrate buffer, pH 6.0 (2 x 10 minutes) before washing in TBS. Human lung tissue did 
not require any unmasking treatment. Endogenous peroxidises were blocked with 
3% H2O2 for 20 minutes. Sections were subsequently incubated with normal goat or 
rabbit serum (Sigma), as determined by the origin of secondary antibody. Antigens 
were localized by overnight incubation with anti-FX (1:100 dilution) and anti-TF 
(1:200 dilution) for mouse lung sections and PAR-1 (1:100 dilution) and PAR-2 
(1:200 dilution) for human lung section. Next day, sections were washed in TBS, 
incubated with a biotinylated goat anti-rabbit, rabbit anti-goat or goat anti-mouse 
secondary antibody (1:200 dilution; Invitrogen) for 1 hour, and washed again in TBS. 
Next, sections were incubated with a streptavidin/peroxidase complex (1:200 
dilution; DAKO) for a further 30 minutes, followed by incubation with Impact 
NovaRed peroxidise substrate reagent (Vector Laboratories, UK) for colour 
development, as per manufacturer’s instructions. Sections were washed, 
counterstained with Gill-2 hematoxylin (Thermo-Shandon), dehydrated, and 
mounted with DPX mountant (Merck). Control sections were incubated with an 
isotype-specific, nonimmune rabbit, goat, or mouse IgG primary antibody (DAKO).  
All sections were subsequently scanned on a Nanozoomer and images were 
captured using NDP.view v 1.2.36 (both from Hamamatsu Corporation, Japan). 
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2.10 Tissue culture 
2.10.1 Fibroblasts  
Mouse lung fibroblasts were king gifts of Dr. Shaun Coughlin (Cardiovascular 
Research Institute, University of California, San Francisco, CA, USA) and used 
between passage 12 and 25 without noticeable alteration in phenotype. 
Normal primary human adult lung fibroblasts were a kind gift of Dr. Robin McAnulty 
from our laboratory and used at passages below 10. Primary fibroblasts were 
initially grown from 1 mm3 explants dissected from normal human lung tissue and 
fixed onto a tissue culture-treated Petri dish. The explants were cultured in 20% FBS 
Dulbecco’s modification of Eagle’s medium (DMEM) supplemented with penicillin 
(200 units/ml, Gibco), streptomycin (200 units/ml, Gibco), glutamine (4 mM, Gibco) 
and with added fungizone (Invitrogen). The culture medium was replaced with fresh 
medium one day after isolation and spiked with additional fungizone every three 
days for three weeks. The fibroblasts were collected by trypsinisation and 
propagated in a humidified atmosphere containing 10% CO2 at 37°C. Fibroblasts 
were separated by morphological characterisation and by differential expression of 
a selection of cell markers including α-smooth muscle actin, vimentin and myosin.    
Both mouse and human fibroblasts were subsequently maintained in static culture 
on 175 cm2 triangular culture flasks. Cells were passaged by routine trypsinisation 
protocols when monolayer cultures reached 80-90% confluence.        
2.10.2 Alveolar epithelial cells 
A549 alveolar epithelial cells were purchased from ATCC and cultured in 10% FBS 
Kaighn’s modification of Ham’s F-12 medium (F12K, Gibco) medium supplemented 
with penicillin (200 units/ml, Gibco), streptomycin (200 units/ml, Gibco), glutamine 
(4 mM, Gibco). Cells were passaged by routine trypsinisation protocols when 
monolayer cultures reached 80-90% confluence. 
Primary human type II alveolar epithelial cells (AEC II) were isolated from human 
lungs of grossly normal appearance, obtained through collaboration with Royal 
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Brompton Hospital and with approval of the Harefield Ethics Committee. Lung 
tissue was extensively washed and perfused with sterile 0.9% saline in order to 
remove blood and inflammatory cells. Subsequently, lung tissue was perfused with 
0.25% trypsin in HBSS (3 x 15 minutes) at 37°C and 5% CO2 in order to dissociate 
cells. Trypsin was promptly neutralised with FBS and DNase (250 μg/ml; Sigma-
Aldrich) and lung tissue manually homogenised. A single cell suspension was 
obtained from the homogenised tissue by passing the mixture through 
progressively smaller filters (pore size 300 μm and 40 μm). Cells suspension was 
next centrifuged (290 RCF, 10 minutes, 20°C) and the resulting cell pellet was 
resuspended in DCCM-1 medium (Biological Industries, Kibbutz Beit Haemek, Israel) 
containing DNase (50 μg/ml). Cells were incubated in tissue culture flasks for 2 
hours at 37°C in a humidified incubator to allow differential adherence of 
contaminating mononuclear cells and fibroblasts. Following the adherence step, 
non-adherent AECII in suspension were removed and centrifuged. The cell pellet 
was resuspended in red blood cell lysis buffer (Sigma-Aldrich) and incubated for 5 
minutes at room temperature. Cell suspension was centrifuged once again and cell 
pellet resuspended in DCCM-1 medium supplemented with 10% FBS, 1% penicillin–
streptomycin, glutamine and 1% fungizone. Cells were subsequently counted and 
seeded at a density of 1 x 106 in 12-well plates with Transwell inserts pre-coated 
with 1% collgen (PureCol, Nutacon). Cells reached confluence by 48 hours and were 
characterised by expression of surfactant C protein and zona occludens (ZO-1).              
2.10.3 Bronchial epithelial cells 
Immortalised bronchial epithelial cells (BEAS2B) were obtained from ATCC, cultured 
in 10% FBS DMEM and grown in humidified atmosphere containing 10% CO2 at 
37°C. Cells were passaged by routine trypsinisation protocols when monolayer 
cultures reached 80-90% confluence. 
Human bronchial epithelial cells (HBECs) were grown out of human bronchial 
biopsies and used up to passage 5 in submerged cultures and up to passage 3 for 
air-liquid interface cultures. Cells were cultured in humidified atmosphere 
containing 5% CO2 at 37°C in 1x bronchial epithelial growth medium (BEGM, Lonza, 
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Switzerland) containing 1x bronchial epithelial basal medium (BEBM) and BEGM 
Singlequots (Triiodothyronine (T3), human Epidermal Growth Factor (hEGF), Insulin, 
Transferrin, Hydrocortisone, Epinephrine, Gentamicin Sulphate/ Amphotericin-B 
(GA-1000), RA, Bovine Pituitary Extract (BPE)) (Lonza, Switzerland). One vial of P1 
HBECs (1 ml at 660,000 cells/ml) was thawed in static flask 25 cm2 at 3,500 cells/ 
cm2 density in 3-5 ml of BEGM. The media was changed 6 hours after plating in 
order to remove the dimethyl sulfoxide (DMSO) in the freezing medium and 
unattached cells and debris. Subsequently, the medium was changed every 48 
hours until 85-90% confluent. HBECs were washed briefly using 3-5 ml/25 cm2 
HANKs- Balanced Salt Solution (HBSS) and were subsequently passaged using 3 
ml/25 cm2 1x trypsin-EDTA at 37°C for 5 minutes. Equal volume of trypsin 
neutralising solution was added and cells centrifuged at 150 RCF for 5 minutes at 
room temperature. Cells were resuspendend in BEGM by mixing gently without 
pipetting up and down. Cells were then mixed 1:1 with 0.4% trypan blue to assess 
cell viability. Alive cells actively pump out trypan blue and appear white in 
microscopic field while dead cells are blue. White cells were counted in using 
haemocytometer and cells/ml calculated according to manufacturer’s formula and 
accounting for dilution factor with trypan blue:   
Total cell number = (average cell number counted/number of small squares counted)               
x 90,000 x 2 
HBECs for air-liquid interface (ALI) were cultured on collagen IV from human 
placenta. Collagen IV was reconstituted with 0.25% acetic acid in ddH2O at 
concentration of 0.66 μg/μl overnight at 4°C. The collagen IV stock was then mixed 
1:1 with 100% ethanol and used to coat Transwell inserts overnight at 
concentration of 50 μg/cm2. Cells at 2-3 passage were seeded apically at 70,000 
cells/cm2 density in 100 μl of BEGM medium on 0.4 μm pore size 24-well plate 
Transwell inserts. Basolaterally, 500 μl of BEGM was added to the well. The medium 
was changed every 2-3 days both apically and basolaterally until cells reached 
confluence, within 5-7 days. The media was then removed from apical site and cells 
were cultured for 21 days at ALI in differentiation medium which consisted of 50% 
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complete BEGM without T3, 50% DMEM and 500 μM All-Trans-Retinoic Acid 
(ATRA).     
2.10.4 Endothelial cells 
Human umbilical endothelial vein cells (HUVEC) and human lung microvascular 
endothelial cells (HMVEC) were purchased from Lonza, UK. Cells were cultured in 
humidified atmosphere containing 5% CO2 at 37°C in 1x endothelial growth medium 
(EGM-2, Lonza, Switzerland) containing 1x endothelial basal medium (EBM-2) and 
EGM-2 Singlequots (human Epidermal Growth Factor (hEGF), Gentamicin Sulphate/ 
Amphotericin-B (GA-1000), Hydrocortisone, FBS, Vascular Endothelial Growth 
Factor (VEGF), human Fibroblast Growth Factor (hFGF-b), Insulin-like Growth Factor 
(IGF), Ascorbic Acid, Heparin) (Lonza, Switzerland). Cells were seeded in 175cm2 
tissue culture flasks at the density of 5000 cells/cm2. The medium was changed 
every 48 hours until 85-90% confluent. HUVECs and HMVECs were washed briefly 
using 3-5 ml/25 cm2 HANKs- Balanced Salt Solution (HBSS) and were subsequently 
passaged using 3 ml/25 cm2 1x trypsin-EDTA at 37°C for 5 minutes. Equal volume of 
trypsin neutralising solution was added and cells centrifuged at 220 RCF for 5 
minutes at room temperature. The cell pellets were re-suspended, counted and 
propagated accordingly.  
2.11 RT-PCR and real-time RT-PCR analysis  
2.11.1 Prevention of RNA degradation 
For all the appropriate steps of RNA isolation protocol molecular biology grade 
chemicals were used and deionised water was pre-treated with 0.1% diethyl 
pyrocarbonate (DEPC) overnight at room temperature, and subsequently 
autoclaved to deactivate DEPC. All the equipment was thoroughly cleaned with 
RNaseZap (Sigma Aldrich, UK) and filtered, nuclease free pipette tips (Continental 
Lab Products, UK) were used to minimise RNA degradation.  
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2.11.2 RNA extraction 
Total RNA from frozen powdered lung tissue or cells cultures was isolated with 
TRIzol reagent as per manufacturer’s protocol (Invitrogen, UK). TRIzol is a solution 
of phenol and guanidine isothiocyanate which disrupts cell membrane and dissolves 
cell components leaving RNA integrity intact. The total RNA was isolated in single 
step as 1ml of TRIzol was added to 50-100 mg of lung tissue. For isolation from lung 
tissue 1 ml of TRIzol was added directly to the cell plate and cells scraped into TRIzol 
with 1 ml pipette tip and transferred to 1.5 ml Eppendorf tube.   
To isolate mRNA from TRIzol the samples were left for 5 minutes at room 
temperature and then 200 μl of chloroform was added. The mixture was mixed 
vigorously and left for 10 minutes at room temperature to allow separation of 
upper aqueous and a lower organic layer. The samples were then centrifuged for 15 
minutes at 16,100 RCF at 4°C and the aqueous phase containing RNA transferred to 
a new Eppendorf tube containing 500 μl isopropanol.  
The RNA was allowed to precipitate for 10 minutes at room temperature and was 
then centrifuged at 16,100 RCF for 15 minutes at 4°C. The supernatants were 
discarded and the RNA pellet was resuspended in 900μl of ethanol (80%) (BDH VWR 
International, UK). Following further 15 minutes centrifugation at 16,100 RCF at 4°C 
the supernatants were discarded, the pellets air dried and then resuspended in 12.5 
μl of nuclease free water (Ambion,UK).  
Contaminating genomic DNA was removed using Ambion DNAfree kit. DNase I and 
RNase inhibitor were added to the total RNA and incubated at 37°C for 20 minutes. 
The DNase reaction was terminated by the addition of resin which was 
subsequently removed from the solution by centrifugation. 
RNA quality was visualised on agarose gel containing 1 g agarose, 10 ml 10x MOPS 
(0.2 M 3-N-morpholino-propane sulphonic acid, 16 nM sodium acetate and 2 nM 
EDTA), 74 ml DEPC-treated water, 16 ml formaldehyde and 0.005% gel red. The 
mixture loaded on the gel was made up of 2 μl RNA and 2 μl loading buffer (48% 
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deionised formamide (Gibco BRL, UK), 6% formaldehyde (BDH, UK, 5% glycerol, 10 
mM MOPS) made up to the volume of 10 μl with DEPC- treated water.            
RNA bands were observed using a Syngene Gene Genius Bio-imaging system 
(Synoptics, UK). The analysis of 28S rRNA and 18S rRNA bands displaying intensities 
ratio of approximately 2:1 was unequivocal of non-degraded RNA. The RNA was 
quantified using Nanodrop 8000 spectrophotometer (Thermo Scientific, UK), by 
measuring the A260 and A260/A280 ratio respectively. The A260/A280 ratio was used as a 
guide to the purity of RNA sample and values between 1.7 and 2.0 were considered 
acceptable. 
2.11.3 DNAse treatment 
cDNA was prepared by reverse-transcription (RT) using qScript cDNA SuperMix ® kit 
(Quanta Biosciences, USA). Following manufacturer’s instructions up to 1 μg of RNA 
sample was made up to volume of 16μl with nuclease-free water. 4 µl of qScript 
cDNA SuperMix ® (5X reaction buffer containing optimized concentrations of MgCl2, 
dNTPs (dATP, dCTP, dGTP, dTTP), recombinant RNase inhibitor protein, qScript 
reverse transcriptase and random primers, was then added to each sample, to 
achieve a final volume of 20 µl. Samples were then incubated for 5 minutes at 25°C, 
30 minutes at 42°C and 5 minutes at 85°C. 
2.11.3 RT-PCR 
Real time RT-PCR was conducted using the Platinum SYBR Green qPCR SuperMix 
UDG (Invitrogen, UK) with ~1 ng of cDNA, and forward and reverse primers each at 
a final concentration of 800 nM, on a Mastercycler EP Realplex (Eppendorf, 
Germany). Cycling conditions were as follows: activation of SYBR Green 95°C for 10 
minutes; cDNA amplification 95°C for 5 seconds, 60°C for 45 seconds for 40 cycles; 
melting curve 95°C, 65°C for 15 seconds, 95°C. 
The efficiency of each primer pair was assessed by determining the relationship of 
primer crossing point (Cp) values with cDNA concentration using a series of half-log 
dilutions of template cDNA. Cp values were defined as the earliest point of the 
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linear region of the logarithmic amplification plot reaching a threshold level of 
detection. The log of cDNA concentrations was plotted against Cp values, and the 
slope of the plot was used to ascertain primer efficiency. Primers efficiency was 
given by the equation: Efficiency= 10(-1/slope) and were only used if the slope was 
close to 1 indicating PCR efficiency greater than 90%. 
GeNorm algorithm was applied to obtain the optimal number of housekeeping 
genes. Geometric mean of two housekeeping genes was shown to produce optimal 
normalisation factor and out of 13 housekeeping genes tested, ATP synthase, H+ 
transporting, mitochondrial F1 complex, beta polypeptide (ATP5B) and beta-2-
microglobulin (B2M) showed highest reference target stability for human samples. 
Calnexin (CANX) and ATP5B have been identified as optimal housekeeping genes for 
mouse samples.    
To examine the quantitative differences in target mRNA expression in each sample, 
Cp values were determined from the linear region of the logarithmic amplification 
plot. Each sample was also tested for the expression of the two housekeeping 
genes, the Cp value of which was used to normalise between samples. Fold change 
was subsequently calculated using the standard 2-ΔΔCp approach. Statistical analysis 
was performed using the ΔCp values. 
The specificity of the products obtained by PCR was confirmed by analysis of the 
melting curve. Double- stranded DNA has a melting temperature (Tm) defined as a 
temperature at which half of the DNA is denatured and its value is primarily 
dependent on the nucleotide sequence. The melting curve analysis is performed by 
measuring a decrease in fluorescence due to the dissociation of DNA helix as a 
function of temperature and a single melting curve is indicative of a single PCR 
product. 
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Human 
Gene Forward sequence Reverse sequence  
hPAR-1 AGGCCAGAATCAAAAGCAAC TCATCCTCCCAAAATGGTTC 
hITGAV TCTGTGCCGCGCCTTCAACC 
 
AACATCCGGGAAGACGCGCTG 
 
hITGB6 AAGTTGAGACCAGGTGGTGCGC 
 
CCATGGAGGCGGAGAGGTCCAT 
 
hSmad2 Primer Design, UK Primer Design, UK 
hSmad Primer Design, UK Primer Design, UK 
Mouse  
Gene Forward sequence Reverse sequence  
muTissue 
factor 
AGCCCTTGGACATGGCGATCCT TTCTCTGGAATGCCTGCACCCG 
muITGAV ACACTTTGGGCTGTGGAATCGCC CGTACAGGATTGCGCTCTTGCCT 
muITGB6 CCGGGAGCCAGAATGTGGAAGT GCCAGGAGTGCCATCCCAATCA 
muITGB5 GGAGCCTGCCTGAGAGCTCATT ACAGGCAGACCAGCTCAATCCC 
muCCL2 AGCTCTCTCTTCCTCCACCAC CGTTAACTGCATCTGGTGA 
muTGFb GGATACCAACTATTGCTTCAGCTCC AGGCTCCAAATATAGGGGAGGTC 
muF10 CAGCGGTTACTTCCTGGGTA GCCACAGACCTCTTCCTACG 
muF7 GACTTTGAGGGTCGGAACTG AGGTACGCTTGGTCCCTACA 
muF5 ACCTCAGGCAGTCACACCACGA GGCCTTGTTAGGCACTGGGCAT 
muPAR-1 AGCCAGCCAGAATCAGAGAG AGGGGGACCAGTTCAAATGTA 
muPAR-2 CGGGACGCAACAACAGTAA GTTCCACCGGAACCCCTTTC 
muPAR-3 TGCCAAAGTGGCATAAATGT TCCAGCCCTCTATGTCAGAA 
muPAR-4 AGACCCCCAGCATCTACGA GTCTGAGGACTTCGGCTCCT 
Table 2.3 List of human and mouse primers 
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2.12 Transfection with siRNA  
A549 cells were transfected following reverse transfection protocol. SMARTpool 
ONTARGETplus Human siRNA targeting Smad2 and Smad3 and the ONTARGETplus 
Nontargeting Pool (Thermo Scientific, UK) were reconstituted to 20 µM stock in RNA 
buffer. A range of siRNA concentrations (100 nM, 30 nM, 10 nM, 3 nM, 1 nM) was 
tested to optimise the conditions and combined with Interferin transfection reagent 
(Polypus, UK) as per manufacturer’s protocol. Interferin is composed of non-
liposomal amphiphilic molecules that form stable complexes with siRNA and 
transport it into the cell cytoplasm. Interferin can be used in the presence of serum 
and antibiotics and does not affect the cell viability. A549 cells were seeded at 
sufficient density to reach 80% confluence and the transfection mix was 
immediately added to the wells. Cells were then incubated for 24 hours, 48 hours 
and 72 hours. After each time the medium was removed and the samples collected 
for mRNA and protein analysis or replaced with serum-free medium for another 24 
hours before cells were stimulated.   
2.13 Western blot 
Buffers: Cell lysis buffer: Phosphosafe extraction buffer (Merck Chemicals, UK), 1 
tablet of protease inhibitor cocktail (Roche , UK) in per 10 ml; Laemmli buffer 5x: 
100 mM dithiothreitol (DTT) 1 M Tris (pH 6.8), 10% sodium dodecyl sulphate (SDS), 
20% glycerol, ddH2O, 0.05% bromophenol blue; Running buffer 1x: 0.1 M Tris, 0.1 M 
Hepes, 0.1% SDS, TBS-Tween: 10 nM Tris (pH8), 150 nM NaCl, 0.1% Tween-20; 
Blocking buffer: 5% non fat milk powder in TBS-Tween.  
2.13.1 Sample preparation 
Cells were seeded in 24-well plates and following appropriate treatment, cells were 
washed with cold PBS and lysed in 100 μl of lysis buffer supplemented with a 
complete protease inhibitor cocktail. Viscous lysates were scraped and collected 
into labelled Eppendorf tubes and centrifuged for 10 minutes at 13,000 g in order to 
remove cell debris. The lysates were stored at -80°C prior to use.  
 
 
  110  
  
2.13.2 Electrophoresis 
BCA assay was used to calculate protein concentration in the cell lysates as 
described in Section 2.14. For electrophoresis, an aliquot of each sample equivalent 
to 8 μg of protein was mixed with Laemmli buffer supplemented with DTT and 
incubated for 10 minutes at 70°C. The samples were then loaded onto a pre-cast 4-
12% polyacrylamide gel (Bolt Bis-Tris Plus gels, Novex, Life Technologies, UK). A Plus 
Prestained Protein Ladder (Fermentas, UK) with 10-25 kDa detection range was run 
in a separate lane to identify the molecular weights of individual proteins. 
Electrophoresis was performed at 165 V for 35 minutes. 
Dry protein transfer onto polyvinyldene difluoride (PVDF) membrane was 
performed using iBlot Gel Transfer Device (Novex, Life Technologies, UK). The 
transfer sandwich was assembled using iBlot Transfer Stacks (Novex, Life 
Technologies, UK) containing PVDF membrane fixed onto the bottom anode stack, 
filter paper and top cathode stack. The transfer parameters were set to 20 V for 7 
minutes. The quality of protein transfer was assessed by briefly staining with 2% 
Ponceau Red solution (Sigma) which was destained by a quick wash in double 
distilled water.     
2.13.3 Detection of proteins 
Following transfer, the membrane bearing the covalently bound proteins was 
incubated in blocking buffer (5% milk) for one hour at room temperature on a 
rotating platform. Then the membrane was incubated overnight at 4°C with specific 
antibodies for protein of interest diluted in blocking buffer. The next day the 
membrane was washed 3x 5 minutes in TBS-Tween and incubated for one hour at 
room temperature with specific horseradish peroxidise (HRP)- linked secondary 
antibody diluted in TBS-Tween. The membrane was washed again 3x5 minutes TBS-
Tween and then developed by enhanced chemiluminescence (ECL) following 
manufacturer’s instructions (Amersham). Immunoreactive protein bands were 
visualised by exposing the membrane to autoradiography film developer (Kodak, 
UK) and the exposure time adjusted to the strength of the signal.    
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Semi-quantitative analysis of Western blots was performed with densitometry. 
Blots underwent transmissive greyscale scanning at 300 dpi on a standard flatbed 
scanner (Epson, UK). The scanned images were transferred to the public domain 
NIH Image J 1.6 program (developed at the U.S. National Institutes of Health and 
available on the Internet) and the optical density of each protein band was 
calculated with reference to calibration curve, which was generated by scanning a 
Kodak photographic step Tablet (Kodak, UK) with known optical density, using the 
same setting as described above. The optical density of the band for the target 
protein was corrected for the loading control and therefore allowing a meaningful 
comparison between samples. 
2.14 Protein detection 
Bicinchoninic acid (BCA) protein assay (Pierce, USA) was used to measure protein 
content in lung homogenates and bronchoalveolar lavage fluid. The assay works on 
a basis of biuret reaction where protein reduces Cu2+ to Cu1+ in an alkaline medium. 
Two bicinchoninic acid molecules chelate with the reduced cuprous cation 
developing intense purple colour. The BCA- copper complex is water soluble and 
linearly proportioned to protein concentration and displaying strong absorbance at 
562 nm. The assay was performed as per manufacturer’s instructions and the 
results compared to a ten point standard curve of bovine serum albumin ranging 
from 2 mg/ml to 0.0039 mg/ml. The assay was conducted in 96-well plate format 
with 10 μl of sample in duplicate mixed with 200 μl freshly prepared BCA working 
reagent. The plate was incubated for 30min at 37°C and the absorbance measured 
at 550nm on a Titertek Multiscan MCC/340 plate reader (Labsystems, Finland).     
2.15 Intracellular calcium measurement  
The assay utilises a Ca2+-binding dye fluo-4 acetoxymethyl ester (Fluo4-AM) to 
detect changes in cytosolic calcium concentration. The non-fluorescent precursor 
form of the dye is uncharged and hence cell permeable. Inside the cell, non-specific 
esterases render the dye sensitive to binding Ca2+ ions. Cation binding causes a 
conformational and energetic change in the molecule which leads to the emission 
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of fluorescence that is proportional to the intracellular Ca2+ concentration. Fluo-4 
NW calcium assay kit was purchased from Invitrogen, UK and used as per 
manufacturer’s instructions.  
Cells were seeded 48 hours prior to experiment in black 96-well plates with a clear 
bottom. On the day of the assay 1 vial of Fluo 4-AM dye was resuspended in 10 ml 
of HBSS/Hepes assay buffer without calcium or magnesium. Cells were incubated 
with the dye, 100 μl/well, for 30 minutes at 37°C and calibrated for another 30 
minutes at room temperature. The PAR antagonists used in this study were added 
and incubated with the dye for an hour prior to the experiment. PAR agonists were 
prepared at 3x final desired concentration in assay buffer and 50 μl per well of 
appropriate compound was added to a 96-well agonist plate.  
Changes in the intracellular Ca2+ were monitored using a fluorescent image plate 
reader FLIPR Tetra (Molecular Devices, USA) and the results displayed and analysed 
using ScreenWorks software. The device is fitted with standard ECCM camera that 
records the fluorescent signal produced by light-emitting diodes (LED) that excites 
the Fluo-4AM dye at wavelength of 494 nm with emission at 516 nm. The 
fluorescence was monitored for 10 seconds before the agonists were 
simultaneously dispensed to the 96-well plate by the overhead pipettor. Two 
reading protocols were used depending on the cell type tested. Standard protocol 
recorded readings every second for first 60 seconds and every 6 seconds for the 
next 120 seconds. Extended protocol recorded readings every second for 180 
seconds and every 6 seconds for another seven minutes. The change in intracellular 
calcium [Ca2+] was quantified as an increase in relative fluorescence units (RFUs). 
The difference between maximum and minimum RFU was used to plot the results.  
2.16 Immunocytofluorescence 
Cells were seeded in 8-well chamber slides (Fisher Scientific, UK) and cultured for 48 
hours in a humidified atmosphere with 5% or 10% CO2 at 37°C. Depending on cell 
type, serum-starvation was carried out for 24 hours. Cells were subsequently 
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treated for another 24 hours or washed in PBS and fixed with 4% paraformaldehyde 
for 10 minutes at room temperature. Cells were washed and stored in PBS. 
Cells were subsequently permeabilised in 0.4% Triton-X for 10 minutes and blocked 
in 3% bovine serum albumin (BSA), 5% goat serum in PBS for 1 hour. Following 
three washes with PBS, 2 minutes each, cells were incubated with appropriate 
antibodies, as listed in Table 2.1, for two hours. The primary antibodies were 
washed off in PBS and cells incubated with 1:100 dilution of secondary antibodies 
FITC- or PE-conjugated (Alexa Fluor 488 and Alexa Fluor 555, Invitrogen, UK) for 
another two hours. Again, three washes were performed and the side walls of the 
chambers carefully removed. Coverslips were mounted onto each slide using three 
drops of mounting medium containing 4,6-Diamidino-2-phenylindole (DAPI, 405) 
which is highly sensitive nucleic acid stain. Images were captured using confocal 
laser scanning microscopy Zeiss 700.           
2.17 ELISA 
DuoSet ELISA Development kits were purchased from R&D Systems, USA, and IFNγ 
and TNFα were bought from Biolegend, UK. Microtest TM 96-well ELISA plates were 
purchased from BD Biosciences, Pharmingen, USA. ELISA detections were 
performed according to manufacturer’s instructions and a general standard 
protocol is described briefly. Microtest TM 96-well ELISA plates were coated with 50 
μl capture antibody diluted in PBS and incubated overnight at 4°C. The next day 
plates were washed with the 0.05% Tween® in PBS wash buffer and blocked with 
150 μl 1% BSA in PBS reagent diluent for minimum 1 hour. After the blocking step, 
plates were washed again and 50 μl of sample and the serial dilutions of the 
standard were added and incubated for 2 hours. Following incubation the plates 
were washed again and incubated for another 2 hours with detection antibody. 
Next Streptavidin-HRP (1:200 dilution) was added and plates incubated for 30 
minutes. After the incubation and washing step, the plates were incubated with 
Tetramethylbenzidine (TMB, Invitrogen, UK)TMP Substrate for approximately 20 
minutes and the reaction terminated with 1M H2SO4 stop solution. The optical 
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density was measured using a plate reader (Multiskan MCC/340, Titertek) at dual 
wavelength A1: 450nm and A2: 540nm. 
2.18 Statystical analysis  
All data in the figures are presented as mean values ± SEM, unless indicated 
otherwise. Statistical analysis was performed between two treatment groups by 
Student’s t-test or Mann-Whitney U test, and between multiple treatment groups 
by one-way analysis of variance (ANOVA) with Tukey post-hoc testing or two-way 
ANOVA with Bonferroni post-hoc test, using Graphpad Prism 5 software. The mean 
values of various parameters were considered to be significantly different when the 
p value was calculated to be less than 0.05. 
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Chapter 3: Results 
3.1 Characterisation of PAR-1 expression and signalling 
in human lung 
3.1.1 Introduction 
Coagulation factors, FXa and thrombin, can act as a danger signals and orchestrate 
inflammatory and tissue repair responses via activation of proteinase activated 
receptors PARs, particularly PAR-1 and PAR-2. Immunohistochemistry studies 
suggest that PAR-1 and PAR-2 are widely expressed in the normal and fibrotic lungs 
(Borensztajn et al., 2010; Mercer et al., 2009) and PAR-1 is overexpressed in lung 
cancer (Cisowski et al., 2011). In lung fibroblasts PAR-1 gene and protein expression 
has been shown to be regulated by a negative feedback mechanism, where PAR-1 
activation induces prostaglandin PGE2 release which in turn inhibits PAR-1 
expression in a time-dependent manner (Sokolova et al., 2005). Furthermore, the 
transcriptional regulation of PAR-1 has been recently a focus in the context of 
cancer research as PAR-1 overexpression in carcinoma cells is associated with an 
aggressive and metastatic phenotype (Nierodzik and Karpatkin, 2006).  
However, the mechanisms of PAR-1 expression and upregulation are not fully 
elucidated and the current findings suggest that PAR-1 regulation is both tissue- and 
cell-specific. Furthermore, our understanding of the role of PAR-1 and PAR-2 
signalling in lung disease comes largely from experimental models of lung injury and 
fibrosis. Although some of the in vivo findings have been translated to human 
biology, there is a need to further understand PAR-1 signalling in human primary 
cells. Therefore, the aim of this study was to gain detailed insight into the relative 
importance of PAR-1 and PAR-2 signalling responses in human primary lung cells: 
fibroblasts, alveolar and bronchial epithelial cells, and lung microvascular 
endothelial cells. Furthermore, using selective pharmacological tools we tested the 
specificity of observed responses and began to dissect which cell types are the most 
important and relevant for potential therapeutic PAR targeting. Finally, PAR-1 
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activation directly leads to release of active TGFβ and we asked whether this key 
profibrotic cytokine affects PAR-1 expression and signalling in human primary lung 
cells.  
3.1.2 PAR-1 expression and signalling in primary human lung 
fibroblasts 
Thrombin is a potent mesenchymal cell mitogen (Furuhashi et al. 2008; Howell et al. 
2001) and an inducer of fibroblast to myofibroblasts differentiation (Bogatkevich et 
al., 2001). It also stimulates production and secretion of collagen (Chambers et al., 
1998), growth factors such as CTGF (Chambers et al., 2000), FGF2 (Duarte et al., 
2006), chemokines and cytokines such as CCL2 (Deng et al., 2008; Ortiz-Stern et al., 
2012). 
Thrombin proteolytically cleaves the extracellular N-terminus of PAR-1 and unmasks 
the tethered ligand, which then interacts with the second extracellular loop of the 
receptor. This interaction causes a conformational change of the receptor, which in 
turn leads to uncoupling of G-protein bound to the intracellular part of the receptor 
and downstream signalling via multiple pathways. Gαq is one of three G-proteins 
types that form stable complexes with PAR-1 and upon uncoupling promotes the 
release of the intracellular calcium via phospholipase C and inositol trisphosphate-
dependent mechanisms (McCoy et al., 2012). Mobilisation of calcium from 
intracellular stores leads to transient and robust increases in cytoplasmic 
concentration from 10-7 M to 10-3 M. Calcium as a second messenger influences 
multiple signalling pathways involved in fibroblasts proliferation (LaMorte et al., 
1993), differentiation (Baffy et al., 1994), production and release of CCL2 (Deng et 
al., 2008; Ortiz-Stern et al., 2012). FXa is also able to cleave PAR-1 and has been 
shown to promote fibroblast proliferation and collagen production (Blanc-Brude et 
al., 2005; Scotton et al., 2009).  
Previous research in our laboratory used single cell cytosolic calcium 
spectrofluorometry to demonstrate that thrombin and FXa signalling leads to 
release of intracellular calcium albeit there are marked differences in the kinetics, 
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magnitude and concentration of the agonist required to elicit the response (Blanc-
Brude et al., 2005). Using a high throughput intracellular calcium monitoring assay, 
the aim of this study was to expand on these previous findings in primary human 
lung fibroblasts and to characterise PAR-1 and PAR-2 signalling responses in these 
cells. Furthermore, the effect of TGFβ stimulation on PARs responses was examined.  
3.1.2.1 Intracellular calcium flux downstream of PAR-1 and 
PAR-2 activation in lung fibroblasts 
In agreement with previous data, both thrombin and FXa elicit a calcium response in 
primary human lung fibroblasts. Figure 3.1 shows representative traces of 
intracellular calcium flux in response to PAR-1 and PAR-2 agonists. The baseline was 
monitored for 10 seconds prior to exposure of fibroblasts to exogenous agonists. 
Addition of thrombin (10 nM) elicited an immediate response with a sharp increase 
suggestive of a simultaneous and synchronised release of intracellular calcium from 
a collective pool of cells. The calcium signal peaked 15 seconds after stimulation and 
lasted for approximately 60 seconds before returning to baseline (Figure 3.1A). In 
comparison, a 10-fold higher concentration of FXa was required to trigger a calcium 
response in fibroblasts. Following addition of FXa (100 nM) an increase in 
fluorescent signal was observed with a 20 second delay. The intracellular calcium 
release in response to FXa was of lower magnitude in comparison to the thrombin-
mediated response and only of slightly extended duration (Figure 3.1B). As 
expected, the PAR-1 activating peptide, TFLLR, elicited a calcium flux of magnitude 
and duration equivalent to that observed for thrombin (Figure 3.1C). PAR-2 has also 
been shown to couple to Gαq (McCoy et al. 2010) and the PAR-2 activating peptide 
(SLIGKV) also triggered intracellular calcium release in fibroblasts (Figure 3.1C). 
However, the response to SLIGKV was of smaller magnitude than that of TFLLR and 
resembled the delayed activation wave observed with FXa.  
The release of intracellular calcium in fibroblasts was agonist concentration-
dependent. Cells were stimulated with a range of thrombin concentrations between 
10 pM and 100 nM and intracellular calcium release was readily detected from 0.3 
nM thrombin onwards, with an EC50 of 1.5 nM (Figure 3.2A). TFLLR also elicited an 
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intracellular calcium release in a concentration-dependent manner with an EC50 of 
3.7 μM (Figure 3.3A). Exposure to TGFβ for 24 hours prior to thrombin or TFLLR 
stimulation did not affect the responsiveness of fibroblasts to thrombin (Figures 
3.2B and 3.3B). The release of intracellular calcium in response to FXa stimulation 
was only observed at high FXa concentration with an EC50 of 150 nM (Figure 3.4). 
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Figure 3.1. Intracellular calcium signalling in response to PAR-1 and PAR-2 agonists 
in primary human lung fibroblasts.  
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates, 
serum-starved for 24 hours and incubated with Fluo-4AM calcium binding dye for 
one hour prior to stimulation with thrombin (10 nM), FXa (100 nM), PAR-1 
activating peptide TFLLR (100 µM), PAR-2 activating peptide SLIGKV (100 µM). The 
release of intracellular calcium was monitored by FLIPR® Tetra with baseline 
recorded for 10 seconds before agonist addition and responses measured for 
another 170 seconds. Data are represented as increase in relative fluorescence 
units (RFU) from the baseline. Panel A shows representative traces for thrombin-
mediated calcium flux, panel B- FXa and panel C- TFLLR and SLIGKV. Each data point 
represents the mean +/- SEM of 3-4 replicate wells.  
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Figure 3.2. Concentration-response curve in primary human lung fibroblasts 
following thrombin stimulation.     
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates 
and serum-starved with or without TGFβ (1 ng/ml) for 24 hours. Cells were then 
incubated with Fluo-4AM calcium binding dye before being exposed to different 
concentrations of thrombin. The release of intracellular calcium was monitored by 
FLIPR® Tetra with calcium baseline recorded for 10 seconds before thrombin 
addition and responses measured for another 170 seconds. Data are represented as 
increase in relative fluorescence units (RFU) from the baseline. Panel A shows a 
concentration-response curve to thrombin and panel B is a comparison of response 
to thrombin when cells were pre-incubated with TGFβ. Each data point represents 
the mean +/- SEM of 3-4 replicate wells. 
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Figure 3.3. Concentration-response curve in primary human lung fibroblasts 
following TFLLR stimulation.     
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates 
and serum starved with or without TGFβ (1 ng/ml) for 24 hours. Cells were 
incubated with Fluo-4AM calcium binding dye before being exposed to different 
concentrations of PAR-1 activating peptide TFLLR. The release of intracellular 
calcium was monitored by FLIPR® Tetra with calcium baseline recorded for 10 
seconds before TFLLR addition and responses measured for another 170 seconds. 
Data are represented as increase in relative fluorescence units (RFU) from the 
baseline. Panel A shows a concentration-response curve to TFLLR and panel B is a 
comparison of response when cells were pre-incubated with TGFβ. Each data point 
represents the mean +/- SEM of 3-4 replicate wells.  
 
 
  122  
  
 
 
 
 
  
 
 
 
 
 
Figure 3.4. Concentration-response curve in primary human lung fibroblasts 
following FXa stimulation.      
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates 
and serum starved for 24 hours. Cells were incubated with Fluo-4AM calcium 
binding dye before being exposed to different concentrations of FXa. The release of 
intracellular calcium was monitored by FLIPR® Tetra with calcium baseline recorded 
for 10 seconds before FXa addition and responses measured for another 170 
seconds. Data are represented as increase in relative fluorescence units (RFU) from 
the baseline. Data are presented as a concentration-response curve to FXa with 
each data point representing the mean +/- SEM of 3-4 replicate wells.  
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3.1.2.2 PAR-1 and PAR-2 expression in lung fibroblasts  
PAR-1 and PAR-2 expression in primary human lung fibroblast was next assessed by 
immunocytofluorescence. Vimentin was used as mesenchymal cell markers and as 
shown in Figure 3.5 fibroblasts intensely expressed vimentin and showed 
characteristic elongated shape. The intensity of PAR-1 was strong with the 
distribution of the receptor throughout the periphery of cells as well as within the 
cytoplasm and around the nucleus. Following stimulation of fibroblasts with TGFβ (1 
ng/ml) for 24 hours, the intensity of PAR-1 staining did not change. Fibroblasts also 
expressed high levels of PAR-2 and the distribution of the receptor was similar to 
PAR-1 with expression in the periphery of cells as well as within the cytoplasm and 
around the nucleus (Figure 3.6). Again, the TGFβ treatment did not appear to have 
any effect on PAR-2 expression.  
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Figure 3.5. PAR-1 expression in primary human lung fibroblasts.     
Primary human lung fibroblasts were seeded at a density of 3x104 in chamber slides 
and allowed to reach over 80% confluence. Cells were serum starved with or 
without TGFβ (1 ng/ml) for 24 hours, fixed in paraformaldehyde and stained for 
PAR-1 (Alexa 555) and vimentin (Alexa 488). DAPI was used to visualise the nucleus. 
The top panel shows images for control cells and lower panels show the staining of 
TGFβ-stimulated cells, x20 original magnification.  
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Figure 3.6. PAR-2 expression in primary human lung fibroblasts.     
Primary human lung fibroblasts were seeded at a density of 3x104 in chamber slides 
and allowed to reach over 80% confluence. Cells were serum starved with or 
without TGFβ (1 ng/ml) for 24 hours, fixed in paraformaldehyde and stained for 
PAR-2 (Alexa 555) and vimentin (Alexa 488). DAPI was used to visualise the nucleus. 
The top panel shows images for control cells and lower panels show the staining of 
TGFβ-stimulated cells, x20 original magnification.  
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3.1.2.3 Intracellular calcium release in lung fibroblasts is PAR-
1-dependent and PAR-2-independent  
Previous data from our laboratory have shown that in murine lung fibroblasts from 
PAR-1 knockout mice, thrombin and FXa fail to induce intracellular calcium release 
(Blanc-Brude et al., 2005). It has been challenging to recapitulate these findings in 
primary human lung fibroblasts, which express PAR-1 in abundance. We addressed 
the question of PAR-1 and PAR-2 contribution to intracellular calcium release in 
response to coagulation factors using PAR-1 specific antagonists, RWJ58259 and 
SCH530348, and the PAR-2 antagonist, GB83. 
The specificity of the antagonists was validated first. RWJ58259 (Damiano et al., 
2003) and GB83 (Suen et al., 2012) are small molecule antagonists that 
competitively bind to the second extracellular loop of PAR-1 and PAR-2, 
respectively, which are the sites of interaction between the tethered ligand and the 
receptor. TFLLR and SLIGKV are small mimetic peptides that activate PAR-1 and 
PAR-2, respectively, by binding also to the second extracellular loop. As shown in 
Figure 3.7A, TFLLR-mediated calcium responses were fully blocked by the PAR-1 
antagonist and unaffected by the PAR-2 antagonist. In Figure 3.7B the calcium flux 
was induced by the PAR-2 activating peptide and consequently blocked by the PAR-
2 antagonist. The PAR-1 antagonist did not affect PAR-2 activation by the agonist 
peptide. 
As shown in Figure 3.8, thrombin-mediated PAR-1 activation elicited a significant 
increase in intracellular calcium flux and this response was dependent on thrombin 
enzymatic activity. Pre-incubation of thrombin with hirudin that yields it 
catalytically inert caused complete inhibition of calcium flux. PAR-1 antagonists 
(RWJ58259 and SCH580348) also completely blocked the release of intracellular 
calcium strongly suggesting that this response was entirely PAR-1 mediated. In 
contrast, the PAR-2 antagonist (GB83) did not affect the thrombin response.  
Similarly FXa triggered a significant increase in intracellular calcium flux but the 
response was half the magnitude of the thrombin response. FXa-mediated calcium 
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flux was also fully inhibited by the PAR-1 antagonists but not by the PAR-2 inhibitor 
(Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Selective antagonists block PAR-1- and PAR-2-mediated calcium 
signalling.   
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates 
and serum starved 24 hours prior to stimulation with TFLLR and SLIGKV (each at 100 
μM). Cells were incubated with Fluo-4AM calcium binding dye with or without PAR-
1 inhibitor RWJ58259 (3 µM) or PAR-2 antagonist GB83 (50 µM). The release of 
intracellular calcium was monitored by FLIPR® Tetra with calcium baseline recorded 
for 10 seconds before agonist addition and response measured for another 170 
seconds. Data are represented as increase in relative fluorescence units (RFU) from 
the baseline. Panel A shows calcium responses in cells stimulated with TFLLR and 
panel B- SLIGKV. Each data point represents the mean +/- SEM of 3-4 replicate 
wells, one-way ANOVA, ***p<0.01 relative to control cells, +p<0.05, +++p<0.01 
relative to TFLLR/SLIGKV responses.  
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Figure 3.8. Thrombin-mediated intracellular calcium signalling in fibroblasts is 
PAR-1- dependent and PAR-2-independent.  
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates 
and serum starved 24 hours prior to stimulation with thrombin (10 nM) or thrombin 
(10 nM) pre-incubated with hirudin (50 nM). Cells were incubated with Fluo-4AM 
calcium binding dye with or without PAR-1 inhibitors RWJ58259 (3 µM) and 
SCH530348 (3 µM) or PAR-2 antagonist GB83 (50 µM). The release of intracellular 
calcium was monitored by FLIPR® Tetra with calcium baseline recorded for 10 
seconds before thrombin addition and responses measured for another 170 
seconds. Data are represented as increase in relative fluorescence units (RFU) from 
the baseline. Upper panel shows the representative intracellular calcium flux traces 
for hirudin inhibition-A, PAR-1 inhibition-B, PAR-2 inhibition-C. Panel D shows a 
graph of different treatments effect on calcium responses in cells stimulated with 
thrombin. Each data point represents the mean +/- SEM of 3-4 replicate wells, one-
way ANOVA, ***p<0.01 relative to control cells, +++p<0.01 relative to thrombin 
responses, ns non-significant.  
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Figure 3.9. FXa-mediated intracellular calcium signalling in fibroblasts is PAR-1 
dependent and PAR-2 independent.  
Primary human lung fibroblasts were seeded at a density of 1x104 in 96-well plates 
and serum starved 24 hours prior to stimulation with FXa (150 nM). Cells were 
incubated with Fluo-4AM calcium binding dye with or without PAR-1 inhibitors 
RWJ58259 (3 µM) and SCH530348 (3 µM) or PAR-2 antagonist GB83 (50 µM). The 
release of intracellular calcium was monitored by FLIPR® Tetra with calcium 
baseline recorded for 10 seconds before FXa addition and responses measured for 
another 170 seconds. Data are represented as increase in relative fluorescence 
units (RFU) from the baseline. Upper panel representative traces of intracellular 
calcium flux with PAR-1 inhibition-A and PAR-2 inhibition-B. Panel C shows the 
effect of different treatments on calcium responses in cells stimulated with FXa. 
Each data point represents the mean +/- SEM of 3 replicates, one-way ANOVA, 
***p<0.01 relative to control cells, +++p<0.01 relative to FXa responses, ns non-
significant.  
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3.1.2.4 Summary  
 Human primary lung fibroblasts express PAR-1 and PAR-2 and activation of 
these receptors leads to a robust and transient increase in intracellular 
calcium release. 
 The pro-fibrotic cytokine TGFβ does not affect PAR-1 signalling responses in 
fibroblasts.   
 Fibroblasts elicit robust responses when PAR-1 is activated by thrombin, 
even at low nanomolar concentrations. In contrast high FXa concentration is 
required to trigger intracellular calcium responses. There are marked 
differences in the kinetics of intracellular calcium responses mediated by 
thrombin and FXa.  
 Thrombin and FXa trigger intracellular calcium release in PAR-1-dependent 
and PAR-2-independent pathway as examined using specific antagonists. 
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3.1.3 PAR-1 expression and signalling in human alveolar 
epithelium  
PAR-1 is abundantly expressed in primary human lung fibroblasts, which signal 
robustly to coagulation proteinases. In contrast, PAR-1 and PAR-2 signalling 
responses to thrombin and FXa are less characterised in alveolar epithelium and will 
be the focus of this section. The alveolar epithelium is composed of two cell types. 
Type I pneumocytes (alveolar epithelial cells type I; AECI) are simple squamous and 
non-proliferating epithelial cells that line the alveolar spaces and facilitate the gas 
exchange. Type II pneumocytes (alveolar epithelial cells type II; AECII) are cuboidal 
in shape and are highly synthetic for chemokines and cytokines as well as being the 
main source of surfactants in the lung necessary for maintaining lung compliance. 
AECII also have large regenerative potential and in case of injury to the epithelium 
can proliferate and differentiate into AECI to restore epithelial barrier integrity. 
Damage to the alveolar epithelium, particularly AECII is the first step in the 
development of multiple detrimental lung conditions, including acute lung injury 
and fibrosis. TGFβ, a central profibrotic cytokine, exerts pleiotropic effects on 
epithelial cells that is highly dependent on the local environment and can promote 
apoptosis (Degryse et al., 2011), epithelial to mesenchymal transition (Kim et al., 
2007) and migration (Yu et al., 2008). In the fibrotic lung, PAR-1 is upregulated in 
the abnormal and hyperplastic epithelium in comparison to normal epithelium 
(Mercer et al., 2009). PAR-1 along with the remaining PAR receptors is also 
upregulated in endotoxin-induced model of acute lung injury (Jesmin et al., 2004, 
2007).  
In this series of experiments, PAR-1 expression and signalling in the alveolar 
epithelium was examined. Growing a fibrotic alveolar epithelium in vitro is currently 
not feasible due to lack of access to clinical specimens and technical limitations. 
However, in our laboratory we are able to isolate normal human alveolar epithelial 
cells from lung explants but the numbers of cells have always been limited and 
culturing them has been challenging. To date the most representative and widely 
used model of abnormal alveolar epithelium has been the A549 cell line, which is a 
hypotripoid human adenocarcinoma cell line. Although A549 cells have been 
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derived from a tumour, they display several characteristics of AECII including 
polygonal morphology, production of surfactants and the presence of cytoplasmic 
lamellar bodies (Lieber et al., 1976). A549 cells were therefore used in these 
experiments as an initial model of alveolar epithelial cells and responses found in 
A549 cell line were subsequently verified in freshly isolated normal human primary 
type II alveolar epithelial cells.   
3.1.3.1 Intracellular calcium signalling in A549 in response to 
different agonist and following stimulation with TGFβ 
Intracellular calcium release in A549 cells was measured in response to stimulation 
with coagulation enzymes and PAR activating peptides. In these cells, thrombin-
induced calcium flux occurred within 20 seconds after stimulation and the signal 
lasted for approximately 100 seconds before returning to baseline. The magnitude 
of the response was lower when compared with the calcium flux observed in 
primary human lung fibroblasts and a higher concentration of thrombin (30 nM) 
was required to achieve consistent and reproducible responses. Stimulation of A549 
cells with TGFβ (1 ng/ml) for 24 hours significantly changed the kinetics of the 
thrombin-mediated calcium response. The delay between the addition of the 
agonist and onset of the signal was reduced and the magnitude of intracellular 
calcium release in response to thrombin was increased (Figure 3.10A). All responses 
were inhibited with the PAR-1 specific antagonist, RWJ58259.  
Similarly to fibroblasts, high concentrations of FXa were required to trigger calcium 
release in A549 cells. The response occurred with a 40 second delay from the 
addition of FXa, was of low magnitude and short duration. All the parameters of the 
intracellular calcium response to FXa were augmented with prior TGFβ stimulation 
for 24 hours (Figure 3.10B).    
Figures 3.10C and 3.10D show that intracellular calcium responses to PAR-1 and 
PAR-2 activating peptides were robust in A549 cells. Furthermore, the onset of 
responses was similar between the two PAR activating peptides suggesting that in 
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A549 cells both PAR-1 and PAR-2 strongly couple to Gαq and hence trigger similar 
release of intracellular calcium. However, the magnitude of the intracellular calcium 
flux downstream of PAR-2 activation was greater in comparison to PAR-1 signalling, 
suggesting that A549 epithelial cells express more PAR-2 than PAR-1. Responses to 
PAR-1 and PAR-2 activating peptides were further enhanced with TGFβ pre-
stimulation.  
As summarised in Figure 3.11A, pre-stimulation of A549 cells with TGFβ significantly 
increased PAR-1 and PAR-2-mediated intracellular calcium fluxes in response to all 
agonists used: thrombin, FXa, TFLLR and SLIGKV. Thrombin enzymatic activity was 
again necessary to trigger the release of intracellular calcium and treatment with 
hirudin completely abolished this signalling response (Figure 3.11B). Furthermore, 
intracellular calcium release was inhibited by the PAR-1 antagonist, RWJ58259. The 
PAR-2 antagonist GB83 partially blocked thrombin-induced intracellular calcium 
release, which suggests that PAR-2 may be partially involved in thrombin-mediated 
signalling in A549 cells. It is possible that PAR-1 transactivates PAR-2 in the alveolar 
epithelium, an event that has been previously reported for endothelium (O’Brien et 
al., 2000).    
Next the concentration range of thrombin capable of triggering calcium responses 
was investigated in A549 cells. Thrombin was found to induce intracellular calcium 
flux in A549 in a concentration-dependent manner with an EC50 of ~13 nM (Figure 
3.12A). When cells had been pre-treated with TGFβ for 24 hours the EC50 was 
achieved at ~20 nM thrombin but the magnitude of response was 2.5 fold higher 
(Figure 3.12B). The significant increase in maximal response to thrombin with TGFβ 
pre-stimulation suggests that TGFβ increased PAR-1 expression in A549 cells.    
At low concentrations FXa failed to elicit a detectable intracellular calcium release in 
A549 cells and the intracellular calcium response increased sharply at the highest 
concentrations of FXa. Pre-treatment with TGFβ for 24 hours again significantly 
increased the maximal response in A549 cells to FXa stimulation (Figure 3.13). In 
this experiment the concentration of FXa was taken up to 600 nM, at which point 
the calcium flux did not reach a plateau. However, this concentration greatly 
 
 
  134  
  
exceeds the physiological concentrations of FXa that can be achieved in any body 
compartment as estimated by the total level of circulating FX being 174 nM (Mann, 
1999). For that reason FXa was not used at higher concentration.     
Taken together, these data show that calcium signalling downstream of specific 
PAR-1 activation is enhanced with TGFβ pre-treatment and that these responses are 
abolished with the PAR-1 specific inhibitor, RWJ58259. Therefore, the direct effect 
of TGFβ on PAR-1 expression was investigated further. 
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Figure 3.10. Intracellular calcium signalling in response to PAR-1 and PAR-2 
agonists in A549 alveolar epithelial cells.  
Human lung epithelial cells A549 were seeded at a density of 2x104 in 96-well plates 
and serum-starved 24 hours with or without exposure to TGFβ (1 ng/ml), then 
incubated with Fluo-4AM calcium binding dye with or without PAR-1 inhibitor 
RWJ58259 (3 µM), prior to stimulation with thrombin (30 nM), FXa (100 nM), PAR-1 
activating peptide TFLLR (100 µM), PAR-2 activating peptide SLIGKV (100 µM). The 
release of intracellular calcium was monitored by FLIPR® Tetra with calcium 
baseline recorded for 10 seconds before agonist addition and response measured 
for another 170 seconds. Data are represented as increase in relative fluorescence 
units (RFU) from the baseline. Panel A shows representative traces for thrombin-
mediated calcium flux, panel B- FXa, panel C- TFLLR and panel D- SLIGKV. Each data 
point represents the mean +/- SEM of 3-4 replicate wells.  
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Figure 3.11. Pre-stimulation with TGFβ enhances PAR-1-mediated calcium 
signalling in human alveolar epithelial A549 cells.     
Human epithelial cells A549 were seeded at a density of 2x104 in 96-well plates and 
serum- starved with or without TGFβ (1 ng/ml) 24 hours and incubated with Fluo-
4AM calcium binding dye for one hour with or without PAR-1 antagonist RWJ58259 
(3 μM) and PAR-2 antagonist GB83 (50 μM) prior to stimulation with agonists: 
thrombin (30 nM), thrombin (30 nM) pre-incubated with hirudin (150 nM), TFLLR 
and SLIGKV (each at 100 μM). The release of intracellular calcium was monitored by 
FLIPR® Tetra with calcium baseline recorded for 10 seconds before agonist addition 
and response measured for another 170 seconds.Data are represented as increase 
in relative fluorescence units (RFU) from the baseline. Panel A shows intracellular 
calcium responses mediated by PAR-1 and PAR-2 agonists. Panel B shows effect of 
inhibitors on calcium signalling. Each data point represents the mean +/- SEM of 3-4 
replicate wells, two-way ANOVA, ***p<0.001 comparison between control and 
TGFβ-pre-treated cells; +++p<0.001 comparison of treatments with relevant control. 
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Figure 3.12. Concentration-response curve in A549 alveolar epithelial cells 
following thrombin stimulation.      
Human epithelial A549 cells were seeded at a density of 2x104 in 96-well plates and 
serum starved with or without TGFβ (1 ng/ml) 24 hours and incubated with Fluo-
4AM calcium binding dye for one hour, prior to stimulation with different 
concentrations of thrombin. The release of intracellular calcium was monitored by 
FLIPR® Tetra with calcium baseline recorded for 10 seconds before thrombin 
addition and response measured for another 170 seconds. Data are represented as 
increase in relative fluorescence units (RFU) from the baseline. Panel A shows a 
concentration-response curve to thrombin and panel B is a comparison of response 
when cells were exposed to TGFβ for 24 hours. Each data point represents the 
mean +/- SEM of 3-4 replicate wells; Two-way ANOVA, ***p<0.001 comparison of 
control and TGFβ pre-treated cells.  
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Figure 3.13. Concentration-response curve in A549 alveolar epithelial cells 
following FXa stimulation.         
Human epithelial A549 cells were seeded at a density of 2x104 in 96-well plates and 
serum starved with or without TGFβ (1 ng/ml) 24 hours and incubated with Fluo-
4AM calcium binding dye for one hour, prior to stimulation with different 
concentrations of FXa. The release of intracellular calcium was monitored by FLIPR® 
Tetra with calcium baseline recorded for 10 seconds before FXa addition and 
response measured for another 170 seconds. Data are represented as increase in 
relative fluorescence units (RFU) from the baseline. Panel A shows a concentration-
response curve to thrombin and panel B is a comparison of response when cells 
were exposed to TGFβ for 24 hours. Each data point represents the mean +/- SEM 
of 3-4 replicate wells; Two-way ANOVA, ***p<0.001 comparison of control and 
TGFβ pre-treated cells.  
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3.1.3.2 TGFβ upregulates PAR-1 expression in A549 alveolar 
epithelial cells  
In order to examine the role of TGFβ in modulating PAR-1 signalling responses to 
thrombin, TGFβ concentration-response experiments were carried out next. A549 
cells were incubated with different concentrations of TGFβ for 24 hours and 
subsequently stimulated with thrombin or TFLLR. TGFβ pre-treatment increased the 
magnitude of intracellular calcium signalling response in a concentration-dependent 
manner when A549 cells were stimulated with thrombin (EC50 of 0.15 ng/ml TGFβ) 
and TFLLR (EC50 of 2 ng/ml TGFβ) (Figure 3.14).  
The effect of TGFβ stimulation on PAR-1 expression was subsequently investigated. 
As shown in Figure 3.15, unstimulated A549 cells were found to express PAR-1 on 
the cell surface at baseline and the expression was enhanced following exposure to 
TGFβ for 24 hours. A549 cells also expressed PAR-2 and the levels of PAR-2 were 
also further enhanced by TGFβ pre-treatment (Figure 3.16). It has previously been 
shown that TGFβ induces epithelial to mesenchymal transition (EMT) in epithelial 
and cancer cells and the hallmark of this phenotypic change is reduced expression 
of epithelial cell markers such as E-cadherin (Dubois-Marshall et al., 2011). In this 
immunocytofluorescence study E-cadherin was used as a marker of epithelial cell 
phenotype. Figures 3.15 and 3.16 show that after exposure of A549 cells to TGFβ 
for 24 hours the intensity of E-cadherin staining diminished when compared to 
control but was still present. This suggests that although the levels of E-cadherin 
appear to be reduced, the A549 cells have not yet undergone change of phenotype. 
Therefore, increased PAR-1 expression could be an early TGFβ-mediated event but 
is not associated with a visible phenotypic change at this time point.    
Stimulation of A549 with TGFβ also led to a significant upregulation of PAR-1 mRNA 
levels from 8 hours through to 24 hours, with a near 5-fold maximal increase at 16 
hours (Figure 3.17). Research in our and other laboratories has shown that PAR-1 
activation promotes the integrin-mediated activation of TGFβ via αvβ6 integrins on 
epithelial cells (Jenkins et al., 2006) and αvβ5 integrins on fibroblasts (Scotton et al., 
2009). Therefore, the next question was whether PAR-1 upregulation in A549 cells 
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was also associated with increased expression of integrins. As shown in Figure 3.18, 
the αv subunit was significantly upregulated at the mRNA level from 6 hours of 
TGFβ stimulation (Figure 3.18A) and the β6 subunit mRNA level increased from 4 
hours onwards (Figure 18B). Both integrin subunits remained significantly elevated 
throughout the duration of the experiment (24 hours).  
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Figure 3.14. TGFβ concentration-response curves in A549 alveolar epithelial cells.  
Human alveolar epithelial A549 cells were seeded at a density of 2x104 in 96-well 
plates and serum starved with varying concentrations of TGFβ for 24 hours prior to 
stimulation with thrombin or TFLLR. Cells were incubated with Fluo-4AM calcium 
binding dye for one hour before being exposed to panel A- thrombin (30 nM) and 
panel B- TFLLR (100µM). The release of intracellular calcium was monitored by 
FLIPR® Tetra with calcium baseline recorded for 10 seconds before thrombin or 
TFLLR addition and response measured for another 170 seconds. Data are 
represented as increase in relative fluorescence units (RFU) from the baseline. Each 
data point represents the mean +/- SEM of 3-4 replicate wells. 
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PAR-1 expression in A549: 
24 hours control 
 
 
 
 
 
 
 
 
24 hours TGFβ 
 
 
 
 
 
 
 
 
Figure 3.15. PAR-1 expression in A549 alveolar epithelial cells.     
Human lung epithelial A549 cells were seeded at a density of 5x104 in chamber 
slides and allowed to reach over 80% confluence. Cells were then serum starved 
with or without TGFβ (1 ng/ml) for 24 hours, fixed in paraformaldehyde and stained 
for PAR-1 (Alexa 555) and E-cadherin (Alexa 488), DAPI was used to visualise the 
nucleus. The top panel shows images for control cells and lower panel show the 
staining of TGFβ-stimulated cells, x20 original magnification.  
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PAR-2 expression in A549: 
24 hours control 
 
 
 
 
 
 
 
 
24 hours TGFβ 
 
 
 
 
 
 
 
 
Figure 3.16. PAR-2 expression in A549 alveolar epithelial cells.     
Human lung epithelial A549 cells were seeded at a density of 5x104 in chamber 
slides and allowed to reach over 80% confluence. Cells were then serum starved 
with or without TGFβ (1 ng/ml) for 24 hours, fixed in paraformaldehyde and stained 
for PAR-2 (Alexa 555) and E-cadherin (Alexa 488), DAPI was used to visualise the 
nucleus. The top panel shows images for control cells and lower panel show the 
staining of TGFβ-stimulated cells, x20 original magnification. 
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Figure 3.17. TGFβ upregulates F2R/PAR-1 mRNA levels in A549 alveolar epithelial 
cells.     
Human alveolar epithelial A549 cells were seeded at a density of 5x104 in 24-well 
plates and serum starved with or without TGFβ (1ng/ml) for 24 hours. The mRNA 
was collected at indicated times in the course of 24 hours. PAR-1 expression was 
quantified by real-time qPCR. Each data point represents the mean +/- SEM of 3 
replicates, statistically analysed by Two-way ANOVA, **p<0.01, ***p<0.001 in 
comparison to control.    
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Figure 3.18. TGFβ upregulates mRNA levels of integrin subunits αv (ITGAV) and β6 
(ITGB6) in A549 alveolar epithelial cells.  
Human epithelial cells A549 were seeded at a density of 5x104 in 24-well plates and 
serum- starved with or without TGFβ (1ng/ml) for 24 hours. The mRNA was 
collected at indicated times. Expression of integrin subunits αv- panel A and β6- 
panel B was quantified by real-time qPCR. Each data point represents the mean +/- 
SEM of 3 replicate wells, two-way ANOVA was performed for statistical analysis, 
*p<0.05, **p<0.01, ***p<0.001 comparison of TGFβ pre-treated vs control cells at 
each time point.    
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3.1.3.3 Mechanism of TGFβ-mediated upregulation of PAR-1 
expression in A549 alveolar epithelial cells  
In order to further investigate whether the observed responses are TGFβ-
dependent, A549 cells were treated with the TGFβ ALK5 receptor inhibitor 
SB431542, for 30 minutes prior to addition of TGFβ. Intracellular calcium responses 
to thrombin were measured 24 hours later. SB431542 inhibited the TGFβ-mediated 
increase in thrombin-induced intracellular calcium flux in a concentration-
dependent manner with an IC50 of 1.7 μM (Figure 3.19). TGFβ binding to the ALK5 
receptor activates the canonical Smad2/3 signalling pathway. The TGFβ-Smad3 axis 
is critically involved in lung fibrosis as demonstrated by the observation that Smad3-
null mice are protected from bleomycin induced pulmonary fibrosis (Zhao et al., 
2002). The role of Smad2 and Smad3 in TGFβ-mediated PAR-1 upregulation was 
subsequently investigated using small interfering RNA (siRNA).  
The silencing of Smad2 and Smad3 expression was validated at the mRNA (Figure 
3.20) and protein levels (Figure 3.21). Smad3 mRNA levels were significantly 
reduced 48 hours post-transfection at high concentrations of siRNA and this effect 
persisted through to 72 hours post-transfection at which point a significant 
reduction in Smad3 mRNA level was detected at all siRNA concentrations (Figure 
3.20A). Smad2 knockdown was achieved at all siRNA concentration from 24 hours 
through to 72 hours post-transfection (Figure 3.20B). Scrambled siRNA sequence 
did not reduce the expression of either Smad2 or Smad3 (Figure 3.20C). Total 
Smad3 protein levels were reduced by over 50% at 48 hours and 72 hours post-
transfection with 1 nM and 3 nM of siRNA and completely blocked at higher 
concentrations of siRNA when compared to non-transfected control levels (Figure 
3.21A and B). Total Smad2 protein expression was reduced by over 90% at all time 
points measured after transfection (Figure 3.20C and D). Since the reduction in 
Smad3 protein levels at 24 hours were modest, 48 hours and 72 hours post-
transfection were chosen as time points to assess the effect of Smad2 and Smad3 
expression knockdown on PAR-1 functional responses. As shown in Figure 3.21 E,F 
and G scrambled siRNA had a modest effect on the Smad2 and Smad3 protein levels 
at these two time points.    
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Figures 3.22A and B show that silencing of Smad3 expression significantly reduced 
the TGFβ-mediated increase in PAR-1 functional responses to thrombin in a 
concentration-dependent manner at 48 hours and 72 hours. Smad2 expression 
knockdown had small but significant reducing effect on TGFβ-mediated increase in 
PAR-1 signalling at 48 hours and siRNA concentrations of 10 nM and 30 nM. 
However, this effect was no longer detected at 72 hours and Smad2 knockdown did 
not overall inhibit the increase in TGFβ-mediated PAR-1 functional responsiveness 
to thrombin (Figure 3.22C and D). 
TGFβ signalling expands beyond Smad-mediated pathways and can activate all 
three MAPK pathways: extracellular signal-regulated kinase (ERK), p38, and c-Jun-N-
terminal kinase (JNK). These signalling pathways can subsequently influence Smad 
signalling or exert Smad-independent effects. ERK has been shown to have 
opposing effect on Smad phosphorylation depending on the cell type (Funaba et al. 
2002; Kretzschmar et al. 1999), while p38 (Furukawa et al., 2003) and JNK (Yoshida 
et al., 2005) tend to promote Smad signalling. However, TGFβ-mediated direct 
activation of ERK has been shown to promote EMT (Zhang, 2009). The MEK1 and 
MEK2 inhibitors, UO126 and PD98059 were used to assess the effect of ERK 
inhibition on TGFβ-mediated increase in PAR-1 signalling responses. A549 cells were 
treated with different concentrations of the inhibitors 30 minutes prior to 
stimulation with TGFβ for 24 hours, at which point cells were stimulated with 
thrombin and intracellular calcium flux monitored. UO126 inhibited the TGFβ-
mediated increase in intracellular calcium flux in response to thrombin stimulation 
in a concentration-dependent manner with an IC50 of 0.35 μM (Figure 3.23A). In 
contrast PD98059 had modest effect on the TGFβ-induced upregulation of PAR-1 
functional responsiveness (Figure 3.23B). In contrast, Inhibition of JNK by SP600125 
had no significant effect on TGFβ-mediated PAR-1 upregulation (Figure 3.23C). The 
p38 inhibitor, SB203580, did not block but appeared to increase the PAR-1 
mediated intracellular flux (Figure 3.23D). This response was observed in TGFβ-
stimulated cells and in control cells suggesting that the inhibitor has a non-specific, 
off-target effect or that p38 is involved in regulating PAR-1 at baseline in A549 cells.  
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TGFβ also activates Rho kinase signalling leading to stress fibre formation in 
epithelial cells (Bhowmick et al. 2004) and so the effect of Rho inhibition by Y-27632 
on TGFβ-mediated increase in PAR-1 functional responses was also investigated. 
The highest concentrations of inhibitor increased baseline thrombin-mediated 
intracellular calcium flux and this response was more pronounced in TGFβ-
stimulated cells (Figure 3.23E). These data could be explained by the inhibitor 
having a non-specific effect at high concentrations. Alternatively, Rho kinase 
signalling may affect PAR-1 expression and functional responsiveness in A549 cells.  
Taken together these data suggest that TGFβ mediates increase in PAR-1 expression 
and functional responses in ALK5/-Smad3- and ERK-dependent mechanism.  
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Figure 3.19. Targeting ALK5 TGFβ receptor prevents the increase in PAR-1 
signalling in A549 alveolar epithelial cells.     
Human alveolar epithelial A549 cells were seeded at a density of 2x104 in 96-well 
plates and treated with varying concentrations of SB431542 for 30 minutes prior to 
stimulation with TGFβ (1 ng/ml) in serum-free medium for 24 hours. Cells were 
incubated with Fluo-4AM caclium binding dye for one hour before being exposed to 
thrombin (30 nM). The release of intracellular calcium was monitored by FLIPR® 
Tetra with calcium baseline recorded for 10 seconds before thrombin addition and 
response measured for another 170 seconds. Data are shown as a percentage of 
maximal thrombin response and the effect of SB431542 is presented as a 
concentration-inhibition curve. The open circles indicate the effect of the different 
concentrations of inhibitor on the calcium signalling in non-TGFβ treated and 
thrombin stimulated control cells. Each data point represents the mean +/- SEM of 
4 replicate wells. 
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Figure 3.20. Validation of Smad3 and Smad2 mRNA knockdown.  
Human alveolar epithelial A549 cells were seeded at a density of 5x104 in 24-well 
plates and transfected with Smad3, Smad2 and scrambled siRNA in serum-free 
medium. The mRNA was collected 24, 48 and 72 hours post-transfection and the 
expression of Smad3-panel A and Smad2-panel B quantified by qPCR. Panel C and D- 
the effect of scrambled siRNA on Smad3 and Smad2 was also quantified by qPCR. 
Each data point represents the mean +/- SEM of 3 replicates; one-way ANOVA, 
*p<0.05, **p<0.01, ***p<0.001, relative to non-transfected control.  
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Figure 3.21. Validation of Smad3 and Smad2 protein knockdown.  
Human alveolar epithelial A549 cells were seeded at a density of 5x104 in 24-well 
plates and transfected with Smad3, Smad2 and scrambled siRNA in serum-free 
medium. The protein was collected 24, 48 and 72 hours post-transfection and the 
Smad3 and Smad2 total protein levels assessed by Western blotting. Panel A- 
Western blot of Smad3 and corresponding loading control at all time points; panel 
B- semi-quantitative densitometry analysis of the Smad3 total protein relative to 
the β-actin loading control; panel C- Western blot of Smad2 and corresponding 
loading control at all time points; panel D- semi-quantitative densitometry analysis 
the Smad2 total protein relative to the loading control; panel E- Western blot of 
Smad2 and Smad3 total protein in the samples transfected with scrambled siRNA at 
48 and 72 hours with a corresponding loading control; panel F and G- semi-
quantitative densitometry analysis of the Smad3 and Smad2, respectively, relative 
to the loading control at 48 and 72 hours. Each data point represents the mean +/- 
SEM of 2 replicates.  
E 
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Figure 3.22. TGFβ-mediated increase in PAR-1 signalling in A549 alveolar epithelial 
cells is Smad3-dependent and Smad2-independent.     
Human alveolar epithelial A549 cells were seeded at a density of 2x104 in 96-well 
plates and treated with varying concentrations of Smad3- panel A and B, Smad2- 
panel C and D and scrambled siRNA- panel E and F, for 48 and 72 hours prior to 
stimulation with TGFβ (1 ng/ml) in serum-free medium for 24 hours. Cells were 
incubated with Fluo-4AM calcium binding dye for one hour before being exposed to 
thrombin (30 nM). The release of intracellular calcium was monitored by FLIPR® 
Tetra with calcium baseline recorded for 10 seconds before thrombin addition and 
response measured for another 170 seconds. Data are shown as an increase from 
baseline in relative fluorescence units (RFU) and the dotted line represent baseline 
response to thrombin in non-TGFβ stimulated A549 cells. Each data point 
represents the mean +/- SEM of 4 replicate wells, one-way ANOVA; *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 3.23. Investigation of the effect of non-Smad signalling pathways in the 
TGFβ-mediated increase in PAR-1 functional responses in A549 alveolar epithelial 
cells.  
Human alveolar epithelial A549 cells were seeded at a density of 2x104 in 96-well 
plates and treated with varying concentrations of specified inhibitors for 30 minutes 
prior to stimulation with TGFβ (1 ng/ml) in serum-free medium for 24 hours. Cells 
were incubated with Fluo-4AM calcium binding dye for one hour before being 
exposed to thrombin (30 nM). The release of intracellular calcium was monitored by 
FLIPR® Tetra with calcium baseline recorded for 10 seconds before thrombin 
addition and response measured for another 170 seconds. Data are shown as a 
percentage of maximal thrombin response and the effect of inhibitors is presented 
as a concentration-inhibition curve. The open circles indicate the effect of the 
different concentrations of inhibitor on the calcium signalling in non-TGFβ treated 
and thrombin stimulated control cells. Panel A- ERK1/2 inhibitor UO126, B- ERK1/2 
inhibitor PD98059, C- JNK inhibitor SP600125, D- p38 inhibitor SB203580, E- Rho 
kinase inhibitor Y-27632. Each data point represents the mean +/- SEM of 4 
replicate wells. 
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3.1.3.4 PAR-1 expression in primary alveolar type II epithelial 
cells  
Following the characterisation of PAR-1 expression in A549 alveolar epithelial cells 
and the TGFβ-mediated upregulation of the receptor, it was next determined 
whether these findings are reflected in primary human type II alveolar epithelial 
cells (AECII). AECII were freshly isolated from lung explants and their phenotype 
confirmed by positive staining for zona occludens (ZO-1) tight junctions and 
cytoplasmic prosurfactant C protein (pro-SPC). As shown in Figure 3.24A ZO-1 tight 
junctions outlined the boarders of the AECII while pro-SPC accumulated largely in 
the cytoplasm. AECII were subsequently stimulated with TGFβ for 24 hours and 
PAR-1 expression visualised by immunocytofluorescence. As shown in Figure 3.24B 
low-intensity PAR-1 staining was detected in control cells and no visible changes 
were observed with TGFβ stimulation.   
Cells were subsequently stimulated with thrombin, PAR-1 and PAR-2 activating 
peptides. Neither thrombin nor TFLLR stimulation of primary human AECII triggered 
a marked increase in intracellular calcium flux. In contrast, the PAR-2 activating 
peptide, SLIGKV, induced a significant calcium flux 20 seconds after the addition of 
the agonist. The signal lasted for approximately 100 seconds (Figure 3.24C). These 
data suggest that primary AECII are functionally responsive to PAR-2 but not PAR-1. 
Furthermore, stimulation with TGFβ for 24 hours did not change PAR-1 expression 
and functional responses in AECII.    
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Figure 3.24. Characterisation of alveolar epithelial cells type II phenotype and 
responses.  
Freshly isolated primary human alveolar epithelial cells were seeded in a collagen-
coated 12-well plate at a density of 1x106 or in 96-well plates at a density of 1x105. 
Cells were cultured to 80% confluence. Panel A- cells were fixed with 
paraformaldehyde and stained for ZO-1 (red) and proSPC (green) (40x original 
magnification). Panel B- cells were stimulated with TGFβ for 24 hours and then fixed 
with paraformaldehyde and stained for ZO-1 (green) and PAR-1 (red) (20x original 
magnification). Panel C- cells were incubated with Fluo-4AM calcium binding dye 
before being exposed to thrombin (30 nM), PAR-1 activating peptide- TFLLR 
(100µM) and PAR-2 activating peptide- SLIGKV (100µM). Intracellular calcium was 
monitored by FLIPR® Tetra with calcium baseline recorded for 10 seconds before 
agonist addition and response measured for another 170 seconds. Data are 
represented as increase in relative fluorescence units (RFU) from the baseline. Each 
data point represents the mean +/- SEM of 4 replicates and the graph is 
representative of data obtained with cells from 4 different donors. 
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3.1.3.5 Summary   
 PAR-1 and PAR-2 activation leads to intracellular calcium release in human 
A549 alveolar epithelial cells. 
 Thrombin- and FXa-mediated calcium flux is fully blocked by PAR-1-
antagonists in A549 cells.  
 TGFβ pre-treatment for 24 hours leads to an increase in PAR-1 mRNA levels, 
protein expression and enhanced PAR-1-mediated calcium signalling.  
 This increase in PAR-1 expression is mediated by TGFβ-ALK5-Smad3 
signalling axis and is also ERK-dependent.   
 TGFβ pre-treatment also increases αv and β6 integrin mRNA levels.   
 Freshly isolated control primary human AECII elicit robust intracellular 
calcium release following stimulation with PAR-2 activating peptide but not  
PAR-1.    
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3.1.4 PAR-1 expression and signalling in human bronchial 
epithelium 
 
The bronchial epithelium is a specialised, pseudostratified epithelium with distinct 
populations of cells including basal cells, terminally differentiated columnar ciliated 
cells, Clara cells and goblet cells, which are non-ciliated secretory cells producing 
mucus. The composition of the bronchial epithelium accounts for its main three 
functions: i) formation of a tight protective barrier preventing the penetration of 
noxious agents into lung tissue, ii) entrapment and mucociliary clearance of these 
potentially damaging agents and iii) secretion of antimicrobial and pro-
inflammatory mediators to prevent injury and combat infection (Velden and 
Versnel, 1998). Bronchial epithelium has also been reported to express all PAR 
receptors (Knight et al., 2001).  
Basal cells are a cytokeratin-14 and cytokeratin-5 (CK14 and CK5) positive cell 
population with large regenerative potential and are considered to be progenitor 
cells of other cell types present in mature bronchial epithelium (Hong et al., 2004). 
Furthermore, basal cells are key effector cells in the initiation of wound healing 
responses and depend on activation of the coagulation cascade and generation of 
fibrin scaffold (Perrio et al., 2007). Basal cells constitutively express tissue factor and 
hence have the potential capacity to assemble the TF-FVIIa-FXa ternary complex on 
their cell surface and locally activate the extrinsic coagulation cascade. The aim of 
this study was to assess the intracellular calcium responses in the primary bronchial 
epithelial cells following PAR-1 and PAR-2 activation in order to determine which 
PAR receptor is involved in mediating coagulation signalling responses in human 
bronchial epithelium.  
Intracellular calcium release in response to thrombin stimulation was initially 
assessed in the immortalised bronchial epithelial cell line, BEAS2B. These cells 
responded to thrombin in a concentration-dependent manner with an EC50 of 0.7 
nM (Figure 3.25). Pre-stimulation of cells with TGFβ slightly but significantly altered 
their responsiveness to thrombin. The intracellular calcium flux was significantly 
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reduced at lower thrombin concentration and increased at higher thrombin 
concentration.  
      
 
 
 
 
 
 
 
 
 
Figure 3.25. Concentration-response curve in BEAS2B cells following thrombin 
stimulation.     
Bronchial epithelial cells BEAS2B were seeded at a density of 2x104 in 96-well plates 
and serum starved with or without TGFβ (1ng/ml) 24 hours prior to stimulation with 
thrombin. Cells were incubated with Fluo-4AM calcium binding dye for one hour 
before being exposed to different concentration of thrombin. The release of 
intracellular calcium was monitored by FLIPR® Tetra with calcium baseline recorded 
for 10 seconds before thrombin addition and response measured for another 170 
seconds. Data are represented as increase in relative fluorescence units (RFU) from 
the baseline. Panel A shows a concentration-response curve to thrombin and panel 
B is a comparison of response when cells were stimulated with TGFβ. Each data 
point represents the mean +/- SEM of 3 replicate wells.  
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3.1.4.1 PAR-1 expression and signalling in primary human basal 
epithelial cells 
Following the encouraging results with BEAS2B cells, PAR responses were next 
assessed in primary bronchial epithelial cells (HBECs), which were grown in our 
laboratory from airways dissected from human lung explants, obtained from several 
donors. Primary human bronchial epithelial cells isolated from lung airway explants 
are composed primarily of CK14- and CK5-positive basal cells. As shown in Figure 
3.26, PAR-1 activating peptide, TFLLR, triggered barely detectable intracellular 
calcium flux while PAR-2 activating peptide, SLIGKV, elicited a strong calcium 
response. Furthermore, thrombin did not elicit measurable intracellular calcium 
release suggesting that the basal cells either do not express much PAR-1 or PAR-1 
activation does not induce intracellular calcium release in these cells.  
Interestingly, intracellular calcium release was observed in primary HBECs following 
stimulation with FXa. This calcium response occurred with a 100 second delay and 
with a prolonged and sustained duration of 300 seconds. This pattern of 
intracellular calcium release in response to FXa stimulation in basal cells is unusual 
and shows different kinetics to the responses observed with other agonists and 
other lung cell populations. The intracellular calcium release was FXa concentration-
dependent (Figure 3.26B) and fully blocked by the PAR-2 antagonist, GB83 (Figure 
3.27). Although the functional data suggest that HBECs do not express much PAR-1, 
the PAR-1 antagonist, RWJ58259, significantly reduced FXa-induced intracellular 
calcium release. Taken together, these data suggest that in bronchial epithelial cells 
FXa-induced calcium flux is both PAR-1- and PAR-2-dependent.      
Subsequently PAR-1 and PAR-2 expression was visualised in basal cells by 
immunocytofluorescence. CK5 was used as a marker of the basal cell phenotype. As 
shown in Figure 3.28 bronchial basal cells expressed little PAR-1 while PAR-2 was 
detected in abundance. Furthermore, this expression pattern was preserved in 
basal cells following differentiation at air-liquid interface for 3 weeks. As shown in 
Figure 3.29 fully differentiated bronchial epithelium expressed large quantities of 
PAR-2 and low levels of PAR-1. A cross-section analysis of the cell layer reveals that 
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PAR-2 largely localised to the apical side of cells. Pre-incubation of the basal cells 
with TGFβ for 24 hours did not change the pattern of PAR-1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26. Characterisation of intracellular calcium responses in primary HBECs.     
Human bronchial basal epithelial cells were seeded at a density of 3x104 in 96-well 
plates coated with collagen IV and cultured for 48 hours. Cells were incubated with 
Fluo-4AM calcium binding dye for one hour before stimulation with PAR-1 and PAR-
2 agonists. Panel A- representative traces for responses triggered thrombin (30 nM), 
FXa (200 nM), TFLLR (100 μM) and SLIGKV (100 μM). Panel B- concentration-
response curve to FXa. The release of intracellular calcium was monitored by FLIPR® 
Tetra with calcium baseline recorded for 10 seconds before thrombin addition and 
response measured for another 700 seconds. Data are represented as increase in 
relative fluorescence units (RFU) from the baseline. Each data point represents the 
mean +/- SEM of 4 replicate wells.  
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Figure 3.27. Intracellular calcium response in bronchial epithelial cells is PAR-2-
dependent.    
Human bronchial epithelial cells were seeded at a density of 3x104 in 96-well plates 
coated with collagen IV and cultured for 48 hours. Cells were incubated with Fluo-
4AM calcium binding dye with or without RWJ58258 (3 μM) or GB83 (50 μM) before 
being exposed to FXa (200 nM). The release of intracellular calcium was monitored 
by FLIPR® Tetra with calcium baseline recorded for 10 seconds before thrombin 
addition and response measured for another 700 seconds. Each data point 
represents the mean +/- SEM of 4 replicate wells, One-way ANOVA was performed 
for statistical analysis: ***p<0.001 relative to medium control; +++p<0.001, +<0.05 
relative to FXa response. 
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Figure 3.28. PAR-1 and PAR-2 expression in basal cells. 
Bronchial basal cells were seeded at a density of 5x104 in chamber slides and 
allowed to reach over 80% confluence. Cells were then fixed in paraformaldehyde 
and stained for PAR-1 (Alexa 555), PAR-2 (Alexa 555) and CK5 (Alexa 488), DAPI was 
used to visualise the nucleus. The top panel shows cells stained for PAR-1 cells and 
lower panel shows the staining for PAR-2 (20x original magnification).  
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Figure 3.29. PAR-1 and PAR-2 expression in primary differentiated bronchial 
epithelium. 
Bronchial epithelium was differentiated for 3 weeks at air-liquid interface. Cells 
were then fixed in paraformaldehyde and PAR-1 (red), PAR-2 (red) and CK14 (green) 
visualised by immunocytofluorescence, DAPI was used to visualise the nucleus. The 
top panel shows cells stained for PAR-1 cells and lower panel shows the staining for 
PAR-2. The side panels show cross-section analysis of the cell layer reconstructed 
from the z-stack images (20x original magnification).   
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3.1.4.2 Summary  
 The BEAS2B bronchial epithelial immortalised cell line signals robustly to 
thrombin in a concentration-dependent manner. 
 Robust intracellular calcium release is observed in primary HBECs in 
response to PAR-2 activation but not PAR-1.   
 Primary basal cells express high levels of PAR-2 and low levels of PAR-1 in 
submerged culture and following differentiation into pseudostratified 
bronchial epithelium at air-liquid interface. 
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3.1.5 PAR-1 expression and signalling in lung endothelial cells 
Similar to fibroblasts, endothelial cells have been reported to express PAR-1 in 
abundance both on the cell surface as well as in intracellular pools. Since activated 
PAR-1 is not recycled, the intracellular store of the receptor allows for quick 
mobilisation and cell re-sensitisation. Furthermore, a positive feedback mechanism 
has been identified in endothelial cells where thrombin and PAR-1 activating 
peptides upregulate PAR-1 mRNA levels between 3 and 6 hours following 
stimulation (Ellis et al. 1999). However, PAR-1 signalling has been primarily 
investigated in human umbilical vein endothelial cells (HUVECs) and large airway 
endothelial cells. In contrast, little is known about PAR-1 expression and signalling 
responses in lung microvascular endothelium. The aim of this set of experiments 
was to investigate intracellular calcium signalling in response to coagulation 
proteinases stimulation in human primary lung microvascular endothelial cells 
(HLMECs).   
Distinct cellular effects have been described downstream of PAR-1 activation in the 
endothelium depending on the type of agonist and expression of co-factors. High 
levels of thrombin induce endothelial cell shape change and loss of tight junctions 
via activation of PAR-1 (Rabiet et al., 1996). Furthermore, PAR-1 signalling in 
endothelial cells promotes tissue factor expression and the upregulation of cytokine 
and adhesion molecule expression such as intracellular adhesion molecules (ICAM), 
E-selectin and P-selectin. These molecules facilitate platelet aggregation and 
leukocyte adhesion as well as extravasation of inflammatory cells and coagulation 
factors to the site of injury, which are the first steps of physiological inflammatory 
and tissue repair responses. 
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3.1.5.1 PAR-1 expression and signalling in human umbilical 
vein endothelial cells (HUVECs)  
The aim of this part of this study was to investigate PAR-1 expression and signalling 
in endothelial cells of the lung. Intracellular calcium signalling and phospholipase C 
activation downstream of thrombin-mediated PAR-1 activation leads to cytoskeletal 
rearrangements and endothelial cell contraction that results in loss of endothelial 
barrier integrity and interstitial oedema (Tiruppathi et al., 2002). In the first series of 
experiments it was confirmed that PAR-1 and PAR-2 agonists trigger a robust 
increase in intracellular calcium release in HUVECs, which were used to model the 
responses in the large lung vessels. As shown in Figure 3.30A thrombin induced a 
transient intracellular calcium flux of high magnitude that occurred within 10 
seconds following agonist stimulation, peaked rapidly and decreased to baseline 
over the next 200 seconds. In contrast, the kinetics of FXa-induced calcium 
signalling followed a different pattern with a delay between the addition of the 
agonists and onset of the response, lower magnitude of response and shorter 
duration (Figure 3.30B). The PAR-1 and PAR-2 activating peptides, TFLLR and 
SLIGKV, elicited robust release of intracellular calcium, with kinetics and magnitude 
of responses comparable to thrombin stimulation (Figure 3.30C). Upon 
quantification of these results (Figure 3.30D), PAR-1 and PAR-2 agonists significantly 
increased the intracellular calcium concentration but FXa-induced calcium flux was 
3-fold lower compared to that seen with thrombin. Furthermore, the responses 
were agonist-concentration dependent with EC50 of 5 nM and 150 nM, for thrombin 
and FXa respectively (Figure 3.31).  
Subsequently, the responses to different agonists were investigated in the presence 
of specific PAR-1 and PAR-2 inhibitors. As shown in Figure 3.32A, thrombin 
enzymatic activity was necessary for triggering the calcium flux and no responses 
were detected when thrombin was yielded catalytically inert by pre-incubation with 
hirudin and antithrombin III (ATIII). Furthermore, thrombin signalling in HUVECS was 
PAR-1-mediated as PAR-1 antagonists, RWJ58259 and SCH530348, fully inhibited 
the calcium response (Figure 3.32A). PAR-2 antagonist, GB83, partially but 
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significantly attenuated thrombin-mediated calcium flux, which suggests a level of 
PAR-1 and PAR-2 interaction as previously described (O’Brien et al., 2000). 
FXa proteolytic activity was also necessary for inducing the calcium flux in HUVECs 
and this response was inhibited by antithrombin III. The calcium response was 
reduced both by PAR-1 and PAR-2 inhibitors (Figure 3.32B), suggesting that at high 
concentration of FXa the calcium response in HUVECs is mediated via both 
receptors.       
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Figure 3.30. Calcium signalling in HUVECs in response to PAR-1 and PAR-2 
activation   
Primary human umbilical vein endothelial cells (HUVEC) were seeded at a density of 
2x104 in 96-well plates and allowed to reach confluence for 48 hours prior to 
stimulation with thrombin (10 nM), FXa (200 nM) and PAR-1 activating peptide 
TFLLR and PAR-2 activating peptide SLIGKV (100 μM). Cells were incubated with 
Fluo-4AM calcium binding dye for one hour and the release of intracellular calcium 
was monitored by FLIPR® Tetra with calcium baseline recorded for 10 seconds 
before agonist addition and response measured for up to 600 seconds. Data are 
represented as increase in relative fluorescence units (RFU) from the baseline. 
Panels A, B and C show representative traces for thrombin, FXa, TFLLR and SLIGKV-
mediated calcium flux, panel D- quantification of calcium flux in response to PAR 
agonist. Data are expressed as an increase in relative fluorescence units (RFU) and 
each data point represents the mean +/- SEM of 3-4 replicate wells; one-way 
ANOVA was performed for statistical analysis. ***p<0.001 compared to baseline 
non-stimulated cells.  
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Figure 3.31. Concentration-response curve to thrombin and FXa in HUVECs.     
Human umbilical vein endothelial cells (HUVEC) were seeded at a density of 2x104 in 
96-well plates and allowed to reach confluence for 48 hours prior to stimulation 
with different concentrations of thrombin- panel A and FXa- panel B. Cells were 
incubated with Fluo-4AM calcium binding dye for one hour and the release of 
intracellular calcium was monitored by FLIPR® Tetra with calcium baseline recorded 
for 10 seconds before agonist addition and response measured for up to 600 
seconds. Data are represented as increase in relative fluorescence units (RFU) from 
the baseline. Each data point represents the mean +/- SEM of 3-4 replicates.  
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Figure 3.32. Thrombin and FXa mediated intracellular calcium release in HUVECs.     
Human umbilical vein endothelial cells (HUVEC) were seeded at a density of 2x104 in 
96-well plates and allowed to reach confluence for 48 hours prior to stimulation 
with thrombin (10 nM), thrombin pre-incubated with hirudin (50 nM), thrombin 
pre-incubated with (100nM) antithrombin III/heparin, FXa (200 nM) and FXa pre-
incubated in antithrombin III/heparin (2 μM). Cells were incubated with Fluo-4AM 
calcium binding dye for one hour with or without PAR-1 antagonists RWJ58259 and 
SCH530348 (3 μM) or GB83 at (50 μM) and the release of intracellular calcium was 
monitored by FLIPR® Tetra with calcium baseline recorded for 10 seconds before 
agonists addition and response measured for up to 600 seconds. Data are 
represented as increase in relative fluorescence units (RFU) from the baseline. 
Panels A shows the responses to thrombin and panel B- to FXA. Data represent the 
mean +/- SEM of 3-4 replicate wells; One-way ANOVA was performed for statistical 
analysis, ***p<0.001 relative to control, +++p<0.001 relative to agonist response.  
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3.1.5.2 PAR-1 expression and signalling in human lung 
microvascular endothelial cells (HLMEC) 
The role of the thrombin-PAR-1 axis in inducing vascular permeability is well 
characterised in the large vessel endothelium but little is known about the effect of 
thrombin on human lung microvascular endothelium. It has been reported that in 
rat lung microvascular endothelium thrombin signalling via PAR-1 promotes 
endothelial integrity. Both thrombin and PAR-1 activating peptides increased 
transendothelial electrical resistance, reduced the formation of stress fibres and 
paracellular gaps (Troyanovsky et al., 2008). The aim of this study was to examine 
the intracellular calcium responses to PAR-1 and PAR-2 agonists in primary human 
lung microvascular endothelial cells (HLMECs).     
Thrombin triggered a robust and transient intracellular calcium flux in HLMECs that 
occurred shortly after agonist addition and was maintained for 200 seconds before 
returning to baseline (Figure 3.33A). Both TFLLR and SLIGKV also elicited robust 
intracellular calcium flux, with PAR-1 activation inducing a response of higher 
magnitude than PAR-2 activation (Figure 3.33B). In contrast to responses observed 
in HUVECs, high concentrations of FXa elicited barely detectable intracellular 
calcium release in HLMECs (Figure 3.33C). Calcium fluxes in response to thrombin 
and TFLLR were found to be concentration-dependent with an EC50 of 7 nM and 36 
μM, respectively (Figure 3.34). Pre-incubation of HLMEC with TGFβ did not have any 
effect on thrombin- and TFLLR-mediated intracellular calcium release downstream 
of PAR-1 activation (Figure 3.34). Furthermore, contrary to HUVECs, in HMLECs 
thrombin-mediated intracellular calcium flux was completely blocked by RWJ58259 
(Figure 3.35), whereas PAR-2 antagonist GB83 did not have a significant effect on 
the response. This data suggests that in the HMLECs PAR-1 is a principal mediator of 
thrombin-mediated calcium signalling.  
The expression of PAR-1 and PAR-2 was subsequently investigated by 
immunocytofluorescence (Figure 3.36). HMLECs phenotype was confirmed by 
staining for von Willebrand factor and platelet endothelial cell adhesion molecule 
PECAM. Representative PECAM staining is shown in Figure 3.36. PAR-1 and PAR-2 
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were found to be expressed in HLMECs and localised to the cytoplasm and 
periphery of cells.  
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Figure 3.33. Intracellular calcium release in response to PAR-1 and PAR-2 agonists 
in HLMECs  
Human lung microvascular endothelial cells (HLMEC) were seeded at a density of 
3x104 in 96-well plates and allowed to reach confluence for 48 hours prior to 
stimulation with thrombin (10 nM), FXa (200 nM)and PAR-1 activating peptide 
TFLLR and PAR-2 activating peptide SLIGKV (100 μM). Cells were incubated with 
Fluo-4AM calcium binding dye for one hour and the release of intracellular calcium 
was monitored by FLIPR® Tetra with calcium baseline recorded for 10 seconds 
before agonists addition and response measured for up to 600 seconds. Data are 
represented as increase in relative fluorescence units (RFU) from the baseline. 
Panels A, B and C show representative traces for thrombin, TFLLR and SLIGKV, and 
FXa-mediated calcium flux, panel D- quantification of calcium flux in response to 
PAR agonist. Each data point represents the mean +/- SEM of 3-4 replicates, one-
way ANOVA was performed for statistical analysis, ***p<0.001.  
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Figure 3.34. Concentration-response curve to thrombin and TFLLR in HLMEC 
Human lung microvascular endothelial cells (HLMEC) were seeded at a density of 
3x104 in 96-well plates, allowed to reach confluence for 24 hours and incubated 
with or without TGFβ (1 ng/ml) for further 24 hours prior to stimulation with 
different concentrations of panel A- thrombin and panel B- TFLLR. Cells were 
incubated with Fluo-4AM calcium binding dye for one hour and the release of 
intracellular calcium was monitored by FLIPR® Tetra with calcium baseline recorded 
for 10 seconds before agonists addition and response measured for up to 600 
seconds. Data are represented as increase in relative fluorescence units (RFU) from 
the baseline. Each data point represents the mean +/- SEM of 3-4 replicates.  
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Figure 3.35. Thrombin-induced intracellular calcium signalling in HMLECs is PAR-1-
dependent.  
Human lung microvascular endothelial cells (HLMEC) were seeded at a density of 
3x104 in 96-well plates, allowed to reach confluence for 48 hours prior to 
stimulation with PAR-1 agonists. Cells were incubated with Fluo-4AM dye 
(Invitrogen) with or without RWJ58259 3μM or GB83 50μM for one hour and the 
release of intracellular calcium was monitored by FLIPR® Tetra with calcium 
baseline recorded for 10 seconds before agonists addition and response measured 
for up to 600 seconds. Each data point represents the mean +/- SEM of 3-4 
replicates, One-way ANOVA was performed for statistical analysis, ***p<0.001 
relative to control, +++p<0.001 relative to thrombin response.  
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Figure 3.36. PAR-1 and PAR-2 expression in human lung microvascular cells. 
Human lung microvascular endothelial cells were seeded at a density of 5x104 in 
chamber slides and allowed to reach over 80% confluence. Cells were then fixed in 
paraformaldehyde and stained for PAR-1 (Alexa 555), PAR-2 (Alexa 555) and 
endothelial cells marker platelet endothelial cell adhesion molecule (PECAM, Alexa 
488), DAPI was used to visualise the nucleus, 20x original magnification.  
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3.1.5.3 Summary 
 
 PAR-1 and PAR-2 activation leads to rapid release of intracellular calcium in 
both HUVECs and HLMECs.  
 Thrombin induces intracellular calcium release in HUVECs and HLMECs. This 
response is PAR-1- and PAR-2-dependent in HUVECs but entirely PAR-1-
dependent in HLMEC. 
 High concentrations of FXa trigger PAR-1- and PAR-2-dependent calcium flux 
in the HUVECs but in HLMECs FXa-mediated increase in intracellular calcium 
is barely detectable.  
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3.1.6 PAR-1 and PAR-2 expression in normal and fibrotic lung  
In this section PAR-1 expression was investigated in several resident cell populations 
present in the lung. Fibroblasts and endothelial cells were found to express large 
amounts of PAR-1 and readily signal to PAR-1 activating peptide and thrombin. In 
contrast alveolar and bronchial epithelial cells signal robustly to PAR-2 activating 
peptide, which suggests that normal epithelium expresses primarily PAR-2. 
However, TGFβ upregulated PAR-1 in A549 alveolar epithelial cell line but not in 
primary AECII within the time-frame of the experiments presented in this study. 
Immunohistochemical analysis was subsequently performed in order to examine 
whether data collected in the in vitro experiments corresponded to the distribution 
of PAR-1 and PAR-2 in the human lung. Previous data from our laboratory have 
shown that PAR-1 is upregulated in abnormal and hyperplastic epithelium in the 
fibrotic lung (Mercer et al., 2009). However, in the control lung PAR-1 expression 
was detected at low levels on alveolar and bronchial epithelium. In contrast PAR-2 
was readily on the alveolar epithelium (Figure 3.37- upper panel) and strongly 
positive on the apical site of bronchial epithelium (Figure 3.37- middle panel). In the 
fibrotic lung PAR-1 was a lot more readily detected and localised to fibroblasts 
within dense fibrotic areas (Figure 3.37- lower panel). PAR-2 was also detected in 
the fibrotic areas but the staining was of much lower intensity. Both PAR-1 and PAR-
2 expression is readily expressed on the endothelium in both normal and fibrotic 
lungs.  
Taken together, data presented in this study show that there are major differences 
in the PAR-1 and PAR-2 distributions between different cell populations in the lung 
and the expression of the coagulation receptors is likely to change in the disease. 
PAR-1 is a major signalling receptor in fibroblasts while in the control alveolar and 
bronchial epithelium PAR-2 appears to be the main signalling receptor. Whereas 
PAR-1 and PAR-2 are both expressed and functional in the endothelium of large 
vessels, PAR-1 appears to be the main signalling receptor in the microvascular 
endothelium.     
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Figure 3.37. PAR-1 and PAR-2 expression in normal and fibrotic human lung. 
Immunolocalisation of PAR-1 and PAR-2 in alveolar and bronchial epithelium in a 
normal lung- two upper panels and the distribution of the receptors in fibrotic lung- 
bottom panel.  10x original magnification, AE-alveolar epithelium, BE-bronchial 
epithelium, End- endothelium, Fib- fibroblasts.  
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3.1.7 Discussion 
3.1.7.1 Overview 
Substantial evidence supports the notion that over-exuberant activation of the 
extrinsic coagulation cascade plays a role in the pathogenesis of lung injury and 
pulmonary fibrosis. Apart from promoting fibrin deposition and clot formation, 
coagulation enzymes exert a plethora of cellular effects via the family of PAR 
receptors. Although thrombin can activate PAR-1, PAR-3 and PAR-4, PAR-1 is 
considered the main high-affinity thrombin receptor (Coughlin, 2000) and PAR-1 
knockout mice are protected in the models of pulmonary injury and fibrosis (Howell 
et al. 2005). PAR-2 is the only receptor in PARs family that is not directly activated 
by thrombin but is efficiently cleaved by the components of the ternary complex, 
TF-FVII-FXa. PAR-2 is widely distributed in the lung and there is some evidence that 
PAR-2 may also contribute to the pathogenesis of pulmonary fibrosis (Wygrecka et 
al., 2011).  
PAR signalling plays a significant role in inflammation, coagulation and restoration 
of tissue homeostasis. Increased expression of PAR-1 has been observed in many 
fibrotic diseases, including fibrosis of the lung (Howell et al. 2005), liver (Rullier et 
al., 2008), skin (Cevikbas et al., 2011) and also in cancer (Zigler et al., 2011). The aim 
of this study was to characterise PAR-1 and PAR-2 expression and calcium signalling 
responses in distinct human pulmonary cell population.  
The expression of PAR-1 and PAR-2 receptors was assessed following stimulation 
with the major coagulation proteinases, thrombin and FXa, as well as in response to 
specific PAR agonist peptides. The mechanism of PAR activation is unusual among 
the family of GPCRs and it involves enzymatic cleavage and unmasking of a tethered 
ligand which subsequently binds to the orthosteric site on the second extracellular 
loop of the receptor. Each member of PAR family has a unique sequence of amino 
acids that form the active site of the tethered ligand. This property of the PAR 
receptors was used to develop specific and selective agonists and antagonists 
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against individual members of PAR family, which were used in this study to dissect 
PAR-1 and PAR-2- mediated calcium responses.  
Similar to other GPCRs, PARs also display biased agonism. PARs can be activated by 
several agonists, with PAR-1 being activated by thrombin but also FXa and APC 
while PAR-2 is activated by FXa, trypsin and tryptase. Both PAR-1 and PAR-2 are also 
efficiently cleaved by the extrinsic coagulation cascade initiation complex, TF-FVIIa-
FXa. Activation of the receptor by a specific agonist leads to stabilisation of distinct 
active conformations that facilitate binding to heterotrimeric G-proteins and 
allosteric modulators such as β-arrestins (Russo et al. 2009). This allows for 
functional selectivity and explains how PAR activation can initiate multiple signalling 
pathways and different cellular effects when activated by different agonists. 
Furthermore, PAR-1 tethered ligand is also an agonist of PAR-2, which was 
discovered when the original small activating peptide based on exact sequence of 
PAR-1 tethered ligand, SFLLRN, was found to also activate PAR-2 (Blackhart et al., 
1996). The potential biological significance of this finding has been demonstrated in 
vitro in endothelial cells when the unmasked ligand of PAR-1 was shown to 
transactivate PAR-2 (O’Brien et al., 2001). Furthermore, PAR-1 and PAR-2 can form 
stable heterodimers on the cell surface that act as a functional unit, are jointly 
internalised and have been shown to modulate the responses to thrombin by 
preferentially recruiting β-arrestins and activating ERK1/2 (Lin and Trejo, 2013). 
PAR-1 couples to Gαq, Gαi/0 and Gα12/13 while PAR-2 couples to Gαq and Gα12/13 
(McCoy et al. 2010). Thrombin-mediated PAR-1 activation leads to Gαq uncoupling 
and robust intracellular calcium release and this functional response was used in 
the present study to evaluate PAR-1 signalling in different lung cell populations. 
Uncoupled Gαq leads to phospholipase C (PLCβ)-mediated generation of inositol 
trisphosphate (IP3), which interacts with IP3 receptors (IP3R) in the endoplasmic 
reticulum (ER). This interaction increases IP3R sensitivity to calcium and the 
receptor operates in a biphasic mode. At low cytoplasmic calcium concentrations 
the IP3R opens and allows efflux of calcium stored in the ER while high 
concentrations of cytoplasmic calcium negatively regulate IP3R permissiveness 
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(Berridge et al. 2003). The ER contains multiple IP3R clusters and upon activation of 
individual receptors blips of calcium are observed that summate into puffs that 
form a global wave of intracellular calcium (Bootman et al. 1997). The number of 
IP3R clusters activated influence the kinetics of the calcium wave and are 
proportionate to the upstroke velocity and the magnitude of the response. Calcium 
signalling regulates multiple cellular processes, including fertilisation of the egg, 
proliferation, differentiation, ion channel opening, cell contraction and shape 
changes. Cells respond to initial calcium waves but are also able to detect changes 
in frequency of calcium spikes and modulate the responses accordingly, which has 
been shown to regulate calcium-mediated exocytosis, mitochondrial function and 
gene expression (Bootman et al. 1997). The IP3/calcium axis also regulates synaptic 
plasticity in the brain involved in learning and memory (Berridge 1993). Abnormal 
calcium signalling has been linked to many pathologies, including cardiac 
hypertrophy, where overexpression of Gαq leads to a severe form of the disease in 
experimental models (Song et al., 2003). Furthermore, thrombin has been shown to 
directly affect the physiological responses of myocytes through increased calcium 
activation (Steinberg et al., 1991). Alzheimer’s disease, schizophrenia and bipolar 
disease have also been associated with abnormal calcium fluxes (Berridge 2012).   
In this study intracellular calcium release was monitored to investigate PAR-1 and 
PAR-2 signalling responses following stimulation with coagulation proteinases in 
primary human lung cells.       
3.1.7.2 PAR-1 expression and signalling in lung fibroblasts   
The current consensus for G-protein activation states that multiple subsets of G-
proteins can become simultaneously uncoupled following receptor activation and 
trigger independent and converging cellular pathways. Thrombin exerts multiple 
stimulatory effects on fibroblasts, including promoting fibroblast to myofibroblast 
differentiation (Baffy et al., 1994; Bogatkevich et al., 2001), production and 
secretion of collagen (Chambers et al., 1998) and growth factors such as CTGF 
(Chambers et al., 2000), FGF2 (Duarte et al., 2006). Thrombin-mediated calcium 
release is a critical event for the coordination of many of these biological functions 
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in fibroblasts, including promoting DNA synthesis and cell proliferation (Baffy et al., 
1994; LaMorte et al., 1993), production and release of CCL2 (Deng et al., 2008; 
Ortiz-Stern et al., 2012).  
In the first part of this study, the relative contribution of PAR-1 and PAR-2 activation 
in response to coagulation proteinases was investigated in primary human lung 
fibroblasts by measuring Gαq-mediated release of intracellular calcium. Thrombin is 
known to trigger IP3 accumulation within a few seconds after stimulation (Steinberg 
et al., 1991) which is followed by a robust calcium wave with high upstroke velocity 
and magnitude. This response suggests that thrombin can activate multiple PAR-1 
receptors and lead to many Gαq uncoupling events in a short-time frame that allows 
for the generation of global long-lasting (approximately one minute) regenerative 
calcium waves. A similar pattern of calcium flux was observed with TFLLR and 
SLIGKV. TFLLR-mediated calcium flux occurred with an even steeper increase than 
observed with thrombin and reached higher magnitude, suggesting that the PAR-1 
activating peptide modulates the response specifically toward Gαq. PAR-2 activation 
with SLIGKV led to a sharp increase in intracellular calcium, although of lower 
magnitude than TFLLR. These data suggest that primary human lung fibroblasts 
express both PAR-1 and PAR-2, but PAR-1 appears to be more abundantly expressed 
than PAR-2. This observation was subsequently supported by 
immunocytofluorescence studies.   
FXa can activate both PAR-1 and PAR-2 but in this study the calcium response was 
only detected with high concentrations of FXa and even then occurred with a delay 
and was of much lower magnitude when compared to thrombin response. 
Although, long-term exposure of lung fibroblasts to FXa produces similar responses 
as thrombin stimulation, i.e. differentiation to myofibroblasts and collagen 
production (Blanc-Brude et al., 2005; Scotton et al., 2009), it is possible that FXa 
activates different subset of G-proteins than thrombin and that PAR-1-Gαq is not 
the preferential signalling pathway downstream of FXa-mediated PAR-1 activation. 
Indeed, the delayed kinetics of the FXa-mediated calcium response may be caused 
by selective triggering of different or multiple signalling events. Furthermore, 
 
 
  189  
  
previous studies have shown that high concentrations of FXa alone are required to 
elicit a response achievable at low nanomolar concentrations when FXa is bound to 
the TF-FVIIa-FXa ternary complex (Riewald and Ruf, 2001). TF-VIIa bind FX with high 
affinity, activate it to FXa and form a stable signalling unit that increases FXa 
efficiency to cleave PAR-1 and PAR-2 by up to 10-fold (Riewald and Ruf, 2001). All 
the components of the TF-FVIIa-FXa ternary complex are locally expressed in the 
lung and FX expression is increased within fibrotic foci (Scotton et al., 2009). It is 
therefore possible that in the lung FXa bound within the ternary complex is able to 
activate PAR-1 with greater efficiency and have profound effects on fibroblast 
biology via other signalling pathways that intracellular calcium release.    
In this study, the PAR-1-mediated calcium response was inhibited by hirudin that 
yields thrombin catalytically inert. This clearly demonstrates that thrombin 
enzymatic activity is necessary for this response to occur. Furthermore, thrombin 
triggered the release of intracellular calcium at low concentrations of 0.3 nM and 
with a half-maximal response at 1.5 nM. Fibroblasts accumulate in the lung 
interstitium and by default are not considered to be exposed to thrombin unless 
there is injury followed by a vascular leak which leads to extravasation of 
prothrombin from the circulation and local thrombin activation. Furthermore, the 
TF-FVIIa-FXa ternary complex can assemble locally in the lung (Scotton et al., 2009) 
and facilitate generation of nanomolar concentrations of thrombin, which as 
reported in this study are sufficient to activate PAR-1 in lung fibroblasts. 
Highly selective PAR-1 and PAR-2 antagonists were used next to investigate the 
contribution of PAR-1 and PAR-2 to calcium responses in fibroblasts following 
stimulation with coagulation proteinases. Thrombin- and FXa-mediated intracellular 
calcium fluxes were fully blocked by two PAR-1 antagonists but were unaffected by 
the PAR-2 inhibitor, which suggests that in lung fibroblasts calcium signalling 
downstream of coagulation proteinases stimulation is fully PAR-1-dependent. This 
observation does not exclude the possibility that FXa activates PAR-2 in primary 
human lung fibroblasts but suggests that all Gαq-mediated responses are PAR-1-
dependent.  
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TGFβ is a major pro-fibrotic cytokine that induces fibroblast to myofibroblast 
differentiation (Hinz, 2009) and fibrotic fibroblasts were reported to be more 
responsive to thrombin stimulation (Deng et al., 2013). Thrombin induced 
significantly higher CCL2 release in the fibrotic fibroblast when compared to the 
normal lung fibroblasts by increased binding of the transcription factors to the CCL2 
promoter in the fibrotic fibroblasts (Deng et al., 2013). Therefore, the next question 
addressed in the present study was whether TGFβ affects PAR-1 expression and 
influences calcium functional responses in primary human lung fibroblasts. TGFβ 
pre-treatment did not affect the PAR-1-mediated calcium responses in human lung 
fibroblasts. However, PAR-1 is constitutively and abundantly expressed by lung 
fibroblasts and it is possible that the observed calcium responses are already 
maximally stimulated and cannot be further augmented by TGFβ. 
In conclusion, PAR-1 and PAR-2 activation in primary human lung fibroblasts led to 
robust intracellular calcium signalling but the high responsiveness to thrombin 
stimulation was PAR-1-dependent. 
3.1.7.3 PAR-1 expression and signalling in alveolar epithelial 
cells   
Persistent and repetitive injury to the alveolar epithelium is considered to be the 
initiating step in the development of fibroproliferative lung disease. Furthermore, in 
acute exacerbation of IPF markers of alveolar epithelial injury are significantly 
upregulated (Collard et al., 2010), which supports the notion that the damage to the 
epithelium drives the fibrotic processes. Profibrotic TGFβ signalling in the epithelial 
cells is known to cause apoptosis (Martin et al., 2005) or the acquisition of 
abnormal phenotype characterised by hyperplasia and bronchiolisation (Chapman 
2011). In IPF lung, strong PAR-1 immunopositivity is localised to the abnormal and 
hyperplastic epithelium (Mercer et al., 2009). PAR-1 is also upregulated in the lung 
epithelium in endotoxin-induced model of acute lung injury (Jesmin et al., 2004, 
2007) and bleomycin-induced lung injury (Howell et al., 2005). 
There are major technical limitations of growing fibrotic alveolar epithelial cells in 
vitro including lack of access to clinical specimens and lack of optimised culture 
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conditions. Culture of normal primary human alveolar epithelial cells isolated from 
lung explants is also challenging due to the low yield and finite life-span of AECII. In 
this study, a model A549 cell line representing abnormal alveolar epithelium was 
used to begin to characterise PAR-1 expression and functional responses in alveolar 
epithelial cells.  
Thrombin stimulation of A549 epithelial cells produced a delayed calcium response 
of smaller magnitude when compared to the responses detected in the lung 
fibroblasts. Although, PAR-1 activation by TFLLR elicited a stronger calcium response 
than thrombin, the strongest calcium flux was observed following PAR-2 activation 
with SLIGKV. These data suggest that A549 cells express low levels of PAR-1 but 
abundant levels of PAR-2. This observation was subsequently confirmed by 
immunocytofluorescence study revealing that PAR-2 is highly expressed on the 
A549 cell surface while PAR-1 was barely detected. Calcium flux was also measured 
following stimulation of A549 cells with FXa but the response was delayed and of 
smaller magnitude, consistent with the low level response observed in fibroblasts. 
Again high concentrations of FXa were required to elicit a detectable calcium 
response.  
Thrombin-mediated calcium responses in A549 cells were fully inhibited by hirudin 
and the PAR-1 antagonist RWJ58259. However, the response was also significantly 
reduced in the presence of PAR-2 antagonist, GB83, suggesting that PAR-1 might 
transactivate a subset of PAR-2 receptors to contribute to the calcium response. 
Unidirectional PAR-2 transactivation by PAR-1 has previously been described for 
endothelial cells (O’Brien et al., 2001). In order for transactivation to occur, the 
receptors need to be in close proximity and PAR-1 and PAR-2 are known to form 
heterodimers in certain cell types including vascular smooth muscle cells (Pawlinski 
and Holinstat, 2011). In this A549 cell study PAR-1 activation was found to be 
necessary for triggering downstream calcium release while PAR-2-Gαq signalling 
appeared to potentiate this response. Inhibition of PAR-2 signalling reduced the 
magnitude of response by approximately 50%. Further work is required to dissect 
the relationship between PAR-1 and PAR-2 on epithelial cell surface.  
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Pre-treatment with TGFβ increased the functional responsiveness of A549 that was 
both TGFβ and PAR-1 agonist concentration-dependent. Thrombin induced 
intracellular calcium flux in A549 with an EC50 of 13 nM and pre-treatment with 
TGFβ did not affect the threshold of activation. However, TGFβ increased the 
maximal response to thrombin by 2.5-fold which is consistent with increased PAR-1 
expression following TGFβ stimulation. Potential explanations for the observed 
signalling pattern include the possibility that thrombin activation of PAR-1 can be 
affected by multiple factors such as thrombin concentration, spatial orientation of 
PAR-1 on the cell surface and localisation to lipid rafts, utilisation of co-receptors 
such as PAR-3, endothelial protein C receptor (EPCR), and the ability of thrombin to 
preferentially signal via different G-proteins (Feistritzer and Riewald 2005). All these 
signalling intricacies have been described for endothelial cells but further work will 
be required to investigate whether these mechanisms apply to alveolar epithelial 
cells. 
TGFβ signalling in epithelial cells has been shown to induce phenotypic changes 
resembling epithelial to mesenchymal transition (EMT), which has been well-
characterised for cancer cells. The hallmark of this phenotypic change is reduced 
expression of epithelial cell markers, such as E-cadherin, and increased expression 
of mesenchymal cell markers, such as vimentin and αSMA (Dubois-Marshall et al., 
2011). In this study, TGFβ stimulation of A549 cells for 24 hours led to increased 
PAR-1 functional responses as measured by increased intracellular calcium flux and 
also increased surface expression as measured by immunocytofluorescence. This 
study also revealed that following 24 hour exposure to TGFβ, E-cadherin is still 
intensely expressed by A549 cells and hence TGFβ-mediated increase in PAR-1 
expression occurred before the loss of epithelial markers associated with EMT.  
Furthermore, TGFβ stimulation of A549 cells led to increased PAR-1 mRNA level 
from 8 hours onwards. Thrombin-PAR-1 signalling axis contributes to activation of 
latent TGFβ via integrins. Robust activation of TGFβ is triggered through the 
interaction of the TGFβ latency complex with αvβ6 integrins on epithelial cells 
(Jenkins et al., 2006) and αvβ5 integrins on fibroblasts (Scotton et al., 2009). As 
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previously described PAR-1 activation and signalling via the Rho-GTPase pathway 
leads to re-arrangement of the actin cytoskeleton resulting in cell contraction and 
redistribution of mechanical forces between the cell and the extracellular matrix. 
This in turn causes activation of surface integrins that are constitutively attached to 
the TGFβ latency complex, alters the interaction of these integrins with the TGFβ 
latency complex and results in the release of active TGFβ. The next question 
addressed in this study was whether increased PAR-1 expression and functional 
responsiveness to thrombin could be a part of a positive feedback mechanism that 
promotes further TGFβ activation. In order to examine this, mRNA levels of the 
integrin subunits αv and β6 were measured. Indeed, TGFβ stimulation led to a 
parallel upregulation in expression of both integrin subunits after 6 hours of 
stimulation. These data suggest a potential feedback loop in A549 cells where TGFβ 
controls the expression of crucial components of the machinery that actively 
contributes to activation of this cytokine. In order to test this hypothesis, future 
studies would involve assessing the surface expression of integrins and changes in 
the rate of TGFβ activation following pre-treatment of A549 cells with TGFβ for 24 
hours and thrombin stimulation.      
Active TGFβ has a high affinity for the type II receptor (TβRII) that is constitutively 
expressed on the cell surface. Ligand-TβRII complexes recruit the type I 
receptor/activin-receptor like kinase (TβRI/ALK). ALK5 is a ubiquitously expressed 
TβRI and the assembly of the heterotetramic ligand-receptor complex triggers the 
phosphorylation and activation of canonical Smad-dependent and non-canonical 
signalling pathways. Smad2 and Smad3 are substrates for ALK5 and following 
phosphorylation translocate to the nucleus together with the co-factor Smad4. The 
Smads then form transcriptional complexes recruiting co-activators such as Sp1 and 
AP-1 and regulate the expression of multiple target genes (Derynck and Zhang, 
2003). There is strong evidence that the TGFβ-Smad3 pathway is essential for 
normal lung alveolarisation and for maintaining alveolar homeostasis but also 
contributes to the development of fibroproliferative lung disease (Gauldie et al., 
2006). Smad3 knockout mice are protected from pulmonary fibrosis induced by 
overexpression of  TGFβ (Bonniaud et al., 2004b) and administration of bleomycin 
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(Zhao et al., 2002). Furthermore, Smad3-null fibroblasts exhibit reduced contractile 
and migratory potential due to their inability to upregulate αSMA expression 
following TGFβ stimulation (Dobaczewski et al., 2010). Finally, inhibition of the ALK5 
receptor is also protective in bleomycin-induced pulmonary fibrosis (Bonniaud et 
al., 2005b; Scotton et al., 2013). In the present study small molecule ALK5 inhibitor, 
SB431542, was used to investigate the mechanism of TGFβ-mediated PAR-1 
upregulation. This compound fully blocked upregulation of PAR-1 expression and 
signalling. Furthermore, siRNA knockdown of the components of canonical 
signalling pathway, Smad2 and Smad3, has showed that the induction of PAR-1 is 
Smad3-dependent and Smad2-independent.  
TGFβ bound to TβRII-ALK5 complexes leads to phosphorylation of serine and 
threonine residues on these receptors which activate Smad2 and Smad3 signalling 
but it can also lead to phosphorylation of tyrosine residues and recruitment of 
adaptor molecules necessary for the activation of MAPK kinases pathways (Zhang, 
2009). TGFβ-activation of the ERK MAPK signalling pathway has been linked to EMT 
in cancer cells (Davies et al., 2005) and genetic profiling of TGFβ-mediated EMT 
revealed that ERK participates in the regulation of expression of cell-matrix 
adhesion and motility genes (Zavadil et al., 2001). Interestingly, activation of the 
ERK MAPK pathway has also been shown to lead to phosphorylation of Smad2 and 
Smad3 and differentially regulate their activity depending on cell type. ERK-
mediated Smad3 phosphorylation has been reported to repress Smad3 
transcriptional functions (Matsuura et al., 2005) but enhance Smad2-mediated gene 
expression (Funaba et al. 2002). In another study ERK signalling was found to 
negatively regulate Smad2 and Smad3 transcriptional activity and this was 
suggested as a mechanism for overriding TGFβ antiproliferative effect in epithelial 
cells (Kretzschmar et al., 1999b). The TGFβ-Smad-ERK-AP-1 axis has also been 
shown to be important for increased cancer cell motility (Davies et al., 2005). The 
other two MAPK signalling pathways, JNK and p38, can also co-operate with Smad-
canonical pathways to induce TGFβ-mediated apoptosis and p38 has been shown to 
play a role in reorganisation of the cell cytoskeleton in the process of EMT (Zhang, 
2009). TGFβ also leads to rapid activation of Rho-pathway that is necessary for the 
 
 
  195  
  
formation of stress fibres during EMT (Bhowmick et al. 2001). Therefore, in the 
present study the role of MAPK and Rho pathways in TGFβ-mediated increase in 
PAR-1 expression was investigated. Inhibition of MEK-ERK signalling with UO126 
completely inhibited TGFβ-mediated increase in PAR-1 calcium signalling responses. 
Another ERK inhibitor, PD98059 had modest effect on PAR-1 functional responses. 
Significant differences have been identified between the two inhibitors. While 
UO126 is a selective and potent MEK1 and MEK2 inhibitor, PD98059 has higher 
affinity for MEK1, which suggests that MEK2 may be important in TGFβ-mediated 
PAR-1 upregulation.  
Inhibition of JNK did not affect the PAR-1 functional responses while p38 inhibition 
appeared to induce increased PAR-1 functional responses, both at baseline and 
following treatment with TGFβ, suggesting that at high concentrations the inhibitor 
may have non-specific off-target effects. Alternatively, p38 may play a role in 
regulating PAR-1 expression at baseline. Inhibition of Rho signalling pathway also 
enhanced PAR-1 functional responses, both at baseline and following TGFβ-
stimulation. Further experiments need to be performed to validate the specificity of 
these inhibitors and their effect on PAR-1 expression.  
The alveolar epithelium has been strongly implicated in the pathogenesis of 
pulmonary fibrosis and increased epithelial apoptosis, hyperplasia and 
bronchiolisation are key features of the abnormal wound healing response in IPF. In 
this study, we began to delineate a potential endogenous pathway which 
perpetuates the generation of active TGFβ. Next it was examined whether this 
mechanism is also observed in primary human type II alveolar epithelial cells (AEC II) 
isolated from donor lungs. The phenotype of AECII was confirmed by positive 
staining for zona occludens (ZO-1) tight junctions and cytoplasmic prosurfactant C 
protein (pro-SPC). In contrast to A549 cells, primary AECII did not elicit intracellular 
calcium release following thrombin stimulation. Furthermore, activation of PAR-1 
and PAR-2 with specific agonist peptides clearly demonstrated that AECII release 
intracellular calcium in response to PAR-2 activation but not PAR-1. 
Immunocytofluorescence studies supported the notion that low levels of PAR-1 are 
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expressed in the primary AECII. Furthermore, stimulation of AECII with TGFβ for 24 
hours did not augment surface expression and functional responses measured in 
this study. These results highlight clear differences in the expression of PAR-1 and 
functional responsiveness to PAR-1 and PAR-2 activation between primary control 
AECII and A549 cell line. There are several potential explanations for these findings. 
The AECII used in this study were isolated from non-fibrotic human lung tissue and 
young donors with no evident lung pathology. Previous laser capture 
microdissection studies in our laboratory have shown that normal human alveolar 
epithelium expresses low levels of PAR-1 mRNA that is significantly upregulated in 
IPF epithelium (Mercer et al., 2009). It is therefore plausible that increased PAR-1 
expression is associated with the abnormal phenotype of alveolar epithelial cells 
and the enhancement of PAR-1 expression after TGFβ stimulation is a sign of further 
aberrant changes to the epithelial cells. In order to investigate whether increased 
PAR-1 expression in hyperplastic alveolar epithelium is a consequence of the 
chronic reparative phenotype in IPF, these in vitro studies will need to be performed 
in the cells isolated from the fibrotic epithelium. Unfortunately, this was not 
achievable in the scope of this study due to the lack of available IPF tissue. In order 
to isolate sufficient numbers of viable AECII a large lung specimen (<150 g) is 
required, which greatly exceeds the size of a regular biopsy. Furthermore, the time 
delay between sampling of the lung and the isolation procedure dramatically 
decreases the viability of AECII. Sufficient amount of tissue can only be obtained in 
the event of a lung transplant but the relative infrequency of these operations is a 
major limitation.      
3.1.7.4 PAR-1 expression and signalling in primary bronchial 
epithelial cells 
Previous immunohistochemistry studies reported that the bronchial epithelium 
expresses all PAR receptors (Knight et al., 2001). Furthermore, bronchial basal cells 
constitutively express tissue factor and can assemble the TF-FVIIa-FXa ternary 
complex on their cell surface (Perrio et al., 2007). This local activation of coagulation 
cascade was found to be essential to generate fibrin scaffold and initiate wound 
 
 
  197  
  
healing response and restoration of bronchial epithelium integrity following injury 
(Perrio et al., 2007). Failure of tissue factor-initiated fibrin network formation, PAR-
1 and PAR-2 activation has been shown to cause basal cell apoptosis, necrosis and 
inefficient wound healing responses of bronchial epithelium in vitro (Ahmad et al., 
2013).  
In this study, we investigated the responses in primary bronchial epithelial cells to 
thrombin stimulation. After determining that the bronchial cell line BEAS2B elicits 
intracellular calcium release following stimulation with thrombin in concentration-
dependent manner and of magnitude comparable to the responses described for 
fibroblasts, the same response was evaluated in primary human bronchial epithelial 
cells (HBECs). HBECs were grown out from large airways excised from lung tissue 
processed in our laboratory. For experimental purposes HBECs were seeded on 
collagen IV, which is the major constituent of the basement membrane and 
enhances cell adhesion and proliferation.     
Investigation of PAR-1 and PAR-2 expression in HBECs by immunocytofluorescence 
and measurements of intracellular calcium release following stimulation with PAR-1 
and PAR-2 agonists have provided strong evidence that HBEC basal cells express low 
levels of PAR-1 and high levels of PAR-2. Thrombin failed to elicit intracellular 
calcium release from HBECs even at high concentrations and TFLLR produced a 
barely detectable response. In contrast, PAR-2 activation triggered a robust calcium 
flux. High concentrations of FXa were required to elicit delayed intracellular calcium 
flux of low magnitude albeit of prolonged duration. Furthermore, this response 
could be blocked with the PAR-2 antagonist, GB83, which suggests that in this 
system high FXa concentrations are capable of activating PAR-2-Gαq signalling. 
Interestingly, despite low PAR-1 expression in these cells, RWJ58259 significantly 
reduced the FXa-mediated calcium flux. This suggests that even at low expression 
levels, PAR-1 activation contributes to PAR-2-mediated calcium signalling responses.  
Immunocytofluorescence studies further confirmed that expression of PAR-1 on the 
basal cell surface is sparse while PAR-2 is abundantly expressed. The mature 
bronchial epithelium is composed of different, specialised and fully-polarised cell 
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types and PAR expression may be different compared with that observed in 
submerged culture composed primarily of basal cells. In order to address this 
question, basal cells were cultured at air-liquid interface and differentiated into a 
pseudostratified cell layer. The differentiation process takes three weeks and once 
completed cells cannot be passaged and therefore it was impossible to perform 
intracellular calcium functional assay in the mature epithelium. Therefore, PAR 
expression was assessed by immunocytofluorescence only. As observed in basal 
cells, PAR-2 was found to be abundantly expressed in the differentiated bronchial 
epithelium and localised to apical side whereas PAR-1 expression remained 
consistently low in the bronchial epithelium. We concluded that PAR-2 is expressed 
at high levels both in basal cells and in fully differentiated bronchial epithelium 
while PAR-1 is scarcely detected. Immunocytofluorescence study of fully 
differentiated cells was also performed after exposure to TGFβ for 24 hours but 
there were no differences in PAR-1 and PAR-2 expression. It is possible that 
exposure to TGFβ for 24 hours is not sufficient to induce changes in PARs 
expression. It has been shown that HBECs undergo EMT after 72 hour exposure to 
TGFβ (Câmara and Jarai, 2010).  
Previous studies have reported that HBECs secrete IL-6 and IL-8 following 
stimulation with PAR agonist peptides (Asokananthan et al., 2002). In this particular 
study HBECs were stimulated for 24 hours with TFLLR and SLIGKV and showed a 
modest increase in cytokine levels with PAR-1 activating peptide and a robust 
response with SLIGKV. These data are in agreement with our observations that PAR-
2 is the main PAR receptor present on these cells.  
Calcium signalling in the bronchial epithelium is essential for regulating airway 
tension (Borchers et al., 2003) as wells as for the release of inflammatory 
mediators. Interestingly in chronic lung disease and infection it has been shown that 
the hypersensitivity to GPCR-mediated intracellular calcium signalling can be 
achieved by expansion of the endoplasmic reticulum and hence calcium stores 
(Ribeiro, 2011). PAR-2 mediates multiple protective effects in the airway epithelium 
including promoting bronchodilation through induction of cyclooxygenase 2 (COX 2) 
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and stimulation of PGE2 production (Cocks et al., 1999; Morello et al., 2005). 
Furthermore, PAR-2 is upregulated on the respiratory epithelium of asthmatic 
patients (Knight et al., 2001) and in animal models of allergic airway inflammation 
lack of PAR-2 protects from excessive inflammatory response while PAR-2 
overexpression drives eosinophilia (Schmidlin et al., 2002). PAR-1 expression in the 
asthmatic bronchial epithelium remains low but thrombin-mediated PAR-1-
activation in airways smooth muscle cells induces increase in cytosolic calcium and 
bronchoconstriction (Hauck et al., 1999). Moreover, lack of PAR-1 expression in the 
lung is protective from goblet cell metaplasia in the experimental model of COPD 
(Atzori et al., 2009). There is also evidence showing that both PAR-1 and PAR-2 are 
upregulated in the LPS-induced acute lung injury (Jesmin et al., 2007). It is possible 
that in the normal respiratory epithelium, including both bronchial and alveolar 
epithelium, PAR-2 is highly expressed at baseline and the expression increases in 
certain disease states, while PAR-1 is expressed at low levels in normal epithelial 
cells and the expression only increases following persistent and chronic injury to the 
epithelium.   
3.1.7.5 PAR-1 expression and signalling in endothelial cells   
Endothelial cells express all four PARs but signalling via PAR-1 and PAR-2 rather than 
PAR-3 and PAR-4 have been shown to contribute to most of the functional 
responses in health and disease (Bunnett, 2006). PAR-1 signalling in the 
endothelium has been shown to elicit different responses depending on the 
activating proteinases, as well as other cellular mechanisms set in place to control 
PAR-1-mediated functional responses. Intracellular calcium signalling downstream 
of thrombin-mediated PAR-1 activation leads to cytoskeletal rearrangement and 
endothelial cells contraction that results in loss of endothelial barrier integrity and 
interstitial oedema (Tiruppathi et al., 2002). Interestingly, while high thrombin 
concentrations increase vascular permeability, at low thrombin concentration PAR-
1-mediated signalling is barrier protective (Feistritzer and Riewald 2005). Bioactive 
lipid sphingosine 1 phosphate (S1P) expressed on the cell surface and activated 
protein C (APC) have the capacity to modulate thrombin signalling and promote the 
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restoration of vascular barrier integrity (Feistritzer and Riewald 2005). APC can also 
cleave PAR-1 directly to elicit cytoprotective signalling (Yang et al., 2007) and 
cleaved PAR-1 is retained on the cell surface providing an endogenous 
desensitisation system (Schuepbach et al. 2008). APC and thrombin exert their 
enzymatic activity at distinct cleavage sites on PAR-1 N-terminus, which could also 
explain different cellular effects. Thrombin unmasks the tethered ligand at arginine 
41 (R41) while APC cleaves PAR-1 at arginine 46 (R46) (Schuepbach et al. 2012). The 
affinity of thrombin to cleave PAR-1 is several magnitudes higher than for APC albeit 
APC augments PAR-1 signalling in other ways. Recruitment of PAR-1 to lipid rafts 
and interaction with APC bound to its receptor, EPCR, prevents excessive thrombin 
cleavage of PAR-1 and switches its function to being barrier protective (Bae et al. 
2007). FXa has also been shown to exert protective responses in endothelial cells 
through the activation of PAR-2 but also by enhancing the interaction between 
EPCR and PAR-1 (Bae et al. 2010). Furthermore, FXa signalling in both PAR-1 and 
PAR-2 has been shown to counteract thrombin-induced vascular permeability 
(Feistritzer et al. 2005).  
The intricacies of the spatial and temporal regulation of thrombin-PAR-1 signalling 
in the endothelial cells have been demonstrated in vivo. Infusion of PAR-1 agonist 
peptide into the circulation increases vascular permeability by 75% as measured by 
Evans blue dye-assessed pulmonary oedema (Kaneider et al., 2007). However, 
targeting of thrombin or PAR-1 signalling during the early phase of sepsis model 
offered protection and improved survival, while the same approaches applied 
during the late stages of sepsis proved detrimental. Moreover, therapeutic 
administration of PAR-1 agonists improved survival rate while PAR-1 antagonism 
exacerbated vascular leak and mortality in the model of sepsis. Interestingly, late 
PAR-1 cytoprotective effects have been linked to PAR-1-mediated PAR-2 
transactivation (O’Brien et al., 2000) and selective activation of distinct G-proteins 
(Kaneider et al., 2007). The initial vascular leak occurs via activation of the 
thrombin-PAR-1-Gα12/13-Rho GTPase signalling axis that orchestrates endothelial cell 
shape change. PAR-1-PAR-2 heterodimer formation and a shift towards activation of 
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the Gαi-dependent pathway was associated with restoration of barrier integrity 
(Kaneider et al., 2007).  
In the present study, HUVECs were used as model endothelial cells of large vessels 
and as expected showed robust intracellular calcium release following stimulation 
with thrombin in a concentration-dependent manner. PAR-1 and PAR-2 agonist 
peptides also elicited robust responses that were of similar magnitude and 
duration. Consistent with observations for other cell types, the FXa-mediated 
calcium flux was delayed and was of lower magnitude.   
Specific PAR-1 and PAR-2 inhibitors were again used to investigate the contribution 
of PAR-1 and PAR-2 signalling responses in HUVECs. PAR-1 antagonists fully blocked 
the calcium response following thrombin stimulation but the PAR-2 inhibitor also 
significantly reduced it by around 25%. FXa-mediated signalling was fully blocked by 
the endogenous inhibitor, antithrombin III, and a partial block was obtained with 
PAR-1 and PAR-2 antagonists. As mentioned before, PAR-1 and PAR-2 can form 
heterodimers and have been shown to signal together in response to FXa 
(Feistritzer et al. 2005). The results presented in this section support the notion that 
thrombin- and FXa-mediated intracellular calcium release is an additive effect of 
signalling via both receptors.   
Thrombin-PAR-1-signalling axis in large vessels has been thoroughly investigated 
but the nature of these responses in the primary human lung microvascular 
endothelial cells is not known. Injury to the microvascular endothelium in IPF has 
been described with evidence of areas of necrosis, denudation and collagen 
deposition in the basement membrane (Magro et al., 2006). Furthermore, these 
changes were found to be associated with the deposits of auto-antibodies in 
capillary vessels that showed reactivity to epitopes expressed by the microvascular 
endothelium, supporting the notion that the pathogenesis of IPF may have an 
autoimmune component (Magro et al., 2006). Although the question of 
autoimmunity as part of IPF pathogenesis is controversial, strong antibody reactions 
to endothelial epitopes correlate with pulmonary fibrosis secondary to systemic 
sclerosis (Ihn et al., 2000). In experimental pulmonary fibrosis bleomycin is also 
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highly cytotoxic for the microvascular endothelium (Patel et al., 2011). While in 
large vessel endothelial cells thrombin signalling is mainly barrier disruptive, 
different responses have been reported for microvascular endothelial cells. In rat 
lung microvascular endothelial cells thrombin and PAR-1 activating peptides 
increased the barrier integrity and reduced formation of stress fibres and 
paracellular gaps in vitro (Troyanovsky et al., 2008). In contrast, in LPS model of ALI 
targeting PAR-1 reduced vascular leak and neutrophilia (Mercer et al., 2013).      
To our knowledge, PAR-1 and PAR-2 signalling responses to coagulation proteinases 
have never been evaluated in primary human lung microvascular endothelial cells 
and therefore the aim of this part of the present study was to examine the 
intracellular calcium response downstream of PAR-1 and PAR-2 activation in 
HMLECs. Thrombin elicited a robust signalling response that was concentration-
dependent, while PAR-1 and PAR-2 agonist peptides also triggered strong signalling 
responses. The high level of PAR-1 and PAR-2 expression was also visualised by 
immunocytofluorescence. In contrast, FXa elicited a barely detectable wave of 
calcium signalling. The thrombin response was fully inhibited by the PAR-1 
antagonist suggesting that in the lung microvascular endothelium the 
responsiveness to thrombin is PAR-1-mediated.  
Taken together, this study has shown a differential distribution and levels of 
expression of PAR-1 receptor in the lung while PAR-2 appears to be expressed in all 
cell types tested. However, this study has highlighted that lung fibroblasts and lung 
microvascular endothelial cells are sensitive to low thrombin concentrations and 
respond to thrombin in entirely PAR-1-dependent manner. In contrast, normal 
bronchial and alveolar epithelial cells do not appear to express sufficient PAR-1 
expression to be sensitive to thrombin signalling. PAR-1 expression can be 
upregulated in the abnormal alveolar epithelium in response to TGFβ-signalling. 
This response was ALK5/Smad3- and ERK-dependent.  
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3.1.7.6 Conclusion and future work 
The aetiology of IPF remains enigmatic and current paradigms place lung epithelial 
cell injury as an initiating event in the development of fibrosis that is subsequently 
driven by dysregulated wound healing responses. Epithelial damage and destruction 
of the alveolar-capillary basement membrane allows fibroblast infiltration into the 
alveolar parenchyma, their proliferation, differentiation into myofibroblasts and 
excessive extracellular matrix protein deposition. Increasingly, bronchial epithelial 
dysfunction has also been implicated in the progression of fibrosis (Peljto et al., 
2013). Markers of endothelial damage are detected in samples from IPF patients 
(Collard et al., 2010) and damage to the lung microvasculature and abnormal re-
modelling of vessels often leads to the development of a common complication of 
IPF, namely pulmonary hypertension (Hanumegowda et. al 2012). Extensive 
evidence accumulated over the years highlights the complexity of intercellular 
interactions that contribute to the pathogenesis of IPF. 
The persistent activation of the coagulation cascade and dysregulated fibrinolysis 
play key roles in the establishment and propagation of the fibrotic response to lung 
injury. The local activation of the coagulation cascade drives lung fibrosis 
independently of activation of the systemic coagulation (Scotton et al. 2009). 
Although the homeostatic alveolar environment is anticoagulant and pro-fibrinolytic 
(reviewed in Chambers 2008), it contains all the components required to trigger the 
extrinsic coagulation cascade. Tissue factor is upregulated on hyperplastic epithelial 
cells (Imokawa et al. 1997) and alveolar macrophages isolated from patients with 
sarcoidosis produce FVII (Chapman et al. 1985). Both alveolar and bronchial 
epithelia have been shown to synthesise and express FX/FXa. Therefore the ternary 
complex that initiates the extrinsic coagulation cascade and thrombin generation 
can be assembled in the alveolar microenvironment and indeed 
immunohistochemical analysis show colocalisation of TF/FVIIa/FXa in injured 
epithelium overlying fibrotic foci (Scotton et al. 2009).  
PAR-1 mediates multiple cellular effects of coagulation proteinases and it is 
upregulated in the fibrotic lung (Mercer et al., 2009). PAR-2 is also activated by 
 
 
  204  
  
coagulation proteinases and there is evidence supporting the role of PAR-2 in IPF 
(Wygrecka et al., 2011). The aim of this study was to investigate the PAR-1- and 
PAR-2-mediated signalling responses to thrombin and FXa in distinct primary human 
lung cell populations.   
Coagulation proteinases can activate PAR-1 and elicit robust intracellular calcium 
response (Blanc-Brude et al., 2005). The calcium flux results from Gαq uncoupling 
and phospholipase C-mediated inositol trisphosphate (IP3) generation. IP3 binds to 
its receptor on the endoplasmic reticulum which opens the calcium store and leads 
to rapid increase in cytosolic calcium. The spatial and temporal distribution of the 
calcium wave is proportionate to surface expression of the receptor (Bootman et 
al., 1997a). In order to ensure that full activation of specific receptor was achieved, 
PAR-1 and PAR-2 agonist peptides were used and compared with thrombin and FXa 
signalling.  
In this study, primary human lung fibroblasts and microvascular endothelial cells 
were identified as cells strongly responsive to thrombin stimulation and expressing 
high levels of PAR-1. All human cell populations investigated in this study expressed 
PAR-2 and in the alveolar and bronchial epithelium PAR-2 activation with the 
agonist peptide led to stronger calcium signalling responses when compared to 
PAR-1 activation by the agonist peptide. In alveolar epithelial cells PAR-1 expression 
was associated with abnormal phenotype and was further enhanced with TGFβ 
stimulation. The results of this study provide unique insights into the expression 
pattern of PAR-1 and PAR-2 in the normal lung setting, which was also confirmed by 
immunohistochemical analysis. This study also shows that the PAR-1 and PAR-2 
expression pattern can change with exposure to a profibrotic mediator. 
Furthermore, these results highlight differences in the signalling pathways between 
the two major coagulation proteinases, thrombin and FXa.     
Intracellular calcium release measured in this study was a summation of calcium 
waves generated through activation of many receptors over a short period of time. 
The number of receptors activated with high frequency and close functional 
coupling are proportionate to the upstroke velocity and magnitude of the response 
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(Bootman et al. 1997). TFLLR and SLIGKV specifically and directly activated PAR-1 
and PAR-2, respectively, and produced the strongest and most rapid calcium fluxes 
that were consistent with the receptor expression pattern on the cell surface. While 
thrombin acted mainly through PAR-1-Gαq, FXa consistently showed delayed 
responses of lower magnitude for all cell populations examined. This is consistent 
with the notion that FXa is a lower affinity agonist of the PAR-1 receptor and 
requires more time to efficiently dock and cleave the N-terminus. This would also 
explain the temporal delay and spatial decrease of the signal since low affinity 
agonists can act in an equivalent mode as low-concentration high affinity agonists. 
It has been previously reported that low affinity agonists trigger small calcium blips 
that fail to reach the frequency to generate a global wave (Bootman et al. 1997).  
As the technology to measure and image cellular signalling is rapidly expanding, the 
traditional consensus stating that individual G-proteins uncouple from the receptor 
upon activation has now been replaced in favour of simultaneous activation of 
multiple G-proteins leading to concurrent activation of second messengers (McCoy 
et al., 2012). It is plausible that FXa causes uncoupling of multiple G-proteins from 
both PAR-1 and PAR-2 and Gαq uncoupling is a small fraction of the overall FXa-
mediated signalling response, which could explain the lower magnitude of the 
observed response in comparison to thrombin. This reasoning is further supported 
by abundant evidence for biased agonism signalling properties of GPCRs (Mosnier et 
al. 2012; Vaidehi and Kenakin 2010; Russo at al. 2009). Furthermore, allosteric 
modulators, such as β-arrestin, have been shown to add another level of complexity 
to PAR signalling pathways by being able to affect G-protein uncoupling, second 
messenger recruitment, phosphorylation and internalisation of the receptor (Gao 
and Jacobson, 2013; Lin and Trejo, 2013). 
Whilst the current study has explored the Gαq-mediated release of intracellular 
calcium, a comprehensive assessment of other signalling pathways downstream of 
thrombin and FXa stimulation would provide a more complete scope of biological 
effects triggered by coagulation proteinases. Studies aimed at expanding the 
understanding of the relationship between PAR-1 and PAR-2 signalling, heterodimer 
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formation and the effect on activation and downstream signalling are also required 
in multiple lung cell types that are affected in disease.  
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3.2 Pro-inflammatory thrombin signalling in human 
lung fibroblasts. 
3.2.1 Introduction 
Previous work in our laboratory demonstrated that cultured human and murine 
fibroblasts constitutively secrete CCL2 over time. These responses increase 
dramatically upon stimulation with thrombin in a time- and concentration-
dependent manner (Deng et al., 2008; Ortiz-Stern et al., 2012). The levels of CCL2 in 
fibroblast supernatants increase significantly from 6 hours onwards and this 
response is maintained until at least 24 hours post-stimulation. Furthermore, as 
little as 0.3 nM thrombin elicits significant upregulation of CCL2 production. Our 
laboratory also showed that in murine fibroblasts thrombin-mediated CCL2 release 
is entirely PAR-1-dependent and occurs downstream of Gαq-induced calcium 
signalling (Deng et al., 2008). The aim of this study was to advance our 
understanding of thrombin-mediated CCL2 release by primary human lung 
fibroblasts. The results presented in this section form a part of publication: “PAR-1-
dependent and PAR-independent pro-inflammatory signalling in human lung 
fibroblasts.” A. Ortiz-Stern et al., Journal of Cellular Physiology, 2012, which is 
attached as Appendix 2.  
3.2.2 Thrombin-mediated CCL2 release from human lung 
fibroblasts   
In order to determine whether thrombin-mediated CCL2 release from human 
fibroblasts is PAR-1 dependent, two PAR-1 specific small molecule inhibitors were 
used: RWJ58259 (Damiano et al., 2003) and SCH530348 (Bonaca and Morrow, 
2009). The dose of the RWJ58259 was previously optimised in our laboratory for 
both murine fibroblasts (Deng et al., 2008) and human fibroblasts (Appendix 2, 
Figure 2C). In the first series of experiments, the efficacy of the antagonist in 
blocking CCL2 release was tested in both murine and human fibroblasts. As shown 
in Figure 3.38A, exposure of murine fibroblasts to thrombin (10 nM) for 6 hours led 
to a 2.5-fold increase in CCL2 levels in the supernatants and this response was fully 
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inhibited by both PAR-1 antagonists. In contrast, stimulation of human fibroblasts 
with thrombin (10 nM) for 6 hours led to a 10-fold increase in the amount of CCL2 
released in the supernatants (Figure 3.38B). RWJ58259 and SCH530348 only 
partially inhibited this response. 
Since both PAR-1 antagonists did not fully block CCL2 release by human lung 
fibroblasts, the next question was whether in human fibroblasts the CCL2 response 
is entirely thrombin-dependent. To address this question we first assessed whether 
thrombin enzymatic activity is necessary for the CCL2 response by using hirudin, a 
peptide naturally produced in the salivary glands of medicinal leeches, which forms 
non-covalent and irreversible bonds with thrombin and renders it catalytically inert. 
As previously observed thrombin stimulation of human fibroblasts for 6 hours 
significantly increased CCL2 release into the cell supernatants and this response was 
fully inhibited when thrombin enzymatic activity was inhibited by hirudin (Figure 
3.39). Subsequently, the inhibitory effects of RWJ58259 and hirudin on CCL2 release 
by human fibroblasts were tested at different thrombin concentrations. RWJ58259 
is a reversible PAR-1 antagonist that binds to the second extracellular loop of the 
receptor and thus does not interfere with thrombin-mediated cleavage of the 
tethered ligand. Another question addressed in this study was therefore whether 
the partial inhibition of the CCL2 release by RWJ58259 was a consequence of the 
displacement rate of the antagonist from the receptor and the tethered ligand 
triggering a response. In order to begin to examine this possibility, hirudin was 
added to fibroblasts after they had been exposed to thrombin for 30 minutes. As 
previously described thrombin induces CCL2 release in a concentration-dependent 
manner. Delayed thrombin inhibition by hirudin (added after 30 minutes) 
significantly reduced CCL2 levels by at least 70% at all thrombin concentrations 
tested (Figure 3.40) and following the short-term exposure to thrombin, CCL2 was 
only significantly elevated above the baseline at the highest thrombin concentration 
(10 nM). This suggests that the high CCL2 levels accumulated in the supernatants 
after 6 hours result from prolonged and constant thrombin stimulation. Consistent 
with previous experiments RWJ58259 did not fully block thrombin-induced CCL2 
release by human lung fibroblasts at any concentration tested. In contrast, 
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combined treatment of RWJ58259 and hirudin achieved a similar level of inhibition 
of CCL2 release as observed with hirudin alone at all thrombin concentrations. 
Taken together, these data supported the previous results that the CCL2 release 
from human fibroblasts is thrombin-dependent but not exclusively mediated by 
PAR-1.  
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Figure 3.38. RWJ58259 and SCH530438 inhibit CCL2 release in murine and human 
lung fibroblasts.  
Primary murine- panel A and human- panel B lung fibroblasts were seeded in 48-
well plates at a density of 2x104 cells/well and serum starved for 24 hours. Cells 
were pre-incubated with RWJ58259 or SCH530348 (3 μM) for 30 minutes before the 
addition of thrombin (10 nM). CCL2 levels in cell supernatants after 6 hours of 
incubation were quantified by ELISA. Data show mean +/- SEM of 6 replicates; two-
way ANOVA ***p<0.001 comparison with basal CCL2 production, +++ p<0.001 
comparison with thrombin stimulated cells.  
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Figure 3.39. Inhibition of thrombin enzymatic activity by hirudin abolishes its 
stimulatory effect on CCL2 release by human lung fibroblasts.  
Primary human lung fibroblasts were seeded in 48-well plates at a density of 2x104 
and serum-starved for 24 hours prior to the experiment. Cells were subsequently 
stimulated with thrombin (10 nM) or thrombin (10 nM) pre-incubated with (50 nM) 
hirudin for 1 hour. After 6 hours, cell supernatants were collected and CCL2 levels 
measured by ELISA. Data show mean +/- SEM of 4 replicates; one-way ANOVA, 
***p<0.001 comparison with thrombin alone stimulated cells.  
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Figure 3.40. Delayed inhibition of thrombin catalytic activity abolishes CCL2 
release while blocking PAR-1 only partially reduces CCL2 release in human lung 
fibroblasts.   
Primary human lung fibroblasts were seeded in 96-well plates at a density of 104 
cells/well and serum-starved for 24 hours. Cells were the pre-incubated with 
RWJ58259 (3 μM) for 30 minutes before addition of thrombin at indicated 
concentrations. Following another 30 minutes hirudin (50 nM) was added to 
designated wells. Level of CCL2 in the supernatants after 6 hours of incubation was 
quantified by ELISA. Data show mean +/- SEM of 4 replicates; two-way ANOVA, 
***p<0.001 comparison with basal CCL2 production, +p<0.05, +++ p<0.001 
comparison with thrombin alone at respective concentrations.  
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3.2.3 Thrombin-mediated intracellular calcium release in lung 
fibroblasts   
As demonstrated in the previous section thrombin enzymatic activity is required for 
CCL2 release from primary human lung fibroblasts but PAR-1 specific antagonists do 
not fully block this response. The efficacy of the PAR-1 antagonists was 
subsequently tested in different PAR-1-mediated signalling responses. Both 
SCH530348 and RWJ58259 are small molecule competitive PAR-1 inhibitors but 
have different chemical properties that affect the nature of binding to the receptor. 
RWJ58259 is considered to be a reversible antagonist whereas SCH530348 binding 
to the receptor has been characterised to be virtually irreversible (Zhang et al., 
2012). Considering that thrombin has a high affinity for the receptor and persists in 
the supernatant for up to 72 hours (Ortiz-Stern et al., 2012), it was possible that at 
high, yet standard, thrombin concentration (10 nM) RWJ58259 may be displaced by 
the activated tethered ligand at a fast enough rate to result in only partial inhibition 
of PAR-1 mediated CCL2 release. To pursue this question further, the efficiency of 
RWJ58259 inhibition was tested by monitoring the release of intracellular calcium, 
which is an immediate response that occurs within seconds of thrombin-mediated 
PAR-1 cleavage. Furthermore, in murine fibroblasts, intracellular calcium release 
downstream of PAR-1 activation was previously shown to be essential for CCL2 
release (Deng et al., 2008).  
As characterised in the previous chapter of this thesis and reproduced in Figure 
3.41A, primary human lung fibroblasts signal robustly to thrombin and the 
magnitude of calcium response is thrombin concentration-dependent. At low 
concentration (0.3 nM) thrombin evoked a delayed intracellular calcium release of 
low magnitude and at high concentrations (3 nM and 10 nM) thrombin elicited a 
rapid and sharp signal. Nonetheless, at all thrombin concentrations RWJ58259 (3 
µM) fully inhibited the release of intracellular calcium (Figure 3.41B).  
Next, the PAR-1 antagonists, RWJ58259 and SCH530348, were tested over a range 
of concentrations in human and murine fibroblasts at fixed thrombin concentration 
(10 nM). As shown in Figure 3.42, both PAR-1 antagonists fully blocked intracellular 
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calcium release at a standard thrombin concentration of 10 nM with an IC50 of 12 
nM and 0.9 nM in murine fibroblasts and 120 nM and 60 nM in human fibroblasts 
for RWJ58259 and SCH530348, respectively.  
Taken together, these data support the notion that the antagonists used in this 
study are potent inhibitors of PAR-1-mediated intracellular calcium responses, 
regardless of thrombin concentration. It is therefore possible that the lack of full 
inhibition of CCL2 release observed in human lung fibroblasts is due to other non-
PAR-1 signalling pathways contributing to thrombin-mediated CCL2 release. 
In order to confirm that intracellular calcium release is essential for CCL2 release by 
human lung fibroblasts, the calcium chelator BAPTA-AM was used to inhibit the 
calcium flux and the levels of CCL2 measured subsequently. As shown in Figure 
3.43, BAPTA-AM blocked CCL2 release in a concentration-dependent manner with 
complete inhibition observed at 2 µM.     
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Figure 3.41. Thrombin-mediated intracellular calcium release in primary human 
lung fibroblasts is inhibited by the PAR-1 specific antagonist RWJ58259.    
Primary human lung fibroblasts were seeded in 96-well plates at a density 1x104 and 
serum starved for 24 hours. Cells were incubated with Fluo-4AM calcium binding  
alone or with addition of 3 μM RWJ58259 in 0.1% DMSO vehicle an hour before 
being exposed to thrombin at the indicated concentrations (0, 0.3, 3 and 10 nM). 
Intracellular calcium release was monitored by FLIPR® Tetra with calcium baseline 
recorded for 10 seconds before thrombin addition as indicated by the arrow and 
the response was measured for 170 seconds thereafter. Panel A shows 
representative calcium traces and panel B shows a quantification of the traces with 
data presented as increase from baseline in relative fluorescence units (RFU), mean 
+/- SEM of 4 replicates, two-way ANOVA, ***p<0.001 comparison to thrombin 
response.   
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Figure 3.42. RWJ58259 and SCH530348 are potent inhibitors of PAR-1-mediated 
intracellular calcium release by human and murine fibroblasts.    
Human and murine primary lung fibroblasts were seeded at a density of 1x104 in 96-
well plates and serum-starved 24 hours. Cells were incubated with Fluo-4AM 
calcium binding  alone or with different concentrations of RWJ58259 and 
SCH530348, an hour before being exposed to thrombin (10 nM). The release of 
intracellular calcium was monitored by FLIPR® Tetra with calcium baseline recorded 
for 10 seconds before thrombin addition as indicated by the arrow and the 
response was measured for 170 seconds thereafter. Concentration-inhibition plots 
are presented for A- murine lung fibroblasts and B- human lung fibroblasts. Each 
data point represents the mean +/- SEM of 3 replicate wells.  
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Figure 3.43. The intracellular calcium chelator BAPTA-AM abrogates thrombin-
PAR-1 mediated CCL2 release in a concentration-dependent manner in primary 
human lung fibroblasts.  
Primary human lung fibroblasts were seeded in 96-well plates at a density of 104 
cells/well and serum starved for 24 hours. Cells were then pre-incubated with 
increasing concentrations of BAPTA-AM calcium chelator for 30 minutes before 
exposure to thrombin (10 nM) for 6 hours. Data are presented as a percentage of 
the maximal thrombin response. Inhibitor vehicle was 0.1% DMSO and was kept 
constant for all treatment conditions. The first bar represents the highest 
concentration of the inhibitor tested and shows no significant effect on basal CCL2 
production. CCL2 levels in cell supernatants were quantified by an ELISA and one-
way ANOVA was performed for statistical analysis. Data show mean +/- SEM of 3 
replicates; ++p<0.01 comparison with vehicle control, ***p<0.001, **p<0.01, 
*p<0.05 comparison with thrombin alone.  
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3.2.4 Contribution of other PARs to thrombin-mediated 
signalling in lung fibroblasts   
In order to further investigate the pathways leading to CCL2 release by human lung 
fibroblasts in response to thrombin, the contribution of other PAR receptors was 
examined. As reported by our group as well as in other studies, human lung 
fibroblasts express PAR receptors 1-3 at the mRNA level and low levels of PAR-4 
(Ortiz-Stern et al., 2012; Ramachandran et al., 2007; Sokolova et al., 2005). We used 
PAR-specific small agonist peptides, which mimic the amino acid sequence of the 
tethered ligand inherent to each PAR receptor, to assess intracellular calcium flux 
and CCL2 release downstream of PAR activation. As demonstrated in Figure 3.44A, 
the PAR-1 activating peptide, TFLLR elicited a calcium response of the same 
magnitude and pattern as thrombin at standard concentration (10 nM). A reverse 
control peptide RLLFT had no effect on the response.  
Although PAR-2 is not directly activated by thrombin, current evidence suggests 
that at high thrombin concentration the unmasked tethered ligand of PAR-1 can 
transactivate PAR-2 in endothelial cells (Kaneider et al., 2007; O’Brien et al., 2001). 
Furthermore, PAR-2 also couples to Gαq (McCoy et al. 2010) and hence is capable of 
triggering calcium signalling responses. As shown in Figure 3.44B, the PAR-2 
activating peptide, SLIGKV, induced intracellular calcium release but the response 
was delayed and of lower magnitude when compared to thrombin at standard 
concentration or TFLLR (Figure 3.44A). Furthermore, experiments performed by Dr 
Ortiz-Stern showed that SLIGKV triggered a small but significant increase in the CCL2 
release from human lung fibroblasts after 24 hours of stimulation (Appendix 2, 
Figure 3B). However, knocking down PAR-2 expression with siRNA in human lung 
fibroblasts did not alter the responsiveness of the cells to TFLLR and did not affect 
the inhibition level achieved with RWJ58259 (Appendix 2, Figure 3C).   
PAR-3 has a short cytoplasmic tail and is generally considered not to signal 
independently but act as a co-receptor and allosteric modulator to amplify 
signalling via other PARs (Madhusudhan et al. 2011; Vidwan et al. 2010; McLaughlin 
et al. 2007). However, other studies have indicated the possibility that PAR-3 is 
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capable of autonomous signalling (Ostrowska and Reiser, 2008). To test the 
signalling capacity of PAR-3 in human lung fibroblasts, the PAR-3 activating peptide, 
TFRGAP was used but failed to trigger intracellular calcium release (Figure 3.44C). 
Furthermore, PAR-3 activation had no impact on supernatant CCL2 levels at either 6 
hours (Figure 3.45A) or after 16 hours (Figure 3.45B) of stimulation at a range of 
TFRGAP concentrations. In contrast, the PAR-1 activating peptide, TFLLR, induced a 
significant increase in CCL2 levels.   
Finally, PAR-4 is expressed at low levels in fibroblasts and the AYPGKF activating 
peptide did not induce increase in intracellular calcium (Figure 3.44D) or CCL2 
release over prolonged period of time (Appendix 2, Figure 3E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  221  
  
0 20 40 60 80 100 120 140 160 180
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Control
TFLLR 100M
RLLFT 100M
Thrombin 10nMPAR-1
Time (seconds)
In
c
r
e
a
s
e
 f
r
o
m
 b
a
s
e
li
n
e
 (
R
F
U
)
0 20 40 60 80 100 120 140 160 180
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Control
SLIGKV 100M
VKGILS 100M
Thrombin 10nM
PAR-2
Time (seconds)
In
c
r
e
a
s
e
 f
r
o
m
 b
a
s
e
li
n
e
 (
R
F
U
)
0 20 40 60 80 100 120 140 160 180
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Control
TFRGAP 100M
Thrombin 10nM
PAR-3
Time (seconds)
In
c
r
e
a
s
e
 f
r
o
m
 b
a
s
e
li
n
e
 (
R
F
U
)
0 20 40 60 80 100 120 140 160 180
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Control
AYPGKF 100M
Thrombin 10nM
PAR-4
Time (seconds)
In
c
r
e
a
s
e
 f
r
o
m
 b
a
s
e
li
n
e
 (
R
F
U
)
A B
C D
 
 
 
 
 
 
 
 
 
 
 
Figure 3.44. Activation of PAR-1 and PAR-2 but not PAR-3 and PAR-4 induces 
intracellular calcium fluxes in primary human lung fibroblasts.    
Primary human lung fibroblasts were seeded in 96-well plates at density 1x104, 
serum starved for 24 hours and incubated with Fluo-4AM calcium binding  for one 
hour prior to stimulation with thrombin (10 nM) or the respective PAR activating 
peptides- A- PAR-1 TFLLR, B- PAR-2 SLIGKV, C- PAR-3 TFRGAP, D- PAR-4 AYPGKF 
(each at 100 μM). PAR-1 and PAR-2 reverse control peptides were used to confirm 
specificity, RFLLT and VKGILS (each at 100 μM) respectively. Intracellular calcium 
release was monitored by FLIPR® Tetra with calcium baseline recorded for 10 
seconds before thrombin addition as indicated by the arrow and measured for 170 
seconds thereafter. Representative traces are presented as increase from baseline 
in relative fluorescence units (RFU) and represents the mean +/- SEM of 4 
replicates. 
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Figure 3.45. The PAR-3 activating peptide does not induce CCL2 release by human 
lung fibroblasts.  
Panel A: Human lung fibroblasts were seeded in 48-well plates at a density 2x104 
cells/well, and serum-starved for 24 hours. Cells were subsequently stimulated with 
thrombin (10 nM), PAR-1 agonist- TFLLR, PAR-3 agonist- TFRGAP and RLLFT control 
peptide (each at 100 μM) for 6 hours. Panel B: Human lung fibroblasts were seeded 
in 96-well plates at a density of 104 cells/well, and serum-starved for 24 hours. Cells 
were subsequently exposed to a range of concentrations of PAR-1 and PAR-3 
activating peptides, TFLLR and TFRGAP for 16 hours. CCL2 levels were measured in 
cell supernatants by ELISA. Data represent a mean +/- SEM of 4 replicates, analysed 
by A: one-way ANOVA ***p<0.001 versus unstimulated cells, B: two-way ANOVA 
*p<0.05 PAR-1 activating peptide versus PAR-3 activating peptide.  
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3.2.5 Summary   
The aim of this study was to investigate the role of PAR-1 in thrombin-induced CCL2 
release in primary human lung fibroblasts and the results show that: 
 Thrombin-mediated activation of PAR-1 elicits a strong intracellular calcium 
response that is entirely PAR-1-dependent but the CCL2 response 
downstream of thrombin signalling is partially PAR-1-independent.  
 PAR-1 and PAR-2 activation trigger robust intracellular calcium release but 
no calcium flux nor CCL2 release is detected after PAR-3 or PAR-4 activation.  
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3.2.6 Discussion    
Thrombin signalling via PAR-1 has multiple effects on human lung fibroblasts 
biology including stimulation of proliferation (Della Rocca et al., 1999), 
differentiation into myofibroblasts (Blanc-Brude et al., 2005) and production of 
collagen (Chambers et al., 1998). CCL2 is a potent profibrotic chemokine and a 
chemoattractant of immune cells and fibrocytes (Moore et al. 2006). Furthermore, 
CCL2 can directly contribute to fibroproliferative processes by upregulating TGFβ 
gene expression (Gharaee-Kermani et al. 1996). CCL2 levels are also increased in 
serum and bronchoalveolar lavage fluid from IPF patients (Baran et al., 2007; Suga 
et al., 1999). 
Previous work in our laboratory showed that in murine lung fibroblasts thrombin 
induces CCL2 gene transcription and protein production downstream of PAR-1-Gαq-
uncoupling and signalling via calcium-independent and ERK1/2-dependent 
pathways, while PAR-1-Gαq-mediated calcium flux is required for the release of this 
chemokine from the cells (Deng et al., 2008). Recently, it has been demonstrated 
that in human lung fibroblasts thrombin signalling increases CCL2 gene transcription 
via two transcription factors. NFκB is involved in the rapid increase in the CCL2 
mRNA levels while AP-1 promotes sustained CCL2 gene transcription (Deng et al., 
2013). Furthermore, fibrotic lung fibroblasts were shown to secrete significantly 
more CCL2 at baseline and following stimulation with thrombin than control 
fibroblasts. This response is due to enhanced binding of transcription factors to the 
CCL2 promoter (Deng et al., 2013). Furthermore, a similar pattern of increased 
binding to the CCL2 promoter region also promotes high levels of CCL2 release in 
fibroblasts isolated from bleomycin-treated murine lungs (Deng et al., 2013).        
In a collaborative study performed with Dr Alejandro Ortiz-Stern, we investigated 
CCL2 release by primary human lung fibroblasts and found that at low thrombin 
concentrations the CCL2 release occurs entirely downstream of PAR-1 activation. 
However, stimulation of human lung fibroblasts with high concentration of 
thrombin in the presence of two pharmacological agents directed against PAR-1, 
RWJ58259 (Damiano et al., 2003) and SCH530348 (Bonaca and Morrow, 2009), 
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significantly reduced but did not fully abolish CCL2 release. Importantly, the level of 
inhibition of CCL2 release with RWJ58259 was thrombin concentration-dependent 
but fully blocked when thrombin catalytic activity was inhibited by hirudin. ERK 
phosphorylation is known to occur within minutes of thrombin-mediated PAR-1 
activation and is essential for CCL2 secretion (Goebeler et al., 2001) from different 
cell types including murine lung fibroblasts (Deng et al., 2008) and dendritic cells 
(Mitchell and Olive, 2010). In primary human lung fibroblasts, we found that at high 
thrombin concentration RWJ58259 did not block ERK phosphorylation (Appendix 2, 
Figure 4). 
The ability of RWJ58259 and SCH530348 to block PAR-1-mediated signalling in 
human lung fibroblasts was subsequently confirmed using the intracellular calcium 
release assay. At all concentrations of thrombin tested both antagonists fully 
blocked the thrombin-induced intracellular calcium flux. Confidence in these 
pharmacological agents was further supported by data obtained with PAR-1 
cleavage blocking antibodies which also failed to completely block CCL2 release 
from human lung fibroblasts (Appendix 2, Figure 2F). Importantly, intracellular 
calcium signalling was found to be essential for thrombin-mediated CCL2 release 
from human lung fibroblasts and this response was fully inhibited by the BAPTA 
calcium chelator. Taken together, this strongly suggests that thrombin-mediated 
CCL2 release from human lung fibroblasts is not exclusively PAR-1-mediated.   
Following validation of the antagonists, the next plausible explanation was that with 
increasing thrombin concentration other PAR receptors are recruited and act 
independently or as co-receptors in order to enhance thrombin-mediated CCL2 
release. Previous studies have shown that RWJ58259 efficiently blocks human 
platelet aggregation at low thrombin concentration but at high thrombin 
concentrations the inhibitory effect is overcome by the contribution of PAR-4 
signalling (Damiano et al., 2003). PAR-4 is a low affinity thrombin receptor and high 
concentrations of thrombin are required to activate PAR-4 and convey signalling 
responses, while at low thrombin concentration PAR-1 mediates the majority of 
thrombin responses in human platelets. Combined PAR-1/PAR-4 activation and 
 
 
  226  
  
signalling constitutes the primary mechanism of human platelet activation and 
aggregation (Kahn et al., 1999) and allows for cellular plasticity in response to 
different concentrations of thrombin, which can reach concentrations up to 140 nM 
in the proximity of a clot (Walz et al., 1985). Although, fibroblasts express low levels 
of PAR-4 mRNA at baseline, the expression of the receptor has been shown to be 
induced by LPS and TNFα in bronchial fibroblasts (Ramachandran et al., 2007). 
Furthermore, increased expression of PAR-4 is matched by the increased functional 
responses following activation of PAR-4 with specific agonist peptide (AYPGKF) and 
thrombin (Ramachandran et al., 2007). However, in the present study, PAR-4 
specific activating peptide failed to induce intracellular calcium responses and CCL2 
release from primary human lung fibroblasts. Therefore PAR-4 signalling as a 
contributing factor to CCl2 release following stimulation with high thrombin 
concentrations was disregarded.     
PAR-3 is expressed by human lung fibroblasts but is considered to be incapable of 
autonomous signalling due to a short cytoplasmic tail, which is a recognised major 
site of G-protein coupling (Ishihara et al., 1997). Instead, PAR-3 is described as a co-
factor receptor enhancing activation of other PARs (McLaughlin et al. 2007; 
Nakanishi-Matsui et al. 2000). The role of PAR-3 is best characterised as a PAR-4 co-
receptor in mouse platelets where PAR-3 concentrates thrombin in the vicinity of 
PAR-4 and enhances PAR-4 activation by allowing efficient receptor cleavage and 
signalling at lower thrombin concentration (Nakanishi-Matsui et al., 2000). 
Furthermore, PAR-3 activation can modulate and potentiate PAR-1 signalling 
(Kaufmann et al., 2005) and the PAR-3 tethered ligand has been shown to directly 
trans-activate PAR-1 and PAR-2 to induce intracellular calcium signalling (Hansen et 
al. 2004). Furthermore, other reports suggest that PAR-3 can be functionally active 
(Ostrowska and Reiser, 2008) and this has been shown to be mechanistically 
plausible since other sites than just the cytoplasmic tail at the PAR receptors 
intracellular interface have been identified to bind the G-proteins, namely the 
intracellular loops (McCoy et al., 2012). However, in this study the PAR-3 specific 
activating peptide TFRGAP failed to initiate intracellular calcium flux or CCL2 
release. Interestingly, in endothelial cells, PAR-3 forms heterodimers with PAR-1 
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and allosterically modulates PAR-1 interaction with G-proteins enhancing coupling 
and signalling via Gα13 (McLaughlin et al. 2007). In endothelial cells, thrombin-PAR-
1- Gα13 signalling leads to increased endothelial permeability that is abolished when 
PAR-1 is silenced. However, PAR-3 allosterically modulates this effect by controlling 
the magnitude of response and in the event of PAR-3 knockdown, thrombin-PAR-1-
induced endothelial permeability is reduced by 50% (McLaughlin et al. 2007). In 
contrast, thrombin-mediated activation of the PAR-1/PAR-3 heterodimer unit also 
triggers the release of intracellular calcium that is PAR-1-Gαq-dependent and is 
unaffected by knockdown of PAR-3. Therefore, future work in this project will 
involve PAR-3 knockdown experiment to conclusively eliminate the possibility that 
PAR-3 contributes to CCL2 release from human lung fibroblasts.       
PAR-2 is not directly activated by thrombin but the unmasked tethered ligand of 
PAR-1 can transactivate PAR-2 in endothelial cells (O’Brien et al., 2000). PAR-2 
activation with the PAR-2 specific activating peptide SLIGKV leads to robust 
intracellular calcium release and induces a small but significant increase in CCL2 
release over extended periods of time. However, the results obtained in the course 
of this study have shown that knockdown of PAR-2 in human lung fibroblasts did 
not affect the magnitude of thrombin-mediated CCL2 release and did not affect the 
inhibition level achieved with PAR-1-targeting strategies (Ortiz-Stern et al., 2012). 
The role for PAR-2 in thrombin-mediated CCL2 release is therefore highly unlikely.  
As shown in the previous chapter of this thesis, human primary fibroblasts express 
high levels of PAR-1 and signal robustly to thrombin. This observation is also 
consistent with other studies showing that following desensitisation of fibroblasts 
with thrombin, the responsiveness to thrombin is rapidly restored (Blanc-Brude et 
al., 2005). Notably human lung fibroblasts secrete vastly more CCL2 than murine 
fibroblasts, which can be explained partially by inter-species variability. Moreover, 
the murine chemokine CCL12 has been shown to be more homologous to human 
CCL2 and is secreted in high levels in the context of pulmonary fibrosis (Moore et al. 
2006). It is possible that levels of CCL2 are complemented by CCL12 release and 
both chemokines play convergent roles to promote pulmonary fibrosis in mice. 
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Furthermore, it is likely that RWJ58259, SCH530348 and PAR-1 blocking antibodies 
produce partial inhibition of CCL2 release due to high rate of PAR-1 turnover at the 
cell surface and mobilisation of the PAR-1 intracellular pool in the human lung 
fibroblasts. Silencing of PAR-1 by siRNA would provide final clarification for the 
thrombin-mediated CCL2 release in lung fibroblasts but we were unsuccessful in 
knocking down PAR-1 in these cells. This could be explained by the observation that 
human lung fibroblasts express PAR-1 in abundance.  
CCL2 acts via G-protein coupled receptor CCR2 and CCL2/CCR2 signalling axis exerts 
multiple autocrine and paracrine cellular effects that involve activation of 
intracellular pathways, some of which overlap with thrombin signalling, including 
intracellular calcium release (Gouwy et al., 2008) and MAPK p38 signalling (Lin et al., 
2012). In systemic sclerosis fibroblast expression of CCR2 was associated with 
overexpression of αSMA, CTGF and CCL2 in these cells (Carulli et al., 2005). 
Furthermore, CCR2 knockout mice are protected from bleomycin-induced 
pulmonary fibrosis (Moore et al. 2001) and the CCL2/CCR2 signalling axis has been 
shown to downregulate prostaglandin PGE2 production in alveolar epithelial cells 
and promote fibroblast proliferation (Moore et al. 2003). Autocrine and paracrine 
signalling of CCR2/CCL2 axis extends beyond fibrosis and has been shown to 
promote expression of inflammatory mediators in different cell types including 
synovial fibroblasts (Giunti et al., 2006; Lin et al., 2012; Liu et al., 2007) and tumour 
cells to enhance survival and angiogenesis (Izhak et al. 2012). It is possible that CCL2 
released following thrombin-mediated PAR-1 activation in human lung fibroblasts 
acts on CCR2 receptors and further propagates CCL2 release in PAR-1-independent 
manner. Future work to assess CCR2 expression in human lung fibroblasts and to 
investigate the existence of potential positive feedback regulation of CCL2 release 
downstream of thrombin signalling in human lung fibroblasts would test this 
possibility.           
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3.3 Herpesvirus infection in pulmonary fibrosis 
3.3.1 Development of the model   
3.3.1.1 Introduction 
Gamma herpesvirus (γHV68) is a naturally occurring murine virus that shares 
homology with human gamma herpesviruses, especially Epstein-Barr virus (EBV) 
that, among other herpesviruses, has been implicated in the aetiology of IPF (Tang 
et al., 2003). γHV68 infection is persistent and occurs in a biphasic mode (Nash et 
al., 2001). The virus enters via respiratory routes and the primary site of infection 
and replication is the alveolar epithelium. Lytic infection is associated with 
extensive epithelial damage when the viral progeny are released and disseminated 
across lung tissue. The lytic phase peaks at day 7 post-infection and the virus 
subsequently establishes latency primarily in B lymphocytes but has been shown to 
persist in epithelial cells, macrophages and dendritic cells (Nash et al., 2001).  
Damage to the epithelium is a well-recognised initiating factor in the development 
of pulmonary fibrosis. Furthermore, latent herpesvirus infection of the human 
alveolar epithelium increases its sensitivity to TGFβ and its potential to undergo 
epithelial to mesenchymal transition (Sides et al., 2011). Infection with γHV68 in the 
FITC model of pulmonary fibrosis has been reported to cause increased collagen 
deposition in the lung and overall worse outcome of fibrosis (McMillan et al., 2008).  
The aim of this study was to establish a model of gamma herpesvirus infection on a 
background of bleomycin-induced pulmonary fibrosis. C57BL/6 male mice (aged 10-
12 weeks) were administered bleomycin at 1 mg/kg via the oropharyngeal route. 
Two weeks later after the establishment of the fibrotic phase, mice where 
inoculated with 80,000-100,000 PFU γHV68 or given saline via the intranasal route. 
Mice were sacrificed at 21 days post-bleomycin administration and 7 days post viral 
inoculation (p.i.), which corresponds to the peak of the lytic phase of γHV68 
infection (McMillan et al., 2008). The second group of mice was sacrificed 28 days 
post-bleomycin instillation and 14 days post-viral inoculation (p.i.).   
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3.3.1.2 The effect of bleomycin and viral infection on mouse 
body weight  
The current study aimed to establish a “two-hit” injury model and therefore we 
reduced our standard bleomycin dose to 1 mg/kg. Mice were weighed every 2 days 
throughout the duration of the experiment (Figure 3.46). The recorded weight loss 
corresponded temporally to the weight loss (on average 15% of starting body 
weight) observed with a “full” dose of bleomycin (2 mg/kg) routinely used in our 
laboratory, which occurs at the peak of inflammatory phase of bleomycin injury 
(between days 4-10) (Scotton et al., 2013). In this study maximum weight loss (on 
average 6% of starting body weight) was recorded 9 days after the bleomycin 
challenge. After this time, body weight stabilised and returned to the baseline 
values by day 14, when mice were infected with the virus. Following viral 
inoculation, infected mice ceased to gain weight and subsequently started losing 
weight again with a nadir around 7 days p.i., which corresponded to the peak of the 
lytic phase of infection. By 14 days post-infection all mice were gaining weight 
again.      
3.3.1.3 The effect of fibrotic insult and viral infection on ex vivo 
lung and spleen weights  
Normal mouse lungs weigh around 150 mg and following 2 mg/kg bleomycin injury 
this increases to 300 mg over the course of a four week model (Scotton et al., 
2013). In this study with reduced bleomycin dose, the fibrotic lungs harvested at 
day 7 p.i. were on average 30% heavier than the historical baseline (Figure 3.47A). 
The weight of virally-infected and bleomycin-challenged lungs was further 
significantly increased to 400 mg when compared to fibrotic only lungs. The weight 
of lungs harvested 14 days p.i. was lower for both control and virally-infected 
animals, although there was still a notable trend for virally-infected lungs to be 
heavier.    
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Murine γHV68 establishes latency primarily in B lymphocytes, which migrate to the 
spleen and hyperproliferate leading to splenomegaly that is usually established by 
two weeks post-infection (Nash et al., 2001). In this study we recorded the spleen 
weights as a surrogate indicator of infection. Normal mouse spleens weigh around 
100 mg and the administration of bleomycin had no effect on spleen weights in this 
study. There was no difference in spleen weight between control and virally-
infected animals at 7 days p.i. but 14 days p.i. spleen weight of virally-challenged 
mice was 3-fold higher (Figure 3.47B).  
3.3.1.4 Viral gene expression in the lung and spleen 
Viral infection was further confirmed by measuring the expression of viral genes in 
the lungs and spleens (Figures 3.48 and 3.49). Expression of viral genes was 
quantified by qPCR and included genes encoding the M3 viral envelope protein 
(involved in the modulation of immune responses of the host), glycoprotein B 
(present on the viral envelope and involved in viral entry into the cell), and viral 
DNA polymerase (responsible for viral genome replication). Glycoprotein B and DNA 
polymerase gene expression is associated with the lytic phase of infection, while M3 
is expressed throughout γHV68 infection (Vannella et al. 2010). At the peak of the 
lytic phase of the infection (7 days p.i.) the expression of all three genes was readily 
detectable in the lungs of infected animals. By day 14 post-infection, when the virus 
establishes latency, the expression of lytic genes in the lungs decreased to barely 
detectable levels (Figure 3.48). In the spleen glycoprotein B expression was 
detected at day 14 p.i., while both M3 and DNA polymerase expression was 
detected at day 7 and 14 post infection (Figure 3.49).    
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Figure 3.46. Changes in mouse body weights in the model of γHV68 infection on a 
background of bleomycin-induced pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 80,000 PFU γHV68 or saline intranasally on day 14 
as indicated. Data represent percentage change in average mouse body weight 
relative to starting body weight at day 0 over the course of the experiment. Each 
point is representative of mean +/- SEM of n=7-9 animals per group; two-way 
ANOVA *p<0.05 at day 21 post-bleomycin challenge and 7 days post-inoculation 
with γHV68.   
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Figure 3.47. Effect of γHV68 infection on a background of bleomycin-induced 
pulmonary fibrosis on mouse lung and spleen weights.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 80,000 PFU γHV68 or saline intranasally on day 
14. Panel A- data represent average mouse lung weights with the dotted line 
indicating historical baseline for a saline-treated mouse lung weights, 
representative of n=4-6 animals per group; and panel B- mouse spleen weights, 
representative of n=7-9 animals per group; measured ex vivo 7 and 14 days post 
infection; Two-way ANOVA, ***p<0.001.    
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Figure 3.48. Determination of viral gene expression in the lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 80,000 PFU γHV68 or saline intranasally on day 
14. The expression of viral genes in the lungs at 7 days p.i. and 14 days p.i. was 
assessed by qPCR and data are presented as fold change in mRNA levels relative to 
two housekeeping genes ATP5B and CANX and representative of mean +/- SEM, 
n=4-6 animals per group. Panel A- M3; panel B- glycoprotein B; panel C- DNA 
polymerase.  
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Figure 3.49. Determination of viral gene expression in the spleens.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 80,000 PFU γHV68 or saline intranasally on day 14. The 
expression of viral genes in the spleens at 7 days p.i. and 14 days p.i. was assessed 
by qPCR and data are presented as fold change in mRNA levels relative to two 
housekeeping genes ATP5B and CANX and representative of mean +/- SEM, n=4-6 
animals per group. Panel A- M3; panel B- glycoprotein B; panel C- DNA polymerase.  
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3.3.1.5 Collagen expression and deposition following viral 
infection on a background of pulmonary fibrosis  
Collagen deposition is a hallmark of fibroproliferative lung disease and marks the 
expansion of extracellular matrix in human disease and animal models of pulmonary 
fibrosis. Therefore, quantification of the lung collagen is the primary endpoint for 
the assessment of fibrosis in the lung. In order to evaluate the effect of viral 
infection on the development of fibrosis, total lung collagen protein and mRNA 
levels were measured.  
Viral infection in the fibrotic lung led to a significant upregulation in collagen gene 
expression 7 days p.i. compared to the bleomycin alone levels. This upregulation 
was no longer significant at 14 days p.i. (Figure 3.50). Total lung collagen, based on 
hydroxyproline levels and measured by high performance liquid chromatography 
(HPLC), doubled following bleomycin challenge at 7 days p.i. compared to our 
historical baseline data for lung collagen levels in C57BL/6 mice. There was no 
difference in total lung collagen between mock- and virally-infected animals (Figure 
3.51A). Published data from our laboratory revealed that in mice instilled with 2 
mg/kg of bleomycin, lung collagen deposition continues to increase through to at 
least day 28 post-administration (Scotton et al., 2013). However, in the present 
study with a lower dose of bleomycin (1 mg/kg), we did not see a further increase in 
lung collagen accumulation at day 28 post-instillation in mock-infected mice (14 
p.i.). Instead, we observed a trend towards a reduction in total lung collagen that 
may be indicative of an ongoing remodelling process. This trend was not observed 
in the bleomycin-challenged virally-infected animals in that total lung collagen 
remained significantly elevated and the difference was significant when compared 
to bleomycin-treated mock-infected animals (Figure 3.51B).  
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3.3.1.6 Histological characterisation of viral infection on a 
background of pulmonary fibrosis  
The increase in collagen at days 21 and 28 post-bleomycin injury (7 and 14 p.i.) was 
corroborated by haematoxylin and eosin (H&E) and modified Martius Scarlett Blue 
staining (MSB) of sections from paraffin-embedded lungs (Figures 3.52 and 3.53). In 
all bleomycin-treated lungs, both mock- and virally-infected, we observed severe 
changes to the lung architecture 21 days into the study (7 days p.i.). The hallmark 
abnormalities included extensive extracellular matrix deposition with visible thick 
bands of collagen, abnormal appearance of the alveolar epithelium, thickening and 
obliteration of alveolar septae, and extensive infiltration of inflammatory cells 
(Figure 3.52A). In the virally-infected fibrotic lungs there were clear signs of acute 
lung injury superimposed on a background of extensive fibrosis. As identified in 
Figure 3.52B and 3.52C, we observed pulmonary oedema, alveolar haemorrhage 
and greatly enhanced infiltration of inflammatory cells forming dense aggregates.  
At day 28 (14 days p.i.), in bleomycin-treated and mock-infected mice, the fibrosis 
appeared to have a structured and condensed pattern with clearly defined borders 
distinguishing it from largely normal-looking lung (Figure 3.53A). The inflammatory 
cell infiltrates were also no longer evident. In contrast, in the fibrotic and virally-
challenged lungs, extensive fibrosis was evident and collagen remained deposited in 
a disorganised manner. Although pulmonary oedema and haemorrhage appeared 
to have cleared, the dense inflammatory cells aggregates were still prominent 
(Figure 3.53B and 3.53C).            
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Figure 3.50. Effect of γHV68 infection in the model of pulmonary fibrosis on 
collagen gene expression.   
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 80,000 PFU γHV68 or saline intranasally on day 
14. Col1A1 mRNA levels were measured by qPCR and normalised to two 
housekeeping genes ATP5B and CANX, and relative to bleomycin alone. Data are 
representative of mean +/- SEM, n=4-6 animals per group, two-way ANOVA, 
**p<0.01 comparison between bleomycin+γHV68 and bleomycin+saline.  
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Figure 3.51. Effect of γHV68 infection on total lung collagen accumulation in the 
bleomycin-induced pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 80,000 PFU γHV68 or saline intranasally on day 
14. Total lung collagen was measured by quantification of hydroxyproline by HPLC 
at A- 7 days p.i. and B- 14 days p.i. Data are representative of mean +/- SEM, n=4-6 
animals per group, analysed by unpaired Student t-test. 
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Figure 3.52. Histological analysis of virally-infected fibrotic lungs 7 days p.i. 
Sections from paraffin-embedded lungs were stained with haematoxylin and eosin 
(H&E) (left column) and modified Martius Scarlett Blue method (MSB) revealing 
collagen fibres stained blue (right column). Panel A shows representative sections 
from a bleomycin-injured lung, panels B and C- γHV68-infected fibrotic lungs; the 
images are representative of n=3 animals per group; original magnification x10; 
panels D and E- H&E, x20 original magnification. IA- inflammatory aggregates, IO- 
interstitial oedema, AH- alveolar haemorrhage, COL- collagen.  
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Figure 3.53. Histological analysis of virally-infected fibrotic lung 14 days p.i. 
Sections from paraffin-embedded lungs were stained with haematoxylin and eosin 
(H&E) (left column) and modified Martius Scarlett Blue method (MSB) revealing 
collagen fibres stained blue (right column). Panel A shows representative sections 
from a bleomycin-treated lung, panels B and C- γHV68-infected fibrotic lungs; the 
images are representative of n=3 animals per group; original magnification x10; 
panels D and E-  H&E, x20 original magnification. IA- inflammatory aggregates, COL- 
collagen.  
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3.3.1.7 Expression of inflammatory mediators in viral infection 
of existing pulmonary fibrosis 
γHV68 infection is associated with a strong Th1-mediated and IFNγ-dependent 
antiviral response and a high lethality has been reported in IFNγ-deficient mice 
when infected with herpesviruses (Nash et al., 2001). Furthermore, IFNγ as well as 
TNFα levels have been shown to increase in the viral infection model of FITC-
induced pulmonary fibrosis (McMillan et al., 2008). In the present study, the levels 
of these two cytokines in lung homogenates were quantified by ELISA. A significant 
increase in IFNγ levels with the viral infection was observed in comparison with 
mock-infected animals at 14 days p.i. (Figure 3.54A). The levels of TNFα were 
comparable between experimental groups both at day 7 and 14 p.i. with a small 
increase in the virally-infected mice that did not reached statistical significance 
(Figure 3.54B). Increased levels of interleukin IL-8 are predictive of poor prognosis 
in IPF patients (Richards et al., 2012) and IL-8 has been shown to be induced during 
herpesvirus infection (Sun et al., 2006). In this study, we found that levels of the 
murine equivalent of human IL-8, keratinocyte-derived chemokine KC, were 
increased at both 7 and 14 days p.i. but this response was variable for virally 
infected-mice at seven days p.i. and only reached statistical significance at day 14 
p.i. when compared with bleomycin-alone treated mice (Figure 3.54C).   
We next examined the expression of CCL2, which is elevated in IPF lung (Mercer et 
al., 2009) and increased levels of CCL2 and CCL12 were also reported in the model 
of herpesvirus infection in FITC-induced pulmonary fibrosis (McMillan et al., 2008). 
CCL2 mRNA level increased 15-fold 7 days p.i. in virally-infected fibrotic lungs when 
compared to the bleomycin-challenged lungs (Figure 3.55A). The CCL2 protein level 
was also significantly increased at both 7 and 14 days p.i. (Figure 3.55B).         
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 Figure 3.54. Expression of inflammatory mediators in virally-infected fibrotic lungs. 
Cytokine and chemokine levels in lung homogenates were quantified by ELISA for A- 
IFNγ, B- TNFα and C- KC. Data are representative of mean +/- SEM, n=4-6 animals 
per group, two-way ANOVA, *p<0.05, **p<0.01 comparison between 
bleomycin+γHV68 and bleomycin+saline. 
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Figure 3.55. CCL2 expression in virally-infected fibrotic lungs.  
CCL2 mRNA levels were measured by qPCR and normalised to two housekeeping 
genes ATP5B and CANX, and relative to bleomycin alone- panel A. Total CCL2 levels 
per mg of protein in lung homogenates was quantified by ELISA- panel B. Data are 
representative of mean +/- SEM, n=4-6 animals per group, two-way ANOVA, 
**p<0.01, ***p<0.001 comparison between bleomycin+γHV68 and 
bleomycin+saline. 
 
 
 
  247  
  
3.3.1.8 Expression of coagulation factors in viral infection on a 
background of pulmonary fibrosis 
Viral infection provides an injurious cue that can lead to the upregulation of tissue 
factor and trigger the activation of the extrinsic coagulation cascade. Research from 
our laboratory has shown that the components of the TF-FVIIa-FXa ternary complex 
are locally upregulated in both human and murine fibrotic lung and co-localise to 
areas of hyperplastic epithelium (Scotton et al., 2009). This creates a potential for 
increased thrombin generation in the event of lung injury and microvascular leak. 
Thrombin is mitogenic for mesenchymal cells and stimulates myofibroblast 
differentiation and the synthesis of extracellular matrix via PAR-1 mediated 
signalling (Chambers et al., 1998, 2000). Therefore, we next examined whether the 
coagulation factors are upregulated in this model of viral infection of bleomycin-
induced pulmonary fibrosis. As shown in Figure 3.56A and B, γHV68 infection in the 
fibrotic lung led to a doubling in the tissue factor and FXa mRNA levels 7 days p.i 
relative to bleomycin-treated and mock infected lungs. This difference was lost by 
14 days p.i.. In contrast, FVII mRNA levels were significantly reduced in virally-
infected fibrotic lungs 7 days p.i. (Figure 3.56C).  
Next, the immunohistochemical analysis of tissue factor and FX protein distribution 
in the lung was performed. As shown in Figure 3.57, tissue factor and FX were 
strongly expressed in both mock- and virally-infected bleomycin-treated lungs 7 
days p.i. and co-localised to the bronchial epithelium and abnormal and 
hyperplastic alveolar epithelium. Macrophages and mesenchymal cells were also 
immunopositive for tissue factor and FX. Figure 3.58 shows representative sections 
from lungs 14 days p.i. Panel A shows bleomycin-challenged lung with a dense 
fibrotic area that was weakly immunopositive for tissue factor and FX. In the γHV68-
infected lungs (Figure 3.57B) the pattern of tissue factor and FX immunoreactivity is 
grossly similar to the sections from 7 days p.i. lungs with evidence of co-localisation 
to the bronchial epithelium, abnormal alveolar epithelium, macrophages and to 
lesser extent mesenchymal cells.     
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Figure 3.56. Expression of coagulation factors in viral infection of fibrotic lung.   
Coagulation factors mRNA levels were measured by qPCR and normalised to two 
housekeeping genes ATP5B and CANX, and relative to bleomycin alone. Panel A- 
tissue factor (TF), panel B- factor X (F10), panel C- factor VII (F7). Presented data are 
representative of mean +/- SEM, n=4-6 animals per group, two-way ANOVA, 
*p<0.05, **p<0.01. 
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Figure 3.57. Immunodetection of coagulation factors in viral infection on a 
background of fibrosis 7 days p.i.  
Sections from paraffin-embedded lungs were probed with antibodies for tissue 
factor (left column) and FX (right column). Panel A shows representative sections 
from a bleomycin-treated and mock-infected lung, panel B- γHV68-infected fibrotic 
lungs. BE- bronchial epithelium, AE- alveolar epithelium. The images are 
representative of n=3 animals per group; original magnification x10.  
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Figure 3.58. Immunodetection of coagulation factors in viral infection on a 
background of fibrosis 14 days p.i.  
Sections from paraffin-embedded lungs were probed with antibodies for tissue 
factor (left column) and FX (right column). Panel A shows representative sections 
from a bleomycin- treated and mock infected lung, panel B- γHV68 infected fibrotic 
lungs. BE- bronchial epithelium, AE- alveolar epithelium, MC- mesenchymal cells. 
The images are representative of n=3 animals per group; original magnification x10.  
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Thrombin exerts a plethora of cellular effects via PAR-1 but can also activate PAR-3 
and PAR-4, which are expressed in different lung cell populations and are 
considered to be modulators of PAR-1 signalling (McLaughlin et al. 2007). FXa, 
particularly when bound within the TF-FVIIa-FXa ternary complex, can also activate 
PAR-1 and PAR-2. Therefore, we next examined the expression of all four PARs at 
mRNA level. PAR-1 is known to be highly expressed by mesenchymal cells and is 
upregulated in the fibrotic epithelium in IPF (Mercer et al., 2009) while PAR-2 is the 
main PAR expressed on normal alveolar and bronchial epithelium. As shown in 
Figure 3.59A and B, PAR-1 (F2R) mRNA levels did not change significantly in the viral 
infection of fibrotic lung while PAR-2 (F2RL1) expression decreased significantly 
between day 7 p.i and 14 p.i. in virally-challenged fibrotic lungs only. As shown in 
Figure 3.59C and D both PAR-3 (F2RL2) and PAR-4 (F2RL3) mRNA levels were 
significantly upregulated 7 days p.i. and an increase was also notable at 14 days p.i. 
in the virally-infected fibrotic lung when compared to bleomycin-treated and mock-
infected lungs.  
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Figure 3.59. PAR receptors expression in viral infection on a background of fibrotic 
lung.   
The mRNA expression of PAR receptors was measured by qPCR and normalised to 
two housekeeping genes ATP5B and CANX, and relative to bleomycin alone: panel 
A- PAR-1 (F2R), panel B- PAR-2 (F2RL1), panel C- PAR-3 (F2RL2), panel D- PAR-4 
(F2RL3). Data are representative of mean +/- SEM, n=5-7 animals per group, one-
way ANOVA, *p<0.05, **p<0.01, ***p<0.001.      
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3.3.1.9 Summary  
 γHV68 infection on a background of bleomycin-induced fibrosis was 
confirmed by the expression of key viral genes in the lung and splenomegaly 
14 days p.i. 
 Bleomycin at a dose of 1 mg/kg increased total lung collagen 21 days post-
administration but by day 28 the level of total collagen appeared to 
decrease. Viral infection prevented this reduction in total lung collagen 
accumulation at day 28 suggesting that viral infection prevents the 
resolution of fibrosis in this model rather than causing exacerbation of 
fibrosis.  
 Viral infection of fibrotic lung induced a profound inflammatory response 
and acute lung injury superimposed on a background of fibrosis.  
 γHV68 infection of fibrotic lung increased the expression of tissue factor and 
factor X at the mRNA level and with the protein distribution localised 
primarily to bronchial and abnormal alveolar epithelium. 
 The expression of PAR-1 and PAR-2 was not affected by viral infection in the 
fibrotic lung but PAR-3 and PAR-4 mRNA levels were increased.  
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3.3 Herpesviruses infection in pulmonary fibrosis 
3.3.2 Blocking TGFβ/ALK5 signalling in the model of viral 
infection on a background of pulmonary fibrosis 
3.3.2.1 Introduction 
Previous section showed that viral infection on the background of bleomycin-
induced pulmonary fibrosis does not exacerbate fibrosis as assessed by 
measurements of total lung collagen, but rather prevents resolution of fibrotic 
response and triggers inflammatory responses. The aim of the next two sections 
was to investigate the potential role of TGFβ/ALK5 signalling and the role of 
coagulation cascade in this model of viral infection on a background of fibrosis. 
There is an irrefutable link between TGFβ signalling and fibroproliferative lung 
disease. Multiple in vitro and in vivo studies have shown that TGFβ signalling 
promotes extracellular matrix production and deposition and fibroblast to 
myofibroblast differentiation (Bonniaud et al., 2004b; Decologne et al., 2007; 
Fernandez and Eickelberg, 2012). Targeting TGFβ signalling by inhibition of the TGFβ 
receptor TβRI/Activin receptor-like kinase 5 (ALK5) with the small molecule 
antagonist SB525334 attenuates experimental pulmonary fibrosis (Scotton et al. 
2013; Bonniaud et al. 2005). Furthermore, a growing body of evidence strongly 
suggests that viral infection increases the rate of TGFβ activation (Stoolman et al. 
2010; Vannella et al. 2010) and increases the cell responsiveness to TGFβ (Naik et 
al., 2011). Having established a model of viral infection on a background of 
pulmonary fibrosis, as described in the previous Section 3.3.1 of this chapter, the 
aim of this study was to investigate whether TGFβ/ALK5 signalling plays a role in the 
development of fibrosis in this model.   
C57BL/6 male mice (aged 10-12 weeks) were administered bleomycin at 1 mg/kg or 
saline via oropharyngeal route. Two weeks later, after the establishment of the 
fibrotic phase, mice were inoculated with 100,000 PFU γHV68 or given saline via 
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intranasal route. Mice were administered SB525334 at 30 mg/kg via oral gavage 
twice daily from the day after the inoculation until the end of the experiment 14 
days later.   
3.3.2.2 Effect of SB525334 treatment on mouse body weight and 
ex vivo lung and spleen weights  
Following the oropharyngeal administration of 1 mg/kg bleomycin, mice lost on 
average 10% of starting body weight with a nadir at day 8, at which time the 
difference was significant for all bleomycin-challenged groups when compared to 
saline-instilled mice with stable body weight. After the initial weight loss, the weight 
stabilised and returned to the starting body weight by day 14, when mice were 
inoculated with the γHV68 virus (Figure 3.60). Treatment with SB525334 did not 
visibly influence mouse body weight in bleomycin-alone treated animals, but 
appeared to have abolished the second wave of the weight loss observed after 
administration of the virus. Mice in the bleomycin-γHV68-vehicle arm of the 
experiment lost approximately 5% body weight between days 18 and 24 of the 
experiment (Figure 3.60B). Saline control groups, mock- and γHV68-infected, 
continued to gain weight throughout the duration of the experiment and mice in all 
experimental groups gained weight by the end of the experiment. 
Bleomycin administration and viral infection lead to an increase in ex vivo lung 
weight. Bleomycin-treated lungs were on average 30% heavier than control saline-
administered lungs, while viral infection on a background of bleomycin-induced 
fibrosis caused a 40% increase in lung weights when compared to relevant control 
(Figure 3.61A). Administration of the virus in saline-treated mice caused a modest 
increase in lung weight. Treatment with SB525334 did not significantly affect the ex 
vivo lung weight although there is a notable trend towards a decrease in the 
bleomycin-alone treated lungs.   
Consistently with the previous study presented in this thesis, at 14 days post-
infection there was a significant splenomegaly observed in all experimental groups 
that have been infected with γHV68 (Figure 3.61B). Administration of bleomycin 
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alone did not affect the spleen weight but a double challenge with bleomycin and 
γHV68 virus significantly increased spleen weight when compared to γHV68 
infection alone. Interestingly, treatment with SB525334 significantly reduced the 
spleen weight when compared to vehicle control.  
In this study the expression of viral genes (Figure 3.62), M3, glycoprotein B and DNA 
polymerase, was readily detected in the infected saline-treated lungs and infected 
fibrotic lungs 14 days p.i., which suggests an ongoing low-level viral replication in 
the lung.     
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Figure 3.60. Effect of the viral infection on a background of lung fibrosis on mouse 
body weight.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28, mice were administered SB525334 (30 mg/kg) twice daily 
via oral gavage. Data represent percentage change in average mouse body weight 
relative to weight at day 0 over the course of the experiment. Each time point 
represents mean +/- SEM of n=7-14 animals per group; two-way ANOVA was 
performed for statistical analysis. Panel A- all experimental groups, **p<0.01 
bleomycin-challenged groups compared to saline-control groups, ++p<0.01 
bleomycin+γHV68+vehicle compared to saline control groups; and panel B- 
comparison of bleomycin-treated mice only, **p<0.01 bleomycin+γHV68+vehicle 
group compared to bleomycin alone groups.  
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Figure 3.61. Ex vivo lung and spleen weights in γHV68 infection of bleomycin-
induced pulmonary fibrosis.   
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were administered SB525334 (30 mg/kg) twice daily 
via oral gavage. Data represent average weights of mouse lungs- panel A; and 
spleens- panel B; measured ex vivo 14 days post infection; representative of n=7-14 
animals per group, One-way ANOVA statistical analysis, ***p<0.001 γHV68-infected 
groups versus each mock-infected groups; +p<0.05, ++p<0.01 comparison of γHV68-
infected saline-treated groups and γHV68-infected bleomycin-challenged groups.    
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Figure 3.62. Determination of viral gene expression in the lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 100,000 PFU γHV68 or saline intranasally on day 
14. The expression of viral genes in the lungs 14 days p.i. was assessed by qPCR and 
data are presented as fold change in mRNA levels relative to two housekeeping 
genes ATP5B and CANX and representative of mean +/- SEM, n=3-8 animals per 
group. Panel A- M3; panel B- glycoprotein B; panel C- DNA polymerase; nd- not 
detected.  
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3.3.2.3 Collagen deposition in infected and fibrotic lungs.  
In the pilot study of the γHV68 infection on a background of pulmonary fibrosis 
(Section 3.3.1), total lung collagen measured by hydroxyproline levels (HPLC) was 
increased 7 days p.i. and there was no difference between the mock- and virally-
infected animals (Figure 3.51A). At 14 days p.i. and 28 days into the study total lung 
collagen in the bleomycin-alone group was reduced in comparison to day 7 p.i. 
while γHV68-infected mice continued to show significantly elevated total lung 
collagen (Figure 3.51B). As shown in Figure 3.63A, in this study, total lung collagen 
was significantly elevated in bleomycin mock- and bleomycin-γHV68-infected mice 
when compared to saline control groups at 14 days p.i.. However, viral infection did 
not further enhance collagen deposition in the lung when compared to the 
bleomycin alone group. The administration of SB525334 reduced the bleomycin-
associated increase in lung collagen accumulation (unpaired Student t-test, 
p=0.048) but did not significantly reduce lung collagen accumulation in the γHV68-
challenged mice.     
Standard Sircol colorimetric assay was also performed to measure soluble collagen 
content in lung homogenates (Figure 3.63B). The levels of collagen detected by 
Sircol were 20-fold lower than those detected by HPLC. Total lung collagen was 
elevated in all bleomycin-challenged groups compared to saline mock-infected 
groups. Treatment with SB525334 significantly reduced total lung collagen 
accumulation when compared to bleomycin-vehicle group. Infection with γHV68 in 
the fibrotic lung did not further increase collagen accumulation in the lungs and 
SB525334 treatment also did not have any effect on total lung collagen in the 
virally-infected fibrotic lungs. In contrast to the HPLC results, the Sircol results 
showed non-significant increase in collagen level in γHV68 infection alone.  
It has been previously reported that serum proteins can interfere with Sircol 
collagen assay (Lareu et al., 2010) and discrepancies between the collagen levels in 
bleomycin-induced fibrosis as measured by HPLC and Sircol have also been reported 
(Scotton et al., 2013). It is therefore possible that the increase in collagen levels 
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detected by Sircol in γHV68-infected saline-treated group reflects serum proteins 
retained in the lungs after the clearance of vascular leak. 
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Figure 3.63. Effect of SB525334 treatment on total lung collagen accumulation in 
γHV68 infection of fibrotic lung. 
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30 mg/kg) twice daily via oral 
gavage. The total collagen in the lungs was quantified by A-HPLC and B-Sircol. Data 
are representative of mean +/- SEM, n=3-8 animals per group and one-way ANOVA 
was performed for statistical analysis, *p<0.05, unpaired Student t-test was 
performed to compare bleomycin alone versus bleomycin+SB525334 groups.  
 
 
  264  
  
3.3.2.4 Ex vivo μCT analysis of fibrosis and viral infection  
A dose of 1 mg/kg bleomycin used in this study caused a significant increase of total 
lung collagen as measured by hydroxyproline levels in the lungs (HPLC) but the viral 
infection in bleomycin-treated lung did not further increase the level of lung 
collagen accumulation. As the traditional HPLC endpoint measurement used to 
evaluate fibrosis has a limited signal window, particularly when the lower dose of 
bleomycin is used, ex vivo micro-computed tomography (μCT) was used in 
conjunction with histological analysis to fully characterise the impact of viral 
infection on pulmonary fibrosis. μCT technology has been validated in vivo for 
repeated longitudinal studies of lung cancer (Namati et al., 2010) and ex vivo for 
investigating the lung architecture (Thiesse et al., 2010; Vasilescu et al., 2012) and 
as an endpoint for evaluating fibrosis (Rodt et al., 2010; Scotton et al., 2013). The 
aim of this part of the study was to evaluate whether viral infection adds to the 
pathology of fibrosis and whether μCT is an informative technique to quantify these 
changes.  
All lungs were scanned at 13 µm resolution and representative reconstructed lung 
images from each experimental group are shown in Figure 3.64. The appearance of 
control lungs is homogenous and reveals a network of airways through a 
transparent parenchyma. In this experimental model of fibrosis peripheral areas of 
the lungs are mostly affected and dense lesions are clearly distinguishable on the 
dorsal side of bleomycin-challenged lungs. These lesions are noticeably dispersed in 
the SB525334 treated lungs. In γHV68-infected lungs with existing fibrosis these 
lesions appear to be more extensive and again are reduced in the SB525334-treated 
lungs. Virally-infected and saline-treated lungs have grossly normal appearance.     
Pattern-recognition software was subsequently applied to quantify abnormal areas 
in the lungs. The software was first “trained” to discriminate between normal 
parenchyma and fibrotic lesions, excluding other tissue such as the heart. Figure 
3.65 shows representative coronal µCT scans matched with a segmentation map 
produced by the software and compared with histology for each experimental 
group. As exemplified by the saline control and saline-SB525334 treated lungs, µCT 
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provides a high resolution image of gross anatomy and architecture of the lung with 
clearly distinguishable airways and airspaces. As confirmed by histology, these lungs 
have normal morphology.  
In contrast, µCT of bleomycin-injured lungs reveals dense fibrotic lesions. These 
areas of consolidation are largely concentrated around broncho-vascular bundles, 
consistent with the route of administration of bleomycin, and extend to the 
periphery of the lung. Prominent subpleural scarring and traction bronchiectasis 
appears to “ruffle” otherwise smooth edges of the lung. At the level of light 
microscopy, these abnormal areas correspond to fibrotic bands of elongated 
fibroblast bundles embedded in collagen fibres as visualised by modified Martius 
Scarlett Blue (MSB) staining. Lungs of mice treated with SB525334 displayed fewer 
areas of dense consolidation and less extensive scarring of the lung.     
Inoculation with the γHV68 virus alone did not appear to cause any lasting 
alterations to the lung architecture. In contrast, γHV68 virus infection in mice 
injured with bleomycin led to increased areas of dense consolidation centred 
around airways. Furthermore, the infected lungs showed large areas with ground 
glass opacities suggestive of inflammatory cell infiltrates. Indeed, the histological 
analysis confirmed that next to dense fibrotic areas, multiple inflammatory cell 
aggregates were apparent in γHV68-infected lungs. μCT scanning and segmentation 
analysis revealed that SB525334 treatment appeared to have reduced these 
abnormal areas, which was also confirmed by histology. Although there was 
discernible reduction in pathological changes to the infected lungs with SB525334, 
the differences were not as dramatic as when fibrotic lungs were treated with the 
ALK5 inhibitor.     
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Figure 3.64. Reconstruction of μCT lung scans showing gross lung appearance. 
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30 mg/kg) twice daily via oral 
gavage. The lungs were insufflated, fixed and scanned at high resolution (13 µm). 
The figure shows representative 3D reconstructed images of the scanned lungs 
from all experimental groups.  
Figure 3.65. Characterisation of the changes in lung morphology of virally infected 
fibrotic lungs.   
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30mg/kg) twice daily via oral 
gavage. Panel A- representative coronal µCT scans with B- corresponding 
segmentation map showing normal parenchyma (green), abnormal lung areas (red) 
and other tissue (blue). Panel C- histology sections stained with haematoxylin and 
eosin (H&E) and panel D- modified Martius Scarlett Blue method (MSB) to visualise 
collagen fibres. Selected areas are shown in 100x magnification. Panel E and F- H&E 
and MSB sections at 200x magnification.  Complete sets of images are shown for 
every experimental group as annotated. AE- alveolar epithelium, BE- bronchial 
epithelium, FB- fibroblasts, COL- collagen, IA- inflammatory aggregates.   
 
  
 
 
  268  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Saline 
A B 
C D 
Saline, SB525334 
A B 
C D 
 
 
  269  
  
  
  
Saline, γHV68 
A B 
C D 
Saline, γHV68, SB525334 
A B 
C D 
 
 
  270  
  
 
  
Bleomycin 
A B 
C D 
Bleomycin, SB525334 
A B 
C D 
 
 
  271  
  
Bleomycin, γHV68 
  
A B 
A B 
C D 
Bleomycin, γHV68, SB525334 
C D 
 
 
  272  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Saline 
Saline, SB525334 
Bleomycin 
Saline, γHV68 
Saline, HV68, SB525334 
AE 
BE 
BE 
AE 
AE 
BE 
AE 
BE 
BE BE 
AE AE 
BE 
AE AE 
BE 
FB FB 
E F 
COL 
 
 
  273  
  
Bleomycin, γHV68 
IA 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Bleomycin, SB525334 
Bleomycin, γHV68, SB525334 
AE 
FB 
AE 
FB 
IA 
COL 
COL 
 
 
  274  
  
3.3.2.5 Quantification of μCT analysis of viral infection on a 
background of pulmonary fibrosis  
 
The InForm analysis and segmentation of the μCT scans was subsequently used to 
quantify the extent of abnormal areas in the lungs. Whole lung volume was 
calculated first to confirm that the measurements were not affected by differences 
in lung insufflation and processing. As shown in Figure 3.66 the average volumes of 
lungs did not differ between experimental groups.  
The abnormal areas were subsequently expressed as a percentage of total lung 
volume for all experimental groups. As shown in Figure 3.67 saline treated groups 
had less than 10% of areas segmented as abnormal by the software while lungs 
challenged with bleomycin showed an average of 40% abnormal areas. The lungs of 
animals treated with SB525334 showed 15% abnormal areas in the lung, which was 
a significant reduction when compared to all other bleomycin-challenged groups. 
Infection with γHV68 further increased the percentage of abnormal lung to an 
average of 50% but this trend fell short of statistical significance in comparison to 
the bleomycin-challenged group. Intervention with SB525334 in virally-infected 
fibrotic lung reduced the percentage of abnormal areas in the lung but this decrease 
was not as striking as observed in fibrotic lungs with the SB525334 treatment.  
This pattern was corroborated by the analysis of associated densities for each lung. 
Abnormal density values in the bleomycin-injured lungs read 4500 voxels while 
normal lungs were below 1000 voxels (Figure 3.68). SB525334 treatment reduced 
the fibrotic lung density to 2000 voxels, which was significantly lower when 
compared to fibrotic infected lungs and bleomycin-challenged lungs. Fibrotic lung 
density increased further following viral infection and reached 6000 voxels density 
but SB525334 only slightly reduced this increase in density in γHV68-infected 
fibrotic lungs. Taken together these data suggest that SB525334 blockade of TGFβ 
signalling in γHV68-infected fibrotic lungs may modulate the inflammatory 
response, which is detected by the software as a change in the appearance of the 
lungs (Figure 3.67). However, in γHV68-infected fibrotic lung SB525334 treatment 
did not appear to interfere with fibrotic responses.  
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Figure 3.66. Total lung volume of µCT scanned lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30 mg/kg) twice daily via oral 
gavage. The graph shows an average of total volume of the lungs +/- SEM, 
processed for μCT and InForm analysis for each experimental group, n=2-5 mice.  
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Figure 3.67. Quantification of abnormal lung area in viral infection on a 
background of pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30 mg/kg) twice daily via oral 
gavage. The abnormal lung area were quantified by InForm analysis of µCT scans 
and are expressed as a percentage of total lung volume. Data are representative of 
n=2-5 animals per group, one-way ANOVA, *p<0.05, **p<0.01, comparison of all 
bleomycin-challenged groups (n=5).  
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Figure 3.68. Quantification of lung density in viral infection on a background of 
pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 at dose of 30 mg/kg twice daily 
via oral gavage. The abnormal lung densities were quantified by InForm analysis of 
µCT scans and are expressed as changes of density in the total lung. Data are 
representative of n=2-5 animals per group, one-way ANOVA, *p<0.05, **p<0.01, 
comparison of all bleomycin-challenged groups (n=5). 
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In order to support the segmentation analysis, voxel density analysis was performed 
which does not rely on the software segmentation output. Mean number of voxels 
per lung at each greyscale value (0 being least dense and 255 being most dense) for 
each experimental group is presented in the form of histograms and Student t-test 
was performed to compare individual groups and indicate statistically significant 
differences in the mean voxels numbers between the groups (Figures 3.69 and 
3.70). Figure 3.69 shows the histogram for all experimental groups and 
demonstrates a clear separation in density between saline controls, bleomycin 
alone and bleomycin and virus double-injured lungs. The majority of voxels in the 
virally infected saline lungs fall close to the saline control lungs and the bleomycin-
injured lungs treated with SB525334 also have voxels of lower density. In the 
bleomycin alone and bleomycin and virally infected lungs there was a marked shift 
to the left indicating more voxels of higher density in comparison to saline controls, 
which corresponded to higher density on μCT scans.  
Density histograms shown in Figure 3.70A demonstrate that for saline control 
groups and γHV68-inoculated saline control groups the greyscale density values 
were similar, which suggests that the viral infection alone did not affect the overall 
density of the lung. In contrast saline control lungs were visibly less dense than 
fibrotic lungs with a significant shift in pixel densities in a range of 50 to 110 (Figure 
3.70B). SB525334 treatment did not affect the architecture of a normal lung but 
reduced the density of bleomycin-challenged lungs and there was no significant 
difference in pixel densities between saline control lungs and SB525334-treated 
fibrotic lungs. Figure 3.70C shows that a significant shift towards higher greyscale 
values was also observed between virally-infected saline lungs and virally-infected 
fibrotic lungs in a pixel density range of 50 to 150.  
The pixel density range of 50 to 150 encompassed the differences in densities 
between the saline control, fibrotic and virally-infected groups and was chosen to 
demonstrate the distribution of density pixels in these lungs. As shown in Figure 
3.70E, this greyscale range represented mainly airway walls in saline lungs and 
virally-infected saline lungs. In contrast, dense fibrotic areas were highlighted in the 
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bleomycin-challenged lungs. In virally infected fibrotic lungs the pixel range also 
covered abnormal changes in the lung parenchyma as well as fibrotic lesions.  
Comparison of bleomycin-injured, fibrotic lungs showed a range of changes 
dependent on infection status and treatment status (Figure 3.70D). Significant 
differences over a wide pixel range (50 to 115) were observed between bleomycin 
alone and bleomycin-γHV68 lungs. The distribution of pixels within this greyscale 
range highlighted fibrotic lesions and also extensive areas of parenchyma in the 
infected-fibrotic lungs (Figure 3.70F). Although SB525334 significantly reduced the 
density of the fibrotic lungs, the pixel range and distribution changed greatly in the 
γHV68-infected fibrotic lungs. ALK5 inhibition in the bleomycin-injured lungs 
reduced the extent and severity of fibrosis when compared with the bleomycin-
vehicle lungs and this observation was further supported by the greyscale density 
differences in a range of 100 to 155, which localised to fibrotic lesions and airway 
walls in the lungs (Figure 3.70F). In contrast, the range of significantly different 
pixels between bleomycin-γHV68 and bleomycin-γHV68-SB525334 was narrow (50 
to 65) and distributed through parenchyma, which suggests that the ALK5 inhibitor 
in the environment of viral infection superimposed on a background of fibrosis 
primarily targets inflammatory changes (Figure 3.70E).          
In summary, these data show that SB525334 treatment in fibrotic lungs reduced the 
density of treated lungs, which suggests that blocking TGFβ signalling attenuates, 
but does not reverse, the development and course of fibrosis. Furthermore, a lack 
of statistical difference between saline and bleomycin-SB525334 treated lungs in 
pixel density further supports the rationale of targeting TGFβ in fibrosis. In contrast, 
the therapeutic effect of SB525334 was reduced in the event of viral infection on a 
background of pulmonary fibrosis.  
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Figure 3.69. Voxel density histograms of μCT scanned lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30 mg/kg) twice daily via oral 
gavage. This density histogram shows distribution of voxels corresponding to each 
experimental groups plotted as a mean number of voxels against the greyscale 
values reflecting the density of the tissue, where 0 is black and 255 is white. Data 
are representative of an average of n=2-5 animals per group. 
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Figure 3.70. Density histograms analysis of μCT scanned lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given SB525334 (30 mg/kg) twice daily via oral 
gavage. This figure shows density histograms corresponding to each experimental 
groups plotted as a mean number of voxels against the greyscale values reflecting 
the density of the tissue, where 0 is black and 255 is white. The histograms are 
matched with the Student t-test analysis of significance and represented as graphs 
of probability value of less than 0.1, where the significance cut off was set as 0.05 as 
indicated by the dotted line against the density denoting greyscale values. Panel A- 
comparison of saline groups with γHV68-infected saline groups and the statistical 
analysis plots; panel B- comparison of saline groups with bleomycin-challenged 
groups and the statistical analysis plots; panel C- comparison of γHV68-infected 
saline groups with γHV68-infected bleomycin-challenged groups and the statistical 
analysis plots; panel D- comparison of bleomycin challenged groups and γHV68-
infected fibrotic groups and the statistical analysis plots; panel E- distribution of 
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Bleomycin γHV68 
F 
Bleomycin γHV68 SB525334 Bleomycin  
Pixel range 100-155 
Bleomycin  
Bleomycin SB525334 
 
 
  284  
  
pixels in a density range 50 to 150, highlighted in red between saline control and 
bleomycin-challenged and γHV68-infected saline and γHV68-infected fibrotic lungs; 
panel F- distribution of significantly different pixels highlighted in red between the 
γHV68-infected fibrotic lung and bleomycin only lung, fibrotic lung and fibrotic lung 
treated with SB525334 and γHV68-infected fibrotic and γHV68-infected fibrotic  
treated with SB525334. Data are representative of an average of n=2-5 animals per 
group. 
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Taken together, these data suggest a shift in the SB525334 therapeutic effect 
between the fibrotic lung and viral infection on a background of pulmonary fibrosis. 
In order to further dissect these differences, we quantified the numbers of 
prominent inflammatory cell aggregates observed in the lungs infected with γHV68 
(Figure 3.65E). The inflammatory aggregates were formed by numerous 
mononuclear cell infiltrates that stained strongly with haematoxylin. Nuance 
multispectral tissue imaging software was used to enhance the areas in the lungs 
with high density of haematoxylin staining and count these areas as regions of 
interest per area of the lung section (ROI/mm2) (Figure 3.71A). As shown in Figure 
3.71B, no inflammatory aggregates were detected in the saline control lungs and 
low numbers were identified in bleomycin-challenged lungs. In contrast γHV68 
infection on a background of pulmonary fibrosis significantly increased the number 
of inflammatory cell aggregates when compared to bleomycin challenged lungs. A 
trend towards reduction in inflammatory aggregates was evident with SB525334 
treatment but the difference was not significant. A degree of variability was 
observed between the sections which may explain the lack of statistical difference. 
This pattern of inflammatory aggregates distribution was closely matched by CCL2 
gene expression in the lungs (Figure 3.71C). Infection with γHV68 increased the 
expression of CCL2 in saline lungs compared to mock-infected saline and bleomycin-
challenged lungs. This response was significantly increased in γHV68 infection on a 
background of existing pulmonary fibrosis and a trend towards a reduction of CCL2 
expression was observed with SB525334 treatment.     
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Figure 3.71. Inflammatory changes in the γHV68 infection on a background of 
pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 100,000 PFU γHV68 or saline intranasally on day 
14. Panel A- inflammatory aggregates were identified as dense areas of 
haematoxylin staining by the Nuance software; Panel B- inflammatory aggregates 
were quantified and expressed as region of interest (ROI/mm2), mean +/- SEM, n=2-
5 animals per group. Panel C- expression of CCL2 in the lungs 14 days p.i. was 
assessed by qPCR and data are presented as fold change in mRNA levels relative to 
two housekeeping genes ATP5B and CANX and representative of mean +/- SEM, 
n=3-8 animals per group. One-way ANOVA was performed for statistical analysis, 
*p<0.05, **p<0.01.   
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3.3.2.6 Summary  
 
The aim of this study was to investigate the role of TGFβ in the γHV68 infection on a 
background of pulmonary fibrosis. 
 Infection with γHV68 caused weight loss in inoculated mice and increased ex 
vivo lung and spleen weights, as previously reported. Furthermore, 
expression of viral genes was readily detected in this study 14 day p.i.  
 Assessment of total lung collagen by measuring hydroxyproline levels (HPLC) 
and soluble collagen (Sircol assay) showed no difference in collagen 
accumulation between fibrotic lung and γHV68 infected fibrotic lung. 
SB525334 reduced the collagen level in the mock-infected fibrotic lungs at 
day 28 post-bleomycin and 14 days p.i. but in virally-infected fibrotic lung 
the therapeutic effect of SB525334 was lost. 
 Further analysis of the lungs was performed using µCT and InForm pattern 
recognition software analysis, which generated informative data that 
expanded on the HPLC and Sircol findings. Virally-infected fibrotic lungs had 
worse appearance on the µCT scans, had higher percentage of abnormal 
areas and increased lung densities when compared with bleomycin-
challenged lungs. These findings were further corroborated by analysis of 
histology sections, which showed mature fibrotic lesions in bleomycin-
challenged lungs while in the viral infection of fibrotic lungs there was 
evidence of inflammation superimposed on a background of existing fibrosis. 
Prominent inflammatory cell aggregates were quantified showing 
significantly increased numbers in the γHV68-infected fibrotic in comparison 
to bleomycin-challenged lungs. SB525334 treatment appeared to reduce the 
inflammation but this failed to reach statistical significance.      
 Taken together, all the parameters analysed in this study support the 
conclusion that targeting TGFβ/ALK5 signalling in the bleomycin-model of 
pulmonary fibrosis attenuates fibrosis but in the virally infected fibrotic 
lungs SB525334 therapeutic effect appears to be re-directed towards 
dampening down the inflammatory response.    
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3.3 Herpesviruses infection in pulmonary fibrosis 
3.3.3 Targeting coagulation in the viral infection on a 
background of pulmonary fibrosis 
3.3.3.1 Introduction 
Excessive activation of coagulation cascade has been strongly implicated in 
fibroproliferative lung disease. In experimental models of pulmonary fibrosis 
targeting either thrombin (Howell et al. 2001) or FXa (Scotton et al., 2009) has been 
reported to attenuate lung collagen accumulation and fibrosis. In contrast, global 
and non-specific anticoagulation therapy has been associated with increased 
mortality in patients with IPF (Noth et al., 2012). In Section 3.3.1 of this study we 
showed evidence for increased expression of tissue factor and factor X (FX) in 
response to γHV68 infection of a fibrotic lung. The aim of this study was to evaluate 
the effect of FXa inhibition in this model of viral infection on a background of 
pulmonary fibrosis using a direct and selective FXa inhibitor, BAY 59-7939 
(marketed as Rivaroxaban or Xarelto). BAY 59-7939 has recently been tested in a 
clinical trial of acute coronary syndrome and proven efficacious in reducing adverse 
cardiovascular events (Fitchett, 2012).  
C57BL/6 male mice (aged 10-12 weeks) were administered bleomycin at the 
reduced dose of 1 mg/kg or saline via oropharyngeal instillation. Two weeks later, 
when the fibrotic phase was established, mice where inoculated with 80,000-
100,000 PFU γHV68 or given saline via intranasal route. Mice were administered 
BAY 59-7939 at 3 mg/kg via oral gavage twice daily for the remaining 14 days of the 
experiment.  
3.3.3.2 Monitoring mouse body weight 
Following the oropharyngeal administration of 1 mg/kg bleomycin, mice have lost 
on average 7% of starting body weight with a nadir at day 6 while the saline-treated 
mice continued to gain weight (Figure 3.72). By day 14, mice were gaining weight 
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again and were inoculated with γHV68 virus. During the first week of infection a 
second wave of weight loss was registered in all γHV68-infected-bleomycin-
challenged groups, with a trend suggesting that treatment with BAY 59-7939 caused 
more weight loss. Saline groups both mock- and γHV68-infected continued to gain 
weight throughout the duration of the experiment and mice in all the experimental 
groups were gaining weight by the end of the experiment. 
3.3.3.3 Effect of treatment with BAY59-7939 on ex vivo lung and 
spleen weights  
Both bleomycin administration and viral infection lead to increase in ex vivo lung 
weights in comparison to saline control lungs. Consistent with previous 
experiments, bleomycin-challenged lungs were on average 30% heavier than saline-
administered control lungs and an increase in lung weight with administration of 
the virus alone was also notable. Viral infection on a background of bleomycin-
induced fibrosis led to a significant 50% increase in lung weight when compared to 
relevant control (Figure 3.73A). BAY 59-7939 did not affect ex vivo lung weight in 
either bleomycin alone or virally-infected and bleomycin-challenged experimental 
groups.   
Consistent with previous observations, a significant splenomegaly was present at 
the end of the experiment (Figure 3.74B). Bleomycin alone did not increase spleen 
weight but combined injury with bleomycin and γHV68 virus significantly increased 
spleen weight when compared to γHV68 infection alone groups.  
Furthermore, in this study the expression of viral genes (Figure 3.74), M3, 
glycoprotein B and DNA polymerase, was also readily detected in the lungs 14 days 
p.i.. This suggests a low-level, ongoing viral replication in the lung as observed in the 
previous study and the viral gene expression was increased in virally infected 
fibrotic lungs compared to viral infection in the saline treated lungs. 
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Figure 3.72. Monitoring mouse body weight in the viral infection of fibrotic lung. 
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY 59-7939 (3 mg/kg) twice daily via 
oral gavage. Data represent percentage change in average mouse body weight 
relative to starting weight at day 0 over the course of the experiment. Panel A- all 
experimental groups; **p<0.01 comparison of saline control group versus 
bleomycin-challenged groups, ++p<0.01 comparison of saline control group with 
bleomycin+γHV68+BAY 59-7939; and panel B- comparison of bleomycin-challenged 
groups only, *p<0.05 comparison of bleomycin+ γHV68+BAY 59-7939 with the 
remaining groups. Each point is representative mean +/- SEM of n=7-14 animals per 
group, two-way ANOVA statistical analysis. 
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Figure 3.73. Ex vivo lung and spleen weights in γHV68 infection of bleomycin-
induced pulmonary fibrosis.   
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY 59-7939 (3 mg/kg) twice daily via 
oral gavage. Data represent average weights of mouse lungs- panel A; and spleens- 
panel B; measured ex vivo 14 days post infection; representative of n=7-14 animals 
per group, one-way ANOVA, ***p<0.001.    
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Figure 3.74. Determination of viral gene expression in the lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY 59-7939 (3 mg/kg) twice daily via 
oral gavage. The expression of viral genes in the lungs 14 days p.i. was assessed by 
qPCR and data are presented as fold change in mRNA levels relative to two 
housekeeping genes ATP5B and CANX and representative of mean +/- SEM, n=3-8 
animals per group. Panel A- M3; panel B- glycoprotein B; panel C- DNA polymerase; 
nd- not detected.  
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3.3.3.4 Collagen deposition in the viral infection of fibrotic lung  
A dose of 1 mg/kg bleomycin alone caused a modest increase in total lung collagen 
of 30% as measured by HPLC that was significant when compared to saline control 
lungs (unpaired Studen t-test p=0.003). As observed in the previous study, viral 
infection in bleomycin-injured lung did not further increase the level of collagen 
deposition in the lung (Figure 3.75A). The greatest increase in collagen 
accumulation (40%) was observed in bleomycin-γHV68-BAY 59-7939 group. 
Measurement of soluble collagen by the standard Sircol colorimetric assay also 
showed no difference in lung collagen deposition between bleomycin alone and 
bleomycin-γHV68 challenged groups (Figure 3.75B). As observed in the previous 
study, an increase in lung collagen was detected in γHV68 infected saline lungs, 
which may reflect cross-reaction of the Sircol assay with other non-collagenous 
proteins (Lareu et al., 2010). This suggests a possible vascular leak caused by the 
viral infection and there is a trend towards a reduction with BAY59-7939. μCT 
analysis was also performed in this study to expand on HPLC results and 
characterise fibrosis and viral infection.    
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Figure 3.75. Total lung collagen accumulation in γHV68 infection on a background 
of pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY 59-7939 (3 mg/kg) twice daily via 
oral gavage. The total lung collagen was quantified by measurements of 
hydroxyproline by HPLC- panel A and soluble collagen by Sircol- panel B. Data are 
representative of mean +/- SEM, n=3-8 animals per group, one-way ANOVA, 
**p<0.01 comparison of bleomycin+γHV68+BAY59-7939 and all saline groups.  
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3.3.3.5 Ex vivo μCT analysis of viral infection in fibrotic lung.  
A dose of 1 mg/kg bleomycin used in this experiment caused a 30% increase in total 
lung collagen as measured by HPLC and the bleomycin-γHV68-BAY59-7939 
experimental group appeared to have further increased collagen deposition, 
although this difference did not reach statistical significance. As demonstrated in 
the previous study by μCT and histology analysis, viral infection of fibrotic lungs 
leads to a prominent inflammatory response superimposed on a background of 
existing fibrosis. The same analysis was subsequently performed in this study to 
assess the effect of FXa inhibition in the model of viral infection in fibrotic lung. 
Figure 3.76 shows a representative reconstructed image of the dorsal side of the 
scanned lung from each experimental group. As observed in the previous study, 
saline treated lungs appear homogenous, with visible small airways. In contrast, 
bleomycin-injured lungs display areas of dense consolidation indicative of fibrosis. 
These areas are also prominent in γHV68-infected fibrotic lungs.  
Figure 3.77 shows a representative µCT scan matched with a segmentation map 
produced by the InForm software and compared with histology for each 
experimental group. Analysis of saline control and saline-BAY59-7939 treated lungs 
shows that these lungs have normal appearance and morphology. In contrast, µCT 
analysis of bleomycin-challenged lungs reveals fibrotic lesions largely concentrated 
around broncho-vascular bundles as observed in the previous study and consistent 
with the route of administration of bleomycin. The fibrotic areas extend to the 
periphery of the lung and classic features of fibrosis are again notable, including 
subpleural scarring and traction bronchiectasis. Microscopically, these abnormal 
areas correspond to areas of high cellularity and increased deposition of 
extracellular matrix as visualised by MSB collagen staining. Treatment with BAY59-
7939 did not appear to affect the macroscopic and microscopic pattern of fibrosis in 
bleomycin-injured lungs.    
In this study minor alterations to the lung appearance were observed with γHV68 
infection alone. The changes resembled glass ground opacities and interlobular 
septal thickening suggestive of inflammation and were identified by the analytical 
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software as “abnormal areas”. Microscopically, these lungs appeared largely normal 
but small areas of scar tissue and thickened alveolar walls could be seen. In 
contrast, γHV68 virus infection in mice challenged with bleomycin was associated 
with extensive areas of dense consolidation centred around airways and spreading 
to the lung periphery. The outline of the lung was visibly distorted. Furthermore, 
virally-infected lungs displayed large areas with ground glass opacities suggestive of 
inflammatory cell infiltrates (confirmed by histology) alongside extensive deposition 
of extracellular matrix. BAY59-7939 treatment appeared to be associated with 
marked inflammatory changes in the virally-infected fibrotic lungs, which were 
further confirmed by histological analysis that also revealed dense fibrotic changes 
with collagen deposition, cellular infiltrates and abnormal epithelium.  
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Figure 3.76. Reconstruction of μCT scans showing gross lung appearance. 
 C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given BAY59-7939 (3 mg/kg) twice daily via oral 
gavage. The lungs were insufflated, fixed and scanned at high resolution (13 µm). 
The figure shows representative 3D reconstructed images of the scanned lungs 
from all experimental groups.  
Figure 3.77. Characterisation of the changes in lung morphology induced by 
bleomycin-challenge and γHV68 infection.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 mice were given BAY59-7939 (3 mg/kg) twice daily via oral 
gavage. Panel A- representative coronal µCT scans with B- corresponding 
segmentation map showing normal parenchyma (green), abnormal lung areas (red) 
and other tissue (blue). Panel C- histology sections stained with haematoxylin and 
eosin (H&E) and panel D- modified Martius Scarlett Blue method (MSB) to visualise 
collagen fibres. Selected areas are shown in 100x magnification. Panel E and F- H&E 
and MSB sections at 200x magnification.  Complete sets of images are shown for 
every experimental group as annotated. AE- alveolar epithelium, BE- bronchial 
epithelium, FB- fibroblasts, COL- collagen, IA- inflammatory aggregates.   
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3.3.3.6 Quantification of ex vivo μCT analysis of fibrosis and 
viral infection 
 
Abnormal lung areas and density were subsequently quantified based on the 
InForm segmentation analysis of μCT scans. Figure 3.78 shows that total lung 
volumes across all experimental groups are comparable, which is consistent with 
homogenous lung insufflation and processing.   
Figure 3.79 shows the percentage of abnormal lung area for all experimental 
groups. Saline control groups have less than 10% of abnormal lung area in the lungs 
but viral infection alone increased this percentage to 20%, which is consistent with 
abnormalities observed on the μCT scans. Bleomycin-induced fibrosis also 
amounted to 20% abnormal lung area and treatment with BAY59-7939 did not 
affect this response. Infection with γHV68 on a background of exiting fibrosis 
increased the abnormal lung area to 35%, again consistent with changes observed 
on μCT scans. The most extensive alterations to lung architecture were detected in 
the bleomycin-γHV68-BAY59-7939 group as reflected by the abnormal lung area 
reaching on average 45%, but the difference between bleomycin-γHV68-vehicle and 
bleomycin-γHV68-BAY59-7939 failed to reach statistical significance.     
Consistent with the previous study, the saline control lungs register a density below 
1000 voxels but there is an increase in density with viral infection alone. Bleomycin-
injured lungs are 2500 voxels dense and treatment with BAY59-7939 did not affect 
lung density. Infected fibrotic lungs were nearly twice as dense as saline control 
lungs and treatment with BAY59-7939 further increased the density to an average 
of 6000 voxels. Taken together, these data suggests that viral infection in the 
fibrotic lung caused the most marked distortion of lung architecture when 
combined with BAY59-7939 therapy (Figure 3.80).    
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Figure 3.78. Total lung volume of µCT scanned lungs. 
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY59-7939 (3 mg/kg) twice daily via 
oral gavage. The graph shows an average of total volume of the lungs processed for 
μCT and InForm analysis for each experimental group, n=2-5 mice.  
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Figure 3.79. Quantification of abnormal lung area in viral infection on a 
background of pulmonary fibrosis  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY59-7939 (3 mg/kg) twice daily via 
oral gavage. The abnormal areas in the lung were quantified by InForm analysis of 
µCT scans and are expressed as a percentage of total lung area. Data are 
representative of n=2-5 animals per group, one-way ANOVA, *p<0.05.  
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Figure 3.80. Quantification of lung density in viral infection on a background of 
pulmonary fibrosis 
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY59-7939 (3 mg/kg) twice daily via 
oral gavage. The changes in the lung were quantified by InForm analysis of µCT 
scans and are expressed as abnormal lung density in the total lung. Data are 
representative of n=2-5 animals per group, One-way ANOVA, **p<0.01.  
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In order to further examine data, voxel density analysis was performed which does 
not rely on the software segmentation output. The mean number of voxels per lung 
at each greyscale value (0 being least dense and 255 being most dense) for each 
experimental group is presented in the form of histograms and a Student t-test 
performed to compare individual groups (Figures 3.81 and 3.82). Density 
histograms of all experimental groups (Figure 3.81) show a clear separation into 
three groups. Saline control lungs have the lowest density voxels, virally-infected 
control lungs and bleomycin only challenged lungs are represented by voxels of 
intermediate density and virally-infected fibrotic lungs are shifted towards the high 
density end of the scale.  
Figure 3.82A shows that lungs from saline control groups were less dense than 
lungs from γHV68 alone infected saline groups with significant differences in voxels 
numbers between 35 and 85 greyscale density values. Treatment with FXa inhibitor 
did not affect the lung densities in this group. Figure 3.82B demonstrates that a 
clear shift towards higher density voxels occurred in the bleomycin-challenged lungs 
when compared to saline controls with statistical difference observed between 40 
to 150 greyscale pixel values. Viral infection in the fibrotic lung significantly shifted 
the density of the lungs towards higher end of the greyscale value when compared 
to infected lungs alone (Figure 3.82C), with the mean voxels numbers significantly 
different between 40 and 90 greyscale values.  
The distribution of density pixels over a range of 40 to 150, visualised in Figure 
3.82F, reveals localisation to airway walls in saline control lungs and areas of 
parenchyma in virally-infected saline lungs. In all bleomycin-injured groups fibrotic 
lesions were highlighted. In bleomycin+γHV68 double injured lungs areas of 
parenchyma displaying extensive opacities were also identified as different from 
other experimental groups. Treatment with BAY59-7939 did not affect the lung 
density and pixel distribution in any of the groups.    
In this study, infection with γHV68 caused density changes in the saline-treated 
lungs that appeared to be comparable to bleomycin-induced fibrosis when 
quantified as density and percentage abnormal lung area. However, a significant 
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difference in the greyscale pixels over a narrow range (35 to 45) was identified 
between γHV68-infected saline groups and bleomycin alone groups (Figure 3.83D), 
which corresponded to changes within the lung parenchyma but not dense fibrotic 
lesions (Figure 3.82G). These data support the μCT and histology findings that the 
virus alone did not cause formation of fibrotic lesion but instead an evidence of lung 
infection remains in the form of diffused increase in density of lung parenchyma. 
While the virally infected lungs show abundant opacities dispersed throughout the 
lung, the fibrotic lung has characteristic consolidation areas consistent with fibrotic 
lesions and localised around the airways and periphery of the lungs. 
Comparison of bleomycin-injured, fibrotic lungs showed a range of changes 
dependent on infection status and treatment status (Figure 3.82E). Significant 
changes were observed between fibrotic lungs and γHV68 infected fibrotic lungs in 
a range of 30 to 140 greyscale values, which corresponded to pixels distributed 
throughout the parenchyma and fibrotic lesions (Figure 3.82F). In this study 
targeting FXa with BA59-7939 in the model of viral infection on a background of 
bleomycin induced pulmonary fibrosis did not have a significant impact either on 
the density of the bleomycin only challenged lungs or infected fibrotic lungs. 
Nonetheless, the widest range of significantly different pixels (35 to 160) was 
identified between bleomycin challenged lungs and bleomycin-γHV68-BAY59-7939 
lungs. Furthermore, a trend towards statistical significance was observed between 
bleomycin-γHV68 and bleomycin-γHV68-BAY59-7939 groups over low density pixels 
(20-30, Figure 3.82E) which localise to the lung parenchyma. These data suggest 
that FXa inhibition in this study did not affect the fibrotic processes in bleomycin-
injured lungs and bleomycin-γHV68 double injured lungs and did not significantly 
influence the inflammatory response to the viral infection.  
 
 
 
 
 
 
 
  312  
  
0 25 50 75 100 125 150 175 200 225 250
0
5.0×105
1.0×106
1.5×106
2.0×106
2.5×106
3.0×106
Bleomycin BAY59-7939
Bleomycin
Bleomycin HV68
Bleomycin HV68 BAY59-7939
Saline
Saline HV68
Saline BAY59-7939
Saline HV68 BAY59-7939
M
e
a
n
 n
u
m
b
e
r 
o
f 
v
o
x
e
ls
Greyscale value (0=black, 255=white)
 
 
 
 
 
 
 
 
 
Figure 3.81. Voxel density histograms of μCT scanned lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY59-7939 (3 mg/kg) twice daily via 
oral gavage. This figure shows density histograms corresponding to each 
experimental group plotted as a mean number of voxels against the greyscale 
values reflecting the density of the tissue, where 0 is black and 255 is white. Data 
are representative of an average of n=2-5 animals per group. 
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Figure 3.82. Density histograms analysis of μCT scanned lungs.  
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 100,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY59-7939 (3 mg/kg) twice daily via 
oral gavage. This figure shows density histograms corresponding to each 
experimental group plotted as a mean number of voxels against the greyscale 
values reflecting the density of the tissue, where 0 is black and 255 is white. The 
histograms are matched with the Student t-test analysis of significance and 
represented as graphs of probability value of less than 0.1, where the significance 
cut off was set as 0.05 as indicated by the dotted line against the density denoting 
greyscale values. Panel A- comparison of saline groups with γHV68-infected saline 
groups and the statistical analysis plots; panel B- comparison of saline groups with 
bleomycin-injured groups and the statistical analysis plots; panel B- comparison of 
saline groups with γHV68-infected bleomycin groups and the statistical analysis 
plots; panel C- distribution of significantly different pixels highlighted in red 
between the saline and bleomycin-challenged and saline and γHV68-infected 
fibrotic lungs; panel D- comparison of γHV68-infected saline groups with bleomycin 
groups and the statistical analysis plots; panel E- comparison of γHV68-infected 
saline groups with γHV68-infected bleomycin groups and the statistical analysis 
plots; panel F- distribution of significantly different pixels highlighted in red 
between the γHV68-infected saline and bleomycin-challenged and γHV68-infected 
saline and γHV68-infected fibrotic lungs; panel G- comparison of saline and γHV68-
infected saline groups and the statistical analysis plots; panel H- comparison of 
bleomycin challenged groups and γHV68-infected fibrotic groups and the statistical 
analysis plots; panel I- distribution of significantly different pixels highlighted in red 
between the saline control lungs and γHV68-infected saline-treated lungs, and 
bleomycin only challenged lungs and γHV68-infected fibrotic lungs. Data are 
representative of an average of n=2-5 animals per group. 
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3.3.3.7 Investigation of inflammation in the viral infection of 
fibrotic lung  
As previously mentioned FXa is a key component of the extrinsic coagulation 
cascade that leads to thrombin generation and can also directly activate both PAR-1 
and PAR-2. In order to assess whether systemic inhibition of FXa affected the 
inflammation in the fibrotic lungs and γHV68 infected fibrotic lungs, inflammatory 
mediators were measured in lung homogenates and serum. Prominent dense 
inflammatory cell aggregates are consistent feature of the viral infection in the 
fibrotic lungs and were also quantified in this study as described in the previous, 
SB525334 study (Figure 3.83B). The inflammatory cell aggregates were detected at 
significantly higher frequency in bleomycin-γHV68 group and the numbers were 
further increased in bleomycin-γHV68-BAY59-7939 group. However, this difference 
fell short of statistical significance, which can be explained by a degree of variability 
between the histology sections.  
Furthermore, increased CCL2 expression was detected in lung homogenates from all 
virally-infected groups. γHV68 infection alone caused a 7-fold upregulation in CCL2 
mRNA levels and infection in the fibrotic lung further significantly increased CCL2 
expression to 17-fold above the saline baseline (Figure 3.83C). A significant increase 
in CCL2 protein levels was also detected in the lung homogenates from all the virally 
infected groups when compared to mock-infected control groups (Figure 3.83D) 
and BAY59-7939 treatment did not affect CCL2 expression in the infected lungs.  
Subsequently, the levels of CCL2, interferon γ (IFNγ) and keratinocyte 
chemoattractant (KC) inflammatory markers were assessed in serum collected in 
this study (Figure 3.84). In control mice and bleomycin-challenged mice 28 days 
post instillation the levels of CCL2 and IFNγ were below the detection range and the 
mouse IL-8 homolog-KC were low. In contrast, in virally-infected control lungs all 
these inflammatory mediators were significantly upregulated. In the bleomycin-
treated and γHV68 infected lungs the levels of CCL2 and IFNγ were further 
significantly increased.  
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Figure 3.83. Inflammatory changes in the γHV68 infection on a background of 
pulmonary fibrosis.  
C57BL/6 mice were administered bleomycin via oropharyngeal instillation at 1 
mg/kg, followed by infection with 100,000 PFU γHV68 or saline intranasally on day 
14. Between days 15 and 28 the mice were given BAY59-7939 (3 mg/kg) twice daily 
via oral gavage. Panel A- inflammatory aggregates were identified as dense areas of 
haematoxylin staining by the Nuance software and panel B- quantified as region of 
interest (ROI), mean +/- SEM, n=2-5 animals per group. Panel C- expression of CCL2 
in the lungs 14 days p.i. was assessed by qPCR and data are presented as fold 
change in mRNA levels relative to two housekeeping genes ATP5B and CANX and 
representative of mean +/- SEM, n=3-8 animals per group; panel D- CCL2 protein 
levels in lung homogenates were quantified by ELISA. Data are representative of an 
average of n=4-8 animals per group. One-way ANOVA was performed for statistical 
analysis, *p<0.05, **p<0.01 relative to mock-infected saline and bleomycin groups; 
++p<0.01 comparison of each γHV68-infected saline groups and each γHV68-
infected fibrotic lungs.   
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Figure 3.84. Assessment of serum inflammatory markers in the γHV68 infection on 
a background of pulmonary fibrosis.   
C57BL/6 mice were administered bleomycin via oropharyngeal route at 1 mg/kg, 
followed by infection with 80,000 PFU γHV68 or saline intranasally on day 14. 
Between days 15 and 28 the mice were given BAY59-7939 at dose of 3 mg/kg twice 
daily via oral gavage. The serum levels of CCL2- panel A, IFNγ- panel B, and KC- 
panel C were assessed by ELISA. Data are representative of an average of n=6-14 
animals per group and analysed with One-way ANOVA, *p<0.05, ***p<0.001 
comparison between mock-infected and γHV68-infected groups; +p<0.05 
comparison between γHV68-infected saline and fibrotic groups.    
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3.3.3.8 Summary 
The aim of this study was to investigate the role of coagulation in the model of viral 
infection on a background of pulmonary fibrosis. 
 As previously observed, infection with γHV68 caused a second wave of 
mouse body weight loss, increased ex vivo lung and spleen weight, and viral 
genes were still readily detected in the lungs. 
 Hydroxyproline and Sircol measurement of collagen showed no difference in 
total lung collagen between fibrotic lung and infected fibrotic lung. BAY59-
7939 did not affect lung collagen level either in bleomycin-challenged lungs 
or in bleomycin-γHV68 double-injured lungs.  
 µCT and lung density analysis showed that in this study the γHV68 infection 
caused architectural changes in the saline infected lungs that were markedly 
different to the fibrosis induced by bleomycin. µCT scans revealed that 
infected fibrotic lungs displayed higher percentage of abnormal areas and 
increased lung density. Treatment with BAY59-7939 did not affect the 
development and course of fibrosis in bleomycin-challenged lungs and in 
γHV68 infected fibrotic lungs.   
 Viral infection promoted the infiltration of inflammatory cells into the lung 
that formed dense aggregates, which were prominent 14 days p.i. 
Furthermore, γHV68 infection, both in saline and fibrotic lungs, led to a 
significant increase in CCL2 expression in the lung and CCL2, IFNγ and KC 
levels were found to be significantly increased in the systemic circulation 14 
days p.i..  
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3.3.4 Discussion 
3.3.4.1 Overview 
Viral infections contribute to the pathogenesis of acute and chronic lung diseases. 
Infections with common respiratory viruses, for instance syncytial virus, rhinovirus 
and influenza virus, have been linked to exacerbations of asthma, chronic 
obstructive pulmonary disease (Holtzman et al., 2011) and cystic fibrosis (Asner et 
al., 2012). Herpes simplex virus infection is a risk factor for the development of 
ARDS in patients in intensive care (Bruynseels et al., 2003) and leads to increased 
complications and prolonged hospitalisation (Luyt et al., 2007). Cytomegalovirus 
reactivation is observed in septic surgical patients and is associated with increased 
incidence of fibroproliferative lung disease in these patients (Cook et al., 2006). 
Long-term antiviral therapy in post-lung transplant patients is protective from 
herpesviruses reactivation and transplant rejection (Finlen Copeland et al., 2011). 
Current evidence of viral involvement in the progression of interstitial lung disease, 
particularly IPF, is conflicting but the γ-herpesviruses family have been strongly 
implicated in the pathogenesis of fibroproliferative lung disease. Epstein Barr virus 
(EBV) is the most common γ-herpesvirus detected in the lung tissue from IPF 
patients, next to HHV-8 and HHV-7 (Stewart et al., 1999; Tang et al., 2003). EBV 
asymptomatically infects 95% of the population. The virus gains entry via the 
nasopharynx epithelium, where it replicates and migrates into lymph nodes to 
establish latency in the B-lymphocytes. Detection of latent membrane 1 (LMP-1) of 
EBV virus is associated with worse outcome and increased mortality in IPF patients 
(Tsukamoto et al., 2000). The default programme of EBV is to establish latency in B-
lymphocytes and the virus is not normally detected in the lungs of healthy 
individuals but in IPF patients EBV has been detected replicating in the lower 
respiratory epithelium (Egan et al. 1995). Furthermore, EBV-positive IPF patients 
harbour virus with increased capacity for spontaneous reactivation (Kelly et al., 
2002). Presence of EBV in the lungs of IPF patients has also been associated with the 
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development of pulmonary hypertension, a major comorbidity that contributes to 
mortality in IPF patients (Calabrese et al., 2013).  
In experimental models, murine γ-herpesvirus-68 (γHV68) has been used to 
investigate the role of viral infection in the pathogenesis of pulmonary fibrosis (PF). 
Murine γHV68 is genetically co-linear with human herpesviruses, EBV and HHV-8, 
and is natural pathogen of rodents that follows a similar infection pattern as human 
herpesviruses i.e. infects the respiratory epithelium and persists in B-cells, 
macrophages and epithelial cells (Nash et al., 2001). 
Pulmonary fibrosis is a multifactorial disease and murine γHV68 has been shown to 
act as a contributing factor for the development and progression of experimental 
pulmonary fibrosis. Infection with γHV68 has been shown to prime otherwise 
resistant BALB/c mice to develop fibrosis following bleomycin injury (Lok et al., 
2001). Transfection of EBV transactivation protein Zta into mouse lungs triggers 
neutrophilic inflammation, expression of Th2 profibrotic cytokines and alternatively 
activated macrophages, but this resolves without fibrosis (Guenther et al., 2010). In 
contrast, mice lacking IFNγ receptor and hence unable to mount antiviral responses 
develop multiorgan fibrosis following infection with γHV68 (Ebrahimi et al. 2001) 
that can be attenuated by antiviral therapy. Furthermore, pulmonary fibrosis in the 
latently-infected lungs develops in response to sub-threshold fibrotic stimulus and 
results in significantly increased lung collagen deposition and increased TGFβ 
activity (Vannella et al. 2010). 
The aim of the studies presented in this thesis chapter was to establish a model of 
γHV68 infection on a background of existing pulmonary fibrosis and to investigate 
the impact of viral infection on the progression of disease. Furthermore, we aimed 
to examine the potential mechanisms by which viral infection promotes more 
severe disease by focusing on blocking TGFβ signalling and the coagulation cascade 
in this model.  
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3.3.4.2 Development of the model of γHV68 infection in 
pulmonary fibrosis  
Infection with γHV68 of fluorescein isothiocyanate (FITC)-challenged  mice has been 
shown to exacerbate pulmonary fibrosis (McMillan et al., 2008). In comparison with 
mock-infected mice, γHV68 infection led to inflammation, high levels of CCL2 and 
CCL12 release and significantly increased lung collagen accumulation.  
In this study we aimed to develop a model of γHV68 infection on a background of 
bleomycin-induced pulmonary fibrosis. In our laboratory, we use oropharyngeal 
administration of bleomycin which reproducibly produces homogenous lung injury 
with evidence of vascular leak, monocytic and neutrophilic inflammation. Two 
weeks into the model peripheral and subpleural fibrotic lesions are detected in the 
lung and this point of established fibrosis was chosen to introduce the viral 
infection. Mice were inoculated with γHV68 via the intranasal route, which is 
considered to be a natural route of viral transmission. The initial study was designed 
to optimise and characterise the model of infection with γHV68 on a background of 
bleomycin-induced pulmonary fibrosis and hence two time points were chosen for 
data collection: 7 days post-infection (p.i.), described as the peak of inflammatory 
response to the infection (McMillan et al., 2008) and 14 days p.i. when lytic 
infection is cleared and virus establishes latency (Nash et al., 2001). Prominent 
splenomegaly was observed 14 days p.i. confirming successful infection. This was 
further confirmed by the detection of viral gene expression in infected lungs 7 day 
p.i. and 14 days p.i.  
Following the administration of bleomycin, the acute phase of injury is associated 
with weight loss and in this study mice lost around 5% of the starting body weight 
(between days 4 and 12 post injury). Inoculation with γHV68 was associated with 
second wave of body weight loss (between days 3 and 7 post infection). Temporally 
the two waves of weight loss correspond to the inflammatory phases of bleomycin 
injury and viral infection. Furthermore, infection with γHV68 caused a significant 
increase in ex vivo lung weight in infected mice 7 days p.i. suggesting an ongoing 
inflammatory response and vascular leak. These inflammatory responses were 
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subsequently confirmed by the analysis of histological sections from virally-infected 
lungs, which in comparison to fibrosis only lungs, revealed widespread infiltration of 
inflammatory cells, which formed dense aggregates around airways and blood 
vessels, and remained prominent at day 14 p.i. Furthermore, at 7 days p.i. virally-
infected fibrotic lungs showed evidence of disrupted alveolar architecture, alveolar 
leak and haemorrhage. These observations were consistent with the previous 
reports that γHV68 infection on a background of FITC-induced pulmonary fibrosis 
triggers a robust inflammatory response in the lung that is also associated with lung 
functional impediment, i.e. reduced total lung capacity, vital capacity and 
compliance (McMillan et al., 2008).  
The extent of fibrosis was subsequently evaluated by measurement of total lung 
collagen in the viral infection on a background of pulmonary fibrosis. A time-course 
study in our laboratory characterised the collagen gene expression and protein 
accumulation in the lungs following oropharyngeal instillation of bleomycin at a 
dose of 2 mg/kg. Collagen mRNA levels increase from day 3 through to 28 post-
injury whereas protein accumulation is stably detected between days 14 and 28 
post-injury, and still significantly increased at day 84 post-injury when compared to 
saline-instilled control mice (Scotton et al., 2013). The current study aimed to 
develop a two-hit injury model and therefore a reduced dose of bleomycin of 1 
mg/kg was used. An increase in total lung collagen was observed 7 days p.i. when 
compared to historical values for the saline control lung but no difference was 
observed between virus-challenged mice and bleomycin-alone treated animals. By 
day 14 p.i. (and 28 days after bleomycin instillation) total lung collagen in mock-
infected fibrotic lungs decreased, which suggests that in this study bleomycin-
induced injury and fibrosis followed different kinetics to the well-characterised 2 
mg/kg bleomycin injury model established in our laboratory. However, at 7 days p.i. 
a 5-fold increase in collagen mRNA levels was detected in virally-infected fibrotic 
lungs when compared to bleomycin-only challenged lung. Collagen expression 
returned to baseline values by day 14 p.i. but total lung collagen remained elevated 
in virally infected fibrotic lungs 14 days p.i. and was significantly higher than in 
mock-infected fibrotic lungs. These observations were further corroborated by the 
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MSB collagen staining of the lung sections, where blue-stained collagen fibres 
formed condensed and well-defined bands running through otherwise normal lung 
architecture in the bleomycin-only treated lungs while in the virally-infected fibrotic 
lung the collagen appeared to be deposited in more dispersed fashion forming 
extensive fibrotic lesions with dense collagen bands.  
The question whether bleomycin causes resolving injury has been controversial with 
different studies reporting contrasting observations. In one study bleomycin-
induced fibrosis has been shown to completely resolve after three months (Degryse 
et al., 2010) while other groups report persistent and lasting fibrotic lesions up to 
six months after injury (Hodges et al., 2004; Scotton et al., 2013). In this pilot study 
of γHV68 infection on a background of pulmonary fibrosis, combined analysis of 
total lung collagen and histology supports the notion that at a lower dose of 
bleomycin the resulting lung fibrosis was being re-modelled four weeks post-injury 
and that viral infection appeared to impede on this process. Analysis of the 
histology sections from virally-infected fibrotic lungs 7 days p.i. revealed evidence of 
acute lung injury superimposed on existing fibrosis. This was associated with 
increased collagen and CCL2 mRNA levels 7 days p.i, which returned to levels 
detected in bleomycin-only lungs by 14 days p.i. However, collagen and CCL2 
protein levels remained significantly higher in virally-infected fibrotic lungs 14 days 
p.i. when compared to fibrotic lungs. Taken together these data suggest that the 
inflammation triggered by γHV68 infection alters the kinetics of bleomycin-induced 
fibrosis in this model.  
In contrast with previously reported data that γHV68 infection exacerbates FITC-
induced pulmonary fibrosis (McMillan et al., 2008), our findings did not show 
increased lung collagen accumulation in virally-infected fibrotic lungs. However, this 
could be explained by several key differences between the two studies. There are 
intrinsic differences between FITC and bleomycin models of pulmonary fibrosis, 
particularly when administered via different routes (FITC- intratracheal, bleomycin- 
oropharyngeal). Bleomycin causes lung injury through direct DNA damage and 
oxidative stress, which evoke strong host inflammatory response characterised by 
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high levels of cytokines, TNFα and IL-1β, and chemokines, CCL12 and CCL2, 
infiltrations of inflammatory cells and vascular leak (Degryse and Lawson, 2011). 
Increased TGFβ activity by day 14 post-injury is associated with the development of 
fibrotic lesions. However, these responses are entirely host-mediated after 
bleomycin has been metabolised by bleomycin hydrolase. In contrast, FITC is a fine 
particle that attaches to the lung proteins and prolonged exposure to this agent 
causes chronic inflammatory and fibrotic responses. However, fibrotic lesions 
develop only in the areas of FITC deposition as visualised by immunofluorescence 
(Moore and Hogaboam, 2008). Therefore, the distribution and severity of the 
resultant fibrosis can potentially account for different responses to viral infection. 
Furthermore, in the FITC study lung collagen was measured only at day 7 days p.i., 
which corresponds to the peak of lytic infection and is characterised by a strong 
inflammatory response. Moreover, the assay used to measure lung collagen in this 
FITC study was colorimetric Sircol assay, which has been shown to also bind non-
collagen serum proteins (Lareu et al., 2010). It is possible that the increased levels 
of collagen reported in that study may represent a combined measurement of 
collagen and protein leak in the lung.  
The Th1-Th2 imbalance is well characterised in the IPF lung (Wuyts et al., 2012) and 
the classical Th2 cytokines, IL-4 and IL-13, are both fibrogenic. Chronic infection 
with γHV68 in IFNγR deficient mice is characterised by Th2-inflammation, 
alternatively activated macrophages and the development of pulmonary fibrosis 
with classical features of epithelial cell hyperplasia, myofibroblast transformation 
and activation of TGFβ (Gangadharan et al., 2008; Mora et al., 2005). Control of viral 
reactivation and antiviral therapy protect IFNγR deficient mice from developing 
severe pulmonary fibrosis (Mora et al., 2007). However, other studies have shown 
that γHV68 infection exacerbates pulmonary fibrosis in the presence of a strong 
IFNγ-driven antiviral response (McMillan et al., 2008). In the current study, IFNγ was 
found to be significantly elevated in lung homogenates of virally infected animals 
suggesting that the mice mounted a strong antiviral response to the γHV68 
infection. However, this IFNγ response was only detected 14 days p.i., which again 
highlights differences between this model and the FITC model of viral exacerbation 
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(McMillan et al., 2008). The lack of an early IFNγ response in comparison to 
bleomycin alone could again be explained by intrinsic differences between 
bleomycin and the FITC fibrosis models. Murine γHV68 has been shown to latently 
infect alveolar macrophages that maintained production of large amounts of IFNγ, 
TNFα, CCL2, CCL12 as well as TGFβ four weeks after infection (Stoolman et al., 
2010). CCL2 is a potent chemoattractant for immune cells as well as for precursor 
cells of fibroblasts, fibrocytes (Moore et al., 2005b) and is significantly upregulated 
in response to viral infection. Mesenchymal cells isolated from γHV68 infected mice 
also showed long-lasting upregulation of profibrotic mediators, notably TGFβ and 
CCL2 (Stoolman et al., 2010). In the present study, CCL2 gene expression was 
significantly increased 7 days p.i. and high CCL2 protein levels were detected both 
at 7 days p.i. and 14 days p.i., when compared to mock-infected fibrotic lungs. 
These findings suggest that in this model of two-hit lung injury viral infection leads 
to persistent inflammation that is ongoing 14 days p.i. and after the virus has 
established latency.  
Excessive activation of the coagulation cascade has been strongly implicated in the 
progression of pulmonary fibrosis. The ternary complex, TF-FVIIa-FXa, can be 
assembled and activated locally in human and murine lungs (Scotton et al., 2009), 
while thrombin is considered to enter the lung as a result of a microvascular leak. 
Herpesvirus infection has previously been shown to trigger the activation of the 
coagulation cascade (Sutherland et al., 1997). Human cytomegalovirus (CMV) and 
parvovirus B19 infections induce microvascular injury (Magro et al., 2003) while 
human herpes simpex virus I (HSV I) and CMV have been shown to “hijack” the 
coagulation cascade in an immune evasion strategy. HSV I and CMV express tissue 
factor and procoagulant phospholipids on their surface providing a platform for the 
assembly of the TF-FVIIa-FXa complex leading to further activation of the 
coagulation cascade and thrombin generation (Sutherland et al., 1997). 
Furthermore, HSV I surface glycoprotein C has been shown to directly bind FX 
(Livingston et al., 2006). Thrombin has also been shown to enhance HSV I and CMV 
adhesion and cell entry in human umbilical vein endothelial cells (HUVEC) and 
human foreskin fibroblasts (HFF) (Sutherland et al. 2007). During the lytic phase, 
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viral infection causes extensive damage to the respiratory epithelium which is 
consistent with the mechanism of activation of the extrinsic coagulation cascade. In 
the current study we evaluated mRNA levels of three components of the ternary 
complex. Both tissue factor and FX mRNA levels were significantly increased 7 days 
p.i. when compared to the bleomycin alone treated lungs. FVII was significantly 
downregulated 7 days p.i. but the physiological importance of this result is difficult 
to evaluate as small amount of FVII are required to assemble the ternary complex. 
However, it is possible that downregulation of FVII is an intrinsic protective 
mechanism preventing excessive activation of the coagulation cascade. It has been 
previously shown that low-FVII-expressing mice are protected from acute 
inflammation and coagulopathy in the model of endotoxemia, which was also 
associated with reduced mortality (Xu et al. 2006). Immunolocalisation of the tissue 
factor and FX revealed that both proteins were expressed primarily in bronchial and 
alveolar epithelium and the intensity of staining was stronger in the virally-infected 
fibrotic lungs 14 days p.i. relative to fibrotic only lung. Finally, thrombin expression 
was not evaluated in this study as the general consensus is that the main source of 
prothrombin and active thrombin is the lung circulation.   
The coagulation cascade exerts a plethora of cellular effects via PAR receptors. The 
high-affinity thrombin receptors, PAR-1, plays an important role in immunity to 
viruses. PAR-1 knockout mice infected with cardiotropic virus coxsackievirus 3 
showed increased viral loads in the heart and liver, worse heart injury and a higher 
incidence of heart failure (Antoniak et al., 2013). This was accompanied by 
significant upregulation of the highly inflammatory cytokines TNFα, IL1β and 
increased accumulation of inflammatory cells in the heart. However, PAR-1 
knockout mice showed reduced levels of cytokines involved in the antiviral 
responses, CXCL10 and IFNβ, and significantly reduced recruitment of NK cells into 
the heart in the early phase of infection. Moreover, lack of PAR-1 on non-
haematopoietic cells was found to contribute to decreased antiviral immunity 
(Antoniak et al., 2013). In contrast, mice with cardiomyocytes overexpressing PAR-1 
were protected from virally-induced heart injury while the cardiac fibroblasts 
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showed synergistic activation of PAR-1 and TLR3 in response to the virus in vitro 
(Antoniak et al., 2013).  
In contrast, PAR-1 activation in mice infected with influenza virus was found to 
increase the viral replication and inflammation in the lungs resulting in higher 
mortality in this model (Khoufache et al., 2013). PAR-1 deficiency and PAR-1 
antagonism were found to protect mice from infection and inflammation-related 
lung injury. Expression of all PARs in respiratory epithelium and airway smooth 
muscle cells has been shown to change following influenza infection and particularly 
increased expression of PAR-1 and PAR-2 significantly augmented the antiviral 
responses in these cells (Lan et al., 2004). These studies strongly suggest that PAR-1 
plays greatly different roles in antiviral immunity depending on the infecting agent.   
In the current study mRNA levels of PAR receptors in total lung homogenates were 
assessed but there was no change in PAR-1 and PAR-2 expression in any of the 
treatment groups. However, these receptors are widely expressed in the lung and it 
is possible that subtle changes in the expression measured in the lung homogenates 
may be missed. In contrast, the expression of PAR-3 and PAR-4 in the lung at 
baseline is low but was significantly increased at day 7 p.i. and this increase was 
maintained at day 14 p.i. Murine platelets express PAR-3 and PAR-4 and histological 
analysis of the virally-infected lungs showed evidence of alveolar haemorrhage. It is 
therefore possible that the increase in PAR-3 and PAR-4 expression is associated 
with the platelet influx into the lungs. Furthermore, PAR-4 has been shown to 
mediate neutrophilia and disseminated intravascular coagulation in the model of 
endotoxemia (Slofstra et al., 2007). CMV virus has been shown to increase mRNA 
levels of all PAR receptor in endothelial cells increasing their responsiveness to 
thrombin (Popović et al., 2010).  Both PAR-3 and PAR-4 are activated by thrombin 
and hence could contribute to procoagulant signalling in response to viral infection 
in the lung.  
Taken together, the results of this study demonstrate that reduced dose of 
bleomycin (1 mg/kg) caused mild fibrosis. γHV68 infection did not increase the lung 
collagen accumulation but interfered with the re-modelling process observed in 
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bleomycin-challenged lungs 14 days p.i.. However, strong inflammatory and 
antiviral responses were mounted in the infected fibrotic lung and persisted until 
day 14 p.i..  
3.3.4.3 Effect of TGFβ inhibition on γHV68 infection in fibrotic 
lung  
TGFβ is ubiquitously expressed in the normal lung and has been shown to be 
significantly upregulated in bleomycin induced pulmonary fibrosis (Santana et al., 
1995). Disruption of TGFβ activation and signalling through direct cytokine 
inhibition (Giri et al. 1993), Smad3 knockout (Bonniaud et al. 2004), ALK5 receptor 
knockout (Li et al. 2011), integrin αvβ6 knockout (Koth et al., 2007; Morris et al., 
2003) offers protection in experimental models of pulmonary fibrosis. TGFβ 
activates multiple cellular signalling pathways to exert its profibrotic effects 
including inducing fibroblast to myofibroblast differentiation and induction of αSMA 
and collagen gene expression, which are Smad3-dependent manner (Hu et al. 2003) 
but also rely on signalling via p38 and ERK kinases (Hu et al. 2006). Interaction 
between Smad3 and MAPK pathways also promotes fibroblast survival (Horowitz et 
al. 2004). Furthermore, TGFβ prevents extracellular matrix degradation by inducing 
the expression of tissue inhibitors of MMPs (TIMPs) (Edwards et al., 1987; Kwak et 
al., 2006) and the plasminogen-activator inhibitor PAI-1 (reviewed in Samarakoon 
2013). 
TGFβ also plays an important role in modulation of immune and inflammatory 
responses during herpesviruses infection. TGFβ signalling has been shown to cause 
activation of latent EBV infection (Liang et al., 2002). TGFβ-Smad canonical 
signalling pathway leads to re-activation of the latent Epstein Barr virus as lytic viral 
genes contain multiple Smad-binding elements in promoter region (Iempridee et al., 
2011). Furthermore, TGFβ-mediated signalling through NFκB also promotes viral 
replication through downregulation of inducible nitric oxide synthase (iNOS) and 
ERK phosphorylation that was necessary for activation of viral genes (Oussaief et al., 
2011). Upon infection of epithelial cells with EBV the level of TGFβ increases and 
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apoptosis markers are initially upregulated (Malizia et al., 2008) but in chronic 
infection epithelial cells infected with EBV are resistant to TGFβ-induced apoptosis 
(Fukuda et al., 2001). Latently infected epithelial cells can be reactivated by TGFβ 
and activate the programme for epithelial to mesenchymal transition (Malizia et al., 
2009b). Latent virus LMP-1 protein has also been shown to act synergistically with 
TGFβ to promote EMT (Sides et al., 2010).  
In this study the pharmacological inhibitor of the TGFβ ALK5 receptor, SB525334 
was used to investigate the role of TGFβ in γHV68 infection on a background of 
existing pulmonary fibrosis. The compound was administered according to a 
therapeutic dosing regimen, from day 15 after bleomycin injury and day one after 
viral inoculation through to day 28 (14 p.i.), when the study was ended. As observed 
in the previous study, a reduced dose of bleomycin caused lung injury initially 
reflected by an early weight loss (between day 4 and 10 post-injury). The second 
wave of weight loss was recorded after the inoculation with γHV68 and the 
bleomycin+γHV68+vehicle mouse group showed the greatest body weight loss. 
Consistent with previous studies with higher dose of bleomycin (Scotton et al., 
2013), SB525334 significantly attenuated lung collagen accumulation as measured 
by hydroxyproline (HPLC) in the bleomycin alone injured lungs. However, there was 
no difference in the total lung collagen between the mock-infected fibrotic lungs 
and virally-infected fibrotic lungs 14 days p.i.. Furthermore, the therapeutic effect 
of SB525334 appeared to be lost in bleomycin+γHV68 double-injured mice. Sircol 
assay was also performed in this study to measure the content of soluble collagen in 
lung homogenates, as this assay was employed by the previous studies of viral 
exacerbation in the FITC model (McMillan et al., 2008). Although the levels of total 
lung collagen quantified by Sircol were 20-fold lower than the levels measured by 
HPLC, the pattern of collagen accumulation within experimental groups was similar. 
SB525334 treatment decreased lung collagen accumulation in response to 
bleomycin injury alone but the therapeutic effect of the drug was again lost in the 
viral infection of fibrotic lung. The only difference between the two assays was 
observed in the collagen levels in the virally infected saline lungs, which showed 
higher collagen levels than saline control lungs. However, this difference was not 
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detected in any other assay analysed in this study to evaluate inflammatory and 
fibrotic changes in the lung and it was most likely due to Sircol assay cross-reacting 
with non-collagen proteins as has been previously reported (Lareu et al., 2010).     
Successful viral infection was again confirmed by prominent splenomegaly 14 days 
p.i.. Spleen weight was significantly increased in virally infected saline-treated 
groups and further increased in virally infected fibrotic lungs. Interestingly, the 
increase in spleen weight with viral infection was significantly attenuated by 
SB525334 treatment in fibrotic lungs, but not in saline-treated lungs. Furthermore, 
all three viral genes were readily detected in the lungs 14 days p.i., which suggests 
that there was still ongoing viral replication in the lung at the time. Taken together, 
these data suggest that despite established latency in the spleen, γHV68 is still 
replicating in the lungs 14 days p.i.. 
In order to further analyse the effect of targeting TGFβ in this model of viral 
infection on a background pulmonary fibrosis, we used ex vivo µCT technology to 
investigate changes in lung morphology. The μCT technology for live animal imaging 
has been validated in vivo for repeated longitudinal studies of lung cancer (Namati 
et al., 2010) but the resolution was restricted by the respiratory movement and 
cardiac motion. This technique has also been applied for ex vivo investigation of the 
lung architecture (Thiesse et al., 2010; Vasilescu et al., 2012) and as an endpoint for 
evaluating fibrosis (Rodt et al., 2010; Scotton et al., 2013). The main advantage of 
µCT technology is that it allows whole-lung scanning and hence avoids the potential 
sampling error associated with standard histological analysis of tissue sections. In 
current study the µCT scans were analysed using pattern recognition software and 
matched with histological sections from the same lungs. Saline control lungs 
showed normal morphology while bleomycin-challenged lungs showed condensed 
fibrotic lesions, interlobular septal thickening, and traction bronchiectasis in areas 
of subpleural scarring. These fibrotic changes were significantly reduced by 
SB525334 treatment in bleomycin-challenged lungs. However, the appearance of 
lungs infected with the virus on a background of fibrosis clearly indicated that 
inflammation was still prominent in these lungs. The inflammatory features that 
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were readily identifiable on the µCT scans included diffuse ground-glass opacities 
and consolidation superimposed on the areas of fibrotic changes. These features 
are also commonly reported in acute exacerbation of IPF (Collard et al., 2007) and 
the scans of virally-infected fibrotic lungs bore resemblance to the scans of 
exacerbated IPF patients. Histological analysis of virally-infected fibrotic lungs 
revealed extensive thickening and distortion of alveolar septae, and dense 
aggregates of inflammatory cells, clearly visible around the airways and vasculature. 
These inflammatory cell aggregates were quantified revealing that 
bleomycin+γHV68 lungs had significantly higher numbers of inflammatory cells 
aggregates than all saline groups and mock-infected fibrotic lungs. Furthermore, 
there was a trend towards a reduction in the number of aggregates with SB525334 
treatment. Taken together, these data suggest that in this study, 14 days p.i. there 
was still significant level of inflammation persistent in the γHV68-infected fibrotic 
lungs.  
The output of µCT scans was subsequently quantified using “trainable” pattern 
recognition software. This software was trained to distinguish between normal lung 
architecture and fibrosis and to quantify these areas based on pixel density. 
Inflammatory cell infiltrations appear on the scans as areas of intermediate density 
between the dense fibrotic consolidations and normal lung parenchyma. To 
increase the accuracy of the analysis, areas different from normal lung parenchyma 
were grouped together as “abnormal lung”. The quantification of abnormal lung 
areas and lung densities confirmed that µCT analysis offers an increased therapeutic 
window to detect the effect of SB525334 when compared with HPLC, as previously 
shown (Scotton et al., 2013). These data also show that 28 days into this model and 
14 days p.i. on average 50% of fibrotic lungs showed abnormal appearance and this 
was modestly increased with viral infection on a background of fibrosis. SB525334 
treatment significantly reduced abnormal lung area in bleomycin alone injured 
lungs but this therapeutic effect was consistently lost in the virally infected fibrotic 
lungs. Furthermore, a detailed greyscale analysis of lung densities independent of 
the segmentation output confirmed that bleomycin injury increased lung density 
and this increase was attenuated with SB525334 treatment in mock-infected 
 
 
  335  
  
fibrosis group. Viral infection on a background of pulmonary fibrosis lungs further 
increased lung density when compared to bleomycin-challenged lungs and ALK5 
inhibition impacted on the lung density but to a lesser degree than in the fibrosis 
alone groups. Furthermore, the statistical analysis of lung densities identified the 
pixel density range that was significantly different between the experimental groups 
and corresponded to specific areas in the lung. The pixel density range that in the 
saline-treated lungs corresponded to dense airway walls, in fibrotic lung localised to 
fibrotic lesions while in virally infected fibrotic lung encompassed fibrotic lesions 
and ground-glass opacities dispersed throughout the parenchyma. Interestingly, the 
range of significantly different density pixels between the bleomycin-injured lung 
and bleomycin+SB525334 lung localised directly to areas of fibrosis supporting the 
notion that blocking TGFβ signalling actively prevents formation of fibrotic lesions. 
This observation is consistent with HPLC and Sircol data showing attenuation of 
fibrosis in mock-infected bleomycin-challenged lungs. In contrast, in virally-infected 
fibrotic lung and bleomycin+γHV68+SB525334 lung the range of significantly 
different density pixels was narrower and distributed throughout the parenchyma, 
suggesting that in the viral infection of fibrotic lung the therapeutic effect of 
SB525334 is targeted against the inflammatory response rather than fibrotic 
response.       
While SB525334 had a therapeutic effect in reducing fibrosis in bleomycin-alone 
injured lungs, in virally infected fibrotic lungs the TGFβ/ALK5 inhibition appeared to 
reduce infiltration of the inflammatory cells into the lung. There are several 
potential explanations for this finding. TGFβ exerts potent anti-inflammatory effects 
and it is possible that inhibition of TGFβ signalling early in the infection allowed for 
a stronger antiviral response in SB525334-treated mice. This would be associated 
with more efficient clearance of the virus as well as reduced capacity of the virus to 
establish latency. This explanation would be consistent with significantly reduced 
splenomegaly reported in this study in bleomycin+γHV68+SB525334 experimental 
group.  
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TGFβ exerts pleiotropic regulatory effects on immune and antiviral responses that 
depend on the site and cause of infection. In the model of eye infection with Herpes 
simplex I virus (HSV) inhibition of TGFβ signalling in innate immune cells reduces 
viral replication in the cornea while blocking TGFβ in T-cells reduces viral replication 
at the latency site, the trigeminal nerve (Allen et al., 2011). However, inhibition of 
TGFβ signalling in innate immune cells does not affect the viral replication in the 
trigeminal nerve, secondary site of infection and established latency (Allen et al., 
2011), suggesting that different mechanism, TGFβ-dependent and -independent 
may be involved in viral clearance at different physiological sites. However, 
inhibition of TGFβ signalling in both innate and adaptive immune cells reduces the 
viral capacity to establish latency and reduces the number of immune cells 
infiltrations into the primary site of infection as wells as to the site of latency (Allen 
et al., 2011). TGFβ is generally immunosuppressive and this effect has been shown 
to converge with the viral immune evasion strategies. Herpesviruses downregulate 
the major histocompatibility complexes MHC class I and MHC class II that are 
required for mounting efficient adaptive immunity against infection. Murine γHV68 
has been shown to ubiqitinate the MHC class I complex targeting it for degradation 
and preventing the upregulation on the cell surface and hence evading the 
recognition of infected cells by T-cells (Boname et al., 2004). TGFβ has also been 
shown to downregulate MHC class I and II and induce T-regulatory cells 
differentiation that dampen the immune response. Moreover, TGFβ-independent 
downregulation of MHC class I and II by virus also has inhibitory effect on T-cell 
activation and proliferation (Odeberg and Söderberg-Nauclér, 2001). Blocking TGFβ 
may therefore contribute to increased T-cell responsiveness and hence clearance of 
the virus. Furthermore, inhibition of TGFβ leads to expansion of NK cells and 
increased IFNγ production and hence better control of viral infection (Allen et al., 
2011).  
In this model of γHV68 infection in the fibrotic lungs targeting ALK5 reduced 
splenomegaly, a hallmark of γHV68 established latency, and reduced the number of 
inflammatory cell aggregates in the lungs. Interestingly, ALK5 inhibition did not 
affect the size of the spleen in virally-infected saline group. These data potentially 
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suggest that inhibition of TGFβ signalling in virally-infected fibrotic lung affects the 
course of infection and inflammatory responses in this model. It has been 
previously reported that viral infection in a lung with pre-existing injury triggers 
different host responses. In bone marrow transplantation model, post-transplant 
mice have been reported to be more susceptible to γHV68 infection in the lung and 
the latent infection led to chronic and persistent pneumonitis and fibrosis (Coomes 
et al., 2011). Furthermore, γHV68-infection in post-transplant lungs led to 
accumulation of alternatively activated macrophages and triggered influx of 
neutrophils and lymphocytes into the lung, with the latter being dominated by CD8 
and CD4 T-cells (Coomes et al., 2011). Blocking TGFβ signalling in T lymphocytes led 
to attenuation of inflammation and fibrosis in that model (Coomes et al., 2010, 
2011).  
In conclusion, the findings of this study show that in the γHV68 infection on a 
background of pulmonary fibrosis viral infection leads to strong inflammatory 
response that persists in the lung 14 days p.i. Furthermore, data suggest that in the 
fibrotic lung the SB525334 effect is strictly anti-fibrotic while in the viral infection of 
fibrotic lung the anti-TGFβ therapy modulates inflammation and influences the 
course of infection.    
3.3.4.4 Effect of coagulation inhibition on γHV68 infection in 
fibrotic lung  
In the initial study of viral infection described in this thesis an increase in tissue 
factor and FX mRNA levels was recorded 7 days p.i. while the infected lungs were 
strongly immunoreactive for TF and FX protein 14 days p.i.. In the second study, an 
extensive inflammation was observed to continue through to 14 days p.i. in virally 
infected fibrotic lung. The aim of this study was to assess whether targeting 
coagulation in the model of viral infection on a background of pulmonary fibrosis, 
through inhibition of FXa, affects inflammatory and fibrotic responses in the lung. 
Previous studies performed in our laboratory have shown that prophylactic 
treatment of bleomycin injured mice with the FXa inhibitor (ZK807834) is protective 
from developing pulmonary fibrosis (Scotton et al., 2009). In the present study, the 
 
 
  338  
  
clinically approved, orally available and direct FXa inhibitor BAY59-7939 (Gulseth et 
al.  2008) was administered twice daily from day 15 after bleomycin instillation and 
one day after viral inoculation to investigate the role of FXa in this two-hit model of 
viral infection and fibrosis. 
As reported in the SB525334 study, this two-hit model of viral infection in fibrotic 
lung is reflected by two waves of weight loss. An early weigh loss (between days 2 
and 8) is associated with bleomycin administration while the second wave is 
recorded post viral inoculation (3 to 7 days p.i.). Mice in bleomycin/γHV68/BAY59-
7939 group experienced the biggest body weight loss in the virus-associated, 
second wave of weight loss. An increase in ex vivo lung weight was observed with 
the virus alone and matched the increase observed in the bleomycin alone group. In 
contrast, weights of virally-infected fibrotic lungs were further, significantly 
increased in comparison to all other groups. These results potentially suggest that 
this group of mice mounted a stronger inflammatory response to infection with 
γHV68. Consistent with the previous studies, prominent splenomegaly was 
observed in the virus alone infected animals and this was significantly increased in 
bleomycin+γHV68 groups. Furthermore, viral gene expression was again readily 
detected in the virally-infected fibrotic lungs.  
Measurement of total lung collagen by HPLC did not show a significant difference 
between the bleomycin alone group and bleomycin+γHV68 group. Furthermore, 
targeting FXa did not affect total lung collagen level. This pattern was mirrored by 
Sircol quantification of collagen levels. As observed in the previous study, the 
collagen levels detected by Sircol were 20-fold lower when compared to 
measurement based on hydroxyproline analysis by HPLC but there was no 
difference in collagen levels between the bleomycin-challenged groups and 
bleomycin/γHV68 groups.  
Further analysis of lungs by µCT and tissue segmentation software was 
subsequently performed. Fibrotic lungs were accurately segmented based on dense 
fibrotic lesions. In contrast, viral infection of fibrotic lung presented as diffuse 
ground-glass opacities and consolidation superimposed on the background of 
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fibrosis. Histological analysis confirmed prominent inflammatory cell aggregates 
together with disorganised collagen deposition and abnormal appearing epithelium 
in virally-infected fibrotic lung. These aggregates were quantified as previously 
described and virally-infected fibrotic lungs displayed greater numbers of 
inflammatory cell aggregates when compared to mock-infected groups. 
Furthermore, a trend was identified towards higher number of aggregates with 
BAY59-7939 treatment. The pathological changes in the lung morphology and 
density were also significantly increased in the bleomycin+γHV68+BAY59-7939 
when compared to bleomycin alone challenged lungs but the difference was not 
statistically different when compared to the bleomycin+γHV68+vehicle group. The 
histogram analysis of lung densities showed clear separation into three groups. 
Saline control lungs were the least dense. Viral infection in saline control lungs and 
bleomycin alone challenged lungs showed the same extent of density changes in 
the lung, despite clear differences in pixel distribution on µCT scans as well as 
marked differences in histological appearance. Statistical analysis and distribution 
of pixel density range between saline+γHV68 and mock-infected bleomycin groups 
revealed that the significantly different pixels were dispersed throughout the 
parenchyma and did not localise to evident fibrotic lesions in the bleomycin-injured 
lung. Finally, virally-infected fibrotic lungs showed the most pronounce shift toward 
dense pixels and there was no significant separation between the treatment and 
the vehicle control. Taken together, the µCT analysis revealed that the viral 
infection leads to inflammatory response that is superimposed on a background of 
fibrosis and increases the pathological changes in the lung. The FXa inhibitor did not 
significantly affect the inflammatory and fibrotic responses in this study.  
It was noted in the previous study that inflammation appears more elusive on µCT 
scans and cannot be separated from fibrosis. In the current study the markers of 
local and systemic inflammation were measured in lung homogenates and serum, 
respectively, 14 days p.i.. The level of CCL2 was significantly increased in the lung 
compartment of all γHV68-infected groups when compared to saline and fibrotic 
lungs and there was no difference between the treatment and vehicle groups. 
However, at the mRNA level, viral infection in the fibrotic lung significantly further 
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increased CCL2 expression when compared to viral infection alone.  Systemic CCL2 
levels were also higher in infected fibrotic lungs in comparison to viral infection 
alone. Viral infection also led to systemic increase in levels of IFNγ and KC as 
measured in the serum from γHV68 infected saline control mice with a further 
significant increase detected in virally infected fibrotic lungs.  
In conclusion, these data suggest that viral infection in the lung triggers 
inflammatory responses and the inflammatory markers are readily detected locally 
in the lung and systemically in the serum 14 days p.i. and after the virus established 
latency. Furthermore, γHV68 infection on a background of fibrosis amplifies the 
inflammatory responses to viral infection. FXa inhibitor did not affect the 
inflammatory responses in this study.  
3.3.4.5 Conclusion and future work  
This body of work investigated the contribution of viral infection to the 
development of experimental pulmonary fibrosis. IPF is a complex lung disease 
displaying a range of heterogeneous phenotypes. A number of environmental and 
genetic cues have been identified to promote persistent epithelial injury, which 
combined with aberrant wound healing response can lead to the development of 
fibroproliferative lung disease. Several studies have shown that occult viral 
infections are detected in IPF patients. Particularly γ-herpesviruses have been 
implicated in the progression of IPF but the causative link remains to be established. 
It is considered highly unlikely that viral infection alone is able to induce lung 
fibrosis but viruses can influence fibrotic responses by promoting a profibrotic 
phenotype in latently infected cells as well as by low levels of re-activation and 
associated chronic damage to the alveolar epithelium. EBV latency membrane 
protein LMP-1 is associated with the transforming capacity of EBV and protects 
infected B-cells from apoptosis (Ackermann, 2006). LMP-1 also inhibits the terminal 
differentiation of the epithelial cells (Dawson et al 1990) and promotes their 
motility (Dawson et al. 2008). Furthermore, a study in human alveolar epithelial 
cells have shown that EBV LMP-1 and TGFβ synergistically induce epithelial-
mesenchymal transition (Sides et al., 2010). 
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In this series of studies murine γHV68 was used to investigate the outcome of viral 
infection in bleomycin-induced pulmonary fibrosis. Bleomycin is an antimicrobial 
agent with anticancer properties but the chemotherapy with this drug is associated 
with high risk of pulmonary toxicity (Muggia et al. 1983). The mechanism of action 
of bleomycin involves interference with the cell cycle, DNA damage and oxidative 
stress, which evokes an inflammatory response, activation of fibroblasts and 
fibrosis. The lungs are particularly susceptible to developing fibrosis following 
exposure to bleomycin because they express low levels of bleomycin hydrolase, an 
enzyme required to metabolise the drug (Degryse and Lawson, 2011; Moeller et al., 
2008). Administration of bleomycin in mice leads to initial acute lung injury phase 
characterised by extensive inflammation and vascular leak. By 14 days post 
instillation dense fibrotic lesions develop associated with fibroblast proliferation 
and deposition of collagen-rich extracellular matrix. Two weeks post injury, 
significant increase in total lung collagen can be detected by measurements of 
hydroxyproline in lung homogenates (Scotton et al., 2009, 2013). This phase of 
bleomycin-induced fibroproliferative lung disease was chosen to be the most 
suitable for introduction of the second injurious factor as the aim of this study was 
to develop a two-hit model of viral infection on a background of existing pulmonary 
fibrosis.  
The natural rodent pathogen, murine γHV68, shares 80% homology with EBV and 
displays parallel invasive features: epithelial and B cell tropism, virus-driven B-cell 
activation and proliferation, and an acute infectious mononucleosis syndrome (Nash 
and Sunil-Chandra 1994). Murine γHV68 promotes activation, survival and 
proliferation of infected B-lymphocytes (Madureira et al., 2005). Furthermore, 
γHV68 can infect other cell types including alveolar macrophages and fibroblasts 
and induce profibrotic phenotype associated with increased expression and 
sensitivity to TGFβ (Stoolman et al., 2010). Notably, in the model of FITC-mediated 
pulmonary fibrosis, infection with γHV68 has been reported to exacerbate fibrosis 
by increasing total lung collagen 7 days post infection (McMillan et al., 2008). 
 
 
  342  
  
The results of the first study presented in this section showed that γHV68 leads to a 
robust inflammatory response 7 days p.i. that persists to 14 days p.i.. Since this 
model was designed as a two-hit injury model, a reduced dose of bleomycin of 1 
mg/kg was used since the standard dose of 2 mg/kg routinely used in our laboratory 
induces a maximal fibrotic response in C57BL/6 mice within the acceptable severity 
range. Despite strong evidence from our laboratory that emphasises non-resolving 
nature of bleomycin-induced injury and fibrosis at a dose of 2 mg/kg, in this initial 
study we observed a degree of scar tissue re-modelling by day 28 post bleomycin 
instillation (14 days p.i.). Prominent fibrotic lesions in the bleomycin-injured lungs 
were evident in histological analysis of lung sections and MSB collagen fibres 
staining revealed organised and consolidated collagen deposition in these lungs. 
However, the areas of fibrosis appeared to be reduced in comparison to histological 
analysis of lung sections from day 7 p.i. in this study and also when compared to 
section from lungs challenged with 2 mg/kg bleomycin in the previous studies 
performed in our laboratory. Assessment of hydroxyproline in lung homogenates by 
HPLC reflected the lesser degree of fibrosis 28 days post-bleomycin challenge when 
compared to day 21. This suggests an ongoing scar tissue re-modelling process in 
these lungs. In contrast, there was no difference in collagen deposition in the 
virally-infected fibrotic lungs between days 21 (7 days p.i.) and 28 (14 days p.i.) and 
at both time-points extensive fibrotic areas with high collagen content were 
detected by histological analysis and HPLC. Analysis of histological sections also 
highlighted extensive inflammatory changes at 7 days p.i. in virally infected fibrotic 
lungs when compared to mock-infected fibrotic lungs. Viral infection of fibrotic lung 
appeared to have caused acute lung injury with hallmark evidence of vascular leak, 
alveolar haemorrhage and prominent inflammatory cell infiltrates superimposed on 
the background of extensive fibrotic lesions. By day 14 p.i. the pulmonary oedema 
and the haemorrhage have been largely cleared but the dense inflammatory cell 
aggregates were still evident and localised around airways and blood vessels. Taken 
together, these data show that in this experiment the viral infection has caused 
extensive inflammatory changes in the lung that interfered with the potential scar 
tissue re-modelling process observed in the mock-infected fibrotic lungs. This 
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process appears to be responsible for the differences in the total lung collagen 
levels detected at day 14 p.i. between mock-infected and γHV68-infected fibrotic 
lungs.   
Persistent inflammation in the lungs was also characterised by increased expression 
of inflammatory markers in the lungs (CCL2, IFNγ and KC) at day 14 p.i..  
Furthermore, 7 days p.i. expression of coagulation factors (tissue factor and FX) was 
increased and the protein was found to strongly localise to bronchial and alveolar 
epithelium 14 days p.i.. Tissue factor is upregulated in response to infection and 
injury and strong immunoreactivity in the lung 14 days p.i. suggests potential 
ongoing damage to the epithelium. Taken together, these data suggest that a 
reduced dose of bleomycin (1 mg/kg) induces lung injury and fibrosis that appeared 
to be controlled by day 28 post-bleomycin instillation but viral infection in the 
fibrotic environment evokes persistent inflammatory response that is associated 
with lasting changes to the gross lung appearance.      
The second study in this chapter was carried out with the aim of evaluating the role 
of TGFβ/ALK5 signalling in the model of viral infection on a background of 
pulmonary fibrosis. Furthermore, the analysis of this model was expanded by the 
use of ex vivo µCT imaging technology. The µCT analysis of the lung scans provided 
an informative tool to characterise changes in lung architecture. As thoroughly 
characterised in our laboratory, µCT scans accurately differentiate between the 
normal lung morphology and dense fibrotic lesions in the bleomycin model (Scotton 
et al., 2013) and show specific pattern of bronchiocentric and subpleural 
distribution of fibrotic lesions. However, µCT analysis of the scans from virally-
infected fibrotic lungs revealed diffuse ground-glass opacities and dense 
consolidation spreading from the airways and major vessels, superimposed on 
existing fibrosis. The advantage of this model is that these µCT appear to resemble 
the HRCT scans of IPF patients with acute exacerbation, as previously characterised 
(Collard et al., 2007). From an analysis point of view, a new challenge was posed 
when the scans were segmented by the pattern recognition software. The software 
is trained to discriminate between normal lung areas and fibrotic areas based on 
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differences in the number and density of pixels as defined by the training process. 
The wide spectrum of changes in density between the relatively widely dispersed 
inflammatory changes and dense mature fibrotic lesions made it difficult for the 
software to accurately discriminate between inflammation and fibrosis in infected 
fibrotic lungs. Therefore, all the changes were grouped as “abnormal lung” areas 
with the full appreciation of the fact that in the bleomycin only injured lungs the 
abnormal areas represent fibrotic changes while in virally-infected fibrotic lungs 
abnormal areas represent both inflammation and fibrosis. Moreover, in this study 
heart tissue was not dissected out in order to help to preserve the integrity of the 
processed lung during the scanning process. Although the heart muscle was gated 
out as “other tissue” during the software training process, some of the mature 
fibrotic lesions of high density were also identified as other tissue because of 
overlapping density spectra. Another method of analysis was therefore applied and 
density histograms were generated based on voxel (cubic pixel) distribution on the 
greyscale of the scans and independent of the segmentation output. These 
histograms displayed the lung density distribution with saline control lungs being 
the least dense, closely followed by virally-infected saline lungs. A clear shift 
towards higher density voxels was recorded in the fibrotic lungs and the infected 
fibrotic lungs shifted further towards increased density voxels. The µCT scans 
analysis was then matched with histological analysis of the same lungs, which 
confirmed that the dense fibrotic areas corresponded to fibrotic tissue with 
abundant collagen deposition while the dispersed inflammatory changes were 
associated with inflammatory infiltrates.            
In this study with the ALK5 inhibitor, SB525334, reduced dose of bleomycin was 
used again and it was consequently found that a smaller degree of lung collagen 
accumulation was detected when compared to historical data. However, viral 
infection of fibrotic lung did not affect the lung collagen levels as measured by 
hydroxyproline levels (HPLC). This result was subsequently confirmed by 
measurement of soluble collagen by Sircol assay. Worse appearance of virally- 
infected lungs in this model was associated primarily with inflammation 
superimposed on existing fibrosis and in the time frame of this study no changes in 
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the fibrotic endpoint readout are evident. This contrasts with the previous reports 
that active γHV68 infection exacerbates FITC-induced pulmonary fibrosis (McMillan 
et al., 2008). This result could be potentially explained by the differences in 
bleomycin and FITC models of pulmonary fibrosis. Bleomycin-induced fibrosis is not 
progressive and a degree of scar tissue re-modelling has been observed in the initial 
study with reduced dose of bleomycin. In contrast, FITC-induced fibrosis results 
from a persistent injury caused by FITC deposition in the lung. It is possible that the 
discrepancy in responses to viral infection between bleomycin- and FITC-challenged 
lungs is driven by the different nature of the original injury.     
As previously observed, ALK5 inhibition attenuated the pulmonary fibrosis as 
evaluated by both total lung collagen and µCT analysis (Scotton et al., 2013). In this 
study, SB525334 inhibition of TGFβ/ALK5 signalling significantly reduced lung 
collagen accumulation in mock-infected bleomycin-challenged lungs but this 
therapeutic effect was lost in virally-infected fibrotic lungs. Interestingly, lung 
density analysis revealed the density pixel range affected by the SB525334 
treatment that localised to fibrotic lesions in bleomycin alone challenged lungs, but 
in viral infection of fibrotic lungs pixels affected by the drug were distributed 
throughout the parenchyma. This suggests that the therapeutic target of SB525334 
is significantly different in fibrotic lungs when compared to virally-infected fibrotic 
lungs and in the latter appeared to have affected the inflammation. This conclusion 
is further supported by the fact that SB525334 reduced the numbers of 
inflammatory cell aggregates in the lung and significantly attenuated splenomegaly.   
In this study we observed that the inflammation caused by the virus appeared to 
persist 14 days p.i., despite the previous reports showing that the lytic phase of 
infection is cleared by that time (Vannella et al. 2010; Nash et al. 2001). 
Furthermore, despite prominent splenomegaly suggestive of established latent 
infection, viral gene expression continued to be detected in the virally infected 
fibrotic lungs 14 days p.i.. The infection with γHV68 is well characterised. Murine 
γHV68 infects the respiratory epithelium and the lytic phase is predominantly 
cleared by day 14 p.i. but a low level of replication can persist in the lung (Nash et 
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al., 2001). The murine virus is more lytic than the human counterpart but eventually 
establishes latency in B-lymphocytes and macrophages. Infected B-lymphocytes 
become a vehicle for systemic spread of the virus and establishment of latency at 
the preferred site, the spleen. Similarly to EBV, γHV68 enters naïve B-cells and 
programmes them to become long-lived memory B-cell. Studies with B-cell deficient 
mice demonstrated that the virus can persists in macrophages as well (Weck et al., 
1997).  
Components of innate and adaptive immune system are involved in mounting 
antiviral responses. Innate immunity to γHV68 involves activation of TLR9, which 
recognises bacterial and viral genome unmethylated CpG nucleotides. Interferons α 
and β (IFNα and IFNβ) are essential for the early containment of the infection while 
IFNγ and IL-6 are the main cytokines that sharply increase during infection (Doherty 
et al., 2001). Levels of IFNα, IL-12 and IL-5 are reduced in TLR9 knockout mice, 
which leads to greatly increased levels of viral load both in lytic and latent phase 
following intraperitoneal administration of the virus (Guggemoos et al., 2008). 
Furthermore, IFNβ is also decreased in these mice which is associated with 
increased fibroblast proliferation and collagen deposition in the lung (Luckhardt et 
al., 2011). Infection with γHV68 has also been associated with alternatively 
activated macrophages that suppress inflammation and promote wound healing 
responses (Gangadharan et al., 2008; Mora et al., 2006). These macrophages are 
characterised by expression of arginase I and insulin-like growth factors IGF-1 and 
stimulate expression of ECM protein, as well as high levels of TGFβ. High levels of 
arginase I are detected in IPF lungs (Mora et al., 2006). 
A strong cytotoxic CD8 T-cell response has been reported in the BALF obtained from 
γHV68 infected mice throughout the lytic phase (Hardy et al., 2001). CD8 cytotoxic 
T-cells are necessary for clearance of the original infection but cannot control 
reactivation of the latent infection and subsequent infections. CD8 T-cells display 
effector memory phenotype and mount efficient immune responses to γHV68 
challenge through large capacity to produce IFNγ, TNFα next to the cytotoxic 
abilities (Cush and Flaño, 2011). The most prominent feature of γHV68 infection is 
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splenomegaly that peaks 14 to 31 days after the infection and is caused by CD4 T-
lymphocyte-mediated stimulation of B-cell clonal expansion (Nash et al., 2001). In 
the spleen, dendritic cells and macrophages are additional reservoirs of latent 
murine γHV68. In the lung, the virus can infect multiple cell types but long-term 
latency is only detected in B-lymphocytes and the alveolar epithelium. EBV and 
murine γHV68 both can infect alveolar epithelium and fibroblasts (Adachi et al., 
2001). EBV has been shown to infect human lung fibroblasts and increase 
production of IL1β and FGF from these cells (Adachi et al., 2001). Viral entry into the 
non-immune cells involves the interaction between viral capsid glycoproteins gHgL 
and the integrins, with αvβ6, αvβ8 and αvβ5 best described targets (Chesnokova 
and Hutt-Fletcher 2011; Chesnokova et al. Hutt-Fletcher 2009). Integrin αvβ6 is 
upregulated in pulmonary fibrosis (Thomas et al. 2006) and strongly associated with 
activation of latent TGFβ  (Wipff and Hinz, 2008). Human cytomegalovirus has also 
been shown to induce the TGFβ activation and expression of αvβ6 integrin in 
human umbilical vein endothelial cells and lung microvascular endothelial cells 
(Tabata et al., 2008). Both in the lung and spleen low level of persistent lytic 
replication can also be detected (Flaño et al., 2003).  
Antiviral responses are crucial for effective infection control and the presence of 
inflammatory cell aggregates in the lung is prominent in all studies described in this 
section of the thesis. In terms of future work, it will be important to analyse the 
cellular components of these inflammatory aggregates and further characterise 
how bleomycin-induced fibrosis affects antiviral responses in the lung. This question 
was partly addressed in the final study where inflammatory mediators were 
measured locally in the lung and systemically in the serum. Viral infection in the 
fibrotic lung significantly augmented systemic inflammation with high levels of IFNγ 
and CCL2 detected in the serum. High levels of CCL2 and CCL12 have previously 
been shown to be produced in response to viral infection and can actively 
contribute to fibrogenesis by facilitating fibrocyte recruitment into the lung 
(McMillan et al., 2008). Furthermore, expression of immunomodulatory M3 viral 
protein at the mRNA level has been detected in all studies 14 days p.i. M3 has been 
shown to disrupt the chemokine gradient and prevent trafficking of the 
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inflammatory cells into the site of infection (Alexander-Brett and Fremont, 2007). 
M3 has also been shown to sequester macrophage inflammatory protein α and 
CCL2 in an immune evasion strategy (Berkel et al., 2000). The high levels of CCL2 
protein and mRNA observed in these studies might also reflect the inadequate 
immune response to the virus.      
Coagulation cascade has also been shown to be activated in response to viral 
infection. Injury to the lung leads to upregulation of tissue factor and in this study, 
mRNA levels of tissue factor and FX were increased 7 days p.i. and showed strong 
immunolocalisation to bronchial and alveolar epithelium 14 days p.i.. The ternary 
complex, TF-FVIIa-FXa, can be assembled locally in the lung (Scotton et al., 2009) 
and there is evidence for vascular leak in the initial study 7 days p.i. which creates 
the potential for prothrombin extravasation from the circulation and local 
activation of thrombin. HSV I and CMV express tissue factor and procoagulant 
phospholipids on their surface providing a platform for the assembly of the TF-
FVIIa-FXa complex leading to the generation of thrombin (Sutherland et al., 1997). 
Thrombin has also been shown to enhance HSV I and CMV cell invasion in human 
umbilical vein endothelial cells (HUVEC) and human foreskin fibroblasts (HFF) 
(Sutherland et al. 2007).  
We next used a direct FXa inhibitor, BAY59-7939, to investigate whether activation 
of coagulation cascade plays a role in the γHV68 infection on a background of 
pulmonary fibrosis. Previous study prophylactically targeting FXa in an early phase 
of bleomycin-induced lung injury and fibrosis showed attenuation of pulmonary 
fibrosis (Scotton et al., 2009). However, in the current study systemic targeting of 
FXa, using BAY59-7939, in the fibrotic phase of bleomycin-induced lung injury and 
viral infection of fibrotic lung did not affect lung collagen accumulation. 
Furthermore, targeting FXa in viral infection of fibrotic lung showed no effect on 
local and systemic inflammation as determined by measuring levels of inflammatory 
markers in lung homogenates and serum. In contrast, BAY59-7939 treatment 
appeared to increase inflammatory cell infiltrates in the lungs. Consequently, µCT 
analysis revealed that inhibition of the coagulation cascade in virally-infected 
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fibrotic lungs appeared to have increased inflammatory changes in the lungs 
evident as ground glass opacities. However, this observation did not correlate with 
lung density analysis and the density histograms showed no difference between the 
virally-infected fibrotic lung treated with vehicle and BAY59-7939. In conclusion, 
this final study in this chapter corroborated the findings of the previous two studies, 
that the viral infection on a background of pulmonary fibrosis evokes strong and 
long-lasting inflammatory response. Local and systemic inflammatory markers 
remained significantly upregulated 14 days p.i. and exceeded the levels observed in 
viral infection in the saline control.  
PAR-1 signalling downstream of activation of coagulation cascade has been 
implicated in the fibroproliferative processes and PAR-1 knockout mice are 
protected from bleomycin-induced pulmonary fibrosis (Howell et al. 2005). An 
interesting next step in dissecting the role of viral infection in pulmonary fibrosis 
would be to experiment with this two-hit model in PAR-1 deficient mice. Multiple 
questions could be addressed in this potential study including whether PAR-1 
knockout mice can be primed by the γHV68 infection to develop more severe 
fibrosis and whether PAR-1 deficiency affects the inflammatory and antiviral 
responses. The last points are of particular interest as PAR-1 signalling has been 
shown to play different roles in antiviral immunity and promote markedly different 
inflammatory responses that were dependent on the type of the virus and site of 
infection (Antoniak et al., 2013; Khoufache et al., 2013). Interestingly, herpesviruses 
show capacity to trigger exacerbation of pulmonary fibrosis but adenovirus 
infection did not affect the progression of the disease (McMillan et al., 2008). 
Similarly, herpesvirus infection has been shown to drive the pathology of 
atherosclerosis (Alber et al. 2000) by infecting and transforming endothelial cells 
(Flore et al., 1998). The identified pathogenic mechanisms revolve around systemic 
inflammation combined with responses of infected cells at the site of injury. Again, 
exacerbation of atherosclerosis was virus-specific and infection with other viruses 
failed to worsen the condition (Alber et al. 2002).  
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The pathology of γHV68 infection also differs between young and old mice (Naik et 
al., 2011), with old mice developing spontaneous fibrosis following viral challenge, 
despite fully immunocompetent immune responses and viral clearance. A robust 
fibrotic response in the aged mice was associated with increased levels of TGFβ and 
increased responsiveness of fibroblasts to TGFβ signalling leading to expression of 
α-SMA and collagen synthesis. Since pulmonary fibrosis affects ageing people, it 
would be relevant to assess the role of coagulation activation in response to viral 
infection on a background of pulmonary fibrosis in the aged mice.   
Acute exacerbation of IPF is marked by epithelial cell injury and increased levels of 
mediators of innate immunity (Konishi et al., 2009). Moreover, antiviral therapy has 
been shown to benefit a small cohort of IPF patients (Egan et al., 2011). Abundant in 
vitro and in vivo evidence describes multiple mechanisms by which γ-herpesviruses 
contribute to the pathogenesis of pulmonary fibrosis. The aim of these studies was 
to investigate the impact of γHV68 infection on bleomycin-induced pulmonary 
fibrosis. In the time-frame of these experiments there were no changes in fibrosis 
endpoints, as assessed by measurement of total lung collagen, between bleomycin 
challenged and virally-infected fibrotic lungs. However, this study has shown in 
three independent experiments that the two-hit model of viral infection on a 
background of bleomycin-induced pulmonary fibrosis caused robust and extensive 
inflammatory responses that were severe and persisted in the fibrotic lungs. 
Furthermore, the therapeutic effect of the ALK5 inhibitor, SB525334, in attenuating 
pulmonary fibrosis was lost in viral infection on a background of existing fibrosis and 
the drug appeared to target the inflammation in response to viral infection. These 
data suggest that TGFβ/ALK5 signalling exerts greatly different effects in the context 
of fibrosis alone and when fibrosis is concomitant with viral infection. Moreover, in 
the third study in this chapter we evaluated systemic inflammation and significantly 
increased levels of inflammatory (CCL2, KC) and antiviral (IFNγ) mediators were still 
detected 14 days p.i. locally in the lung. Targeting the activation of coagulation 
cascade by FXa inhibition did not affect inflammatory and fibrotic responses in this 
model of viral infection on a background of pulmonary fibrosis. Finally, using µCT 
technology we demonstrated that the viral infection on a background of pulmonary 
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fibrosis bears close resemblance to HRCT scans of IPF patients experiencing acute 
exacerbation with a hallmark inflammatory changes superimposed on existing 
fibrosis (Collard et al., 2007).      
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Chapter 4: Final summary and implications  
 
The studies presented in this thesis addressed the following hypothesis: 
Activation of the coagulation cascade in response to lung injury and viral infection 
promotes inflammation and fibrosis via PAR-1 signalling.  
And the following aims: 
• Identify PARs responsible for coagulation proteinases signalling responses 
in human primary lung cells.  
• Determine whether the coagulation cascade contributes to inflammatory 
and fibrogenic responses in the model of viral infection in pulmonary 
fibrosis.  
The first aim of this study was addressed in Chapter 3.1 of this thesis, where PAR-1 
expression and signalling was assessed in different human lung cell populations. The 
results showed that lung fibroblasts and lung microvascular endothelial cells 
express the highest levels of PAR-1 and responded robustly to thrombin, even at 
low nanomolar concentrations. In contrast, the normal respiratory epithelium does 
not express much PAR-1 and is non-responsive to thrombin stimulation. 
Interestingly, primary normal human bronchial and alveolar epithelial cells signalled 
robustly following PAR-2 activation. In contrast, PAR-1 expression is increased in 
abnormal alveolar epithelium represented by A549 cells. Furthermore, fibroblasts 
and lung microvascular endothelial cells signal to coagulation proteinases in PAR-1-
dependent and PAR-2-independent manner whereas in epithelial cells and large 
vessel endothelial cells PAR-2 signalling can modulate the magnitude of PAR-1-
mediated calcium responses. The interaction between PAR-1 and PAR-2 signalling in 
epithelial cells requires further investigation and potentially poses an interesting 
challenge when targeting PAR-1 and PAR-2 in lung disease.   
TGFβ, ubiquitous and pleiotropic profibrotic cytokine, further increases PAR-1 
expression in A549 cells, which is associated with a concurrent upregulation of αv 
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and β6 integrin subunit expression. In this study we also demonstrate a novel 
signalling axis in A549 cells that involves TGFβ/ALK5-mediated and Smad3- and 
ERK1/2-dependent PAR-1 upregulation. PAR-1 signalling has been shown to 
promote TGFβ activation via αvβ6 integrins in epithelial cells and αvβ5 in fibroblasts 
(Scotton et al. 2009; Jenkins 2008). The results of this study suggest that fibroblasts 
constitutively express high levels of PAR-1 and can readily respond to coagulation 
proteinases. Furthermore, in an abnormal wound healing microenvironment the 
alveolar epithelium may become increasingly responsive to the local procoagulant 
environment and may further propagate the pathologic milieu by means of a self-
amplifying PAR-1-integrin-TGFβ feedback loop, as summarised in Figure 4.1. 
 
 
 
 
 
 
 
 
 
Figure 4.1. PAR-1-integrin-TGFβ feedback loop.  
Activation of PAR-1 on fibroblasts and abnormal alveolar epithelium leads to TGFβ 
activation via integrins αvβ5 and αvβ6, respectively. TGFβ signalling via ALK5 
receptor, Smad3 phosphorylation and activation of ERK1/2 signalling pathways 
leads to upregulation of PAR-1 expression in the abnormal alveolar epithelium.     
Fibroblasts constitutively express high levels of PAR-1, which also leads to robust 
pro-fibrotic signalling following thrombin stimulation. As shown in Chapter 3.2 and 
Appendix 2, fibroblasts secreted large amounts of pro-inflammatory chemokine, 
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CCL2, in response to thrombin stimulation. However, at high thrombin 
concentration this effect was only partially PAR-1 mediated which suggests that 
thrombin can influence fibroblast responses in a PAR-1-independent manner.  
Activation of PAR-1 leads to convergence of coagulation signalling, inflammatory 
responses and TGFβ activation, which makes it a potential attractive therapeutic 
target in lung injury and fibrosis. PAR-1 knockout mice are protected from 
bleomycin-induced lung injury and fibrosis (Howell et al., 2005) and a recent study 
using pepducins to block PAR-1 signalling showed attenuation of bleomycin-induced 
fibrosis (Lin et al., 2013). In Chapters 3.1 and 3.2 we used small molecule PAR-1 
antagonists, RWJ58259 and SCH530348, to investigate PAR-1 distribution and 
responsiveness to thrombin. Although these antagonists are specific and potent 
PAR-1 inhibitors, there are limitations for their in vivo application in the setting of 
chronic diseases due to short half-life and consequent need for frequent 
administration. In this study we purified and began to characterise a novel murine 
PAR-1 neutralising antibody as described in Appendix 1. Therapeutic antibodies 
have high specificity and affinity for the target, longer half-life in vivo and reduced 
off-target effects. Although further work is required to optimise the purification of 
the antibody, we demonstrated that mPAR-1 neutralising antibody efficiently blocks 
PAR-1 signalling in vitro, which makes it a potential tool for investigating the 
therapeutic effects of blocking PAR-1 in long-term experimental models of 
pulmonary fibrosis.            
The second aim of this study was addressed in Chapter 3.3. In a series of three 
independent experiments we showed that γ-herpesvirus infection on the 
background of bleomycin-induced pulmonary fibrosis did not exacerbate fibrosis as 
measured by collagen deposition in the lungs but triggered strong and persistent 
inflammatory responses. Several hallmark features of acute lung injury were 
observed in virally-infected fibrotic lungs at the peak of viral lytic cycle (7 days p.i.) 
including interstitial oedema, alveolar haemorrhage and inflammatory cells 
infiltrates. This was associated with increased expression of inflammatory 
mediators, including CCL2 and IFNγ, and components necessary for the activation of 
 
 
  355  
  
the coagulation cascade, TF and FX. Persistent inflammation was also reflected by 
increased levels of inflammatory markers in the sera of infected mice with pre-
existing fibrosis. Furthermore, viral gene expression was readily detected in the 
infected fibrotic lungs 14 days p.i. and the spleen weights were significantly 
increased when compared to virally-infected control mice, suggestive of continuing 
level of viral replication in the infected and fibrotic lungs and increased capacity to 
establish latency. The pathologic changes in the lungs were further investigated by 
analysis of µCT scans, which revealed ground glass opacities and consolidation 
concurrent with fibrotic lesions in viral infection on a background of pulmonary 
fibrosis. Importantly, several features recognised by µCT scanning resembled the 
findings in HRCT scans from IPF patients experiencing acute exacerbation.           
We next investigated the role of TGFβ/ALK5 signalling in viral infection of fibrotic 
lung. The findings of this study agreed with previous reports that inhibition of TGFβ 
receptor, ALK5, attenuates fibrosis in bleomycin model of pulmonary fibrosis. In 
contrast, the therapeutic effect of SB525334 shifted from antifibrotic action in 
fibrotic lungs to anti-inflammatory action in virally infected fibrotic lungs. The 
analysis of µCT scans, lung density and histology supported the notion that while in 
bleomycin-challenged lungs ALK5 inhibitor targeted the fibrotic lesions, in the viral 
infection of fibrotic lung blocking TGFβ/ALK5 signalling appeared to modulate the 
inflammatory responses to infection, as summarised in Figure 4.2. TGFβ plays 
critical role in mediating vascular leak and inhibition of TGFβ signalling in models of 
lung injury protects from pulmonary oedema (Pittet et al. 2001). It is possible that 
inhibition of vascular leak in the early phase of lytic viral infection and lung injury 
impacts on inflammatory responses and lymphocyte trafficking in this model. The 
results of this study highlight pleiotropic nature of TGFβ in lung fibrosis and 
infection and advocate caution when predicting therapeutic effect of blocking TGFβ 
signalling in human disease. 
Finally, we investigated whether inhibition of the activation of the coagulation 
cascade by blocking FXa, affects fibrosis and inflammation in viral infection of 
pulmonary fibrosis. Targeting FXa with specific inhibitor, BAY59-3979, did not 
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significantly augment fibrosis or viral infection on a background of existing 
pulmonary fibrosis in this model.  
 
Figure 4.2. Different therapeutic effect of TGFβ/ALK5 signalling inhibition in 
fibrotic lung versus viral infection of fibrotic lung.  
Viral infection in a lung with a pre-existing injury can trigger different and 
exaggerated host responses. Herpes simplex virus infection is a risk factor for the 
development of ARDS in patients in intensive care (Bruynseels et al. 2003) and leads 
to increased complications and prolonged hospitalisation (Luyt et al. 2007). 
Cytomegalovirus reactivation is observed in septic surgical patients and is 
associated with increased incidence of fibroproliferative lung disease in these 
patients (Cook et al. 2006). In bone marrow transplantation model, post-transplant 
mice are more susceptible to γHV68 infection in the lung and the latent infection 
leads to chronic and persistent pneumonitis and fibrosis (Coomes et al. 2011).  
In this two-hit model of viral infection on a background of bleomycin-induced 
pulmonary fibrosis we observed increased local expression of TF and FX 
concomitant with evidence of vascular leak and haemorrhage, which are considered 
to be major sources of thrombin in the injured lung. Altogether, this can lead to 
enhanced procoagulant state and local activation of coagulation cascade in the 
lung. As characterised in Chapter 3.1 and proposed in Figure 4.1, in an abnormal 
fibrotic microenvironment both mesenchymal cells and the epithelium can become 
more responsive to coagulation signalling via PAR-1 receptor. Increased expression 
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of all PARs in the respiratory epithelium and airway smooth muscle cells has been 
reported in influenza infection and particularly increased expression of PAR-1 and 
PAR-2 significantly augmented the antiviral responses in these cells (Lan et al., 
2004). Furthermore, PAR-1-integrin-TGFβ activation and signalling axis can 
contribute to the progression of viral infection in the lung. Integrins αvβ5 on 
mesenchymal cells and αvβ6 on epithelial cells are major activators of latent TGFβ 
(Scotton et al. 2009; Jenkins et al. 2006) and are also utilised by the herpesviruses 
as auxiliary molecules to facilitate viral entry into the cell (Chesnokova et al. 2009). 
It is possible that in the injured lung profibrotic and procoagulant environment 
facilitates increased viral infectivity, which in turn evokes persistent inflammatory 
response and exacerbates existing injury.  
Thus, major part of future studies of viral infection on a background of bleomycin-
induced pulmonary fibrosis would involve: i) full characterisation of the persistent 
inflammatory response observed in this model, ii) dissecting further the 
mechanisms of differential TGFβ therapeutic effect between bleomycin-only 
challenged mice and γHV68-infected bleomycin-injured mice in this model, and iii) 
investigation of the role of PAR-1 in the viral infection of pulmonary fibrosis.   
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Appendix 1: PAR-1neutralising antibody 
A1.1 Introduction 
Previous work from our laboratory has shown that lack of PAR-1 offers protection in 
a number of lung conditions including bleomycin model of acute lung injury and 
fibrosis (Howell et al., 2005) and experimental model of chronic obstructive 
pulmonary disease (Atzori et al., 2009). The aim of this study was to support these 
finding with a pharmacological targeting of PAR-1 receptor. We have used 
RWJ58259 and SCH530348 to investigate the biological responses in vitro as 
described in Chapter 3.1 of this thesis  and in vivo in LPS model of acute lung injury 
(Mercer et al., 2013). However, both molecules have a short half life in vivo and 
have to be administered frequently at a relatively high dose to fully engage the 
target receptor and produce a significant biological response. Furthermore, neither 
antagonist prevents cleavage of the PAR-1 N- terminus and release of the tethered 
ligand. The inhibitors occupy the second extracellular loop of the receptor where 
the tethered ligand binds and while that blocks PAR-1 activation there is still 
potential to transactivate PAR-2 receptor, which has recently been shown to play a 
role in idiopathic pulmonary fibrosis (Wygrecka et al., 2011).  
In order to find novel ways of targeting PAR-1 receptor in a long term pulmonary 
fibrosis model the aim of this part of the project was to purify a murine PAR-1 
neutralising antibody from the hybridoma cell supernatant and assess its effect on 
thrombin-mediated intracellular calcium release and inflammatory responses in 
murine lung fibroblasts.  
The second aim of this study was to test the efficacy of the mPAR-1 neutralising 
antibody in LPS model of acute lung injury. Main clinical features of acute lung 
injury (ALI) include disruption of the pulmonary epithelium and endothelium 
manifested as diffuse alveolar damage (DAD) (reviewed in Chambers 2008). This 
leads to increased vascular permeability and subsequent protein leak into the lung. 
The resultant oedema is potentiated by impaired fluid clearance in the injured lung 
 
 
  413  
  
(Ware and Matthay 2001). Acute inflammation is also hallmark of ALI, manifested 
by the neutrophillic alveolitis and increased concentration of inflammatory 
cytokines in the lung (Ware and Matthay 2001). The model of LPS-induced acute 
lung injury is a widely used model that recapitulates the two main hallmarks of 
human condition, namely neutrophilic inflammation and vascular leak. Research in 
our laboratory has shown that blocking PAR-1 with a small molecule antagonist, 
RWJ58259, significantly reduced neutrophilia and vascular leak in the in vivo LPS-
model of acute lung injury (Mercer et al., 2013).  
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A1.2 Methods   
A1.2.1 Hybridoma cell culture  
Armenian hamster derived hybridoma cells producing anti-mouse PAR-1 
neutralising antibodies were kindly provided by Novartis Research Centre 
(Horsham, UK). The cells were maintained in DMEM/10% FCS in 250 cm2 tissue 
culture flaks. When cells were 80-90% confluent (every 2-3 days) the supernatant 
was collected and the remaining cells passaged at 1 in 3 ratio. The cells were lightly 
adherent or floating and no trypsin was required for detachment. 
The purification and characterisation approach was chosen based on data available 
for the human PAR-1 neutralising antibody that was also developed and described 
by Novartis. The extracellular N-terminus domain of PAR-1 was cloned and 
expressed in a fusion protein used to immunise laboratory animals- mice for human 
anti-PAR-1 and Armenian hamsters for murine anti-PAR-1. B lymphocytes producing 
antibodies against these fusion proteins were isolated from spleens of the 
immunised animals and transformed by fusion with myeloma cells. This technology, 
described in 1975 by Kohler and Milstein, allows for creation of immortal 
hybridoma cell lines secreting monoclonal antibodies against a specific peptide 
(reviewed in Gura 2002).  
The anti-human PAR-1 and anti-murine PAR-1 antibodies were developed in tandem 
but the detailed procedure and thorough characterisation was described by 
Novartis for anti-human PAR-1 antibodies only. As shown in Figure A1.2.1. the 
human PAR-1 neutralising antibody inhibited thrombin-mediated calcium release in 
concentration-dependent manner in human colon cancer and prostate cancer cells. 
Thrombin-mediated IL-8 release from human umbilical vein endothelial cells 
(HUVECs) was reduced by the human PAR-1 neutralising antibody.  
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Figure A1.2.1 Characterisation of human PAR-1 neutralising antibody. 
Left panel- anti-human PAR-1 antibody inhibits thrombin-induced calcium release in 
a concentration-dependent manner in colon HT29, HCT 116 and prostate DU145 
cell lines; right panel shows reduction in thrombin-induced IL-8 release from human 
umbilical vein endothelial cells (HUVECs) following treatment with two clones of 
anti-human PAR-1 antibody. (Reproduced from Cohen and Nasoff, 2008)  
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A1.2.2 Affinity chromatography 
Buffers: Wash buffer: 30% isopropanol in 10 mM phosphate buffer pH=7.2, Elution 
buffer: 100 mM glycine pH=2.7. 
The murine PAR-1 neutralising antibody was purified in a process of affinity 
chromatography using 1 ml HiTrapTM Protein G High Performance columns (GE 
Healthcare). The HiTrapTM column is pre-packed with protein G linked to sepharose 
matrix (highly cross-linked agarose beads). Protein G is a bacterial cell surface 
protein of Group G Streptococci that binds the Fc region of an IgG antibody in a pH- 
dependent mechanism. Protein G binds IgG over a wide range of pH with optimal 
binding achieved at pH 7. In order to release the antibody the elution buffer pH 
must be lowered to 2.5-3. The recombinant protein G in the HiTrapTM column is 
produced in E.coli and contains two IgG binding regions. The albumin binding region 
of native protein G has been genetically deleted to avoid cross-reactivity. As per 
manufacturer’s description the protein G binding capacity for human IgG is 
approximately 25mg IgG per ml of solution and the affinity for hamster IgG is in 
medium range.  
The automated chromatography system AktaprimeTMplus (GE Healthcare 
Lifesciences) was used to perform the purification process. Supernatant from the 
hybridoma cells was collected, centrifuged for 5 minutes at 200 RCF and filtered 
through Nalgene 0.2 micron sterile filter unit (Thermo Scientific) to remove cell 
debris. All subsequent steps were performed at 4°C. The HiTrapTM column was 
equilibrated with 20 column volumes (CV) of PBS, pH=7.4 prior to running the 
supernatant. The column was then washed with 10 CV of wash buffer and the 
bound protein eluted with 20 CV of elution buffer. Forty 0.5 ml fractions containing 
the protein were collected in the sterile 12ml BD Falcon tubes aligned on the 
AktaprimeTMplus collector. A real-time chromatogram was plotted and purification 
process evaluated using PrimeView™ software.   
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A1.2.3 Coomassie staining  
In order to investigate the presence and purity of protein small aliquots from 
individual fractions were mixed with the loading dye (Invitrogen), with or without 
reducing agent (DTT), and separated in the course of gel electrophoresis. The 
protein was then visualised using Coomassie brilliant blue dye (Invitrogen), which 
binds non-specifically to all proteins. Anionic form of the Coomassie dye interacts 
with basic amino acids, chiefly with arginine residues and weakly with histidine, 
lysine, tyrosine, tryptophan and phenylalanine residues. This interaction causes 
colour change of the solution from reddish brown to bright blue when the protein is 
present.     
A1.2.4 Dialysis  
The individual purification fractions were pooled together and dialyzed into storage 
buffer (10% glycerol, 0.004% Tween-80 in PBS) using Slide-A-Lyzer® Dialysis Cassette 
(Thermo Scientific). The molecular weight cut off of the semi- permeable membrane 
was 20,000 Daltons allowing small molecules and salts to diffuse out of the solution 
and into the buffer. The dialysis cassette was used as per manufacturer’s 
instructions. Briefly, the sample was gently injected between the membranes of the 
cassette that was then left floating in a storage buffer, 200 times the volume of the 
sample. The buffer was changed once after 3 hours and the sample dialyzed 
overnight at 4°C. The following day the sample was gently extracted from the 
cassette and stored in sterile BD Falcon tube. 
A1.2.5 Endotoxin detection  
Endotoxin levels in the antibody stock were detected using the Endpoint 
Chromogenic Limulus Amebocyte Lysate (LAL) (Lonza, UK) with a sensitivity range of 
0.1 EU/ml - 1.0 EU/ml. The assay was developed based on reaction between a 
Gram-negative bacterial endotoxin and a coagulation factor in the blood of the 
horseshoe crab (Limulus polyphemus) that initiates fatal intra-vascular clot 
formation. The current LAL method is based on the endotoxin-mediated lysate 
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activation that exerts enzymatic activity on the synthetic substrate releasing p-
nitroaniline (pNA) (Figure A1.2.2), which leads to the chromogenic change of the 
solution that can then be quantified by measuring absorbance at the wavelength of 
410 nm. The absorbance is directly proportionate to the amount of endotoxin 
present and its concentration can be calculated from a standard curve. 
The kit was used as per manufacturer’s instructions. Briefly, each sample was mixed 
with the LAL and incubated at 37°C (±1°C) for 10 minutes. A substrate solution was 
then added and incubated at 37°C (±1°C) for an additional 6 minutes. The reaction 
was then stopped with stop reagent and the absorbance measured at 410 nm.  
 
 
Figure A1.2.2 Principle of Limulus Amebocyte Lysate LAL assay. 
Endotoxin initiates enzymatic reaction leading to release of pNA that causes colour 
change of the sample; there is linear correlation between the level of endotoxin and 
released chromogen. 
 
A1.2.6 Endotoxin removal 
The Detoxi-Gel Endotoxin Removing Columns (Thermo Scientific) were used to 
remove the endotoxin contamination from the antibody preparation. This method 
utilises immobilized polymyxin B, which belongs to the polymyxins family of 
antibiotics that bind the most conserved domain of bacterial lipopolysaccharide- 
lipid A.  
The gravity-flow columns were washed 3-5 times with 1% sodium deoxycholate 
followed by washes with endotoxin-free water to remove the detergent. The 
columns were then equilibrated with the antibody storage buffer. The sample was 
then applied on the column and flow- through collected.   
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A1.2.7 Acute lung injury 
BALB/c female mice, between 6 and 8 weeks of age (Charles River Laboratories, 
UK), were housed at the Central Biological Services Unit, University College London; 
in a specific pathogen-free facility in individually ventilated cages, with free access 
to food and water (12 hour light/dark cycle, normal sodium dry fishmeal diet, 
temperature 18-20°C). All studies were ethically reviewed and carried out in 
accordance with the UK Home Office Animals for Scientific Procedures Act 1986.   
LPS (125 µg/kg, E.coli 0127:B8, Sigma) or saline were administered intranasally by 
placing 50 μl on the nose of a mouse under light isofluorane-induced anaesthesia 
and allowing it to be inhaled. The PAR-1 neutralising antibody (0.5 mg/kg) or 
Armenian hamster IgG isotype control (BioLegend, UK) were administered by 
intraperitoneal injection 30 minutes or 24 hours prior to LPS insult. The injury was 
allowed to develop for three hours and the mice were then sacrificed by 
intraperitoneal injection of pentobarbitone and severing of the abdominal inferior 
vena cava.  
A1.2.8 Bronchoalveolar lavage fluid (BALF)  
BALF was collected by inserting a cannula into trachea and washing the lungs with 1 
ml PBS. BALF was then stored on ice for further processing. The lungs were 
dissected and snap frozen in liquid nitrogen.  
Total cell counts (cells/ml) were obtained using a haemocytometer following cell 
staining with crystal violet in 0.1% acetic acid. Inflammatory cells from a 200 μl 
volume of BALF were pelleted onto microscope slides by centrifugation and left to 
dry. The cells were subsequently fixed in methanol and stained with eosin and 
methylene blue (Diffquick). Representative numbers of neutrophils and monocytes 
were counted in a total population of approximately 200 giving a respective 
differential ratio. The total neutrophil and monocyte counts (cells/ml) were 
calculated by multiplying the fraction of the neutrophils/monocytes in the sample 
population by the total cell counts. Total protein level in BALF was measured with 
BCA assay as described in Material and Methods section 2.14.     
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A1.3 Results 
A1.3.1 Purification and characterisation of the mPAR-1 
neutralising antibody 
The mPAR-1 neutralising monoclonal antibody was isolated from the supernatant of 
Armenian hamster-derived hybridoma cells. These immortal cells are a sustainable 
source of the monoclonal antibodies and a litre of supernatant was harvested every 
three days when the cells were propagated. A total of 8 litres of supernatant were 
used for the purpose of this study.  
The mPAR-1 neutralising antibody was isolated by affinity chromatography. 
Optimized conditions and maximal efficiency of the process was achieved by the 
use of an automated protein purification system (Aktaprime, GE Healthcare). The 
antibody was purified by exploiting the affinity interactions between protein G and 
immunoglobulins. Protein G is a bacterial cell surface protein of Group G 
Streptococci that binds the Fc region of an IgG antibody in a pH-dependent 
mechanism. Commercially-available recombinant protein G contains two IgG 
binding regions and displays medium affinity towards hamster IgG. Optimal binding 
occurs at pH 7 and the antibody is released when the pH is rapidly decreased to pH 
2.5-3 by the elution buffer. In the course of a purification run changes in UV 
absorbance are monitored and plotted as a chromatogram. Figure A1.3.1 shows a 
representative chromatogram that illustrates stages of the isolation process and 
allows for the qualitative evaluation of the collected protein. The single peak 
observed in the graph indicates the presence of only one elution product. The area 
under the peak is proportionate to the amount of the protein present and the 
fractions collected in that area contain significant concentration of protein.  
The purity and the correct size of the collected protein were confirmed by 
Coomassie dye staining. The anionic form of the Coomassie dye interacts with basic 
amino acids and causes a colour change of the solution from reddish brown to 
bright blue, which is indicative of protein presence. Figure A1.3.2A shows a 
representative Coomassie-stained gel of the protein isolated during the purification 
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run. The non-reduced protein is visualised as a single band of 150 kDa, which 
corresponds to the molecular weight of an antibody. Treatment with a reducing 
agent disrupts the disulphide bonds that bind covalently the polypeptide chains 
forming an antibody. This is visualised by two bands corresponding to the light 
chain (25 kDa) and heavy chain (50 kDa). The isolated antibody was further 
identified to be Armenian hamster IgG by Western blot (Figure A1.3.2B).  
The antibody preparation subsequently underwent overnight dialysis, which 
facilitates removal of small contaminants by selective and passive diffusion through 
a semi-permeable membrane. Furthermore, dialysis allows changing of the elution 
buffer to a storage buffer composed of 10% glycerol and 0.04% Tween-80 in PBS. 
The antibody concentration was quantified by BCA assay. 
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Figure A1.3.1. Isolation of IgG from hybridoma cells supernatant.  
Figure shows a representative chromatogram plotted from the UV absorbance 
changes during the antibody purification run in a process of automated affinity 
chromatography (Aktaprime, GE Healthcare). A litre of supernatant collected from 
antibody-producing hybridoma cells was filtered and optimised to pH 7. Step 1- The 
supernatant was applied to a protein G column at a constant flow rate of 1 
ml/minute. Step 2- Following the supernatant flow, the column was washed as 
indicated and the antibody eluted with elution buffer, pH 2.7. Step 3- Protein was 
detected and visualised by the peak and collected in forty 0.5 ml fractions. 
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Figure A1.3.2. Identification of Armenian hamster IgG.  
Panel A shows representative Coomassie staining of protein collected during 
automated affinity chromatography. A small aliquot from each fraction was 
subjected to gel electrophoresis under reducing (left) and non-reducing (right) 
conditions. The gel was subsequently fixed and stained with Coomassie dye. Panel B 
shows a Western blot in non-reducing conditions of IgG detected with anti- 
Armenian Hamster secondary antibody.  
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A1.3.2 Effect of the mPAR-1 neutralising antibody on thrombin-
mediated intracellular calcium mobilisation 
Following successful purification of the Armenian hamster IgG from the hybridoma 
cell supernatants, the next series of experiments aimed to assess the effect of this 
antibody on thrombin-mediated PAR-1 activation and cellular responses. Firstly, 
murine PAR-1 neutralising antibody effect on intracellular calcium flux was 
investigated in murine lung fibroblasts.  
The cells were pre-incubated with the antibody at a concentration range from 90 
μg/ml to 0.1 μg/ml, before being stimulated with thrombin (10 nM) or the PAR-1 
activating peptide, TFLLR (100 μM). As shown in Figure A1.3.3A, the antibody 
inhibited thrombin-mediated intracellular calcium flux in a concentration-
dependent manner and IC50 of 1.6 μg/ml. The antibody did not affect the TFLLR-
mediated response (Figure A1.3.3B). The PAR-1 activating peptide TFLLR is a highly 
selective PAR-1 peptide agonist that activates PAR-1 independently of proteolytic 
cleavage by direct binding to the second extracellular loop of the receptor. In this 
experiment TFLLR was used as a positive control to demonstrate that the 
intracellular calcium release in murine lung fibroblasts is PAR-1-mediated and also 
to confirm a different mechanism of PAR-1 blocking as predicted for this antibody. 
As characterised by Novartis, the antibody was generated against the N-terminus of 
the receptor.   
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Figure A1.3.3. PAR-1 neutralising antibody inhibits thrombin but not TFLLR- 
induced intracellular calcium release.   
Murine lung fibroblasts were incubated with mPAR-1 neutralising antibody, at a 
concentration range from 90 μg/ml to 0.1 μg/ml and Fluo4-AM calcium binding dye 
an hour prior to the agonist stimulation. A- Concentration-inhibition curve with 
thrombin; B- Concentration-inhibition curve with TFLLR; data are presented as a 
percentage of thrombin response and values represent mean ± SEM of 3 replicate 
wells. 
A 
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A1.3.3  Effect of the mPAR-1 neutralising antibody on thrombin-
mediated CCL2 release 
 
The characterisation of the human PAR-1 neutralising antibody showed its potential 
to inhibit thrombin-mediated intracellular calcium release and reduce IL-8 release 
from endothelial cells (Figure A1.2.1). In the previous section, it was demonstrated 
that the murine PAR-1 neutralising antibody inhibits thrombin-mediated 
intracellular calcium release in a concentration-dependent manner in murine lung 
fibroblasts. As described in detail in Chapter 3.2, thrombin-mediated PAR-1 
signalling leads to CCL2 synthesis and release from murine lung fibroblasts and 
hence the effect of mPAR-1 neutralising antibody on CCL2 release was investigated 
next. As shown in Figure A1.3.4 treatment of fibroblasts with mPAR-1 neutralising 
antibody at concentrations of 50 μg/ml, 5 μg/ml and 0.5 μg/ml prior to stimulation 
with thrombin (10 nM) led to an increase in CCL2 release from the cells. 
Furthermore, the control cells pre-treated with different concentrations of antibody 
alone showed a concentration-dependent increase in CCL2 release.  
The results of this experiment were opposite to expected and potential 
explanations were considered. CCL2 is a potent inflammatory chemokine induced 
and released in response to tissue injury and infection. A potent mediator of CCL2 
release is bacterial endotoxin, which binds to Toll-like receptor 4 (TLR 4) and 
activates signalling pathways via the NFκB pathway. Endotoxin is also a common 
contaminant in the process of antibody generation and purification. The antibody 
preparation was subsequently tested for endotoxin levels and was found to be 
contaminated with endotoxin (approximately 300 endotoxin units per ml (EU/ml), 
equivalent to 30 ng/ml). 
Due to the high levels of endotoxin present, the antibody stock was unsafe for 
further in vitro and in vivo use. Commercially- available endotoxin removal kits were 
used to eliminate the contamination. Following endotoxin removal treatment the 
contamination level was reduced to 10 EU/ml (1 ng/ml).  At this concentration the 
antibody did not induce CCL2 release from murine lung fibroblasts. 
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Figure A1.3.4. Effect of mPAR-1 neutralising antibody on CCL2 release from 
murine lung fibroblasts. 
Murine lung fibroblasts were pre-treated for an hour with mPAR-1 neutralising 
antibody at concentrations of 50, 5 and 0.5 μg/ml and then stimulated with 10nM 
thrombin. Following a 6-hour incubation, cell supernatants were collected and CCL2 
levels measured by ELISA; the results are presented as means ± SEM of n=3 
replicate wells. 
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A1.3.4 mPAR neutralising antibody in LPS model of acute lung 
injury 
BALB/c mice were injected intraperitoneally with 0.5 mg/kg of the mPAR-1 
neutralising antibody or IgG isotype control 30 minutes prior to LPS injury. LPS (125 
µg/kg) or saline were administered intranasally and the injury was allowed to 
develop for 3 hours. After this time, mice were sacrificed and the BALF collected. As 
shown in Figure A1.3.5A, administration of LPS into the lung leads to an influx of 
inflammatory cells into the lung. The differential counts showed a significant 
neutrophilia (Figure A1.3.5B) while the proportion of monocytes and macrophages 
seen in the BALF was significantly reduced in comparison to saline treated animal 
(Figure A1.3.5C). There was no difference in inflammation between the mPAR-1 and 
IgG isotype treated animals.  
LPS administration into the lung also leads to increased vascular permeability and 
oedema formation in the lung. However, in this study no difference in the total 
BALF protein levels between saline control and LPS-injured groups was observed 
(Figure A1.3.6). Furthermore, the baseline levels in the saline-treated animals were 
increased when compared to historical baseline, as indicated by the dotted line, 
recorded in previous experiments performed in our laboratory. This potentially 
suggests that the administration of the isotype control and mPAR-1 antibody alone 
leads to increased vascular leak and increased protein concentration in the lung.  
PAR-1 neutralising antibody has been proven in vitro to fully block the intracellular 
calcium flux (Figure A1.3.3A) but the in vivo results did not show attenuation of 
neutrophilia following LPS challenge. It is possible that the antibody concentration 
used in this experiment was not sufficient to affect the outcome of the lung injury. 
This may have been also caused by the limited bioavailability of the antibody in the 
lung due to systemic administration and potential off-target effects. The potential 
delay between antibody administration and the time it reaches the lung was 
addressed in the second experiment where the mPAR-1 neutralising antibody or 
isotype control were administered 24 hours prior to the LPS challenge.    
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As shown in Figure A1.3.7, LPS evoked a significant inflammatory response with an 
increase of total cell, neutrophils influx into the lung and the decrease in fraction of 
monocytes and macrophages in the BALF. However, again there was no difference 
between animals treated with mPAR-1 neutralising antibody and the isotype 
control.  
The vascular leak has been assessed as previously by measuring the total BALF 
protein levels showing a trend toward increase in LPS-challenged groups (Figure 
A1.3.8), which is more consistent with our historical data. The levels of protein in 
the saline groups were still increased and there was no difference between the 
treatment groups.  
Despite our confidence in the mPAR-1 neutralising antibody ability to block the 
receptor and considering several strategies to optimise it further in vivo, which will 
be described in detail in the discussion, we were concerned with the elevated 
protein levels in BALFs of saline + mPAR-1 IgG-treated animals. We worried that the 
residual level of endotoxin present in the antibody preparation may be responsible 
for this effect and therefore, before proceeding with next experiments, we opted 
for further endotoxin removal treatments.  
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Figure A1.3.5. Assessment of inflammation in the model of LPS-induced acute lung 
injury (ALI).  
BALB/c mice were administered 0.5 mg/kg of mPAR-1 neutralising antibody or 
isotype control 30 minutes prior to the intranasal challenge with 125 µg/kg LPS. 
Control animals were administered saline. After 3 hours, animals were sacrificed 
and BAL fluid collected. Inflammation was assessed by A- total cell counts in BALF; 
B- differential neutrophil counts; C- differential monocyte counts; Data show means 
±  SEM of n= 4-5 animals per group; One way Anova was performed for statistical 
analysis; *p<0.05; **p<0.01. 
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Figure A1.3.6. Assessment of vascular leak in the LPS model of acute lung injury 
(ALI).   
BALB/c mice were administered 0.5 mg/kg of mPAR-1 neutralising antibody or 
isotype control 30 minutes prior to the intranasal challenge with 125 µg/kg LPS. 
Control animals were administered saline. After 3 hours, animals were sacrificed 
and BAL fluid collected and total protein measured. Data present mean ± SEM of n= 
3-5 animals. The dotted line shows historical baseline for protein and albumin levels 
in the 3- hour LPS model of ALI.  
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Figure A1.3.7. Assessment of inflammation in murine model of LPS- induced acute 
lung injury.  
BALB/c mice were administered 0.5 mg/kg of mPAR-1 antagonist antibody or 
isotype control 24 hours prior to intranasal challenge with 50 µl LPS. Control 
animals were administered saline. After 3 hours the animals were sacrificed and 
BAL fluid collected. Inflammation was assessed by A- total cell counts in BALF; B- 
differential neutrophil counts; C- differential monocyte counts; Data show means ± 
SEM of n= 4-5 animals per group; *p<0.05, **p<0.01;  
 
 
  433  
  
0
100
200
300
400
500
LPS
mPAR-1
- -
- -
+ +
++
B
A
L
F
 P
ro
te
in
 (

g
/m
l)
 
 
 
 
 
 
 
 
   
 
Figure A1.3.8. Assessment of vascular leak in the LPS model of acute lung injury 
(ALI)  
BALB/c mice were administered 0.5 mg/kg of mPAR-1 antagonist antibody or IgG 
control 24 hours prior to intranasal LPS challenge. Control animals were 
administered 50 μl of saline. After 3 hours mice were sacrificed and BAL fluid 
collected. BCA assay was used to assess total protein level in the BALF. Data 
represent mean ± SEM of n= 4-5 animals.  
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A1.3.5 Summary  
 
 The Armenian hamster antibody was purified from hybridoma cell 
supernatant and its purity and specificity confirmed by Commassie staining 
and Western blotting.  
 The antibody was subsequently shown to inhibit intracellular calcium 
release in thrombin-stimulated murine lung fibroblasts.  
 The antibody did not affect the intracellular calcium response to PAR-1-
specific activating peptide, TFLLR.   
 The mPAR-1 neutralising antibody appeared to induce the CCL2 release 
from the murine lung fibroblast rather than inhibit it. 
 The antibody preparation was tested and found to be heavily contaminated 
with endotoxin. Following the decontamination treatment, the endotoxin 
level was reduced to 10 EU/ml (1 ng/ml).  
 The mPAR-1 neutralising antibody had no effect on neutrophilia and 
monocytes numbers in the LPS model of acute lung injury. 
 The saline-treated control animals administered the mPAR-1 blocking 
antibody and the isotype IgG showed increased BALF total protein levels.  
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A1.4 Discussion  
Over-exuberant activation of the coagulation cascade in combination with the 
decreased activity of fibrinolytic pathways is strongly implicated in the pathogenesis 
of lung injury and fibrosis. However, recent clinical trial of warfarin in IPF patients 
showed increased mortality in the treatment arm (Noth et al., 2012), which 
suggests that global inhibition of coagulation cascade may be detrimental to the 
disease process. Furthermore, anticoagulants have extensive systemic effects that 
can lead to spontaneous and life-threatening haemorrhage. PAR-1 antagonists may 
provide attractive therapeutic solution through disrupting the local thrombin 
signalling pathways without affecting the systemic coagulation. There are already 
several clinical trials for PAR-1 antagonists ongoing in the setting of cardiovascular 
disease as described in Introduction section of this thesis.      
Thrombin-induced PAR-1 signalling exerts major pro-fibrotic effects in the lung, 
including fibroblast proliferation and differentiation to myofibroblasts (Bogatkevich 
et al. 2009; Bogatkevich et al. 2003), collagen deposition (Chambers et al., 1998), 
release of chemokines, such as CCL2 (Deng et al., 2008; Mercer et al., 2009) and 
growth factors such as connective tissue growth factor (CTGF) from fibroblasts 
(Chambers et al. 2000). As previously discussed, PAR-1 signalling also mediates 
activation of latent TGFβ (Jenkins et al., 2006; Scotton et al., 2009). Furthermore 
PAR-1 knockout mice are protected from bleomycin-induced lung fibrosis (Howell et 
al. 2005), fMLP-induced chronic obstructive pulmonary disease (COPD) (Atzori et al., 
2009), liver fibrosis (Rullier et al., 2008) and renal ischemia reperfusion injury 
(Sevastos et al., 2007).  
In this study a hybridoma cell line producing a novel murine PAR-1 neutralising 
antibody was obtained through collaboration with Novartis Research Centre 
(Horsham, UK). The antibody displays high affinity for the mPAR-1 tethered ligand, 
irrespectively of thrombin cleavage, as demonstrated by Novartis in the 
immunoprecipitation studies. In the physiological system the antibody blocks PAR-1 
by steric hindrance where the antibody binds to the tethered ligand and prevents 
thrombin binding and cleaving of the receptor. The mPAR-1 neutralising antibody 
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was purified from the hybridoma cell supernatants, characterised and its effect on 
thrombin-mediated signalling in murine lung fibroblasts assessed in in vitro assays.  
In human plasma, the zymogen, prothrombin, is present at concentrations around 
1.4 µM and the maximum concentration of active thrombin generated during blood 
clotting in vivo is estimated to be 130 nM (Walz et al., 1985). Thrombin levels in the 
extravascular compartments are expected to be much lower than in blood and in 
vitro experiments in our laboratory have shown that concentrations as low as 1 nM 
cause significant increases in CCL2 release from murine lung fibroblasts while 
intracellular calcium flux is detected from 0.3 nM thrombin. At a concentration of 
10 nM thrombin induces robust intracellular flux and CCL2 release from murine lung 
fibroblasts and therefore this concentration was used to evaluate the blocking 
potential of mPAR-1 neutralising antibody in this set of experiments. The results 
show that mPAR-1 neutralising antibody efficiently inhibited thrombin-induced 
intracellular calcium release in a concentration-dependent manner. Cells were also 
stimulated with the PAR-1 specific agonist peptide TFLLR. The activating peptide 
binds to the second extracellular loop (ECL2) of the receptor and activates the 
receptor independently of proteolytic cleavage. It was therefore used to 
demonstrate the specificity of the intracellular calcium release downstream of PAR-
1 signalling.  
In the second functional assay the effect of mPAR-1 neutralising antibody on CCL2 
release from murine lung fibroblasts was assessed. CCL2 is a potent 
chemoattractant for mononuclear cells, T lymphocytes and immature dendritic cells 
and this effect is largely mediated by PAR-1 (Chen et al. 2008). In the lungs of IPF 
patients, CCL2 immunoreactivity is associated with epithelial cells, monocytes, 
vascular endothelial cells, fibroblasts and fibrocytes (Mercer et al., 2009). CCL2 
expression is also upregulated in the bleomycin model of lung injury and fibrosis 
and in vitro studies demonstrate that CCL2 can stimulate fibroblast collagen 
synthesis via the induction of TGF-β (Gharaee-Kermani et al. 1996). The thrombin- 
PAR-1- Gαq signalling axis leads to upregulation of CCL2 expression in lung 
fibroblasts both at the gene and protein levels as demonstrated in previous studies 
 
 
  437  
  
in our laboratory (Deng et al., 2008). In the present experiments murine lung 
fibroblasts were stimulated with thrombin following pre-treatment with mPAR-1 
neutralising antibody and the CCL2 levels measured in the cell supernatants. 
However, the results of this experiment were opposite to the predicted outcome 
and the antibody appeared to have induced a concentration-dependent increase in 
CCL2 release. The most plausible explanation was that the antibody is contaminated 
with endotoxin, which was subsequently confirmed by the standard endotoxin 
detection LAL assay. CCL2 release can be triggered by bacterial endotoxin, which is 
also the most common contaminant of biological preparations. Endotoxin binds to 
the Toll-like receptor- 4 (TLR-4) expressed on fibroblasts and triggers signalling via 
the NFκB pathway to release inflammatory mediators, including CCL2. The 
concentration of endotoxin matched to the level detected in the antibody 
preparation was shown to elicit CCL2 release of similar magnitude as observed in 
this experiment.  
Endotoxins are components of Gram-negative bacteria’s cell walls and are 
structurally lipopolysaccharides (LPS), composed of a polysaccharide chain that is 
highly variable among bacterial species, and lipid moiety lipid A, which is a constant 
part of the molecule. A commercially available polymyxin B-based treatment was 
used to decontaminate the antibody stock. Polymyxin B is an antibiotic that binds 
the preserved lipid A and is therefore able to neutralize endotoxin from a wide 
range of bacterial species. Furthermore, the polymyxin B is immobilised in a 
chromatography column that allows removal of the bound endotoxin from the 
antibody stock. This technique allowed for a significant reduction of the 
contamination to the levels, which were deemed acceptable for an in vivo use.   
Research in our laboratory has shown that blocking PAR-1 with small-molecule 
antagonist, RWJ58259, in an LPS model of acute lung injury attenuates 
inflammatory cell recruitment and reduces microvascular leak (Mercer et al., 2013). 
Therefore, the initial in vivo experiments to assess the efficacy of the mPAR-1 
antibody were undertaken in the LPS-model of acute lung injury, with a view to 
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progress into the more severe model of bleomycin-induced lung injury and 
pulmonary fibrosis.  
There are many advantages of using a monoclonal neutralising antibody over a 
synthetic antagonist. Antibodies have a high affinity and avidity for the target 
epitope and show relatively low toxicity and side effects. The antigenic responses 
observed with the first murine therapeutic antibodies administered to humans have 
been greatly attenuated by producing chimeric and humanised antibodies. 
Furthermore, the large cost of producing engineered human antibodies has been 
reduced since the generation of transgenic mice encoding the human IgG constant 
region (reviewed in Gura 2002). Unlike RWJ58259, which is rapidly metabolised, 
antibodies have a prolonged half-life of approximately 21 days, which greatly 
reduces the need for frequent dosing.    
To the best of our knowledge the mPAR-1 neutralising antibody was not previously 
used in vivo and hence there were no pharmacokinetic data available. Based on the 
in vitro functional assays, a range of antibody concentrations between 10 and 90 
μg/ml inhibited thrombin-mediated intracellular calcium release and a cautious 
approach was adopted due to the residual endotoxin level still present in the 
antibody preparation. Generic endotoxin limit for humans is 5 endotoxin units (EU) 
per kilogram body weight and levels below that do not induce pyrogenic responses 
in living organisms. This value was also used as the basis to calculate the dose of 
antibody containing acceptable endotoxin level for an in vivo administration in mice 
(Malyala and Singh, 2008). The dose of 10 µg/ml was chosen on the basis that it 
blocked thrombin signalling in vitro and contained endotoxin levels below the 
threshold of triggering inflammatory responses.  
The mPAR-1 neutralising antibody was administered intraperitoneally 30 minutes 
and 24 hours prior to the intranasal LPS challenge in two consecutive experiments. 
LPS-induced lung injury is characterised by neutrophillic inflammation and a 
reduction in monocyte and macrophage numbers and hence the inflammatory cell 
influx into the lung was assessed. Another prominent feature of this model is 
increased microvascular leak which was investigated by measuring total protein 
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levels in the BALF. Data obtained in these experiments are consistent with the 
previous results and show significant neutrophil recruitment into the lung and 
reduced numbers of monocytes and macrophages. However, in both experiments 
there was no difference in neutrophilia and monocytes numbers between the 
control isotype- and mPAR neutralising antibody-treated mice. Furthermore, all 
experimental groups had increased total protein levels suggesting that both saline 
controls and LPS-treated animals experienced increased microvascular leak. This is 
potential explanation for the fact that although the levels of total inflammatory cells 
were increased in LPS-treated mice compared to saline control, the differences 
were not statistically significant.       
Several potential mechanisms were proposed to explain the lack of protective effect 
with the mPAR-1 neutralising antibody. Antibodies are large molecules and injected 
intraperitoneally reach the lung via the lymphatics and blood stream. It was 
postulated that the lack of protective effect was due to a delay between the onset 
of the injury and the antibody reaching the injured site. This issue was addressed in 
the second experiment where the antibody was administered 24 hours prior to LPS 
challenge. However, the level of neutrophil recruitment was comparable between 
the isotype control- and mPAR-1 neutralising antibody treated groups. 
However, the assumption that antibodies have a long half-life may not be accurate 
in this experimental setting. Antibody half-life in vivo is regulated by the neonatal Fc 
receptor (FcRn), which in early stages of life transports the IgG through the placenta 
and across epithelial surfaces and in the adults protects the IgG from proteolytic 
degradation, extending its half-life for up to 21 days. Human FcRn discriminates 
between antibodies coming from different species and the lack of protection 
offered by this receptor can dramatically reduce the half-life of an antibody (Keizer 
et al., 2010; Kontermann, 2009).  Although the mouse FcRn is promiscuous in 
binding IgGs from different species, its affinity for Armenian hamster IgG is uknown. 
Second, the constant Fc fragment of the IgG can potentially cross-react with the Fc 
receptors expressed on the murine cells and elicit an antibody-mediated cytotoxic 
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reaction. In this instance, the antibody would trigger an inflammatory response that 
would mask any potential protective effect.  
Also as previously discussed, PAR-1 is widely expressed on many cell types, 
including endothelial cells and circulating monocytes. It is plausible that the en 
route target-related clearance of the antibody prevents it from reaching the injured 
site in the lung at the sufficient concentrations to have a therapeutic effect. An 
increased dose of the antibody and intranasal route of administration are being 
considered to achieve higher local concentration at the site of injury.   
Also, the protein data obtained in these experiments showing high levels of the 
total BALF protein across all experimental groups do not agree with the previous 
results obtained in our laboratory. This raises a potential technical issue which may 
relate to the sample collection technique or the BCA assay used to measure the 
total BALF protein. The collection of BALF is a disruptive procedure and if not 
performed carefully can dislodge a number of surface proteins or disrupt the lung 
vasculature and cause serum protein contamination. This protein will be then 
detected by BCA assay and obstruct the true magnitude of microvascular leak into 
the lung. 
In conclusion, the aim of this study was to purify mPAR-1 neutralising antibody and 
validate it in the model of acute lung injury before assessing its therapeutic effect in 
bleomycin-induced lung injury and fibrosis. The antibody inhibited thrombin-
mediated signalling in vitro but did not show a therapeutic effect in vivo. Apart from 
potential explanations discussed above, there is a concern that the remaining level 
of endotoxin present in the antibody preparation interferes with the inflammatory 
measurements evaluated in the model of acute lung injury. Therefore, future work 
will involve obtaining an endotoxin-free antibody preparation and further 
optimising of the antibody for in vivo use.  
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Appendix 2: PAR-1-dependent and PAR-1-
independent pro-inflammatory signalling in 
human lung fibroblasts exposed to thrombin 
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PAR-1-dependent and PAR-independent pro-inflammatory signaling in human lung 
fibroblasts exposed to thrombin. 
Ortiz-Stern A1, Deng X, Smoktunowicz N, Mercer PF, Chambers RC. 
Abstract 
Proteinase-activated receptors (PARs) are crucial in orchestrating cellular responses 
to coagulation proteinases, such as thrombin and FXa. Four PARs have been 
characterized and have been shown to be differentially expressed in mice and 
humans and between tissues. We have previously shown that in murine lung 
fibroblasts, PAR-1 is solely responsible for all cellular responses to thrombin and 
FXa. In contrast, we report here that in primary human lung fibroblasts (pHLFs), 
known PARs fail to account for all of the cellular responses to thrombin, in 
particular in the presence of high, but physiologically achievable concentrations of 
thrombin. We report that pHLFs secrete CCL2 in a PAR-1-dependent manner at low 
thrombin concentration (∼0.3 nM). At or above 10 nM thrombin, pharmacological 
antagonism (RWJ-58259) fails to block thrombin-induced CCL2 release; whereas 
PAR-1 cleavage-blocking monoclonal antibodies (ATAP2 and WEDE15) only partially 
inhibit thrombin-induced CCL2 secretion. In addition, activation of PAR-3, PAR-4, 
and transactivation of either PAR-2 or EGFR were ruled out as being responsible for 
thrombin-mediated CCL2 secretion at high yet standard concentrations of the 
proteinase. We further provide evidence that PAR-1-dependent and PAR-
independent signaling involves the rapid phosphorylation of ERK, which in turn is 
absolutely required for thrombin-induced CCL2 secretion at both low and standard 
concentration of the proteinase. Our findings suggest the existence of a PAR-
independent signaling mechanism in human lung fibroblasts and have important 
implications for the design of therapeutic strategies aimed at blocking pro-
inflammatory signaling responses associated with excessive thrombin generation. 
 
